{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.13298"}, {"@name": "filename", "#text": "19217_Adrag%c3%a3o%20Teresa%20TD%202011.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "CALCIFICA\u00c7\u00d5ES VASCULARES \nNOS DOENTES EM DI\u00c1LISE: \n\nELO DE LIGA\u00c7\u00c3O ENTRE DOEN\u00c7A \u00d3SSEA \nE DOEN\u00c7A VASCULAR\n\nTERESA ADRAG\u00c3O\n\n2011\n\n\n\n\n\n1\n\n\u00cdNDICE\n\nAgradecimentos .............................................................................................................. 3\n\nCap\u00edtulo 1\nPref\u00e1cio \u2013 Calcifi ca\u00e7\u00e3o vascular nos doentes em di\u00e1lise: Elo de liga\u00e7\u00e3o entre doen\u00e7a \n\u00f3ssea e doen\u00e7a vascular .................................................................................................. 5\n\nCap\u00edtulo 2\nCria\u00e7\u00e3o de um score semiquantitativo para avaliar a calcifi ca\u00e7\u00e3o nos doentes em di\u00e1lise ... 9\n\nCap\u00edtulo 3\nCalcifi ca\u00e7\u00e3o vascular: Preval\u00eancia e associa\u00e7\u00e3o com mortalidade e morbilidade .......... 17\n\nArtigo 1. A simple vascular calcifi cation score predicts cardiovascular risk \nin haemodialysis patients ..................................................................... 29\n\nCap\u00edtulo 4\nCalcifi ca\u00e7\u00e3o vascular e rigidez arterial ........................................................................... 39\n\nArtigo 2. A plain X -ray vascular calcifi cation score is associated with arterial \nstiffness and mortality in dialysis patients ........................................... 45\n\nArtigo 3. Vascular calcifi cation, cardiovascular risk and arterial stiffness in \nhemodialysis patients ........................................................................... 51\n\nCap\u00edtulo 5\nCalcifi ca\u00e7\u00e3o valvular card\u00edaca nos doentes em di\u00e1lise ................................................... 57\n\nArtigo 4. Vascular and valvular calcifi catons. The same pathogenesis? ............. 61\n\nCap\u00edtulo 6\nExiste um elo de liga\u00e7\u00e3o entre o osso e o vaso nos doentes em di\u00e1lise? (1.\u00aa parte)\nCalcifi ca\u00e7\u00e3o vascular e an\u00e1lise histomorfom\u00e9trica de biopsias \u00f3sseas ........................... 69\n\nArtigo 5. Low bone volume \u2013 a risk factor for coronary calcifi cations \nin hemodialysis patients ...................................................................... 75\n\n\n\n2\n\nArtigo 6. Editorial de London G. Bone -vascular axis in chronic kidney disease: \na reality? .............................................................................................. 81\n\nArtigo 7. Is there a link between bone and vessel in dialysis patients? .............. 85\nArtigo 8. Treatment of hyperphosphatemia with sevelamer hydrochloride in \n\ndialysis patients: Effects on vascular calcifi cation, bone and a close \nlook into the survival data ................................................................... 93\n\nCap\u00edtulo 7\nExiste um elo de liga\u00e7\u00e3o entre o osso e o vaso nos doentes em di\u00e1lise? (2.\u00aa parte)\nDensidade mineral \u00f3ssea, histomorfometria \u00f3ssea e calcifi ca\u00e7\u00f5es vasculares ............... 99\n\nArtigo 9. Bone mineral density, vascular calcifi cations, and arterial stiffness \nin peritoneal dialysis patients .............................................................. 107\n\nArtigo 10. Femoral bone mineral density refl ects histologically determined \ncortical bone volume in hemodialysis. patients ................................... 113\n\nCap\u00edtulo 8\nM\u00e9todos para avaliar a calcifi ca\u00e7\u00e3o vascular .................................................................. 121\n\nArtigo 11. Cardiovascular risk in dialysis patients: an X -ray vision on vascular \ncalcifi cations ........................................................................................ 127\n\nArtigo 12. Evaluation of vascular calcifi cations in CKD patients ........................ 131\n\nCap\u00edtulo 9\nComent\u00e1rios fi nais .......................................................................................................... 137\n\nCap\u00edtulo 10\nResumo da disserta\u00e7\u00e3o .................................................................................................... 153\nAbstract ........................................................................................................................... 155\n\nAutoriza\u00e7\u00e3o de publica\u00e7\u00e3o\nA reprodu\u00e7\u00e3o dos artigos e tabelas publicados foi objecto de autoriza\u00e7\u00e3o expressa dos respectivos editores.\n\nSegundo o acordo ortogr\u00e1fi co em vigor.\n\n\n\n3\n\nAGRADECIMENTOS\n\nA presente disserta\u00e7\u00e3o \u00e9 o resultado de um esfor\u00e7o individual apoiado e amplifi cado por \ndiversas contribui\u00e7\u00f5es valiosas que desejo aqui recordar e agradecer.\n\nEm primeiro lugar, agrade\u00e7o ao Sr. Professor Doutor Jacinto Sim\u00f5es, ao Dr. Jos\u00e9 Miguel \nBoquinhas, \u00e0 Dra. Maria Jo\u00e3o Pais e ao Dr. Jos\u00e9 Diogo Barata que, na sua fun\u00e7\u00e3o de Diretores \ndo Servi\u00e7o de Nefrologia de Hospital de Santa Cruz, confi aram em mim e de diversas maneiras \nestimularam esta vertente de investiga\u00e7\u00e3o cl\u00ednica.\n\nGostaria de exprimir a minha gratid\u00e3o ao Sr. Professor Doutor Fernando Nolasco, pela \nforma enriquecedora com que me orientou durante o per\u00edodo de prepara\u00e7\u00e3o desta tese. Os \ndiversos trabalhos feitos e publicados durante este per\u00edodo confi rmaram a relev\u00e2ncia e a \nutilidade cl\u00ednica deste score de calcifi ca\u00e7\u00e3o vascular simples.\n\nAgrade\u00e7o ao Dr. Ac\u00e1cio Pita Negr\u00e3o e \u00e0 Dra. Helena Boquinhas, diretores m\u00e9dicos, \nrespectivamente das cl\u00ednicas de di\u00e1lise Diaverum Nefrocl\u00ednica do Estoril e de Linda -a -Velha, \npela confi an\u00e7a e apoio que prestaram e continuam a prestar na realiza\u00e7\u00e3o de diversos estudos \ncl\u00ednicos nestas duas unidades.\n\nQuero agradecer ao Dr. Domingos Machado, coordenador da Unidade de Transplanta\u00e7\u00e3o \nRenal do Hospital de Santa Cruz, pela amizade e o incentivo sempre demonstrados ao longo \ndestes anos. O trabalho desenvolvido na equipa de transplanta\u00e7\u00e3o renal constituiu um dos \nper\u00edodos mais estimulantes da minha atividade cl\u00ednica.\n\nA todos os coautores dos trabalhos em que participei agrade\u00e7o a preciosa ajuda manifestada \nde diversas maneiras, sem a qual n\u00e3o seria poss\u00edvel a realiza\u00e7\u00e3o destes estudos. Quero em \nparticular agradecer \u00e0 Dra. Ana Pires, \u00e0 Dra. Patr\u00edcia Branco, \u00e0 Dra. Rita Birne, \u00e0 Dra. Cristina \nJorge e \u00e0 Dra. C\u00e9lia Nascimento a amizade, o entusiasmo e o empenho sempre presentes nos \nbons e nos maus momentos.\n\nQuero agradecer a todos os meus colegas do Servi\u00e7o de Nefrologia do Hospital de Santa \nCruz que, pela sua compet\u00eancia e amizade, contribu\u00edram para o meu enriquecimento como \nm\u00e9dica e como pessoa.\n\nAo Dr. Fernando Carrera, Editor da revista Portuguese Journal of Nephrology and \nHypertension e grande impulsionador da proje\u00e7\u00e3o internacional da Nefrologia portuguesa, \nagrade\u00e7o muito a sua amizade e, concretamente, o ensino dos fundamentos b\u00e1sicos necess\u00e1rios \npara a reda\u00e7\u00e3o de um artigo cient\u00edfi co.\n\n\n\n4\n\nAo Dr. Carlos Aguiar, cardiologista do Hospital de Santa Cruz, agrade\u00e7o a sua amizade \nsempre dispon\u00edvel, os conselhos estat\u00edsticos preciosos e a revis\u00e3o avisada e cr\u00edtica do meu \nprimeiro artigo publicado na Nephrology, Dialysis and Transplantation, que constituiu o \nbaluarte da atual disserta\u00e7\u00e3o.\n\nAo Sr. Professor Jos\u00e9 Dias Curto, doutorado em M\u00e9todos Quantitativos de Gest\u00e3o e \nProfessor Auxiliar no Departamento de M\u00e9todos Quantitativos da ISCTE \u2013 IUL Business \nSchool, agrade\u00e7o toda a colabora\u00e7\u00e3o prestada na an\u00e1lise estat\u00edstica de diversos artigos \npublicados.\n\nAos meus queridos amigos Sr. Professor Doutor Jo\u00e3o Fraz\u00e3o e ao Dr. An\u00edbal Ferreira, \nnefrologistas, investigadores e l\u00edderes de opini\u00e3o com merecida proje\u00e7\u00e3o nacional e \ninternacional, quero agradecer a amizade com que me honram e o apoio e confi an\u00e7a prestados \nem diversos projetos de investiga\u00e7\u00e3o comuns.\n\n\n\n5\n\nCAP\u00cdTULO 1\n\nPREF\u00c1CIO\n\nCalcifi ca\u00e7\u00f5es vasculares nos doentes em di\u00e1lise: Elo de liga\u00e7\u00e3o \nentre doen\u00e7a \u00f3ssea e doen\u00e7a vascular\n\nApesar dos grandes progressos no tratamento dos doentes renais cr\u00f3nicos em di\u00e1lise, a \nmortalidade mant\u00e9m-se muito elevada, verifi cando-se em algumas s\u00e9ries que a sobrevida aos \n5 anos pode ser de apenas 30%1. A principal causa de morte \u00e9 a cardiovascular, que atinge \nvalores 100 vezes superiores aos dos indiv\u00edduos da popula\u00e7\u00e3o geral do mesmo grupo et\u00e1rio2.\n\nEsta elevada mortalidade cardiovascular dos doentes renais cr\u00f3nicos n\u00e3o \u00e9 totalmente \nexplicada pelos fatores de risco tradicionais2,3, e m\u00faltiplos fatores n\u00e3o tradicionais parecem \ncontribuir para este elevado risco nesta popula\u00e7\u00e3o. O esclarecimento destes processos poder\u00e1 \nrepresentar um dos avan\u00e7os mais signifi cativos no tratamento do doente renal cr\u00f3nico.\n\nEm 2001 foi publicado o primeiro estudo que mostrou que as calcifi ca\u00e7\u00f5es vasculares \nnos doentes em di\u00e1lise s\u00e3o preditoras de mortalidade4 e, no momento atual, \u00e9 universalmente \nreconhecido que as calcifi ca\u00e7\u00f5es vasculares s\u00e3o um fator de risco cardiovascular na doen\u00e7a \nrenal cr\u00f3nica5. As altera\u00e7\u00f5es do metabolismo fosfoc\u00e1lcico e a patologia \u00f3ssea destes doentes \ns\u00e3o alguns dos fatores que se associam ao desenvolvimento e \u00e0 progress\u00e3o das calcifi ca\u00e7\u00f5es \nvasculares.\n\nA presente disserta\u00e7\u00e3o para tese de doutoramento apresenta o desenvolvimento e a \nvalida\u00e7\u00e3o de um m\u00e9todo simples e original para o diagn\u00f3stico de calcifi ca\u00e7\u00f5es vasculares em \ndoentes em di\u00e1lise, utilizando um score semiquantitativo obtido em RX simples da bacia e \ndas m\u00e3os criado por n\u00f3s. Este trabalho iniciou -se no ano 2000 e incluiu a avalia\u00e7\u00e3o, ao longo \nde v\u00e1rios anos, deste score de calcifi ca\u00e7\u00e3o em diferentes popula\u00e7\u00f5es de doentes em di\u00e1lise e \nda sua rela\u00e7\u00e3o com a mortalidade, com o risco cardiovascular, com a rigidez arterial e com a \ndoen\u00e7a \u00f3ssea. Em in\u00fameros trabalhos publicados demonstramos que este score \u00e9 preditor, \nnos doentes em di\u00e1lise, de mortalidade cardiovascular e global, de internamentos \ncardiovasculares, de doen\u00e7a vascular e de doen\u00e7a arterial perif\u00e9rica6,7. \u00c9 igualmente preditor \nde rigidez arterial avaliada por velocidade de onda de pulso e por press\u00e3o de pulso7. Este \nscore de calcifi ca\u00e7\u00e3o apresenta uma rela\u00e7\u00e3o inversa com a densidade mineral \u00f3ssea avaliada \npor DXA (dual -energy x -ray absorptiometry)8. Demonstramos que este score \u00e9 um instrumento \n\n\n\n6\n\n\u00fatil e barato para a avalia\u00e7\u00e3o de calcifi ca\u00e7\u00f5es vasculares, permitindo de forma simples \nidentifi car os doentes com mais elevado risco cardiovascular.\n\nSalienta -se que dois dos trabalhos inclu\u00eddos nesta disserta\u00e7\u00e3o foram referenciados nas \nguidelines publicadas pela KDIGO (Kidney disease improving global outcomes) em 2009 \npara validar a associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e mortalidade cardiovascular nos \ndoentes renais cr\u00f3nicos (KDIGO 2009: Tabela suplementar 12; Fig.3.7)5. O primeiro trabalho \nfoi publicado em 2004 e demonstrou a exist\u00eancia de uma associa\u00e7\u00e3o entre este score vascular \nsimples de calcifi ca\u00e7\u00e3o e a mortalidade cardiovascular num grupo de doentes em di\u00e1lise 6. O \nsegundo trabalho foi publicado em 2009 e demonstrou que o score vascular simples se associa \ndiretamente \u00e0 press\u00e3o de pulso e \u00e0 velocidade de onda de pulso e que estes tr\u00eas fatores s\u00e3o \npreditores de mortalidade 7.\n\nO diagn\u00f3stico de calcifi ca\u00e7\u00f5es vasculares tem um interesse pr\u00e1tico para os doentes renais \ncr\u00f3nicos. A presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares \u00e9 um sinal de alerta para a exist\u00eancia de um \nelevado risco cardiovascular, e esta informa\u00e7\u00e3o pode ser utilizada para modifi car a terap\u00eautica \nnestes doentes. No momento atual podemos atuar em alguns destes fatores, nomeadamente \nnas altera\u00e7\u00f5es do metabolismo mineral e \u00f3sseo, como sugerido nas guidelines KDIGO de \n2009 5.\n\nA apresenta\u00e7\u00e3o desta disserta\u00e7\u00e3o ser\u00e1 dividida em diferentes cap\u00edtulos, cada um deles \ncorrespondendo \u00e0s distintas vertentes resultantes da an\u00e1lise do score de calcifi ca\u00e7\u00e3o vascular \nsimples na sua rela\u00e7\u00e3o com os v\u00e1rios desfechos e par\u00e2metros cl\u00ednicos avaliados por n\u00f3s: \nmortalidade, risco cardiovascular, rigidez arterial e doen\u00e7a \u00f3ssea. Cada um destes temas foi \nanalisado em diversos trabalhos apresentados em congressos nacionais e internacionais e \npublicados na revista Portuguese Journal of Nephrology and Hypertension e em revistas \ninternacionais de elevado prest\u00edgio.\n\nRefer\u00eancias\n\n1. US Renal Data System, USRDS 2009 annual data report: Atlas of end -stage renal disease in the \nUnited States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney \nDiseases Bethesda, MD, 2009.\n\n2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal \ndisease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112\u2013S119.\n\n3. Weiner DE, Tighiouart H, Elsayed EF, et al. Griffi th JL. The Framingham predictive instrument in \nchronic kidney disease. J Am Coll Cardiol 2007; 50: 217 -224\n\n\n\n7\n\n4. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular \nrisk in end -stage renal disease. Hypertension 2001;38:938 -942.\n\n5. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global \noutcomes (KDIGO). Kidney Int 2009; 76 (Suppl)113. [Supplementary tables.]\n\n6. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. A simple vascular \ncalcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant \n2004;19(6):1480 -1488. [Epub 2004 Mar 19.]\n\n7. Adrag\u00e3o T, Pires A, Birne R, Curto JD, Lucas C, Gon\u00e7alves M, Negr\u00e3o AP. A plain X -ray vascular \ncalcifi cation score is associated with arterial stiffness and mortality in dialysis patients.Nephrol \nDial Transplant 2009; 24(3):997 -1002. [Epub 2008 Oct 24.]\n\n8. Adrag\u00e3o T, Branco P, Birne R, Curto JD, de Almeida E, Prata MM, Pais MJ. Bone mineral density, \nvascular calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; \n28(6):668 -672.\n\n\n\n\n\n9\n\nCAP\u00cdTULO 2\n\nCRIA\u00c7\u00c3O DE UM SCORE SEMIQUANTITATIVO PARA AVALIAR \nA CALCIFICA\u00c7\u00c3O VASCULAR NOS DOENTES EM DI\u00c1LISE\n\nNos doentes em di\u00e1lise, as calcifi ca\u00e7\u00f5es vasculares e as altera\u00e7\u00f5es do metabolismo \nfosfoc\u00e1lcico t\u00eam sido associadas de forma consistente em diversos estudos a uma maior \nmortalidade, sendo consideradas atualmente fatores de risco cardiovascular nesta popula\u00e7\u00e3o. \nEm 1998, foi publicado o primeiro estudo observacional1 que mostrou que nos doentes em \ndi\u00e1lise existe uma associa\u00e7\u00e3o independente entre as frequentes altera\u00e7\u00f5es do metabolismo \nmineral, como a hiperfosfatemia, a hipercalcemia e as altera\u00e7\u00f5es da paratormona (PTH), e a \nmortalidade. Ap\u00f3s este primeiro estudo, muitos outros se sucederam revelando a exist\u00eancia \nde uma associa\u00e7\u00e3o consistente entre a hiperfosfatemia e a mortalidade nos diferentes est\u00e1dios \nda doen\u00e7a renal cr\u00f3nica (3 a 5 e 5D)2 -4.A associa\u00e7\u00e3o entre hiperfosfatemia e mortalidade n\u00e3o \n\u00e9 exclusiva da doen\u00e7a renal cr\u00f3nica, pois tamb\u00e9m em doentes sem insufi ci\u00eancia renal se \nverifi cou que n\u00edveis mais elevados de f\u00f3sforo s\u00e9rico, embora ainda dentro dos limites normais, \ns\u00e3o preditores de mortalidade 5.\n\nOs mecanismos que associam a hiperfosfatemia e a hipercalcemia \u00e0 mortalidade s\u00e3o \nparcialmente explicados por estudos in vitro realizados em c\u00e9lulas musculares lisas em cultura \nprovenientes de aorta humana6,7. Nestes estudos foi demonstrado que n\u00edveis elevados de \nf\u00f3sforo e de c\u00e1lcio promovem a calcifi ca\u00e7\u00e3o vascular atrav\u00e9s da express\u00e3o de um fator de \ntranscri\u00e7\u00e3o gen\u00e9tico Cbfa1 (core binding factor alpha 1), atualmente conhecido por RunX2 \n(runt related transcription factor 2), pertencente \u00e0 fam\u00edlia dos fatores de transcri\u00e7\u00e3o RunX. \nEste fator codifi ca uma prote\u00edna essencial para a diferencia\u00e7\u00e3o osteobl\u00e1stica. Verifi ca -se, deste \nmodo, que a altera\u00e7\u00e3o da ativa\u00e7\u00e3o de determinados genes torna as c\u00e9lulas musculares lisas \ncapazes de sintetizar matriz \u00f3ssea e de promover a calcifi ca\u00e7\u00e3o dessa matriz. Demonstrou -se \nassim que a calcifi ca\u00e7\u00e3o vascular \u00e9 um processo ativo que resulta de uma diferencia\u00e7\u00e3o das \nc\u00e9lulas musculares lisas em osteoblastos em resposta a diferentes est\u00edmulos.\n\nAl\u00e9m destas altera\u00e7\u00f5es de express\u00e3o gen\u00e9tica, sabemos atualmente que a calcifi ca\u00e7\u00e3o \nvascular resulta de um equil\u00edbrio complexo entre fatores indutores e inibidores, verifi cando-\n-se o aumento de alguns fatores indutores e por vezes tamb\u00e9m a diminui\u00e7\u00e3o de fatores \ninibidores. Nos doentes em di\u00e1lise, a hiperfosfatemia e a hipercalcemia s\u00e3o alguns dos \nfatores indutores de calcifi ca\u00e7\u00e3o. Verifi ca -se igualmente o d\u00e9fi ce de diversos fatores \ninibidores da calcifi ca\u00e7\u00e3o, entre os quais se identifi cam o d\u00e9fi ce de fetu\u00edna A8 geralmente \n\n\n\n10\n\nem rela\u00e7\u00e3o com infl ama\u00e7\u00e3o, e o d\u00e9fi ce de matrix -gla em consequ\u00eancia de um d\u00e9fi ce de \nvitamina K9.\n\nA hiperfosfatemia e a hipercalcemia s\u00e3o frequentes nos doentes em di\u00e1lise e surgem \nhabitualmente em duas situa\u00e7\u00f5es opostas: no hiperparatiroidismo secund\u00e1rio e na doen\u00e7a \n\u00f3ssea adin\u00e2mica. No hiperparatiroidismo o osso apresenta uma elevada remodela\u00e7\u00e3o \u00f3ssea e \nliberta c\u00e1lcio e f\u00f3sforo para a circula\u00e7\u00e3o. Na doen\u00e7a adin\u00e2mica, o osso \u00e9 incapaz de incorporar \nc\u00e1lcio e f\u00f3sforo por apresentar uma baixa remodela\u00e7\u00e3o \u00f3ssea e o c\u00e1lcio e o f\u00f3sforo que o \ndoente recebe na sua dieta habitual (ou no caso do c\u00e1lcio tamb\u00e9m na terap\u00eautica) acumulam-\n-se. Quer num caso quer noutro a consequ\u00eancia desta altera\u00e7\u00e3o do metabolismo do c\u00e1lcio e \ndo f\u00f3sforo \u00e9 o seu dep\u00f3sito extra\u00f3sseo nos tecidos moles e na parede dos vasos.\n\nEstas s\u00e3o as bases para a presente hip\u00f3tese da exist\u00eancia de um elo de liga\u00e7\u00e3o entre a \ndoen\u00e7a \u00f3ssea e a doen\u00e7a vascular nos doentes em di\u00e1lise. A iniciativa mundial KDIGO (Kidney \ndisease improving global outcomes), que tenta unifi car recomenda\u00e7\u00f5es para o tratamento da \ndoen\u00e7a renal cr\u00f3nica, prop\u00f4s em 200610 que as calcifi ca\u00e7\u00f5es vasculares fossem inclu\u00eddas no \ndiagn\u00f3stico da doen\u00e7a mineral e \u00f3ssea da doen\u00e7a renal cr\u00f3nica. As guidelines publicadas pela \nKDIGO em 200911, referentes \u00e0 doen\u00e7a mineral e \u00f3ssea da doen\u00e7a renal cr\u00f3nica consideram \nque os doentes renais cr\u00f3nicos com calcifi ca\u00e7\u00f5es vasculares sejam reconhecidos como \napresentando elevado risco cardiovascular e sugerem que o RX simples de perfi l da aorta \nabdominal e o ecocardiograma sejam usados para detetar, respetivamente, a presen\u00e7a de \ncalcifi ca\u00e7\u00f5es vasculares e valvulares nestes doentes.\n\nTipos de calcifi ca\u00e7\u00f5es vasculares\n\nExistem dois tipos histol\u00f3gicos de calcifi ca\u00e7\u00f5es arteriais: calcifi ca\u00e7\u00f5es da \u00edntima e \ncalcifi ca\u00e7\u00f5es da camada m\u00e9dia. Estes dois tipos de calcifi ca\u00e7\u00f5es t\u00eam sido considerados como \nduas entidades distintas com diferente signifi cado cl\u00ednico e diferente progn\u00f3stico. A calcifi ca\u00e7\u00e3o \nda \u00edntima ocorre durante a evolu\u00e7\u00e3o da placa ateroscler\u00f3tica e relaciona -se com a dislipidemia. \nA calcifi ca\u00e7\u00e3o da m\u00e9dia est\u00e1 presente na arteriolosclerose e desenvolve -se sobretudo em \ndoentes renais cr\u00f3nicos, diab\u00e9ticos e em indiv\u00edduos idosos.\n\nFoi levantada a hip\u00f3tese de estes dois processos poderem corresponder a um fen\u00f3meno \ncont\u00ednuo da patologia vascular12 mas, nos doentes renais cr\u00f3nicos, a calcifi ca\u00e7\u00e3o da camada \nm\u00e9dia pode preceder o aparecimento de placas ateroscler\u00f3ticas e surge na aus\u00eancia de dep\u00f3sitos \nlip\u00eddicos, tendo esta hip\u00f3tese sido contestada13.\n\nAs manifesta\u00e7\u00f5es cl\u00ednicas da calcifi ca\u00e7\u00e3o da \u00edntima relacionam -se com a presen\u00e7a de placas \nateroscler\u00f3ticas que estenosam as art\u00e9rias devido a fen\u00f3menos de rotura da placa ou de trombose. \n\n\n\n11\n\nConsidera -se que a carga de c\u00e1lcio se relaciona com a carga ateroscler\u00f3tica e o score de c\u00e1lcio avaliado \npelo m\u00e9todo de Agatston \u00e9 usado como preditor do risco cardiovascular na popula\u00e7\u00e3o geral14.\n\nA calcifi ca\u00e7\u00e3o da m\u00e9dia n\u00e3o causa estenose arterial e, por esta raz\u00e3o, foi considerada no \npassado como um achado radiol\u00f3gico sem consequ\u00eancias cl\u00ednicas. Sabemos atualmente que \neste tipo de calcifi ca\u00e7\u00e3o modifi ca as propriedades da parede arterial e \u00e9 um dos fatores que \ncontribui para a rigidez arterial. A rigidez arterial provoca uma perda de distensibilidade \na\u00f3rtica. A onda de refl ex\u00e3o sangu\u00ednea habitual acontece mais precocemente devido \u00e0 perda \nde elasticidade da aorta e encontra a v\u00e1lvula a\u00f3rtica ainda aberta, contribuindo para o aumento \ndo volume do ventr\u00edculo esquerdo. A consequ\u00eancia \u00e9 o aumento da press\u00e3o sist\u00f3lica e uma \ndiminui\u00e7\u00e3o da press\u00e3o diast\u00f3lica que se manifestam clinicamente por hipertens\u00e3o sist\u00f3lica e \npor aumento de press\u00e3o de pulso15,16. O aumento da press\u00e3o sist\u00f3lica contribui para o \ndesenvolvimento de hipertrofi a ventricular esquerda. A diminui\u00e7\u00e3o da press\u00e3o diast\u00f3lica \ncompromete a perfus\u00e3o coron\u00e1ria que ocorre durante a di\u00e1stole17. Deste modo, a calcifi ca\u00e7\u00e3o \nda camada arterial m\u00e9dia pode associar -se a doen\u00e7a coron\u00e1ria sintom\u00e1tica, mesmo na aus\u00eancia \nde les\u00f5es esten\u00f3ticas das art\u00e9rias coron\u00e1rias. A compreens\u00e3o desta fi siopatologia \u00e9 fundamental \npara interpretar os resultados por vezes contradit\u00f3rios entre a coronariografi a e a avalia\u00e7\u00e3o \nquantitativa das calcifi ca\u00e7\u00f5es coron\u00e1rias nos doentes renais cr\u00f3nicos18.\n\nO diagn\u00f3stico diferencial entre calcifi ca\u00e7\u00e3o da \u00edntima e da m\u00e9dia \u00e9 feito atrav\u00e9s do exame \nhistol\u00f3gico. Letho et al19 propuseram uma metodologia simples, usando RX simples para avalia\u00e7\u00e3o \ndas calcifi ca\u00e7\u00f5es da camada m\u00e9dia em doentes diab\u00e9ticos, e este grupo foi o primeiro a demonstrar \nque estas calcifi ca\u00e7\u00f5es n\u00e3o estenosantes se associavam a maior morbilidade. London et al20 utilizaram \nesta mesma metodologia nos doentes renais cr\u00f3nicos e demonstraram que a calcifi ca\u00e7\u00e3o da m\u00e9dia \ne a calcifi ca\u00e7\u00e3o da \u00edntima eram preditores independentes de mortalidade nesta popula\u00e7\u00e3o.\n\nO score de Agatston, avaliado por tomografi a computorizada de feixe de eletr\u00f5es ou por \ntomografi a axial computorizada multicorte, n\u00e3o distingue a calcifi ca\u00e7\u00e3o da \u00edntima e da m\u00e9dia. \nEstes dois tipos de calcifi ca\u00e7\u00e3o podem estar presentes no mesmo doente e no mesmo vaso. \nO score de calcifi ca\u00e7\u00e3o vascular simples criado por n\u00f3s21 considera apenas a presen\u00e7a ou \naus\u00eancia de calcifi ca\u00e7\u00e3o vascular nos diferentes setores, sem distinguir estes dois tipos de \ncalcifi ca\u00e7\u00e3o. Esta metodologia simplifi ca a sua utiliza\u00e7\u00e3o pelo nefrologista, pois n\u00e3o \u00e9 \nnecess\u00e1ria a interpreta\u00e7\u00e3o por um radiologista.\n\nDesenvolvimento do score de calcifi ca\u00e7\u00e3o vascular simples\n\nApercebemo -nos cedo da elevada preval\u00eancia da doen\u00e7a arterial perif\u00e9rica nos doentes \nem di\u00e1lise e das suas consequ\u00eancias cl\u00ednicas dram\u00e1ticas: claudica\u00e7\u00e3o incapacitante, \u00falceras \n\n\n\n12\n\nisqu\u00e9micas e elevado n\u00famero de amputa\u00e7\u00f5es22. No estudo radiol\u00f3gico simples do esqueleto, \nque nessa altura era feito rotineiramente para avaliar as manifesta\u00e7\u00f5es \u00f3sseas do \nhiperparatiroidismo secund\u00e1rio dos doentes em di\u00e1lise, era frequente observar o que se \ndenominava \u201carteriografi as espont\u00e2neas\u201d e que resultavam da presen\u00e7a de calcifi ca\u00e7\u00f5es \nvasculares desenhando as paredes vasculares.\n\nA exist\u00eancia de uma aparente discord\u00e2ncia entre as manifesta\u00e7\u00f5es cl\u00ednicas de doen\u00e7a \narterial perif\u00e9rica e os dados laboratoriais do metabolismo mineral e \u00f3sseo nos doentes em \ndi\u00e1lise foram a raz\u00e3o e o incentivo para a cria\u00e7\u00e3o de um m\u00e9todo simples e acess\u00edvel para \navaliar as calcifi ca\u00e7\u00f5es vasculares nestes doentes.\n\nNo in\u00edcio da d\u00e9cada de 90, a exist\u00eancia de calcifi ca\u00e7\u00f5es vasculares e de partes moles \nobservada nos doentes em di\u00e1lise era habitualmente explicada como sendo devida ao \nhiperparatiroidismo secund\u00e1rio, provavelmente em rela\u00e7\u00e3o com o elevado produto fosfoc\u00e1lcico \ndestes doentes. No entanto, s\u00f3 em 2000 fi cou demonstrado, num modelo celular in vitro, usando \nc\u00e9lulas musculares lisas da aorta humana, que a hiperfosfatemia causava calcifi ca\u00e7\u00e3o por um \nmecanismo ativo de transcri\u00e7\u00e3o gen\u00e9tica6. S\u00f3 em 2004, no mesmo modelo, foi feita uma \ndemonstra\u00e7\u00e3o semelhante para a hipercalcemia23. A arteriolopatia ur\u00e9mica c\u00e1lcica, ou calcifi laxis, \numa entidade cl\u00ednica catastr\u00f3fi ca causada por calcifi ca\u00e7\u00f5es vasculares das arter\u00edolas subcut\u00e2neas \ne que origina extensas \u00e1reas de necrose cut\u00e2nea, era tamb\u00e9m classicamente atribu\u00edda ao \nhiperparatiroidismo secund\u00e1rio. Preconizava -se a paratiroidectomia de urg\u00eancia nestes doentes \npara reverter este quadro cl\u00ednico, muitas vezes fatal. Contudo, os n\u00edveis de paratormona (PTH) \ndestes doentes nem sempre eram elevados, contrariamente ao que estava descrito.\n\nA exist\u00eancia de valores baixos ou normais de PTH em doentes com extensas calcifi ca\u00e7\u00f5es \nvasculares e com manifesta\u00e7\u00f5es cl\u00ednicas de calcifi laxis ou de doen\u00e7a arterial perif\u00e9rica foram a \nbase para a cria\u00e7\u00e3o de um m\u00e9todo para avaliar as calcifi ca\u00e7\u00f5es vasculares e de partes moles e tentar \ncorrelacion\u00e1 -lo com as altera\u00e7\u00f5es do metabolismo mineral e \u00f3sseo dos doentes em di\u00e1lise.\n\nCom base nas calcifi ca\u00e7\u00f5es detetadas no RX simples do esqueleto, realizamos um primeiro \nestudo transversal em que relacionamos a presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares e de partes moles \ncom as altera\u00e7\u00f5es do metabolismo mineral e \u00f3sseo dos doentes em di\u00e1lise. Nesse estudo, as \ncalcifi ca\u00e7\u00f5es das partes moles foram pesquisadas na regi\u00e3o periarticular das articula\u00e7\u00f5es \nacromioclavicular e coxofemoral. As calcifi ca\u00e7\u00f5es vasculares foram avaliadas nas art\u00e9rias il\u00edacas \ne femorais. A hip\u00f3tese de avaliar as art\u00e9rias dos membros inferiores foi tamb\u00e9m considerada, \nmas, devido aos in\u00fameros casos de amputa\u00e7\u00f5es, consideramos que n\u00e3o seria um m\u00e9todo \ncomparativo fi \u00e1vel. Optamos ent\u00e3o por pesquisar as calcifi ca\u00e7\u00f5es vasculares noutro territ\u00f3rio \ncom art\u00e9rias distais, tendo por esta raz\u00e3o inclu\u00eddo a avalia\u00e7\u00e3o das art\u00e9rias das m\u00e3os.\n\nCom base nestes estudos radiol\u00f3gicos criamos um score de calcifi ca\u00e7\u00e3o global (vascular \ne partes moles) que resultava da presen\u00e7a de calcifi ca\u00e7\u00e3o em cada territ\u00f3rio avaliado. Neste \n\n\n\n13\n\nprimeiro estudo, apresentado no ano 2000 no Congresso da Sociedade Portuguesa de \nNefrologia24, foram estudados 183 doentes em di\u00e1lise, e neste grupo de doentes, em an\u00e1lise \nmultivariada, verifi camos uma correla\u00e7\u00e3o inversa entre o score de calcifi ca\u00e7\u00e3o e os n\u00edveis de \nPTH e de albumina e uma correla\u00e7\u00e3o positiva com os valores de press\u00e3o sist\u00f3lica e com o \ntempo de perman\u00eancia em di\u00e1lise. N\u00e3o encontramos correla\u00e7\u00e3o entre o score de calcifi ca\u00e7\u00e3o \ne os n\u00edveis de f\u00f3sforo ou c\u00e1lcio s\u00e9ricos, e estes resultados foram considerados discordantes \ndos conhecimentos prevalentes \u00e0 data.\n\nNo entanto, no ano seguinte (2001), Blacher demonstrou pela primeira vez uma associa\u00e7\u00e3o \nindependente entre as calcifi ca\u00e7\u00f5es vasculares e a mortalidade nos doentes em di\u00e1lise25. Neste \nestudo, as calcifi ca\u00e7\u00f5es vasculares tinham sido avaliadas por ecografi a na aorta e nas art\u00e9rias \ncar\u00f3tidas, il\u00edacas e femorais. Os autores n\u00e3o encontraram igualmente nenhuma correla\u00e7\u00e3o \nentre as calcifi ca\u00e7\u00f5es e os n\u00edveis s\u00e9ricos de c\u00e1lcio ou de f\u00f3sforo. Encontraram uma associa\u00e7\u00e3o \ndirecta com a mortalidade e, tal como n\u00f3s, uma rela\u00e7\u00e3o inversa com os n\u00edveis de albumina \ns\u00e9rica.\n\nNum estudo pr\u00e9vio deste mesmo grupo, Gu\u00e9rin et al tinham mostrado uma associa\u00e7\u00e3o \nindependente entre as calcifi ca\u00e7\u00f5es vasculares e a rigidez arterial nos doentes em di\u00e1lise26. \nNeste estudo, os valores de PTH apresentavam uma correla\u00e7\u00e3o inversa com as calcifi ca\u00e7\u00f5es \nvasculares e tamb\u00e9m n\u00e3o havia correla\u00e7\u00e3o entre as calcifi ca\u00e7\u00f5es e o produto fosfoc\u00e1lcico. \nEstes dois estudos foram a confi rma\u00e7\u00e3o da veracidade dos nossos resultados pr\u00e9vios.\n\nDecidimos ent\u00e3o avaliar prospetivamente a mortalidade associada \u00e0s calcifi ca\u00e7\u00f5es vasculares \navaliadas por RX simples e criamos, para este fi m, um m\u00e9todo semiquantitativo para avaliar \nas calcifi ca\u00e7\u00f5es vasculares nos mesmos territ\u00f3rios que t\u00ednhamos previamente analisado. O RX \nda bacia foi dividido por duas linhas imagin\u00e1rias em quatro setores: uma linha vertical sobre a \ncoluna vertebral e uma linha horizontal tangencial \u00e0 extremidade superior da cabe\u00e7a dos f\u00e9mures. \nO RX das m\u00e3os foi dividido em cada m\u00e3o por uma linha horizontal tangencial \u00e0 extremidade \nsuperior dos metacarpos. Ficaram assim defi nidos quatro setores no RX da bacia e quatro no \nRX das m\u00e3os (Fig 2.1). A presen\u00e7a de alguma calcifi ca\u00e7\u00e3o vascular em qualquer setor era \ncontada como 1 e a aus\u00eancia como 0. Os limites deste score de calcifi ca\u00e7\u00e3o eram 0 e 8.\n\nAvaliamos as calcifi ca\u00e7\u00f5es vasculares num grupo de 123 doentes em di\u00e1lise. Ap\u00f3s um \nseguimento de 37 meses, verifi camos que um score vascular superior a 3 se associava a maior \nmortalidade cardiovascular e que este score, em an\u00e1lise multivariada, se associava a maior \nrisco de morte cardiovascular, a internamentos cardiovasculares, a doen\u00e7a arterial perif\u00e9rica \ne a doen\u00e7a vascular em geral. Este trabalho foi publicado como artigo original na revista \nNephrology Dialysis and Transplantation em 2004 21.\n\nEstava assim definido um m\u00e9todo simples e econ\u00f3mico para avaliar as calcifica\u00e7\u00f5es \nvasculares e predizer o risco cardiovascular nos doentes em di\u00e1lise. Foi este m\u00e9todo que \n\n\n\n14\n\nconstituiu a base de um trabalho de investiga\u00e7\u00e3o cl\u00ednica que avaliou a exist\u00eancia de \ncorrela\u00e7\u00f5es entre as calcifica\u00e7\u00f5es vasculares e a doen\u00e7a vascular e \u00f3ssea nos doentes \nem di\u00e1lise.\n\nScore de calcifi ca\u00e7\u00e3o vascular simples (SCVS)\n\nFig. 2.1. Calcifi ca\u00e7\u00f5es vasculares no RX bacia (art\u00e9rias il\u00edacas e/ou suas colaterais e art\u00e9rias femorais) e \nno RX das m\u00e3os (art\u00e9rias radiais e digitais). O SCVS \u00e9 a soma da presen\u00e7a (1) ou aus\u00eancia (0) das \ncalcifi ca\u00e7\u00f5es vasculares em cada setor defi nido pelas linhas horizontais e verticais. Neste exemplo, o score \nda bacia = 1+1+1+1=4 e o score das m\u00e3os = 1+1+1+1=4. O score total \u00e9 o SCVS = 8.\n\nRefer\u00eancias\n\n  1. Block GA, Hulbert -Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium \nx phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J \nKidney Dis 1998; 31(4):607 -617.\n\n  2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, \nmortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15(8):2208-\n-2218.\n\n  3. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, \nAkiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk for dialysis patients with different \nlevels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study \n(DOPPS). Am J Kidney Dis 2008; Sep;52(3):519 -530. [Epub 2008 Jun 2.]\n\n  4. Kalantar -Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, et al. Survival predictability of time-\n-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: \n771 -780.\n\n\n\n15\n\n  5. Dhingra R, Sullivan LM, Fox CS, Wang TJ, et al. Relations of serum phosphorus and calcium \nlevels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167(9):879-\n-885.\n\n  6. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate \nregulation of vascular smooth muscle cell calcifi cation. Circ Res 2000; 87(7):E10 -17.\n\n  7. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004; 15:2959 -2964.\n  8. Ketteler M, Vermeer C, Wanner C et al. Novel insights into uremic vascular calcifi cation: role of \n\nmatrix Gla protein and alpha -2 -Heremans Schmid glycoprotein/fetuin. Blood Purif 2002;20(5):473-\n-476. [Review.]\n\n  9. Cranenburg EC, Vermeer C, Koos R et al. The circulating inactive form of matrix Gla Protein \n(ucMGP) as a biomarker for cardiovascular calcifi cation. J Vasc Res 2008;45(5):427 -36. [Epub \n2008 Apr 10.]\n\n10. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of \nrenal osteodystrophy: A position statement from kidney disease: Improving global outcomes \n(KDIGO). Kidney Int 2006; 69: 1945 -1953.\n\n11. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney Disease: Improving \nglobal outcomes (KDIGO). Kidney Int 2009; 76 Suppl.S113.\n\n12. McCullough PA, Agrawal V, Danielewicz E, et al. Accelerated atherosclerotic calcifi cation and \nMonckeberg\u2019s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. \nClin J Am Soc Nephrol 2008; 3: 1585 - 1598.\n\n13. Amann K. Media calcifi cation and intima calcifi cation are distinct entities in chronic kidney \ndisease. Clin J Am Soc Nephrol 2008; 3: 1599 -1605.\n\n14. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcifi cation: Patophysiology, epidemiology, \nimaging methods and clinical implications. A statement for health professionals from the American \nHeart Association. Circulation 1996; 94: 1175 -1192.\n\n15. London GM, Gu\u00e9rin A. Infl uence of arterial pulse and refl ective waves on systolic blood pressure \nand cardiac function. J Hypertens 1999; 17(Suppl 2):S3 -6. [Review.]\n\n16. London GM, Blacher J, Pannier B et al. Arterial wave refl ections and survival in end -stage renal \nfailure. Hypertension 2001; 38: 434 -438.\n\n17. Watanabe H, Ohtsuka S, Kakihana M, et al. Coronary circulation in dogs with an experimental \ndecrease in aortic compliance. J Am Coll Cardio 1993;21:1497 -1506.\n\n18. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcifi cation is related to coronary \natherosclerosis in chronic renal disease patients: a study comparing EBCT -generated coronary \nartery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19: 2307 -2312.\n\n19. Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of \ncardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb \nVasc Biol 1996; 16: 978 -983\n\n\n\n16\n\n20. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: \nimpact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731 -1740\n\n21. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. A simple vascular \ncalcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant \n2004; 19(6):1480 -1488. [Epub 2004 Mar 19.]\n\n22. O\u2019Hare A, Johansen K. Lower -extremity peripheral arterial disease among patients with end -stage \nrenal disease. J Am Soc Nephrol 2001; 12: 2838 -2847.\n\n23. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle \ncell matrix mineralization in vitro. Kidney Int 2004;66:2293 -2299.\n\n24. Pires A, Adrag\u00e3o T, Carilho P, Magalh\u00e3es L, Gon\u00e7alves M, Gusm\u00e3o L, Silva M, Andrade S, Negr\u00e3o \nAP, Boquinhas H. Calcifi ca\u00e7\u00f5es vasculares e das partes moles em doentes em hemodi\u00e1lise. Abstract. \nCPN 2000.\n\n25. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular \nrisk in end -stage renal disease. Hypertension 2001; 38:938 -942.\n\n26. Gu\u00e9rin AP, London GM, Marchais SJ, Metivier F Arterial stiffening and vascular calcifi cations \nin end -stage renal disease. Nephrol Dial Transplant 2000; 15(7):1014 -1021.\n\n\n\n17\n\nCAP\u00cdTULO 3\n\nCALCIFICA\u00c7\u00d5ES VASCULARES NOS DOENTES RENAIS CR\u00d3NICOS: \nPREVAL\u00caNCIA E ASSOCIA\u00c7\u00c3O COM MORTALIDADE E MORBILIDADE\n\nPreval\u00eancia de calcifi ca\u00e7\u00f5es vasculares em doentes em di\u00e1lise\n\nA preval\u00eancia de calcifi ca\u00e7\u00f5es vasculares \u00e9 elevada nos doentes renais cr\u00f3nicos, variando com \no est\u00e1dio da doen\u00e7a renal cr\u00f3nica e com o m\u00e9todo utilizado no seu diagn\u00f3stico. M\u00e9todos quantitativos, \ncomo a tomografi a axial computorizada helicoidal multicorte ou a tomografi a computorizada de \nfeixe de eletr\u00f5es, mostraram que nos doentes prevalentes em di\u00e1lise as calcifi ca\u00e7\u00f5es coron\u00e1rias \nest\u00e3o presentes em cerca de 80% dos casos1,2. Utilizando m\u00e9todos menos sens\u00edveis, como a \necografi a, Blacher et al diagnosticaram calcifi ca\u00e7\u00f5es vasculares em 66% de um grupo de 110 \ndoentes em di\u00e1lise3. Em quatro estudos analisando diferentes popula\u00e7\u00f5es de doentes e utilizando \no score de calcifi ca\u00e7\u00e3o vascular simples avaliado no RX simples da bacia e das m\u00e3os, verifi camos \na presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares em 75% de 123 doentes4, em 76% de 101 doentes5, em \n70% de 219 doentes6 em hemodi\u00e1lise e em 61% de 70 doentes em di\u00e1lise peritoneal7.\n\nPara avalia\u00e7\u00e3o da preval\u00eancia das calcifi ca\u00e7\u00f5es vasculares nos doentes renais cr\u00f3nicos, \nas KDIGO 20098 selecionaram 22 estudos publicados entre 2003 e 2009, entre os quais foi \ntamb\u00e9m inclu\u00eddo o nosso estudo, publicado em 2004, no qual defi nimos o score de calcifi ca\u00e7\u00e3o \nvascular simples4 (KDIGO 2009: Tabela suplementar 10; Fig. 3.6). Para avalia\u00e7\u00e3o da associa\u00e7\u00e3o \nentre calcifi ca\u00e7\u00f5es e mortalidade, as KDIGO 2009 selecionaram apenas 12 estudos publicados \nentre 2001 e 2009, nos quais foram tamb\u00e9m inclu\u00eddos o nosso primeiro estudo4, que mostrou \numa associa\u00e7\u00e3o entre o score de calcifi ca\u00e7\u00e3o vascular simples e mortalidade, e um segundo \nestudo, publicado em 20095, mostrando que o score vascular simples \u00e9 preditor de rigidez \narterial (KDIGO 2009: Tabela suplementar 12).\n\nA inclus\u00e3o de estudos observacionais nas presentes recomenda\u00e7\u00f5es KDIGO 20098 baseou-\n-se em conceitos defi nidos pelo sistema GRADE9 (Grades of recommendation, assessment, \ndevelopment, and evaluation). O sistema GRADE considera que os estudos observacionais \npodem ter elevada qualidade de evid\u00eancia se avaliarem par\u00e2metros de seguran\u00e7a e de efi c\u00e1cia \nimportantes, se mostrarem uma associa\u00e7\u00e3o forte com estes par\u00e2metros e se a metodologia \nutilizada for de elevada qualidade. A inclus\u00e3o dos nossos estudos nas refer\u00eancias das KDIGO \n2009, em que foi utilizado um m\u00e9todo de selec\u00e7\u00e3o muito exigente, valida o interesse cient\u00edfi co \ndo nosso trabalho.\n\n\n\n18\n\nAssocia\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e mortalidade nos doentes em di\u00e1lise\n\nA mortalidade cardiovascular nos doentes renais cr\u00f3nicos \u00e9 superior \u00e0 da popula\u00e7\u00e3o geral, \nquer nos doentes em di\u00e1lise, quer nos doentes em est\u00e1dios pr\u00e9 -di\u00e1lise10,11. Os fatores de risco \ntradicionais n\u00e3o explicam integralmente este elevado risco cardiovascular12, e considera -se \nque in\u00fameros fatores de risco n\u00e3o tradicionais possam contribuir para este resultado.\n\nNos \u00faltimos anos, um novo fator foi acrescentado \u00e0 j\u00e1 extensa lista de fatores de risco \ncardiovascular dos doentes renais cr\u00f3nicos. Demonstrou -se que nestes doentes as calcifi ca\u00e7\u00f5es \nvasculares apresentam uma associa\u00e7\u00e3o consistente com a mortalidade. Blacher et al3, em \n2001, foram os primeiros a demonstrar esta associa\u00e7\u00e3o. O m\u00e9todo que utilizaram para \ndiagnosticar as calcifi ca\u00e7\u00f5es vasculares foi a ecografi a de grandes vasos: aorta, car\u00f3tidas, \nart\u00e9rias il\u00edacas e femorais. Em 110 doentes, com um seguimento de 80 meses, estes autores \ndemonstraram que, quanto maior o n\u00famero de vasos afetados, menor a sobrevida dos doentes. \nLondon et al13, em 2003, demonstraram que calcifi ca\u00e7\u00f5es vasculares avaliadas por RX simples \neram preditoras de mortalidade. Neste estudo de London, as calcifi ca\u00e7\u00f5es foram avaliadas em \n202 doentes em di\u00e1lise, nas art\u00e9rias il\u00edacas e femorais visualizadas num RX simples do \nabd\u00f3men. Utilizando uma metodologia previamente descrita por Letho em doentes diab\u00e9ticos14, \nestes autores distinguiram calcifi ca\u00e7\u00e3o da \u00edntima e calcifi ca\u00e7\u00e3o da m\u00e9dia e verifi caram que, \ndurante um seguimento de 80 meses, estes dois tipos de calcifi ca\u00e7\u00e3o foram preditores \nindependentes de mortalidade global e cardiovascular nos doentes em di\u00e1lise. Alguns meses \nap\u00f3s esta publica\u00e7\u00e3o, publicamos o nosso estudo, que utilizou um score de calcifi ca\u00e7\u00e3o vascular \navaliado em RX simples da bacia e das m\u00e3os4. Verifi camos que em 123 doentes prevalentes \nem di\u00e1lise, durante um seguimento de 37 meses, um score de calcifi ca\u00e7\u00e3o superior ou igual \na 3 se associou a 14 mortes cardiovasculares, enquanto nos doentes com um score de calcifi ca\u00e7\u00e3o \ninferior a 3 se verifi caram apenas tr\u00eas mortes (Fig. 3.1). Esta associa\u00e7\u00e3o foi confi rmada em \nan\u00e1lise multivariada, ajustando para idade, sexo, tempo em hemodi\u00e1lise, diabetes, produto \nfosfoc\u00e1lcico, n\u00edveis s\u00e9ricos de PTH e albumina. Um score de calcifi ca\u00e7\u00e3o vascular simples \nsuperior ou igual a 3 associou -se a um risco 3,9 vezes superior de morte cardiovascular, quando \ncomparado com um score inferior a 3 (HR=3,9; IC 95% 1,1 a 13,4, p=0,03) (Fig. 3.2).\n\nNoutra popula\u00e7\u00e3o de 101 doentes em di\u00e1lise, em que analisamos a associa\u00e7\u00e3o entre \ncalcifi ca\u00e7\u00f5es vasculares e rigidez arterial avaliada por velocidade de onda de pulso e pela \npress\u00e3o de pulso, verifi camos que um score de calcifi ca\u00e7\u00e3o superior a 3 foi preditor de \nmortalidade de causa global 5. Em an\u00e1lise multivariada e ajustando para a idade, a dura\u00e7\u00e3o \nda hemodi\u00e1lise, a diabetes, a doen\u00e7a vascular pr\u00e9via, o \u00edndice de massa corporal, a press\u00e3o \nsist\u00f3lica, as doses de calcitriol e o carbonato de c\u00e1lcio, os doentes com score de calcifi ca\u00e7\u00e3o \nvascular superior a 3 apresentaram um risco de morte 3,3 superior, quando comparados com \n\n\n\n19\n\nos doentes com score inferior ou igual a 3 (HR=3,3; IC 95% 1,1 a 9,8, p=0,03). Outros estudos, \nutilizando diferentes metodologias, confi rmaram esta associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares \ne mortalidade2,15,16.\n\nFig. 3.1. O score de calcifi ca\u00e7\u00e3o vascular simples, SCVS ? 3, associou -se a uma maior mortalidade cardiovascular\n\nFig. 3.2. Risco cardiovascular em rela\u00e7\u00e3o com o score de calcifi ca\u00e7\u00e3o vascular simples, SCVS?3, sendo a \nrefer\u00eancia o SCVS&lt;3. O risco foi calculado por odds ratio com regress\u00e3o log\u00edstica (doen\u00e7a arterial perif\u00e9rica \ne doen\u00e7a coron\u00e1ria) e por hazard ratio com regress\u00e3o COX (internamentos cardiovasculares e morte \ncardiovascular)\n\n\n\n20\n\nAssocia\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e morbilidade nos doentes \nem di\u00e1lise\n\nNeste primeiro estudo, publicado em 20044, demonstr\u00e1mos tamb\u00e9m que o score de \ncalcifi ca\u00e7\u00e3o vascular simples foi um preditor independente de morbilidade cardiovascular \navaliada pelos internamentos cardiovasculares e pela presen\u00e7a de doen\u00e7a coron\u00e1ria, doen\u00e7a \narterial perif\u00e9rica e doen\u00e7a vascular em geral (Fig. 3.2). As doen\u00e7as coron\u00e1ria, arterial \nperif\u00e9rica e cerebrovascular foram defi nidas por crit\u00e9rios cl\u00ednicos. Diagnosticamos doen\u00e7a \ncoron\u00e1ria nos doentes com sintomas inequ\u00edvocos de angina de peito ou com uma prova \nde esfor\u00e7o ou ecografi a de stress positivos ou que tivessem tido um enfarte do mioc\u00e1rdio \nou sido submetidos a angioplastia coron\u00e1ria ou cirurgia de revasculariza\u00e7\u00e3o coron\u00e1ria. \nConsideramos a exist\u00eancia de doen\u00e7a arterial perif\u00e9rica nos doentes com hist\u00f3ria de \nclaudica\u00e7\u00e3o intermitente ou \u00falceras isqu\u00e9micas ou com diagn\u00f3stico de obstru\u00e7\u00e3o arterial \npor doppler ou angiografi a ou que tivessem sido submetidos a revasculariza\u00e7\u00e3o arterial \nou a amputa\u00e7\u00f5es distais dos membros inferiores. Consideramos a exist\u00eancia de doen\u00e7a \ncerebrovascular nos doentes com o diagn\u00f3stico de acidente vascular cerebral ou acidente \nisqu\u00e9mico transit\u00f3rio ou com evid\u00eancia de um enfarte na tomografi a axial computorizada \ncranioencef\u00e1lica. No fi nal do estudo, 43 doentes (35%) tinham o diagn\u00f3stico de doen\u00e7a \ncoron\u00e1ria, 33 (27%) o diagn\u00f3stico de doen\u00e7a arterial perif\u00e9rica, 16 (13%) o diagn\u00f3stico \nde doen\u00e7a cerebrovascular e 61 doentes (50%) tinham pelo menos um destes tr\u00eas tipos de \ndoen\u00e7a vascular.\n\nEm an\u00e1lise multivariada e ajustando para idade, sexo, tempo em hemodi\u00e1lise, diabetes, \nproduto fosfoc\u00e1lcico, n\u00edveis s\u00e9ricos de PTH e albumina, um score superior ou igual a 3 \nassociou -se a um risco aumentado de internamentos cardiovasculares (HR=4,4; IC 95% \n2,1 a 10,2, p=0,02), de doen\u00e7a arterial perif\u00e9rica (OR=10,4; IC 95% 2,7 a 40,3), de doen\u00e7a \ncoron\u00e1ria (OR=3,2; IC 95% 1,4 a 7,4) e de doen\u00e7a vascular em geral (OR=4,3; C 95% 1,9 \na 9,9) (Fig. 3.2).\n\nCalcifi ca\u00e7\u00f5es vasculares e doen\u00e7a arterial perif\u00e9rica\n\nDesde logo, na primeira avalia\u00e7\u00e3o do score de calcifi ca\u00e7\u00e3o vascular simples, detectamos \nque este score se relacionou fortemente com a doen\u00e7a arterial perif\u00e9rica4. Os doentes com \num score superior ou igual a 3 apresentaram um risco 10,4 vezes aumentado de associa\u00e7\u00e3o \na doen\u00e7a arterial perif\u00e9rica sintom\u00e1tica (Fig. 3.2). Neste primeiro estudo, a doen\u00e7a arterial \nperif\u00e9rica foi diagnosticada com base em crit\u00e9rios cl\u00ednicos. Nos doentes em di\u00e1lise, a doen\u00e7a \n\n\n\n21\n\narterial perif\u00e9rica \u00e9 frequentemente de diagn\u00f3stico tardio, porque a neuropatia perif\u00e9rica \nmascara os sintomas de claudica\u00e7\u00e3o intermitente e as art\u00e9rias r\u00edgidas distais continuam a \napresentar pulso palp\u00e1vel. Um m\u00e9todo simples e n\u00e3o invasivo de avaliar a doen\u00e7a arterial \nperif\u00e9rica \u00e9 atrav\u00e9s do \u00edndice tornozelo -bra\u00e7o. Nos doentes em di\u00e1lise existe at\u00e9 ao momento \napenas um estudo que demonstrou associa\u00e7\u00e3o entre mortalidade e este \u00edndice17, verifi cando-\n-se maior mortalidade nos doentes com um \u00edndice inferior a 0,9 ou superior a 1,3. Um \u00edndice \nsuperior a 1,3 \u00e9 considerado um falso negativo no diagn\u00f3stico de doen\u00e7a arterial obliterativa \ne resulta de art\u00e9rias r\u00edgidas e n\u00e3o compress\u00edveis, provavelmente devido \u00e0 presen\u00e7a de \ncalcifi ca\u00e7\u00f5es vasculares.\n\nIniciamos em 2008 um estudo com o objetivo de analisar a correla\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es \nvasculares avaliadas por RX simples e o \u00edndice tornozelo -bra\u00e7o (ITB) avaliado por doppler. \nOs resultados preliminares deste estudo foram apresentados sob a forma de poster no \nEDTA Congress of Nephrology 20106. Neste estudo analisamos 219 doentes em hemodi\u00e1lise. \nAs calcifi ca\u00e7\u00f5es vasculares foram avaliadas por RX simples usando dois m\u00e9todos diferentes: \no score de calcifi ca\u00e7\u00e3o vascular simples no RX simples da bacia e das m\u00e3os e o score de \ncalcifi ca\u00e7\u00e3o a\u00f3rtico avaliado no RX simples de perfi l da aorta abdominal, de L1 a L4, \ndescrito por Kauppila L18. Em an\u00e1lise multivariada e ajustando para a idade, o sexo, a \ndura\u00e7\u00e3o de hemodi\u00e1lise, a diabetes, os h\u00e1bitos tab\u00e1gicos, a press\u00e3o de pulso e os n\u00edveis \ns\u00e9ricos de albumina verifi camos um associa\u00e7\u00e3o independente entre as calcifi ca\u00e7\u00f5es \nvasculares das grandes art\u00e9rias (aorta, il\u00edacas e femorais) e um ITB&lt;0,9 e entre as \ncalcifi ca\u00e7\u00f5es vasculares de art\u00e9rias colaterais da bacia e perif\u00e9ricas das m\u00e3os com um ITB \n>1,3 (Fig. 3.3).\n\nNeste grupo de doentes, um ITB&lt;0,9 e um ITB >1,3 associaram -se a um aumento \nde risco de morte ajustando para idade, dura\u00e7\u00e3o da hemodi\u00e1lise, diabetes e n\u00edveis de \nalbumina s\u00e9rica. O tipo de calcifica\u00e7\u00f5es nas grandes art\u00e9rias \u00e9 irregular e corresponde a \ncalcifica\u00e7\u00f5es da \u00edntima13, \u00e0s quais se podem associar ou n\u00e3o calcifica\u00e7\u00f5es da m\u00e9dia. O \ntipo radiol\u00f3gico das calcifica\u00e7\u00f5es nas art\u00e9rias colaterais e perif\u00e9ricas \u00e9 linear e cont\u00ednuo, \no que, segundo Letho14 e London13, corresponde a calcifica\u00e7\u00e3o da camada m\u00e9dia da \nparede arterial. A associa\u00e7\u00e3o das calcifica\u00e7\u00f5es de grandes vasos com um ITB &lt;0,9 sugere \numa contribui\u00e7\u00e3o da aterosclerose na doen\u00e7a arterial obliterativa. A associa\u00e7\u00e3o das \ncalcifica\u00e7\u00f5es das art\u00e9rias colaterais e perif\u00e9ricas com um ITB >1,3 sugere que este tipo \nde calcifica\u00e7\u00f5es da camada m\u00e9dia arterial pode contribuir para a rigidez das art\u00e9rias \ndistais, que se tornam n\u00e3o compress\u00edveis, raz\u00e3o pela qual apresentam um aumento do \n\u00edndice tornozelo -bra\u00e7o.\n\n\n\n22\n\nOR, odds ratio; ITB, \u00edndice tornozelo -bra\u00e7o; SCAA, score de calcifi ca\u00e7\u00e3o na aorta abdominal; SCVS, score \nde calcifi ca\u00e7\u00e3o vascular simples; M+P, calcifi ca\u00e7\u00f5es vasculares m\u00e3os ou p\u00e9lvis.\n\nFig. 3.3. Risco de ITB&lt;0,9 associou -se a calcifi ca\u00e7\u00f5es vasculares nos grandes vasos. Risco de ITB > 1,3 \nassociou -se a calcifi ca\u00e7\u00f5es vasculares nos vasos colaterais ou distais (regress\u00e3o log\u00edstica).\n\nEste estudo permitiu ainda a compara\u00e7\u00e3o entre o score vascular simples de calcifi ca\u00e7\u00e3o \ne o score de calcifi ca\u00e7\u00e3o da aorta abdominal (SCAA). Esta compara\u00e7\u00e3o \u00e9 atualmente importante, \npois a avalia\u00e7\u00e3o da calcifi ca\u00e7\u00e3o na aorta abdominal por RX simples \u00e9 o m\u00e9todo sugerido pelas \nguidelines KDIGO 2009 para a avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es vasculares como alternativa \nrazo\u00e1vel \u00e0 tomografi a computorizada. Verifi camos que valores mais elevados do score vascular \nsimples se associam a valores mais elevados do SCAA (Fig. 3.4) e, em an\u00e1lise de curvas \nROC, o score vascular simples de calcifi ca\u00e7\u00e3o superior a 3 apresentou uma alta sensibilidade \n(73%) e especifi cidade (86%) para detetar um SCAA > 6 (Fig. 3.5).\n\nNoutro estudo, ainda n\u00e3o publicado, avaliamos os padr\u00f5es histol\u00f3gicos da doen\u00e7a \narterial perif\u00e9rica distal em 56 doentes submetidos a amputa\u00e7\u00f5es distais. Trinta e nove \ndestes doentes faziam di\u00e1lise, 10 eram diab\u00e9ticos n\u00e3o em di\u00e1lise e 7 n\u00e3o tinham nem \ndiabetes mellitus nem doen\u00e7a renal cr\u00f3nica. Em an\u00e1lises histol\u00f3gicas em 65 amostras de \nmaterial de amputa\u00e7\u00e3o verifi camos a presen\u00e7a de placas ateroscler\u00f3ticas classe II/III em \n24 (38%), de calcifi ca\u00e7\u00f5es vasculares da camada m\u00e9dia em 31 (48%), e n\u00e3o encontramos \nevid\u00eancia de calcifi ca\u00e7\u00e3o da \u00edntima. As calcifi ca\u00e7\u00f5es vasculares associaram -se a placas \nateroscler\u00f3ticas em 50% dos casos. As calcifi ca\u00e7\u00f5es da m\u00e9dia, as placas ateroscler\u00f3ticas \nou ambas apresentaram uma distribui\u00e7\u00e3o semelhante nas diferentes entidades cl\u00ednicas. \nEstes dados confi rmam a associa\u00e7\u00e3o de calcifi ca\u00e7\u00f5es da camada m\u00e9dia \u00e0 doen\u00e7a arterial \ncr\u00f3nica distal19,20.\n\n\n\n23\n\nNestes dois estudos, ainda n\u00e3o publicados, quer com avalia\u00e7\u00e3o cl\u00ednica quer histol\u00f3gica \nda doen\u00e7a arterial perif\u00e9rica, constatamos que as calcifi ca\u00e7\u00f5es vasculares se associam a esta \npatologia. No caso particular dos doentes renais cr\u00f3nicos, em que as altera\u00e7\u00f5es do metabolismo \nmineral e \u00f3sseo se associam ao desenvolvimento e \u00e0 progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares, \nsurge a possibilidade de um novo campo de interven\u00e7\u00e3o terap\u00eautica na doen\u00e7a arterial perif\u00e9rica \ndiferente do da popula\u00e7\u00e3o geral. \u00c9 necess\u00e1rio avaliar se o manejo das altera\u00e7\u00f5es do metabolismo \nmineral e \u00f3sseo pode ter um papel na evolu\u00e7\u00e3o e no progn\u00f3stico da doen\u00e7a arterial perif\u00e9rica \nnos doentes renais cr\u00f3nicos.\n\nFig. 3.4. Valores mais elevados de score de \ncalcifi ca\u00e7\u00e3o vascular simples SCVS associam -se a \nvalores mais elevados de score de calcifi ca\u00e7\u00e3o na \naorta abdominal SCAA (Kruskal -Wallis)\n\nFig. 3.5. Um SCVS>3 teve uma sensibilidade de 73% \ne uma especificidade de 86% de diagnosticar um \nSCAA>6 (an\u00e1lise de curvas ROC)\n\nEm conclus\u00e3o, nestes diferentes estudos4,5,7,19,20 demonstramos que o score de calcifi ca\u00e7\u00e3o \nvascular simples \u00e9 um m\u00e9todo acess\u00edvel e barato que permite identifi car o risco cardiovascular \nnos doentes em di\u00e1lise. A simplicidade e baixo custo deste score tornam a sua utiliza\u00e7\u00e3o \npass\u00edvel de ser aplicada em larga escala, fornecendo dados muito importantes para o \nacompanhamento dos doentes insufi cientes renais.\n\n\n\n24\n\nSupplemental table 10. Overview Table of selected studies presenting data on calcifi cation prevalence\n\nAuthor, Year\nStudy Design\n\nCountry\n\nN\nPopulation\n\nRepresentative\nTest (s)\n\nPrevalence of \nCalcifi cation\n\nHernandez, 200559\nChart Review\nSpain\n\n1117\nCKD 5D, At transplant\n\nPlain X-ray of abdomen \nand pelvis\n\n24.4%\n\nHonkanen, 200860\nCross-sectional\nBelgium, Netherlands, \nSweden, Denmark, Finland, \nNorway\n\n933\nCKD 5D on HD/PD\n\nAbdominal aorta \ncalcifi cation by lumbar \n(L1-L4) radiographs\n\n81%\n\nIx, 200761\nCross-sectional\nUSA\n\n653\nCKD 3-5\n\nValvular calcifi cation \nby MSCT/EBCT\n\n20/25%\n\nOkuno, 200762\nProspective\nJapan\n\n515\nCKD 5D, HD\n\nPlain X-ray 56.5%\n\nAdeney, 200863\nRetrospective\nUS\n\n439\nCKD Stage 3-5\n\nCAC and valvular \ncalcifi cations by EBCT \nor multi-detector CT\n\n67% coronary\n49% aortic\n20% mitral valve\n25% aortic valve\n\nPanuccio, 200464\nProspective\nItaly\n\n202\nCKD 5D, HD\n\nValvular calcifi cation \nby echocardiography\n\n23.3%\n\nLondon, 200365\nProspective\nFrance\n\n202\nCKD 5D, HD\n\nCalcifi cation score by \nultrasound and \nconventional X-ray\n\n63.9%\n\nWang, 200366\nProspective\nHong Kong\n\n193\nCKD 5D, PD\n\nValvular calcifi cation \nby echocardiography\n\n32.3%\n\nRodriguez-Garcia, 200949\nProspective\nSpain\n\n193\nCKD 5D, HD\n\nVascular calcifi cations \nby thoracic, lumbar \nspine, pelvic and hand \nX-rays\n\n79%\n\nJean, 200967\nProspective\nFrance\n\n161\nCKD 5D on HD\n\nVascular calcifi cation \nby plain radiograph\n\n83%\n\nKronenberg, 200368\nProspective\nAustria\n\n155\nCKD 5D on Incident \nHD and PD\n\nConventional X-ray of \npelvis and calves\n\n67%\n\nSharma, 200769\nProspective\nUK\n\n140\nCKD 4-5D, Predialysis, \nHD and PD on \ntransplant waiting list\n\nValvular calcifi cation \nby echocardiography\n\n40%\n\nVarma, 200570\nChart review\nUSA\n\n137\nCKD 5D, HD\n\nValvular calcifi cation \nby echocardiography\n\n47%\n\n(Continua)\n\n\n\n25\n\nAuthor, Year\nStudy Design\n\nCountry\n\nN\nPopulation\n\nRepresentative\nTest (s)\n\nPrevalence of \nCalcifi cation\n\nSigrist, 200652\nSigrist, 200771\nProspective\nUK\n\n134\nCKD 4, 5D on HD/PD\n\nArterial calcifi cation by \nMSCT\n\nCKD 4: 47%\nPD: 71%\nHD 73% + higher \nscores\n\nAdrag\u00e3o, 200472\nProspective\nPortugal\n\n123\nCKD 5D, HD\n\nCalcifi cation score by \nconventional X-ray\n\n61% iliac\n60% femoral\n36% radial\n5% digital\n\nGarland, 200873\nCross-sectional\nCanada\n\n119\nCKD 3-5\n\nCAC by MSCT 83.2%\n\nBlacher, 200174\nProspective\nFrance\n\n110\nCKD 5D, HD\n\nCalcifi cation score by \nultrasound and \nconventional X-ray\n\n66.4%\n\nMatsuoka, 200475\nProspective\nJapan\n\n104\nCKD 5D, HD\n\nCAC by EBCT 81.7%\n\nRusso, 200776\nProspective\nItaly\n\n90\nCKD Stage 3-5\n\nCAC by MSCT 83%\n\nShroff, 200755\nRetrospective\nUSA\n\n85\nChildren aged 5-18 y\nCKD 5D\n\nCAC by MSCT 20%\n\nChertow, 200277\nRaggi 200478\nRCT\nUSA, Germany, Austria\n\n70\nCKD Stage 5D on HD\n\nCAC by EBCT\nValvular calcifi cation \nby EBCT\n\n83% coronary\n80% aortic\n46% mitral valve\n33% aortic valve\n\nStompor, 200656\nProspective\nPoland\n\n61\nCKD 5D on PD\n\nTotal CAC by MSCT >51% (51% w/ a CAC \nscore of&lt;10, median 0)\n\nRusso, 200779\nProspective\nItaly\n\n53\nCKD Stage 3-5\n\nCAC by MSCT 51%\n\nBlock, 200580\nRCT\nUSA\n\n53\nCKD 5D on Incident \nHD\n\nCAC by EBCT 63%/69%\n\nNitta, 200458\nProspective\nJapan\n\n53\nCKD 5D on HD\n\nCAC by MSCT 92.5%\n\nCAC, coronary artery calcifi cation; CKD, chronic kidney disease; CT, computed tomography; EBCT, electron-\nbeam CT; HD, hemodialysis; MSCT, multislice spiral computed tomography; N, number of subjects; PD, \nperitoneal dialysis; RCT, randomized controlled trial.\n\nFig. 3.6. KDIGO Guidelines 2009: Tabela suplementar 10\n\n(Supplemental table 10. \u2013 Continua\u00e7\u00e3o)\n\n\n\n26\n\nSupplemental table 12. Overview table of selected studies demonstrating the risk relationship \nbetween vascular calcifi cation and mortality in CKD\n\nStudy Design\nCountry\n\nN\nPopulation\nFollow-up\n\nVascular Calcifi cation Mortality\nCategorizationTechnique Categorization\n\nHernandez, 200559\nChart Review\nSpain\n\n1117\nAt transplant\nMedian 49 mo\n\nPlain X-ray of \nabdomen and \npelvis\n\n\u2013  Vascular \ncalcifi cation\n\n\u2013 None\n\n\u2013 All cause\n\u2013 Cardiovascular\n\nOkuno, 200762\nProspective\nJapan\n\n515\nHD\n51 mo\n\nPlain \u2013  Abdominal aortic \ncalcifi cation\n\n\u2013 None\n\n\u2013 All cause\n\u2013 Cardiovascular\n\nLondon, 200365\nProspective\nFrance\n\n202\nHD\nUp to ~100 mo\n\nB-mode US \u2013 Arterial medial\n\u2013 Arterial intimal\n\u2013 None\n\n\u2013 All cause\n\u2013 Cardiovascular\n\nRodriguez-Garcia, 200949\nProspective\nSpain\n\n193\nHD\n24 mo\n\nX-ray of thoracic, \nlumbar spine, \npelvis and hands\n\n\u2013  Vascular \ncalcifi cations\n\n\u2013  Abdominal aortic \ncalcifi cations\n\n\u2013 All-cause\n\nBlock, 200783\nRCT\nUSA\n\n127\nHD\nMedian 44 mo\n\nEBCT CAC score 0, \n1-400, >400\n\n\u2013 All cause\n\nAdrag\u00e3o, 200484\nProspective\nPortugal\n\n123\nHD\n37 mo\n\nPlain X-ray of \npelvis and hands\n\nVascular \ncalcifi cation score \n<or ? 3\n\n\u2013 Cardiovascular\n\nBlacher, 200174\nProspective\nFrance\n\n110\nHD\n53 mo\n\nUS Arterial calcifi cation \nscore 0-4\n\n\u2013 All cause\n\u2013 Cardiovascular\n\nMatsuoka, 200475\nProspective\nJapan\n\n104\nHD\n44 mo\n\nEBCT CAC score\n<or ? 200\n\n\u2013 Cardiac\n\u2013 Stroke\n\u2013 Infection\n\u2013 Other\n\nAdrag\u00e3o, 200972\nProspective\nPortugal\n\n101\nHD\n43 mo\n\nPlain X-ray of \npelvis and hands\n\nVascular \ncalcifi cation score &lt;\nor ?3\n\n\u2013 All-cause\n\nKushiya, 200585\nProspective\nJapan\n\n84\nHD\n24 mo\n\nCT ACI > or&lt;0.3 \u2013 All cause\n\nACI, aortic calcifi cation index; AVC, aortic valve calcifi cation; CAC, coronary artery calcifi cation; CKD, chronic \nkidney disease; CT, computed tomography; EBCT, electron-beam CT; HD, hemodialysis; N, number of subjects; \nPD, peritoneal dialysis; RCT, randomized controlled trial; US, ultrasound.\n\nFig. 3.7. KDIGO Guidelines 2009: Tabela suplementar 12\n\nRefer\u00eancia: KDIGO, Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global outcomes \n(KDIGO). Kidney Int 2009; 76 (Suppl): S113. [Supplementary tables.] \n\n\n\n27\n\nRefer\u00eancias\n\n  1. Chertow GM, Burke SK, Raggi P Sevelamer attenuates the progression of coronary and aortic \ncalcifi cation in hemodialysis patients.Treat to Goal Working Group. Kidney Int 2002;62(1):245-\n-252.\n\n  2. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcifi cation score \n(CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8(1):54 -58.\n\n  3. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular \nrisk in end -stage renal disease. Hypertension 2001;38:938 -942\n\n  4. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. A simple vascular \ncalcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant \n2004;19(6):1480 -1488.\n\n  5. Adrag\u00e3o T, Pires A, Birne R, Curto JD, Lucas C, Gon\u00e7alves M, Negr\u00e3o AP A plain X -ray vascular \ncalcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol \nDial Transplant 2009;24(3):997 -1002.\n\n  6. Adrag\u00e3o T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Bordalo J, Prata MM. Ankle \nbrachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3 \n(Suppl 3): 492. [Abstract Su545.]\n\n  7. Adrag\u00e3o T, Branco P, Birne R, Curto JD, de Almeida E, Prata MM, Pais MJ. Bone mineral density, \nvascular calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; \n28(6):668 -672.\n\n  8. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global \noutcomes (KDIGO). Kidney Int 2009; 76 (Suppl): S113.\n\n  9. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. \nGRADE Working Group. BMJ 2004;19;328(7454):1490.\n\n10. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic \nrenal disease. Am J Kidney Dis 1998; 32 (5) (Suppl3): S112\u2013S119.\n\n11. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular \nevents, and hospitalization. N Engl J Med 2004; 23;351(13):1296 -1305.\n\n12. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic \nhemodialysis patients. Kidney Int 2000; 58(1):353 -362\n\n13. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: \nimpact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-\n-1740.\n\n14.  Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of \ncardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb \nVasc Biol 1996; 16: 978 -983.\n\n\n\n28\n\n15. Okuno S, Ishimura E, Kitatani K, et al. Presence of abdominal aortic calcifi cation is signifi cantly \nassociated with all -cause and cardiovascular mortality in maintenance hemodialysis patients. Am \nJ Kidney Dis 2007;49 (3):417 -425.\n\n16. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcifi cation and binder choice \nin incident hemodialysis patients. Kidney Int 2007;71:438 -441.\n\n17. Ono K, Tsuchida A, Kawai H, et al. Ankle -brachial blood pressure index predicts all -cause and \ncardiovascular mortality in hemodialysis patients. J Am Soc Nephro 2003;14(6):1591 -1598.\n\n18. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression \nof calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245-\n-250.\n\n19. Adrag\u00e3o T, Gouveia R, Birne R, et al. Histological vascular patterns in lower limb amputations \nin distal artery disease. JASN 2005; 16: 474. [Abstract (PO639).]\n\n20. Adrag\u00e3o T. Vascular calcifi cation, cardiovascular risk and arterial stiffness in hemodialysis patients. \nRev Port Nefrol Hipert 2005; 19 (Suppl 1): 51 -56.\n\n\n\n29\n\nNephrol Dial Transplant (2004) 19: 1480\u20131488\n\nDOI: 10.1093/ndt/gfh217\n\nAdvance Access publication 19 March 2004\n\nOriginal Article\n\nA simple vascular calcification score predicts cardiovascular risk in\n\nhaemodialysis patients\n\nTeresa Adragao, Ana Pires, Carlos Lucas, Rita Birne, Lu??s Magalhaes, Margarida Gonc?alves and\nAca?cio Pita Negrao\n\nNefroclinica-Estoril, Rua Vale de S Rita, 19, 2765-293 Esteril, Portugal\n\nAbstract\n\nBackground. Cardiovascular morbidity and mortality\nare highly prevalent in haemodialysis (HD) patients\nand have been recently associated with vascular\ncalcifications. The objective of our study was to\nassess the value of a simple vascular calcification\nscore for the prediction of cardiovascular death,\ncardiovascular hospitalizations and fatal and non-\nfatal cardiovascular events in HD patients, and to\ncorrelate this score with cardiovascular disease and\nwith other known predictors of vascular disease.\nMethods. In this observational, prospective study 123\nchronic HD patients (75 males and 48 females; 20%\ndiabetic) were included, who were on low-flux HD\ntreatment for 46.6\u00b152 months (mean\u00b1SD). We set up\na simple vascular calcification score based on plain\nradiographic films of pelvis and hands. Brachial pulse\npressure and mean arterial pressure (MAP) were\nmeasured and cardiovascular events and hospitaliza-\ntion episodes were assessed.\nResults. During an observational period of 37 months\nthere were 17 cardiovascular deaths; 28 patients needed\ncardiovascular hospitalizations and 32 patients suf-\nfered fatal and non-fatal cardiovascular events.\nCoronary artery disease was diagnosed in 43 patients\n(35%), peripheral arterial disease in 33 patients\n(26.8%), cerebrovascular disease in 16 patients (13%)\nand vascular disease (coronary artery disease or\nperipheral arterial disease or cerebral vascular disease)\nin 61 patients (49.6%). By binary logistic regression,\ndiabetes (P \u00bc 0.01), male sex (P<0.001), age\n(P \u00bc 0.02), HD duration (P \u00bc 0.02) and MAP\n(P \u00bc 0.03) were independently associated with a\nvascular score ?3. This score ?3 was independently\nassociated with coronary artery disease (P \u00bc 0.008),\nperipheral arterial disease (P<0.001) and vascular\n\ndisease (P \u00bc 0.001). Patients with a vascular calcifica-\ntion score ?3 had a 3.9-fold higher risk of cardio-\nvascular mortality (P \u00bc 0.03), a 2.8-fold higher risk of\ncardiovascular hospitalizations (P \u00bc 0.02) and a 2.3-\nfold higher risk of fatal or non-fatal cardiovascular\nevents (P \u00bc 0.04).\nConclusions. The present vascular calcification scoring\nrepresents a simple tool for the assessment of\ncardiovascular risk related with vascular calcifications\nin chronic HD patients.\n\nKeywords: haemodialysis; mortality; vascular calcifi-\ncation; vascular disease\n\nIntroduction\n\nCardiovascular mortality is the main cause of death in\nhaemodialysis (HD) patients and can be 20-fold higher\nthan in the general population, with greater differences\nin the younger population [1,2].\n\nThere are two main types of vascular calcifications\nin HD patients: (i) common atherosclerosis, with\nintimal patchy calcifications of atherosclerotic plaques\nand (ii) mediasclerosis with medial linear calcifications\nthat seem to be related to mineral metabolism\ndisturbances [3,4]. It has been recently demonstrated\nthat mediasclerosis is an active cellular process,\nsimilar to bone formation [4,5] and is not the result\nof a passive metastatic calcification. Vascular muscle\ncells can differentiate into osteoblasts due to different\nstimuli, one of which may be hyperphosphataemia\n[3,4,6]. Deposition of bone matrix proteins can\nprecede vascular calcification [5]. Different vascular\ncalcification scores have been evaluated in HD\npatients by various methods, mainly using B-mode\nultrasonography [7] and electron beam computed\ntomography [8,9]. These scores have been related to\noral calcium load [9], cardiovascular disease [9,10]\n\nCorrespondence and offprint requests to: Maria Teresa Pulido\nAdragao, Nefroclinica-Estoril, Rua Vale de S Rita, 19, 2765-293\nEsteril, Portugal. Email: tadragao@netcabo.pt\n\nNephrol Dial Transplant Vol. 19 No. 6 ? ERA\u2013EDTA 2004; all rights reserved\n\n\n\n30\n\nand mortality [7,11] in HD patients. Medial artery\ncalcifications have already been differentiated from\nintimal calcifications by plain radiography in non-\ninsulin diabetic patients and have been associated\nwith all-cause and cardiovascular mortality [12]. In\nHD patients, these different calcification patterns\nwere both associated with cardiovascular and all-\ncause mortality and intimal artery calcifications were\nassociated with a lower survival [13]. The early\ndiagnosis of vascular calcifications and the identifica-\ntion of their cause raise the hope for a possible direct\ntherapeutic intervention that might reduce cardio-\nvascular disease in HD patients. It has already been\ndemonstrated that calcium carbonate and calcium\nacetate are associated with the progression of vascular\ncalcification, a phenomenon that can be attenuated\nor arrested by sevelamer, a phosphorus binder that\ndoes not increase calcium levels and also reduces\nLDL-cholesterol [14,15].\n\nThe main objective of this study was to evaluate the\nusefulness of a simple vascular calcification score based\non plain radiographic films, for prediction of cardio-\nvascular mortality in HD patients. Secondary objec-\ntives were to correlate this score with cardiovascular\nhospitalizations, fatal and non-fatal cardiovascular\nevents, cardiovascular disease, with simple arterial\nproperties [pulse pressure (PP) and mean arterial\npressure (MAP)], and with calcium, phosphorus,\ncalcium and phosphorus product and intact parathor-\nmone (iPTH) levels.\n\nPatients and methods\n\nStudy design\n\nAn observational, prospective, single-centre study of a cohort\nof prevalent patients treated with HD was used.\n\nPopulation\n\nOne hundred and twenty-three patients, 75 males and\n48 females, treated with low flux HD, without previous\nparathyroidectomy, constituted the study population (Table\n1); 25 patients (20.3%) were diabetic. On the day of the\nvascular score evaluation, mean age was 62\u00b114 years\n(24\u201391) and mean HD duration was 46.6\u00b152 months\n(6\u2013271). During an observational period of 37 months, 36\npatients died and one patient received a renal transplant.\nMean follow-up was 32\u00b19 months (4\u201337).\nThe primary endpoint after 37 months was cardiovascular\n\nmortality. Secondary endpoints were cardiovascular hospi-\ntalizations, fatal and non-fatal cardiovascular events, and the\ndiagnosis of vascular disease (coronary artery disease and/or\ncerebral vascular disease and/or peripheral arterial disease).\nThe diagnosis of vascular disease was based on a query\nanswered by the attending physicians of the study patients\nand was dependent on clinical manifestations. Coronary\nartery disease was diagnosed if the patient had developed\ntypical angina pectoris, had a positive stress test, suffered a\nmyocardial infarction, or underwent a percutaneous coron-\nary intervention or coronary bypass surgery; diagnosis of\ncerebral vascular disease was based on the occurrence of\n\nTable 1. Univariate analysis\n\nAll patients Score ?3 Score&lt;3 Significance (P)\n\nNumber of patients 123 65 (53%) 58 (47%) NS\nAge (years) 62.9 (14.5) 64.5 (12.8) 61.3 (16.2) NS\nHD (months) 46.6 (52.) 53.0 (57.1.) 39.4 (44.1) NS\nMale gender (%) 75 (61%) 51 (79%) 24 (41%)\nFemale gender (%) 48 (39%) 14 (22%) 34 (58%)&lt;0.001\nDiabetes (%) 25 (20%) 18 (28%) 7 (12%) 0.02\nCa (mg/dl) 9.9 (0.7) 9.9 (0.7) 9.8 (0.9) NS\nP (mg/dl) 4.9 (1.4) 4.8 (1.5) 4.9 (1.3) NS\nCaXP (mg/dl)\n\n2\n48.8 (15.4) 49 (16) 49 (15) NS\n\niPTH (pg/ml) 302 (379) 292 (354) 313(408) NS\nAl 18.6 (7.0) 18.8 (7.2) 18.1 (6.7) NS\nAlbumin (g/dl) 3.72 (0.36) 3.76 (0.32) 3.68 (0.28) NS\nHaemoglobin (g/dl) 11.3 (1.2) 11.5 (1.4) 11.2 (1.1) NS\nKt/v 1.38 (0.19) 1.37 (0.18) 1.42 (0.21) NS\nPP (mmHg) 67.3 (17) 69.0 (18) 65.4 (15.7) NS\nMAP (mmHg) 105.3 (14) 107.4 (14.9) 102.9 (12.4) NS\nInitial CAD (%) 32 (26%) 20 (31%) 12 (21%) NS\nFinal CAD (%) 43 (35%) 28 (43%) 15 (26%) 0.03\nInitial CVD (%) 6 (5%) 4 (6%) 2 (3%) NS\nFinal CVD (%) 16 (13%) 11 (17%) 5 (9%) NS\nInitial PAD (%) 16 (13%) 12 (19%) 4 (7%) 0.06\nFinal PAD (%) 33 (27%) 28 (43%) 5 (9%)&lt;0.001\nInitial VASCD (%) 36 (29%) 22 (34%) 14 (24%) NS\nFinal VASCD (%) 61 (50%) 43 (66%) 18 (31%)&lt;0.001\nCV deaths (%) 17 (14%) 14 (22%) 3 (5%) 0.008\nCV hospitalizations (%) 28 (23%) 22 (34%) 6 (10%) 0.002\nCV events (%) 32 (26%) 24 (37%) 8 (14%) 0.004\n\nResults in mean values (SD); CAD, coronary arterial disease; CVD, cerebrovascular disease; PAD, peripheral arterial disease; VASCD,\nvascular disease; CV, cardiovascular; NS, not significant.\n\nA simple vascular calcification score predicts cardiovascular risk 1481\n\n\n\n31\n\nstroke or transient ischaemic attack or the detection of an old\ncerebral infarction using computed tomography; peripheral\narterial disease was diagnosed if there was claudication,\nischaemic ulcers, lower limbs amputation, revascularization\nor diagnosis of obstruction by Doppler or angiography.\nVascular disease diagnosis was performed in two steps: at\nbaseline and at the end of the follow-up. For each patient,\nhospitalizations during the observational period were\nclassified as cardiovascular, non-cardiovascular or absent.\nCalcium, phosphorus, haemoglobin, albumin and Kt/V were\nevaluated every month and iPTH and aluminum every 3\nmonths, in the 6 months that preceded vascular calcifica-\ntion score evaluation. Levels of iPTH were determined by\na first generation immunochemiluminometric assay. PP and\nMAP were evaluated once a month, based on blood pressure\n(BP) measurement before HD, on the day of the blood\nchemistry analysis, during the same 6 months period. PP was\ncalculated by the formula PP \u00bc SBP ? DBP; MAP \u00bc DBP \u00fe\n(SBP ? DBP)/3 (SBP, systolic blood pressure; DBP, diastolic\nblood pressure).\nHD duration was evaluated on the day of vascular\n\ncalcification assessment. A simple vascular calcification\nscore was evaluated in all patients during a 4 month period\nand marked the beginning of the study for each patient. This\n\nvascular calcification score was evaluated in plain radio-\ngraphic films of pelvis and hands, performed in the same\ncentre. The pelvis radiographic films were divided into four\nsections by two imaginary lines: a horizontal line over the\nupper limit of both femoral heads and a median vertical line\nover the vertebral column. The films of the hands were\ndivided, for each hand, by a horizontal line over the upper\nlimit of the metacarpal bones. The presence of linear\ncalcifications in each section was counted as 1 and its\nabsence as 0. The final score was the sum of all the sections,\nranging from 0 to 8. Vascular calcifications were deliberately\nevaluated only in muscular arteries: iliac, femoral, radial and\ndigital. Pelvis films evaluated iliac and femoral arteries\n(Figure 1); hand films evaluated radial and digital arteries\n(Figure 2). The analysis of all the radiographic films was\nperformed by one single experienced clinician blinded to\npatient information. Only linear calcifications, with or\nwithout patchy calcifications, were considered for the final\ncalcification score, because they outline the vessel wall and\nhave undoubtedly vascular localization. Patchy isolated\ncalcifications that may be associated with intimal calcifica-\ntions were not considered in this score because they may be\nconfused with other types of extra-vascular calcifications, for\ninstance, phleboliths.\n\nFig. 1. Calcification score is the sum of the presence (1) or absence (0) of parallel linear calcifications in each section. In the example,\npelvis score \u00bc 1 \u00fe 1 \u00fe 1 \u00fe 1 \u00bc 4.\n\n1482 T. Adragao et al.\n\n\n\n32\n\nStatistics\n\nVariables were expressed as frequencies, percentages for\ndiscrete factors, and mean value for normally distributed\ncontinuous factors. Statistical comparison of baseline char-\nacteristics and endpoints was performed using the two-tailed\nchi-square test with Yates\u2019 correction or Fisher exact test\nwhen appropriate, for categorical variables, and the two-\ntailed Student t-test for continuous variables. Kaplan\u2013Meier\nsurvival curves of patients with vascular calcification\nscore ?3 and&lt;3 were compared by log-rank test. The\nindependent variables associated with cardiovascular death,\ncardiovascular hospitalizations and fatal and non-fatal\ncardiovascular events were identified by Cox regression\nmodels. The covariates in Cox regression models were age,\nsex, HD duration, diabetes, CaXP, iPTH, albumin, vascular\ndisease at baseline and vascular score. The independent\nvariables associated with PP and MAP were identified by\nlinear regression models. Variables included in these models\nwere: age, sex, diabetes, HD duration, albumin, Ca, P,\nCaXP, iPTH and vascular calcification score. The indepen-\ndent variables associated with vascular calcifications, vascu-\nlar disease at baseline and vascular disease at the end of\nfollow-up were identified by binary logistic regression\nmodels. Covariates for vascular calcification analysis were:\nage, sex, diabetes, HD duration, albumin, Ca, P, CaXP and\niPTH. Covariates for vascular disease analysis were the\nabove plus PP, MAP and vascular calcification score. To\nidentify those patients at highest risk for the study endpoint,\nthe vascular calcification score values and the corresponding\n\nendpoint rates were related via a receiver operating\ncharacteristic (ROC) curve. The value associated with the\nhighest accuracy was considered as the cut-off point for\ndefining an elevated cardiovascular risk. The risk estimates\nfor death, cardiovascular hospitalizations and fatal and non-\nfatal cardiovascular events were the adjusted hazard ratios\n(HRs) obtained by Cox regression. Statistical analyses were\nperformed with the SPSS system 10.0 (SPSS Inc., Chicago,\nIL) and the Medcalc program version 6.0 (Medcalc software;\nMariakerke, Belgium). For all comparisons, a P-value&lt;0.05\nwas considered statistically significant.\n\nResults\n\nDuring an observational period of 37 months, there\nwere 36 all-cause deaths and 17 cardiovascular deaths;\n28 patients needed cardiovascular hospitalizations, and\n32 patients suffered fatal or non-fatal cardiovascu-\nlar events. At baseline, clinical vascular disease was\ndiagnosed in 36 patients (29%): coronary artery disease\nin 32 patients (26%), peripheral arterial disease in 16\npatients (13%) and cerebral vascular disease in six\npatients (5%); at the end of the follow-up coronary\nartery disease had been diagnosed in 43 patients (35%),\nperipheral arterial disease in 33 patients (27%), cerebral\nvascular disease in 16 patients (13%) and vascular\ndisease in 61 patients (50%) (Table 1). Cardiovascular\n\nFig. 2. Hands score in this example is 4; total score is the sum of pelvis and hands score [8].\n\nA simple vascular calcification score predicts cardiovascular risk 1483\n\n\n\n33\n\ndeath was associated with coronary artery disease in 12\npatients, peripheral arterial disease in three patients\nand cerebral vascular disease in two patients. Coronary\nartery disease in 14 patients, peripheral arterial disease\nin 12 patients and cerebral vascular disease in three\npatients led to cardiovascular hospitalizations. One\npatient experienced two hospitalization episodes,\none for coronary artery disease and one for cerebral\nvascular disease.\n\nVascular calcification score frequency\n\nAnatomical calcification distribution was the following:\niliac calcifications were present in 75 patients (61%),\nfemoral calcifications in 74 patients (60%), radial\ncalcifications in 45 patients (36.6%) and digital\ncalcifications in six patients (5%). The distribution of\nvascular calcification score in the 123 patients was the\nfollowing: score 0 in 31 patients (25.2%), score 1 in\neight patients (6.5%), score 2 in 19 patients (15.4%),\nscore 3 in two patients (1.6%), score 4 in 25 patients\n20.3%, score 5 in eight patients (6.5%), score 6 in 26\npatients (21.1%), score 7 in zero patients and score 8 in\nfour patients (3.3%). This parameter does not present\na normal distribution mainly due to the less frequent\ncases of unilateral vascular calcification: unilateral iliac\ncalcifications in three patients, unilateral femoral\ncalcifications in five patients, unilateral radial calcifica-\ntions in 12 patients and unilateral digital calcifications\nin one patient.\n\nBy ROC curve analysis, the vascular calcification\nscores of the four anatomical regions (iliac, femoral,\nradial and digital) showed a similar relationship with\ncardiovascular mortality: iliac score >0 (AUC \u00bc 0.613;\n95% CI 0.522\u20130.699); femoral score >0 (AUC \u00bc\n0.630; 95% CI 0.539\u20130.715); radial score >0\n(AUC \u00bc 0.604; 95% CI 0.512\u20130.690); digital score >0\n(AUC \u00bc 0.589; 95% CI 0.498\u20130.677).\n\nUnivariate analysis\n\nROC curve analysis identified vascular calcification\nscore ?3 as the best cut-off value associated with\ncardiovascular mortality (AUC \u00bc 0.716; 95% CI\n0.629\u20130.793) and cardiovascular events (AUC \u00bc 0.687;\n95% CI 0.598\u20130.766). The vascular score ?3 was\nmeasured in 65 patients (53%) (Table 1) and was\nmore frequent among men and diabetic patients.\nFurthermore, a vascular score ?3 was more frequently\nassociated with cardiovascular hospitalizations, cardio-\nvascular mortality and fatal and non-fatal cardio-\nvascular events, coronary artery disease, peripheral\narterial disease and vascular disease at the end of the\nfollow-up period (Table 1). By univariate analysis,\nthere were no significant differences between higher\nscore and lower score patients with regards to age,\nHD duration, calcium, phosphorus and iPTH levels\n(Table 1). By Kaplan\u2013Meier analysis, the cumulative\nhazard for cardiovascular death at 37 months was\nhigher in patients with a vascular score ?3: 23 vs 5%,\nlog-rank \u00bc 5.7; P \u00bc 0.01 (Figure 3).\n\nMultivariate analysis\n\nEvaluation of the association of calcium, phosphorus\nand iPTH with vascular calcification score and vascular\ndisease. Calcium, phosphorus and iPTH levels were\nevaluated during the 6 months that preceded the\nvascular calcification score assessment. Calcium levels\nwere independently associated with iliac calcifications\n(P \u00bc 0.03) (Table 2) and with PAD (P \u00bc 0.01) (Table 3);\nphosphorus levels were independently associated with\nCAD (P \u00bc 0.01) (Table 3). PTH levels were not\ncorrelated with vascular calcifications or with vascular\ndisease in these patients.\n\nFactors independently associated with PP and MAP. By\nmultiple linear regression, PP was associated with\ndiabetes (B \u00bc 12.8; 95% CI \u00bc 5.8\u201319.7; P<0.001) and\ncorrelated with age (B \u00bc 0.33; 95% CI \u00bc 0.13\u20130.52;\nP \u00bc 0.001). MAP was associated with a vascular\ncalcification score ?3 (B \u00bc 5.6; 95% CI \u00bc 0.8\u201310.4;\nP \u00bc 0.02). PP was an independent predictor of PAD\n(P<0.001) (Table 3).\n\nFactors independently associated with vascular calcifi-\ncation score. Binary logistic regression (Table 2)\nshowed that a vascular calcification score ?3 was\nassociated with diabetes (P \u00bc 0.01), male sex\n(P<0.001), age (P \u00bc 0.02), HD duration (P \u00bc 0.02)\nand MAP (P \u00bc 0.03). There was no correlation between\nfinal vascular score and calcium metabolism factors,\nbut when analysing the different vascular calcification\nregions, in the same model, calcium levels were\nindependently associated with iliac calcifications\n(P \u00bc 0.03) (Table 2).\nFactors independently associated with cardiovascular\nmorbidity and mortality. By binary logistic regression\n(Table 3), vascular disease at the end of the follow-up\nwas associated with vascular calcification score\n\n4 03 02 0100\n\n,3\n\n,2\n\n,1\n\n0 ,0\n\nMon t h s of  f ol l ow-u p\n\nO\nn\n\ne\n m\n\nin\nu\n\ns \nsu\n\nrv\niv\n\na\nl\n\np=0.01\n\nLog rank=5.7 14 deaths\n\n23% \n\n3 deaths\n\n5% \n\nn= 58 vsc &lt;3\n\nn= 65 vsc ? 3\n\nFig. 3. Higher cardiovascular death risk in patients with vascular\ncalcification score ?3.\n\n1484 T. Adragao et al.\n\n\n\n34\n\n(P<0.001), age (P \u00bc 0.01) and diabetes (P \u00bc 0.04);\ncoronary artery disease at the end of the follow-up\nwas associated with phosphorus levels (P \u00bc 0.01) and\nvascular calcification score (P \u00bc 0.003); peripheral\nartery disease at the end of the follow-up was associ-\nated with diabetes (P<0.001), vascular calcification\nscore (P<0.001), PP (P \u00bc 0.001) and calcium levels\n(P \u00bc 0.02). Vascular disease at baseline was not\nassociated with any of these factors. Fatal and\nnon-fatal cardiovascular events were associated with\nvascular calcification score (P \u00bc 0.009); cardiovascular\nhospitalizations were associated with vascular calcifica-\ntion score (P \u00bc 0.003); cardiovascular mortality was\nassociated with vascular calcification score (P \u00bc 0.01).\nAll-cause mortality was inversely associated with\nalbumin levels (P<0.001).\n\nFor a better evaluation of the cardiovascular risk, a\nvascular calcification score cut-off defined by ROC\ncurve analysis was applied to the same statistical tests.\nThe cardiovascular risk evaluation was the HR\nadjusted for sex, age, HD duration, diabetes, calcium\nand phosphorus product, iPTH levels and albumin. In\npatients with a vascular calcification score ?3, the HR\nwas 2.8 (95% CI 1.151\u20137.012; P \u00bc 0.02) for cardio-\nvascular hospitalizations, 2.3 (95% CI 1.044\u20135.182;\nP \u00bc 0.04) for fatal and non-fatal cardiovascular\nevents, and 3.9 (95% CI 1.108\u201313.422; P \u00bc 0.03) for\n\ncardiovascular mortality (Figure 4). In patients with\na vascular calcification score ?3 the odds ratio was\n3.2 (95% CI 1.358\u20137.448; P \u00bc 0.008) for association\nwith CAD, was 10.4 (95% CI 2.676\u201340.381; P \u00bc 0.001)\nfor association with PAD and was 4.3 (95% CI\n1.884\u20139.929; P \u00bc 0.001) for association with vascular\ndisease (Figure 4).\n\nTable 3. Cardiovascular morbidity and mortality: multivariate analysis\n\nDependent variable Independent variable Risk CI (95%) Significance (P)\n\nFinal CAD Vsc >0 1.3 1.091\u20131.555 0.003\nPhosphorus 1.5 1.094\u20131.967 0.01\n\nFinal PAD Vsc >0 1.7 1.278\u20132.259 0.000\nDiabetes 13.7 3.132\u201356.360 0.000\nPP 1.1 1.024\u20131.101 0.001\nCalcium 2.9 1.205\u20137.343 0.02\n\nFinal VASCD Vsc >0 1.4 1.168\u20131.698 0.000\nDiabetes 3.3 1.071\u201310.044 0.04\nAge 1.04 1.008\u20131.074 0.01\n\nCV hospitalizations Vsc >0 1.3 1.093\u20131.554 0.003\nCV events Vsc >0 1.2 1.054\u20131.446 0.009\nCV death Vsc >0 1.4 1.107\u20131.803 0.01\n\nFinal, at the end of the follow-up; CAD, coronary artery disease; PAD, peripheral artery disease; VASCD, vascular disease; CV,\ncardiovascular; Vsc, vascular calcification score.\n\nTable 2. Vascular calcification score: multivariate analysis\n\nDependent variable Independent variable Risk CI (95%) Significance (P)\n\nVsc ?3 Diabetes 4.2 1.4\u201313.1 0.01\nMale gender 7.47 2.9\u201319.1 0.000\nAge 1.04 1.008\u20131.077 0.02\nHD duration (months) 1.01 1.002\u20131.021 0.02\nMAP 1.04 1.004\u20131.074 0.03\n\nIliac score >0 Diabetes 4.6 1.4\u201314.7 0.01\nMale gender 3.5 1.5\u20138.3 0.004\nAge 1.04 1.012\u20131.072 0.005\nCalcium 1.8 1.050\u20133.143 0.03\n\nVsc, vascular calcification score.\n\ncardiovascular hospit alizations\n\n0.01 0.1 1 10 100\n\nperipheral vascular disease\n\nvascular disease\n\ncardiovascular death\n\n9.3\n\n3.8\n\n3.9\n\n4.4\n\nFig. 4. Cardiovascular risk for vascular calcification score ?3.\n\nA simple vascular calcification score predicts cardiovascular risk 1485\n\n\n\n35\n\nIn summary, this simple vascular calcification score\nwas independently associated with coronary artery\ndisease, peripheral artery disease and vascular disease\npresent at the end of the follow-up. A vascular\ncalcification score ?3 was an independent predictor of\ncardiovascular mortality, cardiovascular hospitaliza-\ntions, and fatal or non-fatal cardiovascular events.\n\nDiscussion\n\nVascular calcifications in HD patients have already\nbeen related to arterial stiffness [7,11,16], cardiovasc-\nular disease [8,10] and cardiovascular mortality [7,11],\nand are more common than in the general population\n[8]. These extensive vascular calcifications, found even\nin young HD patients [9], may represent one of the\nfactors contributing to the extremely high cardio-\nvascular mortality for HD patients when compared\nwith the general population [1].\n\nThe diagnosis of vascular calcification is usually\nmade with very expensive and highly technical devices\nlike electron beam computed tomography or multislice\ncomputed tomography [8,17,18]. The use of plain\nradiographic films of bone has already been suggested\nin the recent KDOQI clinical practice guidelines for\nbone metabolism and disease [19], not for bone disease\nevaluation but for vascular calcification assessment.\nIn our score, vascular calcifications were deliberately\nevaluated only in muscular arteries: iliac, femoral,\nradial and digital, because muscular arteries are more\nprone to linear calcification in contrast with elastic\narteries that are more prone to intimal calcification.\nOur objective was to have a simple tool for the\nevaluation of peripheral muscular arteries calcifica-\ntions. Lower limb arteries were not chosen because of\nthe high prevalence of amputations in HD patients.\nThe radial artery was included in our score based on\na previous evaluation by Mourad et al. [20] who\ndemonstrated that the radial artery, a muscular artery\ndevoid of atherosclerosis, had an increased stiffness\nthat was independent of the BP level. Intimal calcifica-\ntions have already been differentiated from medial\ncalcifications by plain radiography and these different\ncalcification patterns have been associated with differ-\nent cardiovascular and all-cause mortality results [13].\nIn our score, only linear calcifications that outline the\nvessel wall, with or without patchy calcifications, were\nconsidered because they have an obvious vascular\norigin. Patchy isolated calcifications were not consid-\nered because of their possible non-vascular origin.\nThese linear calcifications may correspond to the linear\nrailroad calcifications described by Lehto et al. [12] and\nby London et al. [13] and identified by these authors as\nmedial calcifications. However, vascular calcifications\nwere evaluated in four vascular territories, and medial\nand intimal calcifications may coexist in the same\npatient and in the same vessel. Our vascular score does\nnot exclude association of intimal and medial calcifica-\ntions. This would explain why this score was a good\n\npredictor of cardiovascular mortality. In another study,\nthis vascular calcification score was also correlated in\nunivariate and multivariate analysis with pulse wave\nvelocity measured by Complior\n\n?\n[21]. This finding\n\nconfirms the value of this simple score, suggesting that\nlinear calcifications identified by this method are\nassociated with changes of the arterial wall properties.\nThis calcification score that we have developed is a very\nsimple tool, easy to use by the attending physician\nwithout assistance of a radiologist and may help\nidentify patients at higher cardiovascular risk.\n\nChanges of arterial wall properties with age are\nassociated with SBP increase and DBP decrease. PP\nincrease has been established as a cardiovascular\ndisease risk factor in the general population [22] and\nin HD patients as well [23,24]. In our study, PP in\nmultivariate analysis was not correlated with vascular\ncalcification score but was correlated with age and\ndiabetes and was independently associated with per-\nipheral arterial disease. However, MAP, which is\nrelated to cardiac output and vascular resistance, was\nindependently associated with a vascular calcification\nscore ?3. The fact that BP was evaluated immediately\nbefore an HD procedure, in a clinical situation of\nhypervolaemia, may have contributed to this result.\n\nIt has already been shown that PTH levels are\noverestimated with the common iPTH assays because\nthey detect not only PTH (1\u201384), but also evaluate C-\nterminal fragments, which can have inhibitory activity.\nNewer \u2018whole PTH\u2019 assays can detect exclusively PTH\n(1\u201384), but the predictive power of these new assays\nis still unknown [19]. In the present study, vascular\ncalcification score was independent of PTH values. This\nhas already been demonstrated in other studies [8,16].\nHyperphosphataemia and high calcium phosphate\nproduct are predictors of mortality in HD patients\n[25]. In our study, there is some evidence for a\nrelationship between calcium or phosphorus levels\nand vascular disease: phosphorus levels were correlated\nwith coronary artery disease and calcium levels were\ncorrelated with peripheral arterial disease. The final\nvascular calcification score was not correlated with\ncalcium, phosphorus or iPTH levels, but calcium levels\nwere correlated with the presence of iliac calcifications.\nSimilarly, Gue?rin et al. [16] did not find any association\nbetween a semi-quantitative vascular calcification score\nevaluated by B-mode ultrasonography and calcium,\nphosphorus and iPTH levels [16]. Previous hyperphos-\nphataemia episodes that would have initiated this\nvascular calcification process may have been missed\nbecause of the time limited monitoring phase in these\npatients.\n\nVascular disease, present at the end of the follow-up,\ncorrelated with the vascular calcification score. Con-\nversely, clinical vascular disease diagnosed at base-\nline did not predict vascular mortality or vascular\nevents and did not correlate with the vascular calcifi-\ncation score. Vascular disease is oligosymptomatic in\nthis population and sub-clinical vascular disease was\nnot diagnosed at baseline, reflecting what happens in\ncurrent practice. As many patients do not have a very\n\n1486 T. Adragao et al.\n\n\n\n36\n\nactive life style, symptoms of cardiovascular disease\nmay be delayed, explaining the absence of correlation\nof clinical vascular disease at baseline with cardio-\nvascular death and cardiovascular events. Clinical\nevidence of vascular disease at the end of the follow-\nup, however, was strongly associated with the vascular\ncalcification score. This association strongly supports\nthe usefulness of this simple vascular tool at a stage of\nsub-clinical vascular disease.\n\nLimitations of this vascular calcification score\n\nThis vascular calcification score is not quantitative and\ntherefore is not adequate for accurately assessing the\nprogression of calcifications, as opposed to the scores\nevaluated by electron beam computed tomography\n[14,15]. However, in a retrospective study of long-term\nHD patients where the authors also used a vascular\ncalcification score based on radiographic films [26], it\nwas possible to evaluate regression and aggravation of\nthe calcifications over time.\n\nConclusion\n\nCardiovascular morbidity and mortality in this\ncohort of HD patients were related, among other\nfactors, to a simple vascular calcification score\nevaluated by plain radiographic films of pelvis and\nhands. This simple vascular calcification score was\nindependently associated with coronary artery dis-\nease, peripheral artery disease and vascular disease\ndiagnosed at the end of the follow-up. Male sex,\ndiabetes, age, HD duration and MAP were inde-\npendently associated with a vascular calcification\nscore ?3. A vascular calcification score ?3 was an\nindependent predictor of cardiovascular mortality,\ncardiovascular hospitalizations, and fatal or non-fatal\ncardiovascular events. This vascular calcification\nscore represents a simple and inexpensive tool for\nassessing the cardiovascular risk related to vascular\ncalcifications in HD patients.\n\nAcknowledgements. The authors would like to thank Dr Fernando\nCarrera for critical review of the manuscript, Dr Carlos Aguiar\nwho supervised and revised the statistical analysis and reviewed the\nmanuscript and Dr Diogo Cavaco who prepared the pictures.\n\nConflict of interest statement. We have had no involvements that\nmight raise the question of bias in the work reported or in the\nconclusions, implications or opinions stated.\n\nReferences\n\n1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of\ncardiovascular disease in chronic renal disease. Am J Kidney\nDis 1998; 32 [5 Suppl 3]: S112\u2013S119\n\n2. US Renal Data System. USRDS 2002. Annual Data Report:\nAtlas of End-Stage Renal Disease in the United States. National\nInstitutes of Health, National Institute of Diabetes and\nDigestive and Kidney Diseases, Bethesda, MD: 2002\n\n3. Jono S, McKee MD, Murry CE et al. Phosphate regulation of\nvascular smooth muscle cell calcification. Circ Res 2000; 87:\nE10\u2013E17\n\n4. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii\nH. Vascular calcification and inorganic phosphate. Am J\nKidney Dis 2001; 38 [4 Suppl 1]: S34\u2013S37\n\n5. Moe SM, O\u2019Neill KD, Duan D et al. Medial artery\ncalcification in ESRD patients is associated with deposition of\nbone matrix proteins. Kidney Int 2002; 61: 638\u2013647\n\n6. Moe SM, Duan D, Doehle BP, O\u2019Neill KD, Chen NX. Uremia\ninduces the osteoblast differentiation factor Cbfa1 in human\nblood vessels. Kidney Int 2003; 63: 1003\u20131011\n\n7. Blacher J, Gue?rin AP, Pannier B, Marchais SJ, London GM.\nArterial calcifications, arterial stiffness, and cardiovascular risk\nin end-stage renal disease. Hypertension 2001; 38: 938\u2013942\n\n8. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft\nFC. Electron beam computed tomography in the evaluation of\ncardiac calcification in chronic dialysis patients. Am J Kidney\nDis 1996; 27: 394\u2013401\n\n9. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery\ncalcification in young adults with end-stage renal disease\nwho are undergoing dialysis. N Engl J Med 2000; 342:\n1478\u20131483\n\n10. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification\nin adult hemodialysis patients. A link between end-stage renal\ndisease and cardiovascular disease? J Am Coll Cardiol 2002; 39:\n695\u2013701\n\n11. Blacher J, Gue?rin AP, Pannier B, Marchais SJ, Safar ME,\nLondon GM. Impact of aortic stiffness on survival in end-stage\nrenal disease. Circulation 1999; 99: 2434\u20132439\n\n12. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M.\nMedial artery calcification. A neglected harbinger of cardio-\nvascular complications in non-insulin-dependent diabetes\nmellitus. Arterioscler Thromb Vasc Biol 1996; 16: 978\u2013983\n\n13. London GM, Gue?rin AP, Marchais SJ, Metivier F, Pannier B,\nAdda H. Arterial media calcification in end-stage renal disease:\nimpact on all-cause and cardiovascular mortality. Nephrol Dial\nTransplant 2003; 18: 1731\u20131740\n\n14. Chertow GM, Burke SK, Raggi P, Treat to Goal Working\nGroup. Sevelamer attenuates the progression of coronary and\naortic calcification in hemodialysis patients. Kidney Int 2002;\n62: 245\u2013252\n\n15. Chertow GM, Raggi P, McCarthy JT et al. The effects of\nsevelamer and calcium acetate on proxies of atherosclerotic and\narteriosclerotic vascular disease in hemodialysis patients. Am J\nNephrol 2003; 23: 307\u2013314\n\n16. Gue?rin AP, London GM, Marchais SJ, Metivier F. Arterial\nstiffening and vascular calcifications in end-stage renal disease.\nNephrol Dial Transplant 2000; 15: 1014\u20131021\n\n17. Becker CR, Jakobs TF, Aydemir S et al. Helical and\nsingle-slice conventional CT versus electron beam CT for\nthe quantification of coronary artery calcifications. AJR 1999;\n174: 543\u2013547\n\n18. Goodman WG, Salusky IB. Non-invasive assessments of\ncardiovascular disease in patients with renal failure. Curr\nOpin Nephrol Hypertens 2001; 10: 365\u2013369\n\n19. National Kidney Foundation. KDOQI Clinical Practice\nGuidelines for Bone Metabolism and Disease in Chronic\nKidney disease. Am J Kidney Dis 2003; 42 [Suppl 3].\n\n20. Mourad JJ, Girerd X, Boutouyrie P, Laurent S, Safar M,\nLondon G. Increased stiffness of radial artery wall material in\nend-stage renal disease. Hypertension 1997; 30: 1425\u20131430\n\n21. Adragao T, Pires A, Lucas C et al. Pulse wave velocity\ncorrelates with simple vascular calcification score in hemodial-\nysis patients. Nephrol Dial Transplant 2003; 18 [Suppl 4]: 702,\nAbstract W487\n\n22. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is\npulse pressure useful in predicting risk for coronary heart\nDisease? The Framingham heart study. Circulation 1999; 100:\n354\u2013360\n\nA simple vascular calcification score predicts cardiovascular risk 1487\n\n\n\n37\n\n23. Tozawa M, Iseki K, Iseki C, Takishita S. Pulse pressure and\nrisk of total mortality and cardiovascular events in patients on\nchronic hemodialysis. Kidney Int 2002; 61: 717\u2013726\n\n24. Klassen PS, Lowrie EG, Reddan DN et al. Association\nbetween pulse pressure and mortality in patients undergoing\nmaintenance hemodialysis. J Am Med Assoc 2002; 287:\n1548\u20131555\n\n25. Block GA, Hubet-Shearon TE, Levin NW, Port FK.\nAssociation of serum phosphorus and calcium phosphate\nproduct with mortality risk in hemodialysis patients: a national\nstudy. Am J Kidney Dis 1998; 31: 607\u2013617\n\n26. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular\ncalcification in long-term haemodialysis patients in a single\nunit: a retrospective analysis. Nephron 1997; 77: 37\u201343\n\nReceived for publication: 11.8.03\nAccepted in revised form: 13.02.04\n\n1488 T. Adragao et al.\n\n\n\n\n\n39\n\nCAP\u00cdTULO 4\n\nCALCIFICA\u00c7\u00c3O VASCULAR E RIGIDEZ ARTERIAL\n\nA rigidez arterial resulta da modifi ca\u00e7\u00e3o das propriedades da parede arterial e \u00e9 preditora \nde risco cardiovascular nos doentes com e sem doen\u00e7a renal cr\u00f3nica1,2. Diversos fatores \ncontribuem para o aumento da rigidez arterial, como idade avan\u00e7ada, diabetes, hipertens\u00e3o \narterial e calcifi ca\u00e7\u00f5es vasculares. Nos doentes em di\u00e1lise, todos estes fatores apresentam \nelevada preval\u00eancia, e a rigidez arterial \u00e9 um achado comum nesta popula\u00e7\u00e3o. Em estudos \nanteriores, a rigidez arterial foi associada a maior risco de mortalidade2, mas esta associa\u00e7\u00e3o \nn\u00e3o \u00e9 universal3.\n\nAs calcifi ca\u00e7\u00f5es vasculares provocam uma diminui\u00e7\u00e3o da elasticidade da parede da aorta \nrespons\u00e1vel por uma onda de refl ex\u00e3o mais precoce, encontrando ainda a v\u00e1lvula a\u00f3rtica \naberta. Esta ocorr\u00eancia contribui para o aumento do volume sist\u00f3lico com consequente \nhipertens\u00e3o sist\u00f3lica e diminui\u00e7\u00e3o da press\u00e3o diast\u00f3lica. O aumento da press\u00e3o sist\u00f3lica \ncontribui para o aumento da p\u00f3s -carga card\u00edaca e para o desenvolvimento da hipertrofi a \nventricular esquerda. A diminui\u00e7\u00e3o da press\u00e3o diast\u00f3lica pode comprometer a perfus\u00e3o \ncoron\u00e1ria que se faz predominantemente durante a di\u00e1stole4. Objetivamente, o aumento da \npress\u00e3o sist\u00f3lica e a diminui\u00e7\u00e3o da press\u00e3o diast\u00f3lica traduzem -se por um \u00edndice cl\u00ednico \nfacilmente mensur\u00e1vel, o aumento da press\u00e3o de pulso, que se avalia simplesmente pela \ndiferen\u00e7a aritm\u00e9tica entre o valor da press\u00e3o sist\u00f3lica e da press\u00e3o diast\u00f3lica. Na popula\u00e7\u00e3o \ngeral j\u00e1 foi demonstrado que, em doentes com idade superior a 60 anos, \u00e9 o aumento da press\u00e3o \nde pulso que se associa a maior risco cardiovascular, enquanto em indiv\u00edduos mais novos o \naumento da press\u00e3o diast\u00f3lica \u00e9 que apresenta maior associa\u00e7\u00e3o ao risco cardiovascular5. \nTamb\u00e9m em doentes em di\u00e1lise o aumento da press\u00e3o de pulso avaliado no in\u00edcio ou no fi nal \nde uma sess\u00e3o de hemodi\u00e1lise se associou a maior mortalidade em doentes n\u00e3o diab\u00e9ticos6 \nou em todos os doentes7.\n\nO grupo de trabalho de imagiologia da iniciativa KDIGO 20068 prop\u00f4s a investiga\u00e7\u00e3o \ncl\u00ednica de diversas quest\u00f5es, na altura ainda sem resposta, entre as quais a an\u00e1lise da associa\u00e7\u00e3o \nentre rigidez arterial avaliada por velocidade de onda de pulso e press\u00e3o de pulso e a exist\u00eancia \nde calcifi ca\u00e7\u00f5es vasculares avaliadas por m\u00e9todos radiol\u00f3gicos. Em 2000, Gu\u00e9rin et al tinham \nsido os primeiros a demonstrar que calcifi ca\u00e7\u00f5es vasculares avaliadas por ecografi a em grandes \nart\u00e9rias se associavam a rigidez arterial nos doentes em di\u00e1lise9. Ap\u00f3s a proposta de investiga\u00e7\u00e3o \n\n\n\n40\n\ncl\u00ednica feita pela KDIGO 2006, Raggi et al analisaram a associa\u00e7\u00e3o entre a rigidez arterial \navaliada por velocidade de onda de pulso carotidofemoral com calcifi ca\u00e7\u00f5es coron\u00e1rias e da \naorta abdominal10. As calcifi ca\u00e7\u00f5es coron\u00e1rias foram avaliadas por tomografi a computorizada \nde feixe de eletr\u00f5es e as calcifi ca\u00e7\u00f5es da aorta abdominal por RX simples utilizando um score \nde calcifi ca\u00e7\u00e3o semiquantitativo descrito por Kauppila11. Neste estudo verifi cou -se que as \ncalcifi ca\u00e7\u00f5es da aorta abdominal se associaram a um aumento da velocidade de onda de pulso \ncarotidofemoral. Em an\u00e1lise multivariada, as calcifi ca\u00e7\u00f5es coron\u00e1rias n\u00e3o se associaram ao \naumento de rigidez arterial.\n\nEm 2005, apresentamos, no XVII Congresso Portugu\u00eas de Nefrologia, um estudo \nem que verificamos que a velocidade de onda de pulso era preditora de mortalidade num \ngrupo de doentes em hemodi\u00e1lise e em que demonstramos que o score de calcifica\u00e7\u00e3o \nvascular simples se associava \u00e0 velocidade de onda de pulso. Este estudo ganhou o \npr\u00e9mio para a melhor comunica\u00e7\u00e3o oral na \u00e1rea da hemodi\u00e1lise desse ano e foi apresentado \ncomo poster na 38th Annual Renal Week Meeting, da Sociedade Americana de Nefrologia. \nAceitando a proposta da iniciativa KDIGO 2006, aprofundamos este estudo para poder \nresponder a todas as quest\u00f5es levantadas e disp\u00fanhamos j\u00e1 de um tempo de seguimento \nque nos permitiu tamb\u00e9m avaliar a associa\u00e7\u00e3o entre a rigidez arterial e a mortalidade. \nA rigidez arterial foi avaliada por velocidade de onda de pulso carotidofemoral com um \nm\u00e9todo n\u00e3o invasivo usando o Complior (Artech Medical, Pantin, France) e pela press\u00e3o \n\nFig. 4.1. Um score de calcifi ca\u00e7\u00e3o vascular simples (SCVS) > 3 associou -se a valores mais elevados de velocidade \nde onda de pulso e de press\u00e3o de pulso (teste T de Student)\n\n\n\n41\n\nde pulso. A press\u00e3o de pulso, calculada pela diferen\u00e7a entre a press\u00e3o sist\u00f3lica e a press\u00e3o \ndiast\u00f3lica, correspondeu ao valor m\u00e9dio da press\u00e3o de pulso medida no in\u00edcio de uma \nsess\u00e3o de hemodi\u00e1lise durante os 6 meses que precederam a medi\u00e7\u00e3o da velocidade de \nonda de pulso. Nos nossos doentes verificamos que o score de calcifica\u00e7\u00e3o vascular \nsimples superior a 3 se associou a valores mais elevados da velocidade de onda de pulso \ne da press\u00e3o de pulso (Fig. 4.1).\n\nEsta an\u00e1lise foi ajustada para idade, dura\u00e7\u00e3o de hemodi\u00e1lise, diabetes, n\u00edveis de \ncolesterol, press\u00e3o sist\u00f3lica, \u00edndice de massa corporal e doses de calcitriol e de carbonato \nde c\u00e1lcio. A idade e a press\u00e3o sist\u00f3lica foram os outros fatores preditores da velocidade \nde onda de pulso. A diabetes mellitus e a dose de carbonato de c\u00e1lcio foram igualmente \npreditores da press\u00e3o de pulso. Verifi camos ainda que valores de press\u00e3o de pulso \nsuperiores a 70 mmHg, valores de velocidade de onda de pulso superiores a 10,4 m/s e \num score de calcifi ca\u00e7\u00e3o vascular simples superior a 3 se associaram a maior mortalidade \n(Fig. 4.2), com semelhante \u00e1rea sob a curva na an\u00e1lise de curvas ROC (receiver operating \ncharacteristic) (Fig. 4.3).\n\nEm an\u00e1lise multivariada, o risco de morte ajustado para in\u00fameras vari\u00e1veis foi semelhante \npara estes tr\u00eas fatores (Tabela 4.1), mas a velocidade de onda de pulso foi preditora de \nmortalidade apenas nos doentes n\u00e3o diab\u00e9ticos. Este achado pode ser explicado pelo facto \nde, nos doentes diab\u00e9ticos, a mortalidade ter sido elevada e ter -se verifi cado tanto nos doentes \ncom velocidade de onda de pulso alta como normal.\n\nCalcifi ca\u00e7\u00f5es vasculares, rigidez arterial e mortalidade\n\nFig. 4.2. Um SCVS >3, uma velocidade de onda de pulso (VOP) >10,4 m/s e uma press\u00e3o de pulso (PP) > 70 \nmmHg associaram -se a menor sobrevida (Kaplan -Meier)\n\n\n\n42\n\nRisco de morte avaliado por Cox regression\n\nB HR IC 95% Sig.\nTodos os doentes SCVS >3 1,196 3,308 1,109 -9,863 0,032\nTodos os doentes PP >70 mmHg 1,171 3,227 1,114 -9,347 0,031\nN\u00e3o diab\u00e9ticos VOP > 10,5 m/s 1,092 2,981 1,013 -8,775 0,047\n\nHR, hazard ratio; IC, intervalo de confian\u00e7a.\n\nTabela 4.1. HR ajustado para idade, dura\u00e7\u00e3o de hemodi\u00e1lise, diabetes mellitus, doen\u00e7a vascular pr\u00e9via, \n\u00edndice de massa corporal, press\u00e3o arterial sist\u00f3lica e doses de carbonato de c\u00e1lcio e de calcitriol\n\nEm resumo, demonstramos que calcifi ca\u00e7\u00f5es vasculares avaliadas por RX simples se \nassociam a um aumento da rigidez arterial. Este estudo foi publicado na revista Nephrology \nDialysis and Transplantation em 200912 e foi um dos estudos selecionados pelas guidelines \nKDIGO 2009 para mostrar a associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e mortalidade, \nconfi rmando assim a utilidade e a validade do score de calcifi ca\u00e7\u00e3o vascular simples na \nidentifi ca\u00e7\u00e3o dos doentes com mais elevado risco cardiovascular.\n\nFig. 4.3. A \u00e1rea sob a curva em rela\u00e7\u00e3o \u00e0 mortalidade foi semelhante para o score de calcifica\u00e7\u00e3o vascular \nsimples (SCVS), para a velocidade de onda de pulso (VOP) e para a press\u00e3o de pulso (PP) (an\u00e1lise de \ncurvas ROC)\n\n\n\n43\n\nRefer\u00eancias\n\n  1. Sutton -Tyrrell K, Najjar SS, Boudreau RM, et al. Elevated aortic pulse wave velocity, a marker \nof arterial stiffness, predicts cardiovascular events in well -functioning older adults. Circulation \n2005;28;111(25):3384 -390.\n\n  2. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end -stage renal \ndisease. Circulation 1999; 11;99(18):2434 -2439.\n\n  3. Covic A, Mardare N, Gusbeth -Tatomir P, et al. Arterial wave refl ections and mortality in \nhaemodialysis patients -only relevant in elderly, cardiovascularly compromised? Nephrol Dial \nTransplant 2006;21: 2859 -2866.\n\n  4. London GM, Gu\u00e9rin A. Infl uence of arterial pulse and refl ective waves on systolic blood pressure \nand cardiac function. J Hypertens 1999; 17 (Suppl 2):S3 -S6. [Review.]\n\n  5. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart \ndisease risk change with aging? The Framingham Heart Study. Circulation 2001; 103: 1245-\n-1249.\n\n  6. Tozawa M, Iseki K, Iseki C, et al. Pulse pressure and risk of total mortality and cardiovascular \nevents in patients on chronic hemodialysis. Kidney Int 2002; 61: 717 -726.\n\n  7. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in \npatients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548 -1555.\n\n  8. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of \nrenal osteodystrophy: A position statement from kidney disease: improving global outcomes \n(KDIGO). Kidney Int 2006; 69: 1945 -1953\n\n  9. Gu\u00e9rin AP, London GM, Marchais SJ, et al. Arterial stiffening and vascular calcifi cations in end-\n-stage renal disease. Nephrol Dial Transplant 2000; 15 (7): 1014 -1021.\n\n10. Raggi P, Bellasi A, Ferramosca E, et al. Association of pulse wave velocity with vascular and \nvalvular calcifi cation in hemodialysis patients. Kidney Int 2007; 71: 802 -807.\n\n11. Kauppila LI, Polak JF, Cupples LA et al. New indices to classify location, severity and progression \nof calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997; 132: \n245 -250.\n\n12. Adrag\u00e3o T, Pires A, Birne R, Curto JD, Lucas C, Gon\u00e7alves M, Negr\u00e3o AP. A plain X -ray vascular \ncalcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol \nDial Transplant 2009; 3:997 -1002.\n\n\n\n\n\nNephrol Dial Transplant (2009) 24: 997\u20131002\ndoi: 10.1093/ndt/gfn584\nAdvance Access publication 24 October 2008\n\nOriginal Article\n\nA plain X-ray vascular calcification score is associated with arterial\nstiffness and mortality in dialysis patients\n\nTeresa Adraga?o1, Ana Pires1, Rita Birne1, Jose Dias Curto2, Carlos Lucas1, Margarida Gonc?alves1\n\nand Aca?cio Pita Negra?o1\n\n1Nefrocl??nica-Estoril, Diaverum, Estoril and 2ISCTE, Business School, Lisbon, Portugal\n\nAbstract\nBackground. Vascular calcifications are highly prevalent\nin dialysis patients and are associated with arterial stiffness\nand mortality. The use of simple and inexpensive methods\nto evaluate arterial stiffness and vascular calcifications is\ndesired. The objective of this study was to evaluate the\nrelationship of a simple vascular calcification score (SVCS)\nwith pulse wave velocity (PWV) and pulse pressure (PP)\nand to evaluate their association with all-cause mortality.\nMethods. 101 haemodialysis patients (71 men; 19% di-\nabetic) were evaluated. At baseline, arterial stiffness was\nmeasured by PP and by PWV with Complior. SVCS was\nevaluated in plain X-ray of pelvis and hands.\nResults. During a 43-month observational period,\n31 patients died. By Kaplan\u2013Meier analysis, SVCS >3\n(P = 0.001), PP > 70 mmHg (P = 0.001) and PWV >\n10.5 m/s (P &lt;0.001) were found to be associated with\nlower cumulative survival. Adjusting for multiple variables,\nassociation with mortality was maintained for SVCS >3\n(HR = 3.308, P = 0.032) and PP > 70 mmHg (HR =\n3.227, P = 0.031) in all patients and for PWV > 10.5 m/s\n(HR = 2.981, P = 0.047) in non-diabetic patients. Age\n(P &lt;0.001), systolic pressure (P = 0.004) and SVCS >\n3 (P = 0.032) were associated with PWV. Diabetes (P =\n0.031), calcium carbonate dose (P = 0.009) and SVCS >\n3 (P = 0.012) were associated with PP.\nConclusion. Higher SVCS, PWV and PP were associated\nwith higher mortality in this population. SVCS was associ-\nated with arterial stiffness. Simple and inexpensive methods\nsuch as PP or SVCS may be used to detect mortality risk\nand to provide important information that may be relevant\nfor guiding therapeutic intervention in dialysis patients.\n\nKeywords: arterial stiffness; haemodialysis; mortality;\nvascular calcification\n\nCorrespondence and offprint requests to: Teresa Adraga?o, Nefrocl??nica\nEstoril, Diaverum, Rua Vale de S Rita 19, 2765-293 Estoril,\nPortugal. Tel: +00351967037522; Fax: +00351214872931; E-mail:\ntadragao@netcabo.pt\n\nIntroduction\n\nIt is clearly demonstrated that dialysis patients have a much\nhigher cardiovascular mortality when compared with the\ngeneral population [1]. This high cardiovascular risk in\nchronic kidney disease (CKD) patients is only partly ex-\nplained by traditional risk factors [2]. Vascular calcifica-\ntions evaluated by ultrasonography [3], plain X-ray [4],\nelectron beam computed tomography [5] or multislice com-\nputed tomography [6] have been associated with mortality\nin dialysis patients. KDIGO has recommended a new clas-\nsification for mineral and bone disorder of chronic kidney\ndisease patients (CKD-MBD) that includes the evaluation\nof vascular calcifications [7]. Arterial stiffness is an alter-\nation of the arterial wall properties with multiple causes,\nsome of which are old age, diabetes, hypertension and me-\ndial calcification. All these features are highly prevalent in\ndialysis patients, and arterial stiffness is a common finding\nin this population. In dialysis patients, arterial stiffness has\nbeen associated with all-cause and cardiovascular mortality\n[8], but this finding is not universal [9]. One of the KDIGO\nImaging Work Group research questions is the evaluation of\nthe relationship between the radiological vascular calcifica-\ntion assessment and the measurement of vascular stiffness\nby pulse wave velocity (PWV) and pulse pressure (PP) [7].\nVascular calcifications evaluated by ultrasonography [10]\nand by plain X-ray [11] have already been associated with\narterial stiffness in dialysis patients. We developed a sim-\nple vascular calcification score (SVCS) evaluated in plain\nX-ray of pelvis and hands that was a predictor of cardio-\nvascular mortality and was associated with higher risk of\ncoronary disease, peripheral artery disease and cardiovas-\ncular hospitalizations [12]. The objective of this study was\nto evaluate the relationship of this SVCS with PWV and\nPP and to evaluate the association of vascular calcifica-\ntion and arterial stiffness with all-cause mortality in our\npatients.\n\nStudy design\n\nThis study was a cross-sectional analysis performed in a\ngroup of prevalent haemodialysis (HD) patients to evaluate\nthe relationship between a SVCS evaluated in plain X-ray\n\nC\u00a9 The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.\nFor Permissions, please e-mail: journals.permissions@oxfordjournals.org\n\n\n\n998 T. Adraga?o et al.\n\nwith PWV and PP. This group of patients was followed\nprospectively during a period of 43 months for evaluation\nof the impact of vascular calcifications and arterial stiffness\nin all-cause mortality.\n\nPopulation\n\nOne hundred and one patients (71 men and 30 women),\ntreated with HD for at least 6 months, with a mean age of\n58.8 \u00b1 15.5 (26\u201389) years and mean HD duration of 55.8 \u00b1\n54.8 (6\u2013289) months, from a single HD unit, accepted to\nparticipate in this study that was approved by the institu-\ntional scientific board; 19 patients (18.8%) were diabetic.\nIn the 6 months before PWV evaluation, 89 and 41 patients\nwere treated with calcium carbonate and calcitriol, respec-\ntively. The mean calcium carbonate and calcitriol prescribed\ndoses in these patients were 2.5 \u00b1 1.3 [1\u20138] g/day and 1.1 \u00b1\n0.6 [0.25\u20133] ?g/week, respectively. Oral or intravenous cal-\ncitriol was administered in 25 and 16 patients, respectively.\nNo patients received sevelamer or cinacalcet as they were\nnot available at the time of the study; 71 patients received\nanti-hypertensive treatment (one single medication in 25\npatients and two different medications in 46 patients). At\nbaseline, diagnosis of vascular disease was based on a query\nanswered by the attending physicians, concerning previous\nclinical manifestations and test results, according to the\nusual standard of care. Coronary artery disease was diag-\nnosed if the patient had a positive stress test, had suffered\na myocardial infarction or had been submitted to a percu-\ntaneous coronary intervention or coronary bypass surgery.\nDiagnosis of cerebral vascular disease was based on the\noccurrence of stroke or transient ischaemic attack or the\ndetection of an old cerebral infarction in computed tomog-\nraphy. Peripheral arterial disease was diagnosed if there\nwas claudication, ischaemic ulcers, lower limb amputation,\nrevascularization or diagnosis of obstruction by Doppler\nor angiography. Coronary artery disease was diagnosed in\n20 patients (19.8%), peripheral artery disease was present\nin 16 patients (15.8%) and cerebral vascular disease was\nidentified in 4 patients (4%). During a period of 43 months,\n31 patients died and 8 patients received a kidney transplant.\nNo patient was lost for follow-up.\n\nVascular calcifications and arterial stiffness\n\nVascular calcifications were evaluated at baseline by a sin-\ngle observer blind to clinical data, in plain X-ray of pelvis\nand hands by a method previously described in detail [12].\nPelvis films were divided into four sections by two imag-\ninary lines: a horizontal line over the upper limit of both\nfemoral heads and a median vertical line over the verte-\nbral column. Hands films were divided for each hand by\na horizontal line over the upper limit of the metacarpal\nbones. Pelvis films evaluated iliac and femoral arteries\n(ileo-femoral score) and hands films evaluated radial and\ndigital arteries (hands score). Any vascular calcification\nlining the vessel walls, either in an irregular pattern or in\na linear pattern, was considered. The presence of vascular\ncalcifications in each section was rated as 1 and its absence\nas 0. The total vascular calcification score was the sum of\n\nall sections and ranged from 0 to 8. Arterial stiffness was\nevaluated by PWV and by PP. PWV was evaluated twice, at\nbaseline, 24 h after a HD session, using a non-invasive auto-\nmated device, Complior. Complior measures the propaga-\ntion of the same individual pulse wave between two arterial\npoints. The proximal and distal sensors were located in the\ncarotid and femoral arteries, respectively. The velocity of\nthe pulse wave is calculated with the formula distance/time,\nwhere the distance corresponds to the distance between the\nsuprasternal notch and the femoral artery pulse at the groin,\nand the time corresponds to the time that takes a pulse wave\nthat originates in the heart to reach the femoral artery. The\nComplior software calculates the velocity of conduction.\nPP was evaluated by the formula (systolic blood pressure ?\ndiastolic blood pressure). The mean values of PP were time\naveraged for the 6-month period preceding PWV evalua-\ntion, corresponding to the mid-week HD session in the day\nof the monthly blood sample collection. PP was calculated\nfrom the predialysis evaluation of blood pressure.\n\nBiochemical analysis\n\nMid-week Kt/V and predialysis serum levels of the follow-\ning biochemical parameters were evaluated and time aver-\naged for the 6 months preceding the evaluation of PWV.\nKt/V, Ca, P, Ca \u00d7 P product, alkaline phosphatase, albumin\nand C-reactive protein (CRP) were evaluated every month.\nCa levels were adjusted to albumin levels. Total intact iPTH\n(iPTH) was evaluated every 3 months by immunochemilu-\nminescence (three evaluations per patient) using a second\ngeneration assay, Elecsys 2010 from Roche Diagnostics,\nBasel, Switzerland. CRP was evaluated with an immunotur-\nbidimetric assay. Total cholesterol, HDL cholesterol, LDL\ncholesterol and triglycerides were evaluated twice.\n\nStatistical analysis\n\nData are presented as frequencies for categorical variables\nand mean values with SD for continuous variables. Com-\nparison between groups was performed by the indepen-\ndent samples t-test, chi-square and Fisher exact test when\nappropriate. Correlation was performed using the Pearson\ncorrelation coefficient. Survival curves were estimated by\nKaplan\u2013Meier analysis and compared by the log-rank test.\nA Cox regression model was used to identify predictors\nof mortality. Variables in this model, besides the vascular\ncalcification score, PWV and PP, were age, HD duration,\ndiabetes, presence of previous vascular disease, body mass\nindex (BMI), systolic pressure and calcitriol and calcium\ncarbonate doses. Separate Cox regression models using the\nenter method were applied to evaluate the adjusted hazard\nratio mortality of vascular calcification score, PWV and\nPP. Independent association of vascular calcification with\nPWV and with PP was evaluated in linear regression models\nadjusting for age, HD duration, diabetes, cholesterol levels,\nsystolic pressure, BMI, and calcitriol and calcium carbon-\nate doses. The absence of collinearity among explanatory\nfactors was checked in all models based on standard pro-\ncedures. The receiver operating characteristic (ROC) curve\n\n\n\nArterial stiffness and mortality in haemodialysis patients 999\n\nTable 1. Demographic, biochemical and clinical factors\n\nAll patients Pulse wave velocity (m/s) Pulse pressure (mmHg) Plain X-ray score\n\n?10.5 >10.5 ?70 >70 ?3 >3\n\nN (%) 101 61 (60%) 40 (40%) 68 (67%) 33 (33%) 42 (42%) 58 (58%)\nAge (years) 58.9 \u00b1 15.5 53.1 \u00b1 15.2 67.6 \u00b1 11.3?? 56.2 \u00b1 15.8 64.3 \u00b1 13.6? 51.1 \u00b1 15.9 64.4 \u00b1 12.7??\nMale gender\n\n(N, %)\n71 (70%) 45(74%) 26 (65%) 47 (69%) 24 (73%) 27 (64%) 44 (75%)\n\nDiabetes (N, %) 19 (19%) 6 (10%) 13 (33%)? 8 (12%) 11 (33%)? 3 (7%) 16 (27%)?\nHD duration\n\n(months)\n55.8 \u00b1 54.8 56.7 \u00b1 59.0 57.4 \u00b1 45.6 54.2 \u00b1 51.8 62.7 \u00b1 58.3 47.8 \u00b1 48.6 63.5 \u00b1 56.8\n\nSystolic pressure\n(mmHg)\n\n145.1 \u00b1 25.7 141.3 \u00b1 24.4 151.0 \u00b1 26.8 133.3 \u00b1 19.8 169.4 \u00b1 18.5?? 136.521.4 151.3 \u00b1 26.9??\n\nDiastolic pressure\n(mmHg)\n\n82.7 \u00b1 13.7 84.2 \u00b1 14.9 80.6 \u00b1 11.5 81.0 \u00b1 14.0 86.3 \u00b1 12.5 82.2 \u00b1 13.7 83.1 \u00b1 13.8\n\nMean arterial\npressure\n(mmHg)\n\n103.5 \u00b1 16.3 103.2 \u00b1 17.1 104.0 \u00b1 15.1 98.5 \u00b1 15.3 114.0 \u00b1 13.1?? 100.3 \u00b1 15.5 105.8 \u00b1 16.6\n\nCa (mg/dL) 9.3 \u00b1 0.9 9.3 \u00b1 0.9 9.4 \u00b1 0.8 9.2 \u00b1 0.9 9.5 \u00b1 0.8 9.2 \u00b1 1.0 9.4 \u00b1 0.7\nP (mg/dL) 5.2 \u00b1 1.4 5.4 \u00b1 1.3 4.9 \u00b1 1.5 5.4 \u00b1 1.4 4.9 \u00b1 1.4 5.4 \u00b1 1.2 5.1 \u00b1 1.5\niPTH (pg/mL) 476.4 \u00b1 442 526.2 \u00b1 483.7 400.3 \u00b1 362.2 495.7 \u00b1 441.9 436.4 \u00b1 446.5 452.5 \u00b1 394.3 493.3 \u00b1 475.7\nTotal cholesterol\n(mg/dL)\n\n203.4 \u00b1 49.3 201.6 \u00b1 49.8 206.4 \u00b1 49.1 208.4 \u00b1 50.0 192.0 \u00b1 46.7 207.449.5 200.6 \u00b1 49.4\n\nAlbumin (g/dL) 4.4 \u00b1 0.6 4.4 \u00b1 0.7 4.3 \u00b1 0.4 4.4 \u00b1 0.6 4.4 \u00b1 0.4 4.4 \u00b1 0.7 4.4 \u00b1 0.4\nCRP (mg/dL) 1.28 \u00b1 0.6 1.23 \u00b1 0.3 1.35 \u00b1 0.8 1.25 \u00b1 0.2 1.33 \u00b1 0.9 1.25 \u00b1 0.36 1.31 \u00b1 0.7\nKt/V 1.41 \u00b1 0.2 1.43 \u00b1 0.2 1.38 \u00b1 0.2 1.40 \u00b1 0.2 1.41 \u00b1 0.1 1.43 \u00b1 0.2 1.38 \u00b1 0.2\nBody mass index\n\n(Kg/cm2)\n24.2 \u00b1 4.8 24.1 \u00b1 5.2 22.9 \u00b1 3.9 24.8 \u00b1 5.1 23.1 \u00b1 4.0 24.9 \u00b1 5.7 23.7 \u00b1 4.1\n\nCa dose (g/day) 2.45 \u00b1 1.31 2.47 \u00b1 1.22 2.41 \u00b1 1.49 2.33 \u00b1 1.16 2.72 \u00b1 1.61 2.52 \u00b1 1.55 2.39 \u00b1 1.13\nCalcitriol dose\n(?g/week)\n\n1.14 \u00b1 0.6 1.13 \u00b1 0.66 1.15 \u00b1 0.52 1.14 \u00b1 0.65 1.13 \u00b1 0.53 1.17 \u00b1 0.74 1.12 \u00b1 0.53\n\nAnti-HTA drugs\n(?2) (N, %)\n\n46 (46%) 26 (43%) 20 (50%) 20 (29%) 26 (79%)?? 12 (29%) 34 (74%)??\n\nCAD (N, %) 20 (20%) 7 (12%) 13 (33%)? 12 (18%) 8 (24%) 7 (17%) 13 (22%)\nPAD (N, %) 16 (16%) 4 (7%) 12 (30%)? 4 (6%) 12 (36%)?? 2 (5%) 14 (24%)?\nVascular disease\n\n(N, %)\n32 (32%) 11 (18%) 21 (53%)?? 16 (24%) 16 (49%)? 8 (19%) 24 (41%)?\n\nAll-cause death\n(N, %)\n\n31 (31%) 10 (16%) 21 (53%)?? 14 (20%) 17 (52%)?? 5 (12%) 26 (44%)??\n\nCRP = C-reactive protein; CAD = coronary artery disease; PAD = peripheral artery disease.\n?P &lt;0.05; ??P &lt;0.01.\n\nanalysis allowed the identification of the best cut-off val-\nues in relation with all-cause mortality for plain X-ray score\n(SVCS >3), PWV (>10.5 m/s) and PP (>70 mmHg). These\ncut-off values were used to compare groups in univariate\nanalysis and to compare survival.\n\nStatistical analyses were performed with the SPSS sys-\ntem 15.0 (SPSS Inc., Chicago, IL, USA) and with the Med-\ncalc program version 6.0 (Medcalc software, Mariakerke,\nBelgium). For all comparisons and statistical tests, a P-\nvalue &lt;0.05 implied the rejection of the null hypothesis\nand the result was considered statistically significant.\n\nResults\n\nDescriptive and univariate analysis\n\nIn this group of 101 patients, vascular calcifications were\npresent in 77 patients. A SVCS > 3, a PWV > 10.5 m/s\nand a PP > 70 mmHg were observed in 59, 42 and 33 pa-\ntients, respectively. In univariate analysis (Table 1), higher\nPWV, higher PP and higher vascular calcification score\nwere associated with older age and with higher prevalence\n\nFig. 1. A simple vascular calcification score >3 was associated with\nhigher pulse wave velocity and with higher pulse pressure.\n\nof diabetes, vascular disease and all-cause mortality. The\ncalcium carbonate dose was correlated with systolic pres-\nsure (r = 0.277; P = 0.005) and with PP (r = 0.226; P =\n0.023). Patients with SVCS > 3, when compared with pa-\ntients with SVCS ? 3, had a higher PWV (11.2 \u00b1 1.9 versus\n9.3 \u00b1 1.5 m/s; P &lt;0.001) and a higher PP (68.2 \u00b1 20.4\nversus 54.3 \u00b1 13 mmHg, P &lt;0.001) (Figure 1).\n\n\n\n1000 T. Adraga?o et al.\n\nTable 2. Vascular calcification and arterial stiffness (linear regression)\n\nDependent variable Independent variables B CI Significance R2\n\nAge 0.055 0.032\u20130.079&lt;0.001\nPulse wave velocity (all patients) Systolic pressure 0.021 0.007\u20130.035 0.004 0.424\n\nSVCS >3 0.845 0.074\u20131.615 0.032\n\nDiabetes 10.102 0.926\u201319.278 0.031\nPulse pressure (all patients) Calcium carbonate (g/day) 3.281 0.844\u20135.719 0.009 0.268\n\nSVCS >3 10.103 2.315\u201317.890 0.012\n\nSVCS = simple vascular calcification score; PP = pulse pressure; PWV = pulse wave velocity.\n\nFig. 2. ROC curves of simple vascular calcification score, pulse wave\nvelocity and pulse pressure in relation with all-cause mortality.\n\nFactors independently associated with PWV and with PP\n\nIn all patients, using linear regression with the enter method\nand adjusting for multiple factors (Table 2), a higher vas-\ncular calcification score was directly associated with PWV\n(P = 0.032) and with PP (P = 0.012). Other factors ex-\nplaining PWV were age (P &lt;0.001) and systolic pressure\n(P = 0.004). Diabetes (P = 0.031) and calcium carbonate\ndose (P = 0.009) were directly associated with PP.\n\nROC curve analysis of mortality\n\nDuring a 43-month observational period, 31 (30.7%) pa-\ntients died. All-cause mortality was associated with a SVCS\n>3 (AUC = 0.701; 95% CI [0.602\u20130.788]; 84% sensitiv-\nity, 53% specificity, 88% negative predictive value and 1.78\npositive likelihood ratio), with a PWV >10.5 m/s (AUC =\n0.738; 95% CI [0.641\u20130.820]; 71% sensitivity, 69% speci-\nficity, 85% negative predictive value and 2.26 positive like-\nlihood ratio) and with a PP >70 mmHg (AUC = 0.640;\n95% CI [0.539\u20130.733]; 48% sensitivity, 81% specificity,\n78% negative predictive value and 2.61 positive likelihood\nratio) (Figure 2). There was no difference in the AUC be-\ntween ROC curves.\n\nCumulative survival and all-cause mortality risk\n\nLower cumulative survival (Figure 3) was observed in pa-\ntients with a SVCS >3 (32.7 versus 40.8 months; log\n\nrank = 10.8; P = 0.001), with a PP >70 mmHg (30.9\nversus 38.8 months; log rank = 10.8; P = 0.001) and with\na PWV >10.5 m/s (31.3 versus 39.3; log rank = 13.3;\nP &lt;0.001). In diabetic patients, higher PWV was not as-\nsociated with higher mortality: 4 deaths in 6 patients with\nPWV ?10.5 m/s (67%) versus 8 deaths in 13 patients with\nPWV >10.5 m/s (62%). In Cox regression analysis, using\nthe enter method (Table 3), the mortality-adjusted hazard\nratio was 3.308 (P = 0.032) for SVCS >3, 3.227 (P =\n0.031) for PP > 70 mmHg in all patients and was 2.981\n(P = 0.047) for PWV >10.5 m/s in non-diabetic patients.\nEntering vascular calcification score, PWV and PP in the\nsame model and using the enter method, SVCS > 3 (HR =\n4.247, P = 0.015), PP > 70 mmHg (HR = 3.795, P =\n0.031), lower BMI (HR = 0.856, P = 0.017) and vascular\ndisease at baseline (HR = 2.551, P = 0.047) were associ-\nated with mortality (Table 4).\n\nDiscussion\n\nIn general population, it was demonstrated that, in patients\nolder than 60 years of age, higher PP was associated with\nhigher cardiovascular risk [13]. In dialysis patients it was\ndemonstrated that a higher PP evaluated before or after HD\nwas associated with higher mortality in non-diabetic pa-\ntients [14] or in all patients [15] and that higher aortic PWV\nwas associated with mortality [8]. Vascular calcifications,\nevaluated by different methodologies [3\u20136,12], have been\nassociated with mortality in dialysis patients. In this study,\nwe tried to answer one of the research questions suggested\nby the KDIGO Imaging Work Group: the evaluation of the\nrelationship between the radiological vascular calcification\nassessment and the measurement of vascular stiffness by\nPWV and by PP [7]. Vascular calcifications evaluated by ul-\ntrasonography have already been associated with increased\nstiffness of large elastic-type arteries [10]. The Kauppila\nscore, [16] evaluating calcifications in the abdominal aorta,\nwhich is an elastic artery, was the first plain X-ray calcifica-\ntion score to be correlated with arterial stiffness, evaluated\nby carotid-femoral PWV [11]. In this study, we used a SVCS\nevaluated in plain X-ray of pelvis and hands that has been\npreviously associated with higher cardiovascular mortal-\nity, cardiovascular disease and cardiovascular hospitaliza-\ntions [12]. We verified that this score, although evaluating\nonly muscular arteries, was associated both with carotid-\nfemoral PWV and with PP. In the same dialysis population,\n\n\n\nArterial stiffness and mortality in haemodialysis patients 1001\n\nTable 3. Adjusted hazard ratio of all-cause mortality (Cox regression)\n\nIndependent variables B HR CI Significance\n\nAll patients SVCS >3 1.196 3.308 1.109\u20139.863 0.032\nAll patients PP >70 mmHg 1.171 3.227 1.114\u20139.347 0.031\nNon-diabetic patients PWV >10.5 m/s 1.092 2.981 1.013\u20138.775 0.047\n\nSVCS = simple vascular calcification score; PP = pulse pressure; PWV = pulse wave velocity; HR = adjusted hazard ratio.\n\nTable 4. Predictors of all-cause mortality (Cox regression)\n\nDependent variable Independent variables B HR CI Significance\n\nAll-cause mortality (all patients) Age 0.004 1.004 0.966\u20131.044 0.824\nHD duration (months) 0.000 0.999 0.992\u20131.006 0.805\nDiabetes 0.348 1.416 0.508\u20133.948 0.506\nVascular disease at baseline 0.936 2.551 1.014\u20136.419 0.047\nSystolic pressure (mmHg) ?0.022 0.978 0.955\u20131.002 0.077\nBody mass index (kg/cm2) ?0.156 0.856 0.753\u20130.972 0.017\nCalcium carbonate (g/day) ?0.100 0.905 0.651\u20131.259 0.554\nCalcitriol (?g/week) ?0.161 0.851 0.455\u20131.594 0.615\nSVCS >3 1.446 4.247 1.319\u201313.673 0.015\nPP >70 mmHg 1.334 3.795 1.132\u201312.722 0.031\nPWV >10.5 m/s ?0.026 0.974 0.367\u20132.589 0.958\n\nSVCS = simple vascular calcification score; PP = pulse pressure; PWV = pulse wave velocity; HR = adjusted hazard ratio.\n\nFig. 3. A simple vascular calcification score >3, a pulse wave velocity >10.5 m/s and a pulse pressure >70 mmHg were associated with lower survival.\n\nhigher vascular calcification score, higher PWV and higher\nPP were associated with mortality with comparable hazard\nratios and with similar AUC in ROC curve analysis. In\nour study, PWV was an independent predictor of mortality\nonly in non-diabetic patients, probably because, in diabetic\npatients, mortality was equally high with higher or lower\nPWV. In a study evaluating a large cohort of HD patients,\nTozawa et al. [14] observed that PP was also a predictor\nof mortality only in non-diabetic patients. Covic et al. [9]\nverified an opposite situation: in a group of young HD\npatients with a low prevalence of cardiovascular disease,\narterial stiffness evaluated by the augmentation index was\nnot a predictor of mortality. PWV evaluation requires a spe-\ncific device and is not widely available. In our study, simple\nand inexpensive methods such as the evaluation of PP or\nthe assessment of the SVCS with plain X-ray were enough\nto detect higher cardiovascular risk. Diagnosis of arterial\nstiffness and vascular calcification has the advantage of\nalso providing important information that can be used for\n\nguiding therapeutic intervention in dialysis patients. Identi-\nfication of patients with higher PP may orientate the choice\nof anti-hypertensive treatment with special indication for\ninhibition of the renin\u2013angiotensin axis and avoidance of\ninappropriate reduction of diastolic blood pressure that may\nthreaten coronary reserve [17]. At the present time, it also\nseems possible to interfere in some factors associated with\nthe development of vascular calcifications. Some studies\nin dialysis patients have already demonstrated that vascular\ncalcifications may progress or remain stable depending on\nthe control of mineral metabolism alterations [5,18] and that\nphosphate binder choice may have an impact on mortality\n[5]. London et al. showed an association between vascular\ncalcifications and low bone turnover [19] and found a sig-\nnificant interaction between calcium-containing phosphate\nbinders and aortic calcification and stiffness in the presence\nof adynamic bone disease [20]. The presence or extension of\nvascular calcifications may be an indication for an intensive\nhyperphosphataemia control, for an adequate choice of\n\n\n\n1002 T. Adraga?o et al.\n\nphosphate binder and for avoidance of PTH oversuppres-\nsion. In several studies, association of a calcium carbonate\ndose with vascular calcifications [3\u20135,18,20,21] and with\nPWV [8,20] has already been described and in our patients\nwe have also verified a correlation between the calcium\ncarbonate dose and PP. We have not verified any associ-\nation between calcium carbonate and calcitriol treatment\nwith survival.\n\nDifferent methods can be used to evaluate vascular calci-\nfications in dialysis patients. Electron beam computed to-\nmography and multislice computed tomography are consid-\nered to be the gold standard for the evaluation of coronary\ncalcifications. They perform a quantitative assessment of\ncoronary calcification that permits the evaluation of calcifi-\ncation progression but are very expensive. Screening vascu-\nlar calcifications in dialysis patients may be performed by\ndifferent and inexpensive plain X-ray methods [4,11,12,22]\nthat have the advantage of being easily interpreted by the\nattending physician. The SVCS and Kauppila score are\nsemi-quantitative scores with cut-off values associated with\nhigher cardiovascular risk. A cardiovascular calcification\nindex using the Kauppila score and valvular calcification\nevaluated by echocardiography has been demonstrated to\nbe associated with coronary calcification in HD patients\n[23]. Simpler methods to evaluate vascular calcifications\nseem to be an attractive option but the final choice would\ndepend on the available tests and on the preference of the\nnephrologist.\n\nIn summary, a SVCS evaluated in plain X-ray and PP\nwere associated with higher mortality in dialysis patients.\nPWV was associated with higher mortality in non-diabetic\npatients. In this study, we demonstrate that a SVCS evalu-\nated in plain X-ray of pelvis and hands is associated with the\narterial stiffness evaluated by PWV and PP. Identification of\nvascular calcifications in dialysis patients is included in the\nclassification of CKD-MBD, and simple and inexpensive\nplain X-ray methods are available for that purpose. Arterial\nstiffness or the presence of vascular calcifications are an\nalert sign for an increased mortality risk, and this informa-\ntion may be relevant for guiding therapeutic intervention\nin dialysis patients, such as selecting the most adequate\nanti-hypertensive regimen or achieving an effective min-\neral metabolism management.\n\nConflict of interest statement. Teresa Adragao has received research grants\nfrom Genzyme, has received lecture fees from Amgen, Genzyme, Abbot\nand Novartis and consultancy fees from Genzyme and Abbot. The other\nauthors have no conflict of interest of any type (personal, commercial,\npolitical, academic or financial) in the elaboration and presentation of this\nwork.\n\nReferences\n\n1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardio-\nvascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5\nSuppl 3): S112\u2013S119\n\n2. Cheung AK, Sarnak MJ, Yan G et al. Atherosclerotic cardiovascular\ndisease risks in chronic hemodialysis patients. Kidney Int 2000; 58:\n353\u2013362\n\n3. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial\nstiffness, and cardiovascular risk in end-stage renal disease. Hyper-\ntension 2001; 38: 938\u2013942\n\n4. London GM, Gue?rin AP, Marchais SJ et al. Arterial media calcifica-\ntion in end-stage renal disease: impact on all-cause and cardiovascular\nmortality. Nephrol Dial Transplant 2003; 18: 1731\u20131740\n\n5. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary\ncalcification and phosphate binder choice in incident hemodialysis\npatients. Kidney Int 2007; 71: 438\u2013441\n\n6. Matsuoka M, Iseki K, Tamashiro M et al. Impact of high coronary\nartery calcification score (CACS) on survival in patients on chronic\nhemodialysis. Clin Exp Nephrol 2004; 8: 54\u201358\n\n7. Moe S, Dru?eke T, Cunningham J et al. Kidney disease: improving\nglobal outcomes (KDIGO). Definition, evaluation, and classification\nof renal osteodystrophy: a position statement from kidney disease:\nimproving global outcomes (KDIGO). Kidney Int 2006; 69: 1945\u2013\n1953\n\n8. Guerin AP, Blacher J, Pannier B et al. Impact of aortic stiffness\non survival in end-stage renal disease. Circulation 1999; 99: 2434\u2013\n2439\n\n9. Covic A, Mardare N, Gusbeth-Tatomir P et al. Arterial wave reflec-\ntions and mortality in haemodialysis patients\u2014only relevant in el-\nderly, cardiovascularly compromised? Nephrol Dial Transplant 2006;\n21: 2859\u20132866\n\n10. Gue?rin AP, London GM, Marchais SJ et al. Arterial stiffening and\nvascular calcifications in end-stage renal disease. Nephrol Dial Trans-\nplant 2000; 15: 1014\u20131021\n\n11. Raggi P, Bellasi A, Ferramosca E et al. Association of pulse wave\nvelocity with vascular and valvular calcification in hemodialysis pa-\ntients. Kidney Int 2007; 71: 802\u2013807\n\n12. Adragao T, Pires A, Lucas C et al. A simple vascular calcification\nscore predicts cardiovascular risk in haemodialysis patients. Nephrol\nDial Transplant 2004; 19: 1480\u20131488\n\n13. Franklin SS, Larson MG, Khan SA et al. Does the relation of blood\npressure to coronary heart disease risk change with aging? The Fram-\ningham Heart Study. Circulation 2001; 103: 1245\u20131249\n\n14. Tozawa M, Iseki K, Iseki C et al. Pulse pressure and risk of total mor-\ntality and cardiovascular events in patients on chronic hemodialysis.\nKidney Int 2002; 61: 717\u2013726\n\n15. Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse\npressure and mortality in patients undergoing maintenance hemodial-\nysis. JAMA 2002; 287: 1548\u20131555\n\n16. Kauppila LI, Polak JF, Cupples LA et al. New indices to classify\nlocation, severity and progression of calcific lesions in the abdominal\naorta: a 25-year follow-up study. Atherosclerosis 1997; 132: 245\u2013250\n\n17. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Arterial stiffness in renal\npatients: an update. Am J Kidney Dis 2005; 45: 965\u2013977\n\n18. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Seve-\nlamer attenuates the progression of coronary and aortic calcification\nin hemodialysis patients. Kidney Int 2002; 62: 245G\u2013252G\n\n19. London GM, Marty C, Marchais SJ et al. Arterial calcifications and\nbone histomorphometry in end-stage renal disease. J Am Soc Nephrol\n2004; 15: 1943\u20131951\n\n20. London GM, Marchais SJ, Ge?rin AP et al. Association of bone activity,\ncalcium load, aortic stiffness, and calcifications in ESRD. J Am Soc\nNephrol 2008; 19(9): 1827\u20131835\n\n21. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcifica-\ntion in young adults with end-stage renal disease who are undergoing\ndialysis. N Engl J Med 2000; 342: 1478\u20131483\n\n22. Okuno S, Maeno Y, Maekawa K et al. Presence of abdominal aortic\ncalcification is significantly associated with all-cause and cardiovas-\ncular mortality in maintenance hemodialysis patients. Am J Kidney\nDis 2007; 49: 417\u2013425\n\n23. Muntner P, Ferramosca E, Bellasi A et al. Development of a cardiovas-\ncular calcification index using simple imaging tools in haemodialysis\npatients. Nephrol Dial Transplant 2007; 22: 508\u2013514\n\nReceived for publication: 10.7.08\nAccepted in revised form: 24.9.08\n\n\n\nRevista Portuguesa de Nefrologia e Hipertens\u00e3o 51\n\nVASCULAR CALCIFICATION, CARDIOVASCULAR RISK AND ARTERIAL STIFFNESS\nIN HEMODIALYSIS PATIENTS\n\nRev Port Nefrol Hipert 2005; 19 (Suppl 1): 51-56\n\nINTRODUCTION\n\nIntimal and medial calcification, the two main\ntypes of arterial calcification, are associated,\nrespectively, with arteriosclerosis and medios-\nclerosis. In non-dialysis patients, both intimal1\nand medial calcification2 may be the result of an\nactive regulated process with different aetio-\nlogies, where local cells, such as macrophages\nin the intima or vascular smooth cells in the\nmedia, differentiate into osteoblasts3. In haemo-\ndialysis patients it has also been demonstrated\nthat medial calcification is an active cellular pro-\ncess, similar to bone formation4,5. Vascular\nsmooth muscle cells can differentiate into\nosteoblasts due to different stimuli, some of\nwhich may be hyperphosphatemia or hypercal-\ncemia6. A passive calcification mechanism is,\nhowever, not excluded. High calcium phospho-\n\nVascular calcification, cardiovascular risk and\narterial stiffness in hemodialysis patients\n\nTeresa Adrag\u00e3o\nDepartment of Nephrology. Hospital de Santa Cruz. Carnaxide. Portugal\n\nArtigo Original\n\nrus product may also contribute to the matrix\nmineralization6. Reduction of calcification inhibi-\ntors in dialysis patients, such as fetuin-A or\nmatrix-Gla protein, may be other factors asso-\nciated with the development of calcification7. It\nhas already been demonstrated that calcium\ncarbonate and calcium acetate are associated\nwith the progression of vascular calcification, a\nphenomenon that can be attenuated or arrested\nby sevelamer, a phosphorus binder that does\nnot increase calcium levels and also reduces\nLDL-cholesterol8,9. In a rat model of hyperpa-\nrathyroidism treatment with calcitriol or cina-\ncalcet reduced PTH but, unlike calcitriol,\ncinacalcet did not produce hypercalcemia, in-\ncrease in calcium phosphorus product or aortic\ncalcification10.\n\n\n\nRevista Portuguesa de Nefrologia e Hipertens\u00e3o52\n\nTeresa Adrag\u00e3o\n\nVASCULAR CALCIFICATION AND\nCARDIOVASCULAR RISK\n\nBlacher et al.11 showed for the first time that\na vascular calcification score evaluated by B-\nmode ultrasonography in large arteries was as-\nsociated with an increased risk of mortality in\ndialysis patients. Brawn et al.12 had previously\ndemonstrated that dialysis patients, when com-\npared with non-dialysis patients, presented a\nhigher coronary calcification score evaluated by\nelectron beam computed tomography (EBCT).\nIn general population this score, the Agatston\nscore, is mainly caused by intimal calcification\nand is related with arteriosclerosis and coronary\nstenosis13,14. The higher values of this score in\ndialysis patients may be explained by the pre-\nsence of both intimal and medial calcification.\nMedial calcification is not occlusive but modi-\nfies the properties of the arterial wall and may\nalso contribute to coronary ischemia. The quan-\ntitative significance of Agatston score may be\ndifferent from that described for the general\npopulation where a score greater than 400 is\nassociated with a very high cardiovascular risk.\nIn a study evaluating 43 dialysis patients a mean\nscore of 559\u00b1255 was found in patients with\nnormal coronary angiographies while abnormal\ncoronary angiographies were associated with a\nmean score of 2869\u00b141715. In dialysis patients,\nhigh values of Agatston score may occur in the\nabsence of occlusive coronary atherosclerosis16\nbut, like other calcification scores, Agatston\nscore was an independent predictor of death in\nhaemodialysis patients16. The discriminative sig-\nnificance of Agatston score in dialysis patients\nremains, however, to be identified.\n\nMultislice computed tomography (MSCT)17\nhas already been employed for the diagnosis of\nvascular calcifications in dialysis patients, but,\nas well as EBCT, it is very expensive to be used\nin a routine way. Evaluation of vascular calcifi-\n\ncations in plain radiographs has been proposed\nby KDOQI guidelines18. We have already veri-\nfied that a simple vascular calcification score\nbased on plain radiographs of pelvis and hands\nwas a predictor of cardiovascular mortality, car-\ndiovascular hospitalizations and fatal and non-\nfatal cardiovascular events19. Radial, iliac and\nfemoral arteries were the arteries evaluated for\nthe estimation of this score. This score may be\nused as a simple and inexpensive tool for the\nassessment of cardiovascular risk in haemodi-\nalysis patients.\n\nDevelopment of a numeric cardiovascular\ncalcification index for cardiovascular risk evalua-\ntion in dialysis patients has been recently sug-\ngested20. The methodology recommended for\nthe assessment of this calcification index should\nbe non-invasive and low-cost, in order to be\nwidely accessible, such as conventional blood\npressure measurements for pulse pressure\nevaluation, standard radiographs for vascular\ncalcifications assessment and echocardio-\ngraphy for valvular calcifications diagnosis.\n\nVascular11 and valvular21 calcification are de-\nmonstrated risk factors for cardiovascular death\nin dialysis patients. Pulse pressure increase is\nassociated with vascular stiffness and has been\nrelated with cardiovascular risk in general popu-\nlation22 and in haemodialysis patients as well23.\n\nWe have developed, in a cohort of haemodi-\nalysis patients, a combined cardiovascular\nscore based on pulse pressure and on vascu-\nlar and valvular calcifications and compared it\nwith the previously described simple vascular\ncalcification score. This combined cardiovas-\ncular score was a stronger predictor of cardio-\nvascular risk than the simple vascular calcifica-\ntion score24. We verified that the addition of a\nvalvular and of a pulse pressure score to the\nsimple vascular calcification score allowed a\nmore accurate prediction of cardiovascular risk\nin this group of patients.\n\n\n\nRevista Portuguesa de Nefrologia e Hipertens\u00e3o 53\n\nVASCULAR CALCIFICATION, CARDIOVASCULAR RISK AND ARTERIAL STIFFNESS\nIN HEMODIALYSIS PATIENTS\n\nflection that finds the aortic valve still opened\nand causes a systolic blood pressure increase\nand a diastolic blood pressure decrease. In-\ncrease in systolic pressure provides an increase\nin after load that can contribute to the develop-\nment left ventricular hypertrophy. Decrease in\ndiastolic pressure decreases coronary perfusion\nwhich occurs during diastole and may aggra-\nvate coronary ischemia.\n\nPulse pressure increase has already been\nconnected to cardiovascular risk in the general\npopulation22 and in haemodialysis patients23.\n\nPulse wave velocity is also a marker of arte-\nrial stiffness. The loss of elasticity of the arterial\nwall increases the velocity of the blood flow\nthrough the arterial system. Gu\u00e9rin et al de-\nmonstrated that, in haemodialysis patients, vas-\ncular calcifications were associated with in-\ncreased stiffness of elastic type arteries like the\naorta and common carotid artery27. In this study\nvascular calcifications were evaluated by ultra-\nsonography. We have also verified in a cohort\nof haemodialysis patients that the simple vas-\ncular calcification score, assessed in plain ra-\ndiographs of hands and pelvis and evaluating\nnot elastic arteries but muscle arteries such as\nradial, iliac and femoral arteries, was indepen-\ndently and directly associated with pulse wave\nvelocity28. This study was another evidence of\nthe usefulness of this simple vascular calcifica-\ntion score in this population.\n\nPERIPHERAL ARTERY DISEASE\nIN DIALYSIS PATIENTS\n\nThere is a remarkably high prevalence of\nperipheral artery disease among patients with\nrenal insufficiency. Its prevalence may reach\n24% of patients with creatinine clearance &lt;60ml/\nmin versus 3.7% of persons with creatinine\nclearance \u00b3  60 ml/min29. Both moderate and\n\nCLINICAL SIGNIFICANCE OF INTIMAL\nAND MEDIAL CALCIFICATION IN\nHAEMODIALYSIS PATIENTS\n\nIntimal and medial calcifications are highly\nprevalent in dialysis patients. Intimal calcifica-\ntion corresponds to the type Vb of atheroscle-\nrotic plaques (American Heart Association clas-\nsification) and medial calcification is associated\nwith mediosclerosis. Standard radiographs can\nbe employed to differentiate these two different\ntypes of arterial calcification25 since other more\nsophisticated diagnostic techniques such as\nultrasonography, EBCT or MSCT can not dis-\ncriminate these calcification types. Using this\nmethodology, London et al. demonstrated that\nintimal and medial calcification are independent\npredictors of cardiovascular and all-cause death\nin dialysis patients26. Intimal calcification was\nassociated with older age and lower survival\nwhen compared with medial calcification. Me-\ndial calcification was associated with haemo-\ndialysis duration, diabetes, hyperphosphatemia\nand with calcium carbonate dose treatment.\n\nVASCULAR CALCIFICATION\nCONTRIBUTES TO ARTERIAL STIFFNESS\nIN HAEMODIALYSIS PATIENTS\n\nArterial stiffness is an alteration of the arte-\nrial wall properties with multiple causes, some\nof which are old age, diabetes, hypertension and\nmedial calcification. All these features are highly\nprevalent in dialysis patients and arterial stiff-\nness is a common finding in this population.\nSome of the manifestations of arterial stiffness\nare isolated systolic hypertension, pulse pres-\nsure increase and high pulse wave velocity.\nPulse pressure is the difference between\nsystolic and diastolic pressure. The arterial wall\nstiffness creates an early aortic pulse wave re-\n\n\n\nRevista Portuguesa de Nefrologia e Hipertens\u00e3o54\n\nTeresa Adrag\u00e3o\n\nsevere renal insufficiency are associated with\nan increased risk of death in patients with pe-\nripheral artery disease30. In this study, the per-\ncentages of patients who presented with gan-\ngrene or ischemic ulceration rather than rest pain\nincreased with declining renal function. Lower\nlimb amputations are a major problem in dialy-\nsis patients. Histological patterns found in 11\ndialysis patients submitted to distal amputations\n(figures 1 to 3) reflect the diversity of lesions\npresent in this population that may contribute to\nthe chronic distal artery disease31. Occlusive le-\nsions consisted of luminal thrombi and choles-\nterol emboli. Arteriosclerosis plaques and me-\ndial calcification may be present in the same\npatient and even in the same artery. In other\nevaluation of 56 patients submitted to lower limb\namputations (non-published data) medial calci-\nfication was present in 48% of the samples and\nwas associated with atherosclerotic plaques\ntype II or III (American Heart Association classi-\nfication) in 50% of cases. In this group of pa-\ntients submitted to lower limb amputations there\nwas no histological evidence of intimal calcifi-\ncation in any sample. This data confirm the as-\nsociation of medial calcification with distal ar-\ntery disease. Dialysis vintage, diabetes, calcium\n\ncarbonate dose and hyperphosphatemia have\nalready been associated with medial calcifica-\ntion26. In a registry study, hyperphosphatemia\nwas independently associated with future am-\nputations32. These observations raise the hope\nof modifying the evolution of peripheral artery\ndisease in dialysis patients by the correction of\nsome of these factors.\n\nIn summary, vascular calcifications are highly\nprevalent in dialysis patients, and contribute to\ncardiovascular mortality and morbidity. Plain\n\nFig. 1 \u2013 Muscular artery: cholesterol emboli. (Elastic van Giesen\nx 100)\n\nFig. 2 \u2013 Exuberant medial calcification. (Hemotoxilin Eosin x\n100)\n\nFig. 3 \u2013 Type II atherosclerosis lesion and medial calcification.\n(Hemotoxilin Eosin x 100)\n\n\n\nRevista Portuguesa de Nefrologia e Hipertens\u00e3o 55\n\nVASCULAR CALCIFICATION, CARDIOVASCULAR RISK AND ARTERIAL STIFFNESS\nIN HEMODIALYSIS PATIENTS\n\nradiographs are a simple and inexpensive tool\nfor the assessment of cardiovascular risk. Ar-\nteriosclerosis and mediosclerosis are the his-\ntological setting for the development of vascu-\nlar calcifications. Intimal calcification is asso-\nciated with arteriosclerosis and medial\ncalcification with mediosclerosis. In dialysis pa-\ntients, medial calcification has been associated\nwith diabetes, dialysis vintage, hyperphos-\nphatemia and treatment with calcium carbonate.\nDecrease of calcification inhibitors facilitates this\nprocess. Sevelamer can arrest vascular calci-\nfication progression. In a rat model of hyperpa-\nrathyroidism Cinacalcet, unlike calcitriol, was not\nassociated with vascular calcification develop-\nment. It is necessary to demonstrate that the\ncorrection of those factors contributing to vas-\ncular calcification is associated with a better car-\ndiovascular outcome in dialysis patients.\n\nReferences\n\n1. Shanahan CM, Cary NR, Metcalfe JC, Weissberg P. High\nexpression of genes for calcification-regulating proteins\nin human atherosclerotic plaques. J Clin Invest 1994;\n93:2393-40.\n\n2. Parhami F, Bostrom K, Watson K, Demer LL. Role of mo-\nlecular regulation in vascular calcification. J Atheroscler\nThromb 1996; 3:90-4\n\n3. Shanahan CM, Proudfoot D, Tyson KL, Cary NR, Edmonds\nM, Weissberg PL. Expression of mineralisation-regulating\nproteins in association with human vascular calcification.\nZ Kardiol 2000; 89 (Suppl 2) 63-8.\n\n4. Jono S, McKee MD, Murry CE et al. Phosphate regulation of\nvascular smooth muscle cell calcification. Circ Res 2000;\n87:E10-7.\n\n5. Moe SM, O\u2019Neill KD, Duan D et al. Medial artery calcification\nin ESRD patients is associated with deposition of bone\nmatrix proteins. Kidney Int 2002; 61:638-47.\n\n6. Giachelli CM. Vascular calcification mechanisms. J Am Soc\nNephrol 15:2959-64.\n\n7. Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahnen-\nDechent W, Floege J. Novel insights into uremic vascular\ncalcification: role of matrix Gla protein and alpha-2-\nHeremans Schmid glycoprotein/fetuin. Blood Purif 2002;\n20:473-6.\n\n8. Chertow GM, Burke SK, Raggi P.Treat to Goal Working\n\nGroup. Sevelamer attenuates the progression of coro-\nnary and aortic calcification in hemodialysis patients. Kid-\nney Int 2002; 62:245-52.\n\n9. Chertow GM, Raggi P, McCarthy JT et al. The effects of\nsevelamer and calcium acetate on proxies of atheroscle-\nrotic and arteriosclerotic vascular disease in hemodialysis\npatients. Am J Nephrol 2003; 23:307-14.\n\n10 . Henley C, Colloton M, Cattley RC et al. 1,25-\nDihydroxyvitamin D3 but not cinacalcet HCl (Sensipar_/\nMimpara_) treatment mediates aortic calcification in a rat\nmodel of secondary hyperparathyroidism. Nephrol Dial\nTransplant 2005; 20: 1370-7\n\n11. Blacher J, Gu\u00e9rin AP, Pannier B, Marchais SJ, London GM.\nArterial calcifications, arterial stiffness, and cardiovascu-\nlar risk in end-stage renal disease. Hypertension 2001;\n38: 938\u2013942.\n\n12. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft\nFC. Electron beam computed tomography in the evaluation\nof cardiac calcification in chronic dialysis patients. Am J\nKidney Dis 1996; 27:394-401.\n\n13. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantifica-\ntion of coronary artery calcium using ultrafast computed\ntomography. J Am Coll Cardiol 1990; 15:827-32.\n\n14. Bielak LF, Rumberger JA, Sheedy PF, et al. Probabilistic model\nfor prediction of angiographically defined obstructive coro-\nnary artery disease using electron beam computed tomog-\nraphy score strata. Circulation 2000; 102:380-85.\n\n15. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M,\nGoldsmith DJ. Coronary artery calcification is related to\ncoronary atherosclerosis in chronic renal disease patients:\na study comparing EBCT-generated coronary artery cal-\ncium scores and coronary angiography. Nephrol Dial Trans-\nplant 2004; 2307-12. Epub 2004 Jun 22.\n\n16. Matsuoka M, Iseki K, Tamashiro M et al. Impact of high\ncoronary artery calcification score (CACS) on survival in\npatients on chronic hemodialysis. Clin Exp Nephrol 2004;\n8:54-8.\n\n17. Moe SM, O\u2019Neill KD, Fineberg N et al. Assessment of vas-\ncular calcification in ESRD patients using spiral CT. Nephrol\nDial Transplant 2003; 18:1152-8.\n\n18. KDOQI Clinical Practice Guidelines for Bone Metabolism\nand Disease in Chronic Kidney disease. Am J Kidney Dis\n2003; 42 (Suppl 3).\n\n19. Adragao T, Pires A, Lucas C et al. A simple vascular calci-\nfication score predicts cardiovascular risk in hemodialysis\npatients. Nephrol Dial Transplant 2004; 19: 1480-88.\n\n20. Moe SM, Drueke TM. Special report: controversies in bone\nand mineral metabolism in chronic kidney disease. Vascu-\nlar calcification in chronic kidney disease. Am J Kidney\nDis 2004; 43:572-9.\n\n21. Wang AY, Wang M, Woo J et al. Cardiac valve calcification\nas an important predictor for all-cause mortality and car-\ndiovascular mortality in long-term peritoneal dialysis pa-\ntients: a prospective study. J Am Soc Nephrol 2003; 14:\n159-68.\n\n\n\nRevista Portuguesa de Nefrologia e Hipertens\u00e3o56\n\nTeresa Adrag\u00e3o\n\n22. Franklin S, Larson MG, Khan SA et al. Does the relation of\nblood pressure to coronary heart disease risk change\nwith aging? The Framingham heart study. Circulation 2001;\n103: 1245-9.\n\n23. Klassen PS, Lowrie EG, Reddan DN et al. Association\nbetween pulse pressure and mortality in patients under-\ngoing maintenance hemodialysis. J Am Med Assoc 2002\n287: 1548-55.\n\n24. Adragao T, Pires A, Macedo A et al. A New Cardiovascu-\nlar Calcification Index is an Independent Predictor of Car-\ndiovascular Risk In Hemodialysis Patients. J Am Soc\nNephrol 15: 2004 174A F-PO491(Abstract).\n\n25. Lehto S, Niskanen L, Suhonen M, Ronnemaa T, Laakso M.\nMedial artery calcification. A neglected harbinger of car-\ndiovascular complications in non-insulin-dependent dia-\nbetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16:\n978-83.\n\n26. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B,\nAdda H. Arterial media calcification in end-stage renal dis-\nease: impact on all-cause and cardiovascular mortality.\nNephrol Dial Transplant 2003; 18:1731-40.\n\n27. Gu\u00e9rin AP, London GM, Marchais SJ, Metivier F. Arterial\nstiffening and vascular calcificatins in end\u2013stage renal\ndisease. Nephrol Dial Transplant 2000; 15: 1014-21\n\n28. T Adragao, A Pires, C Lucas et al. Pulse wave velocity\ncorrelates with simple vascular calcification score in\nhemodialysis patients. Nephrol. Dial. Transplant 2003; 18\n(suppl 4): 702 (Abstract  W487).\n\n29. O\u2019Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence\nof peripheral arterial disease in persons with renal insuffi-\nciency: results from the National Health and Nutrition Exami-\nnation Survey 1999-2000. Circulation 2004; 109:320-3.\n\n30. O\u2019Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM.\nImpact of renal insufficiency on mortality in advanced lower\nextremity peripheral arterial disease. J Am Soc Nephrol\n2004;16:514-9\n\n31. Gouveia R, Birne R, Adragao T, Pina A, Nogueira A, Pais M\nJ, Messias H, Martins AP. Histological vascular patterns in\nlower limb amputations in hemodialysis patients. Nephrol\nDial Transplant EDTA 2004 abstract book, page 141\n(SP370).\n\n32. O\u2019Hare AM, Bacchetti P, Segal M, Hsu CY, Johansen KL;\nDialysis Morbidity and Mortality Study Waves. Factors as-\nsociated with future amputation among patients undergo-\ning hemodialysis: results from the Dialysis Morbidity and\nMortality Study Waves 3 and 4. Am J Kidney Dis 2003;\n41:162-70\n\n\n\n57\n\nCAP\u00cdTULO 5\n\nCALCIFICA\u00c7\u00c3O VALVULAR CARD\u00cdACA NOS DOENTES EM DI\u00c1LISE\n\nA calcifi ca\u00e7\u00e3o valvular card\u00edaca foi durante muito tempo considerada um processo \ndegenerativo passivo de les\u00e3o valvular. Contudo, nos \u00faltimos anos foram identifi cados \nmecanismos de calcifi ca\u00e7\u00e3o valvular associados a um fen\u00f3meno de ativa\u00e7\u00e3o osteobl\u00e1stica. \nV\u00e1rios fatores habitualmente expressos nos osteoblastos foram tamb\u00e9m identifi cados em \nv\u00e1lvulas card\u00edacas calcifi cadas, como osteopontina1, BMP (bone morphogenic protein) 2 e \n4,2 ou Runx2 (runt related transcription factor 2) e osterix3. Em alguns casos foram mesmo \nidentifi cadas verdadeiras zonas ossifi cadas com forma\u00e7\u00e3o de osso lamelar apresentando \natividade osteobl\u00e1stica e osteocl\u00e1stica, traduzindo a exist\u00eancia de remodela\u00e7\u00e3o \u00f3ssea2. \nAtualmente considera -se que a calcifi ca\u00e7\u00e3o valvular card\u00edaca n\u00e3o \u00e9 um processo passivo mas \nativo que resulta da muta\u00e7\u00e3o fenot\u00edpica de c\u00e9lulas valvulares locais ainda n\u00e3o identifi cadas, \nprovavelmente miofi broblastos ou pericitos que se transformam em osteoblastos2,3. Os \nmecanismos respons\u00e1veis por estas altera\u00e7\u00f5es ainda n\u00e3o s\u00e3o totalmente conhecidos, mas \napresentam algumas semelhan\u00e7as com o processo aterog\u00e9nico vascular. Estas les\u00f5es valvulares, \ncomo as les\u00f5es ateroscler\u00f3ticas, podem ser precedidas por ruptura da membrana basal, \ninfi ltra\u00e7\u00e3o por c\u00e9lulas infl amat\u00f3rias, dep\u00f3sito de l\u00edpidos e podem estar associadas a diabetes, \nhipercolesterolemia, hipertens\u00e3o arterial ou consumo de tabaco4. Esta forma\u00e7\u00e3o de tecido \n\u00f3sseo descrito nas v\u00e1lvulas card\u00edacas calcifi cadas assemelha -se ao processo de calcifi ca\u00e7\u00e3o \nativa tamb\u00e9m descrito nas art\u00e9rias e resultante da transforma\u00e7\u00e3o das c\u00e9lulas musculares lisas \nem osteoblastos5.\n\nA preval\u00eancia de calcifi ca\u00e7\u00f5es valvulares \u00e9 elevada nos doentes em di\u00e1lise, variando entre \n32% e 47% em diferentes estudos6 -9. Na popula\u00e7\u00e3o geral10 e tamb\u00e9m nos doentes em di\u00e1lise7 -9 \ncomprovou -se que as calcifi ca\u00e7\u00f5es valvulares se associam a mortalidade mais elevada. Nos \ndoentes em di\u00e1lise j\u00e1 foi demonstrado que a presen\u00e7a de calcifi ca\u00e7\u00f5es valvulares se associa a \nmarcadores cl\u00e1ssicos de aterosclerose como o aumento da espessura \u00edntima -m\u00e9dia carot\u00eddea, \nplacas carot\u00eddeas e aumento da prote\u00edna C -reactiva11, mas as altera\u00e7\u00f5es do metabolismo \nfosfoc\u00e1lcico tamb\u00e9m parece estarem implicadas, como foi demonstrado por Ribeiro S, et al6.\n\nNum grupo de 127 doentes em hemodi\u00e1lise analisamos a preval\u00eancia das calcifi ca\u00e7\u00f5es \ndas v\u00e1lvulas a\u00f3rtica e mitral, o risco de mortalidade destas calcifi ca\u00e7\u00f5es valvulares e a sua \nrela\u00e7\u00e3o com as calcifi ca\u00e7\u00f5es arteriais diagnosticadas pelo score de calcifi ca\u00e7\u00e3o vascular \n\n\n\n58\n\nsimples12. As calcifi ca\u00e7\u00f5es valvulares card\u00edacas mitrais ou a\u00f3rticas foram diagnosticadas por \necocardiografi a e estavam presentes, respectivamente, em 37 (29%) e em 19 doentes (15%); \n39 doentes (31%) apresentavam calcifi ca\u00e7\u00f5es valvulares. A presen\u00e7a de calcifi ca\u00e7\u00f5es valvulares \nassociou -se a menor sobrevida, avaliada ao longo de 48 meses (Fig 5.1).\n\nFig. 5.1. A presen\u00e7a de calcifi ca\u00e7\u00f5es valvulares (CV+) associou -se a maior mortalidade de causa global ou \ncardiovascular (Kaplan Meier)\n\nAs calcifi ca\u00e7\u00f5es vasculares avaliadas pelo score de calcifi ca\u00e7\u00e3o vascular simples estavam \npresentes em 72% dos doentes. O score de calcifi ca\u00e7\u00e3o vascular foi um preditor independente \nde calcifi ca\u00e7\u00e3o das v\u00e1lvulas a\u00f3rtica ou mitral. Por cada aumento de 1 ponto no score de \ncalcifi ca\u00e7\u00e3o houve um aumento, respectivamente, de 46% e de 66% de risco de apresentar \ncalcifi ca\u00e7\u00e3o valvular a\u00f3rtica ou mitral. Verifi cou -se tamb\u00e9m uma associa\u00e7\u00e3o direta entre os \nvalores da paratormona e a calcifi ca\u00e7\u00e3o da v\u00e1lvula a\u00f3rtica e os valores do f\u00f3sforo s\u00e9rico e a \ncalcifi ca\u00e7\u00e3o da v\u00e1lvula mitral.\n\nEstes dados sugerem que a calcifi ca\u00e7\u00e3o valvular possa partilhar mecanismos patog\u00e9nicos \nsemelhantes aos da calcifi ca\u00e7\u00e3o vascular e que nos doentes em di\u00e1lise a calcifi ca\u00e7\u00e3o valvular \nfa\u00e7a parte de um processo sist\u00e9mico de calcifi ca\u00e7\u00e3o.\n\nAs guidelines KDIGO 200913 consideram que o rastreio das calcifi ca\u00e7\u00f5es nos doentes \nrenais cr\u00f3nicos possa ser feito atrav\u00e9s de RX simples ou atrav\u00e9s da avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es \nvalvulares por ecocardiografi a. A presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares ou valvulares identifi cam \nos doentes com maior risco cardiovascular, e esta informa\u00e7\u00e3o pode ser usada para orientar a \n\n\n\n59\n\nterap\u00eautica nestes doentes. Podemos tentar corrigir os mecanismos associados ao \ndesenvolvimento e progress\u00e3o das calcifi ca\u00e7\u00f5es, nomeadamente tentar corrigir as altera\u00e7\u00f5es \ndo metabolismo fosfoc\u00e1lcico, entre outros. Verifi c\u00e1mos que nos nossos doentes a preval\u00eancia \nde calcifi ca\u00e7\u00f5es valvulares \u00e9 bastante inferior \u00e0 preval\u00eancia de calcifi ca\u00e7\u00f5es vasculares. Em \nan\u00e1lise por curvas ROC, avaliamos que a presen\u00e7a de calcifi ca\u00e7\u00f5es valvulares apresenta um \nvalor preditivo positivo de 87% e preditivo negativo de 34% para indicar presen\u00e7a de \ncalcifi ca\u00e7\u00f5es vasculares. Isto signifi ca que, no caso de haver calcifi ca\u00e7\u00f5es valvulares, existe \n87% de probabilidades de tamb\u00e9m haver calcifi ca\u00e7\u00f5es vasculares. No caso de n\u00e3o haver \ncalcifi ca\u00e7\u00f5es valvulares, a probabilidade de n\u00e3o haver calcifi ca\u00e7\u00f5es vasculares \u00e9 de apenas \n34%. Esta limita\u00e7\u00e3o deve ser tida em considera\u00e7\u00e3o se s\u00f3 usarmos o ecocardiograma para \nrastreio das calcifi ca\u00e7\u00f5es nos doentes em di\u00e1lise, pois podemos subavaliar o risco cardiovascular \ndestes doentes. O ecocardiograma n\u00e3o substitui a utiliza\u00e7\u00e3o do RX simples para identifi car \no risco cardiovascular associado \u00e0s calcifi ca\u00e7\u00f5es.\n\nEm resumo, o score de calcifi ca\u00e7\u00e3o vascular simples foi um preditor independente de \ncalcifi ca\u00e7\u00f5es valvulares, sugerindo que o processo de calcifi ca\u00e7\u00e3o cardiovascular \u00e9 \nsist\u00e9mico, podendo partilhar fatores patog\u00e9nicos comuns. \u00c9 prov\u00e1vel que a terap\u00eautica \nutilizada no controlo da progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares possa tamb\u00e9m afetar a \nprogress\u00e3o das calcifi ca\u00e7\u00f5es valvulares. \u00c9 necess\u00e1rio avaliar se o manejo das altera\u00e7\u00f5es \ndo metabolismo mineral e \u00f3sseo pode ter um papel na evolu\u00e7\u00e3o e no progn\u00f3stico da \ncalcifi ca\u00e7\u00e3o valvular destes doentes. O estudo ADVANCE, apresentado durante o XLVVII \nERA -EDTA Congress 2010, em Munique, demonstrou que a terap\u00eautica com Cinacalcet, \nagente calcimim\u00e9tico usado no tratamento do hiperparatiroidismo secund\u00e1rio, e baixas \ndoses de vitamina D se associaram a uma redu\u00e7\u00e3o significativa da progress\u00e3o das \ncalcifi ca\u00e7\u00f5es na v\u00e1lvula a\u00f3rtica.\n\nRefer\u00eancias\n\n  1. O\u2019Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular \nlesions. Circulation 1995;92:2163 -2168.\n\n  2. Mohler ER, Gannon F, Reynolds C, et al. Bone formation and infl ammation in cardiac valves. \nCirculation 2001;103:1522 -1528.\n\n  3. Alexopoulos A, Bravou V, Peroukides S, et al. Bone regulatory factors NFATc1 and osterix in \nhuman calcifi c aortic valves. Int J Cardiol 2008; 17.\n\n  4. Goldbarg SH, Elmariah S, Miller MA, et al. Insights into degenerative aortic valve disease. J Am \nColl Cardiol 2007; 25,50(13): 1205 -1213.\n\n  5. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2564.\n\n\n\n60\n\n  6. Ribeiro S, Ramos A, Brand\u00e3o A, et al. Cardiac valve calcifi cation in haemodialysis patients: role \nof calcium -phosphate metabolism. Nephrol Dial Transplant 1998 (8):2037 -2040.\n\n  7. Wang AY, Wang M, Woo J, et al. Cardiac valve calcifi cation as an important predictor for all -cause \nmortality and cardiovascular mortality in long -term peritoneal dialysis patients: a prospective \nstudy. J Am Soc Nephrol 2003; 14(1):159 -168.\n\n  8. Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve \ncalcium with coronary artery disease, atherosclerotic vascular disease, and all -cause mortality in \n137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 15;95(6):742-\n-743.\n\n  9. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcifi cation predicts mortality and coronary \nartery disease in end stage renal disease. Atherosclerosis 2007;191(2):348 -354.\n\n10. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic -valve sclerosis \nwith cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142 -147.\n\n11. Wang AY, Ho SS, Wang M, et al. Cardiac valvular calcifi cation as a marker of atherosclerosis and \narterial calcifi cation in end -stage renal disease. Arch Intern Med 2005; 14;165(3):327 -332.\n\n12. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. Vascular and \nvalvular calcifi cations in dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; \n21(4): 293 -300.\n\n13. KDIGO, Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global \noutcomes (KDIGO). Kidney Int 2009; 76 (Suppl):S113.\n\n\n\n293\n\nABSTRACT\n\nOsteoblastic bone formation has been described\nin cardiac valves resembling the active calcification\nprocess already demonstrated in arteries, in relation\nto osteoblastic transformation of vascular smooth\nmuscle cells. The aim of our study was to evaluate\nthe mortality risk of cardiac valvular calcification in\nhaemodialysis patients and to analyse the associa-\ntion of valvular calcification with arterial vascular cal-\ncification. Valvular calcification (VC) was diagnosed\nby B-Mode echocardiography. A simple vascular cal-\ncification score (SVCS) was evaluated in plain X-ray\nof hands and pelvis (0-8). We studied 127 prevalent\nHD patients (75 males and 52 females) with a mean\nHD duration of 48\u00b153 months. Aortic VC (AVC) was\ndiagnosed in 19 patients (15%), mitral VC (MVC) in\n37 patients (29%) and AVC or MVC in 39 patients\n(31%); SVCS > 0 was diagnosed in 91 patients (71%)\nand SVCS ? 3 in 63 patients (50%). After 48 months\nfollow-up there were 43 all cause deaths and 21 car-\ndiovascular deaths. Vascular and all valvular calcifi-\ncations were associated with lower cumulative sur-\nvival. The adjusted risk of all cause death was 3.7\nfold higher in AVC (p<0.001). For each unit increment\nof the SVCS there was 56% increase in cardiovascu-\nlar death risk (p<0.001). SVCS was associated with\naortic (p=0.002) and mitral (p<0.001) valvular cal-\ncification. In conclusion, in these patients valvular\nand vascular calcifications were independent predic-\ntors of mortality. Vascular calcification was independ-\nently associated with cardiac valvular calcification,\n\nsuggesting that these two types of calcification may\nshare common characteristics.\n\nKey-Words:\nHaemodialysis; mortality; valvular calcification; vas-\ncular calcification.\n\nINTRODUCTION\n\nVascular calcifications are highly prevalent in dial-\nysis patients and have been associated with an\nincreased risk of total and cardiovascular death1.\nSome mechanisms linking vascular calcifications with\ncardiovascular risk, such as the association between\nvascular calcifications and arterial stiffness, have\nalready been recognised2. Loss of arterial distensi-\nbility is associated with increased pulse pressure3,\nleft ventricular hypertrophy and decrease of coro-\nnary perfusion during diastole. It has been demon-\nstrated that vascular calcification in dialysis and non-\ndialysis patients is an active cellular process, similar\nto bone formation4-6. Vascular smooth muscle cells\ncan differentiate into osteoblasts due to different\nstimuli, which, in dialysis patients, may be hyper-\nphosphataemia and hypercalcaemia7. Reduction of\ncalcification inhibitors, such as fetuin-A or matrix-\nGla protein, may be another factor associated with\nthe development of calcification8. Valvular calcifica-\ntion is an independent predictor of cardiovascular\ndeath in the general population9 and ectopic bone\n\nVascular and valvular calcifications\nin dialysis patients: the same\npathogenesis?\n\nTeresa Adrag\u00e3o, Ana Pires, Carlos Lucas, Rita Birne, Lu\u00eds Magalh\u00e3es, Margarida Gon\u00e7alves, Ac\u00e1cio Pita Negr\u00e3o\n\nGambro-Healthcare, Nefroclinica. Estoril, Portugal\n\nPort J Nephrol Hypert 2007; 21(4): 293-300\n\nReceived for publication: 31/05/2007\n\nAccepted in revised form: 11/09/2007\n\nORIGINAL ARTICLE\n\n\n\n294 Port J Nephrol Hypert 2007; 21(4): 293-300\n\nformation has been also identified, most likely orig-\ninating from differentiated myofibroblasts10, resem-\nbling the active calcification process already demon-\nstrated in arteries. It has already been demonstrated\nthat valvular calcification is also a predictor of car-\ndiovascular mortality in peritoneal dialysis patients11.\nThe aim of this study was to evaluate in a group\nof haemodialysis patients the risk of all cause death\nand of cardiovascular death related to cardiac valvu-\nlar calcification and to analyse the association of car-\ndiac valvular calcification with arterial vascular cal-\ncification.\n\nPATIENTS AND METHODS\n\nStudy design\n\nAn observational, prospective, single-centre study\nof a cohort of prevalent haemodialysis patients was\nused.\n\nPopulation\n\nOne hundred and twenty seven patients, 75\nmales and 52 females, without previous parathy-\nroidectomy were evaluated. Twenty six patients\n(21%) were diabetic. At baseline, mean age was\n62\u00b115 years (24-91) and mean haemodialysis dura-\ntion was 47\u00b156 months (4-271). During an obser-\nvational period of 48 months, 43 patients (34%)\ndied. The diagnosis of vascular disease at base-\nline was based on previous clinical manifestations\nand test results. Coronary artery disease was diag-\nnosed if the patient had typical angina pectoris, a\npositive stress test, suffered a myocardial infarc-\ntion, or underwent a percutaneous coronary inter-\nvention or coronary bypass surgery. Diagnosis of\ncerebral vascular disease was based on the occur-\nrence of stroke or transient ischaemic attack or the\ndetection of an old cerebral infarction in comput-\ned tomography. Peripheral arterial disease was diag-\nnosed if there was claudication, ischaemic ulcers,\nlower limbs amputation, revascularisation or diag-\nnosis of obstruction by Doppler or angiography.\nCoronary artery disease was diagnosed in 33\npatients (25%). Peripheral artery disease was pres-\nent in 17 patients (13%) and 6 patients (5%) had\nhad a previous stroke. \n\nVascular and valvular calcifications\n\nVascular calcifications were evaluated in plain X-ray\nof pelvis and hands by a method previously described12.\nPelvis films were divided into four sections by two imag-\ninary lines: a horizontal line over the upper limit of both\nfemoral heads and a median vertical line over the ver-\ntebral column (Fig. 1). Hand films were divided for each\n\nTeresa Adrag\u00e3o, Ana Pires, Carlos Lucas, Rita Birne, Lu\u00eds Magalh\u00e3es, Margarida Gon\u00e7alves, Ac\u00e1cio Pita Negr\u00e3o\n\nFigure 1\n\nIleo-femoral score evaluates the presence of vascular calcifications in iliac and\n\nfemoral arteries. Calcification score is the sum of the presence (1) or absence\n\n(0) of vascular calcifications. In this example, pelvis score (1+1+1+1) = 4\n\nFigure 2\n\nHand score evaluates the presence of vascular calcifications in radial and\n\ndigital arteries. In this example hand score (1+1+1+1) = 4. Total score is\n\nthe sum of pelvis and hand score (8)\n\n\n\nPort J Nephrol Hypert 2007; 21(4): 293-300 295\n\nhand by a horizontal line over the upper limit of the\nmetacarpal bones (Fig. 2). Pelvis films evaluated iliac\nand femoral arteries (ileo-femoral score) and hand films\nevaluated radial and digital arteries (hand score). Any\nvascular calcification lining the vessel walls either in an\nirregular pattern or in a linear pattern was considered.\nThe presence of vascular calcifications in each section\nwas rated as 1 and its absence as 0. Final score was\nthe sum of all sections and ranged from 0 to 8.\n\nValvular calcifications of mitral and aortic valve\nwere assessed with B-mode Echocardiography \n\nBiochemical analysis\n\nSerum levels of the following biochemical param-\neters were evaluated and time averaged for the 6\nmonths preceding the evaluation of vascular and\nvalvular calcifications: Ca, P, CaxP product, alkaline\nphosphatase, albumin, total iPTH. Total iPTH was\nevaluated every three months by immunochemilumi-\nnescence using a second generation assay.\n\nStatistical analysis\n\nData are expressed as frequencies for categorical\nvariables, mean values with SD for normally distrib-\nuted variables. Comparison between groups was per-\nformed by Mann-Whitney U and chi-square tests. Multi-\nvariate analysis was performed by Binary logistic\nRegression Models. Survival evaluation was performed\nwith Cox regression models. Survival curves were per-\nformed using Kaplan Meyer with evaluation of log rank.\nVariables entered in multivariate analysis were age, gen-\nder, haemodialysis duration, diabetes, CaxP, iPTH, albu-\nmin, cardiovascular disease at baseline and vascular\nand valvular calcifications. Statistical analyses were per-\nformed with the SPSS system 14.0 (SPSS Inc.,\nChicago,IL) and the Medcalc program version 6.0 (Med-\ncalc software; Mariakerke, Belgium). For all comparisons,\na P value&lt;0.05 was considered statistically significant.\n\nRESULTS\n\nDuring an observational period of 48 months there\nwere 43 all-cause deaths (34%) and 21 (17%) car-\ndiovascular deaths and 34 patients (27%) needed \n\ncardiovascular hospitalisations. Demographic and bio-\nchemical values of the whole group are shown in Table\n1. Aortic and mitral valvular calcification were detect-\ned in 19 (15%) and in 37 (29%) patients respective-\nly. Aortic or mitral calcifications were detected in 39\npatients (31%). Presence of vascular calcifications was\nidentified in 91 patients (72%). A simple vascular cal-\ncification score (svcs) ? 3 was observed in 63 patients\n(49.6%). Mean calcium carbonate dose was 2.1\u00b11.01\ng/day. Thirty three patients (26%) were treated with\ncalcitriol and the mean dose was 1.54\u00b11.01 ?g / week.\n\nDemographic, biochemical parameters and calci-\nfications (Table I)\n\nHaemodialysis duration was longer in patients with\naortic and mitral calcification (Table I). All cause death\nand cardiovascular death were more frequent in\npatients with valvular or vascular calcifications (Table\nI). Other demographic or biochemical parameters were\nnot different in patients with or without valvular and\nvascular calcifications.\n\nMean Survival and Cumulative Survival \n\nAll cause death (Table II; Fig. 3) and cardiovascular\ndeath (Table III; Fig. 4) were responsible for significant\nlower mean survival and lower cumulative survival in\npatients with valvular and vascular calcifications. \n\nMortality risk of valvular and vascular calcifica-\ntions (Table IV)\n\nIn separate Cox regression models, in all patients,\nadjusting for age, gender, HD duration, diabetes,\niPTH, CaxP product, albumin and cardiovascular dis-\nease at baseline, the mortality risk for each type of\nvalvular calcification and for the vascular calcifica-\ntion score was evaluated (Table IV). The adjusted risk\nof all cause death and of cardiovascular death was,\nrespectively, 3.8 and 2.6 fold higher in patients with\naortic valvular calcification. The adjusted risk of all\ncause death and of cardiovascular death was, respec-\ntively, 2.4 and 2.9 fold higher in patients with mitral\nvalvular calcification. In non-diabetic patients, mitral\nvalvular calcification and mitral or aortic valvular cal-\ncification were also associated with increase in all-\ncause mortality (Table IV).\n\nVascular and valvular calcifications in dialysis patients: the same pathogenesis?\n\n\n\n296 Port J Nephrol Hypert 2007; 21(4): 293-300\n\nTable I\n\nValvular Calcifications\n\nAll Patients\nAortic Valve Mitral Valve Aortic or Mitral Valve\n\nN=127\nAVC=0 AVC>0 MVC=0 MVC>0 AMVC=0 AMVC>0\n\nN=108 N=19 N=89 N=38 N=87 N=40\n\nAge 62\u00b115 61\u00b115 66\u00b112 61\u00b115 65\u00b114 61\u00b115 65\u00b114\n\nMale gender 75 (59%) 65 (60%) 10 (53%) 57 (63%) 18 (49%) 56 (64%) 19 (49%)\n\nDiabetes 26 (21%) 23 (21%) 3 (16%) 18 (20%) 8 (22%) 18 (21%) 8 (21%)\n\nHD duration (months) 48\u00b153 44\u00b152 65\u00b149* 38\u00b142 71\u00b166** 38\u00b142 69\u00b166*\n\nCa (mg/dL) 9.9\u00b10.7 9.9\u00b10.8 10\u00b10.6 9.9\u00b10.8 10.0\u00b10.6 9.9\u00b10.8 10.0\u00b10.6\n\nP (mg/dL) 4.9\u00b11.4 4.8\u00b11.4 5.3\u00b11.3 4.8\u00b11.4 5.2\u00b11.4 4.8\u00b11.4 5.2\u00b11.4\n\nCaXP (mg2/dL2) 49.3\u00b115.6 48.6\u00b115.7 53.6\u00b114.0 47.7\u00b115.6 53.2\u00b115.0 47.8\u00b115.6 52.7\u00b115.1\n\niPTH (pg/mL) 302\u00b1380 272\u00b1313 476\u00b1624 315\u00b1394 273\u00b1347 287\u00b1320 337\u00b1492\n\nAP (ng/mL) 30.0\u00b122.4 30.1\u00b123.3 29.2\u00b117.4 30.9\u00b122.3 28.1\u00b123.1 30.9\u00b122.3 28.1\u00b123.1\n\nAlbumin (g/L) 3.7\u00b10.3 3.7\u00b10.3 3.7\u00b10.3 3.7\u00b10.3 3.7\u00b10.3 3.7\u00b10.3 3.7\u00b10.3\n\nCaCO3 dose (g/day) 2.1\u00b11.5 2.2\u00b11.5 1.6\u00b11.4 2.2\u00b11.6 1.9\u00b11.3 2.2\u00b11.6 1.8\u00b11.3\n\nEjection fraction (%) 38\u00b17 38\u00b16 38\u00b17 37\u00b16 38\u00b17 38\u00b16 38\u00b17\n\nLVPW (mm) 10.2\u00b11.8 10.3\u00b11.6 9.5\u00b13.4 10.3\u00b11.6 10\u00b12.5 10.2\u00b11.6 10.1\u00b12.5\n\nAll cause death 43 (34%) 32 (30%) 11 (58%)* 24 (27%) 19 (51%)* 24 (27%) 19 (49%)*\n\nCardiovascular death 21 (17%) 15 (14%) 6 (32%) 10 (11%) 11 (30%)* 10 (11%) 11 (28%)*\n\nCardiovascular hospitalisation 34 (27%) 26 (24%) 8 (42%) 17 (19%) 17 (46%)** 17 (19%) 17 (44%)**\n\nSVCS > 0 91 (72%) 74 (69%) 17 (90%) 58 (64%) 33 (89%)** 57 (65%) 34 (87%)*\n\nSVCS ? 3 63 (50%) 49 (45%) 14 (74%)* 37 (41%) 26 (70%)** 37 (42%) 26 (67%)*\n\n*p<0.05; **p<0.01\n\nComparison between means: Mann-Whitney U; comparison between frequencies: chi-square. SVCS, simple vascular calcification score; AVC, aortic valve calcification; MVC, mitral\n\nVC; AMVC, aortic or mitral VC; LVPW left ventricular posterior wall\n\nTable II\n\nAll cause mortality (Kaplan Meier)\n\nAortic Valve Mitral Valve Aortic or Mitral Valve Plain X-ray score\nAVC=0 AVC>0 MVC=0 MVC>0 AMVC=0 AMVC>0 SVCS=0 SVCS>0\n\nN=108 N=19 N=90 N=37 N=88 N=39 N=36 N=91\n\nNumber of events 32 11 24 19 24 19 6 37\n\nMean survival (SE), months 40.0 (1.2) 34.5 (3.2) 41.1 (1.2) 34.5 (2.3) 40.9 (1.3) 35.2 (2.3) 42.4 (1.9) 37.9 (1.4)\n\nCum. survival (%) 70% 42% 73% 49% 73% 51% 83% 59%\n\nLog Rank 5.78 7.75 5.94 5.48\n\nSig. 0.016 0.005 0.015 0.019\n\nAVC, aortic valve calcification; MVC, mitral VC; AMVC, aortic or mitral VC; SVCS, simple vascular calcification score\n\nTable III\n\nCardiovascular mortality (Kaplan Meier)\n\nAortic Valve Mitral Valve Aortic or Mitral Valve Plain X-ray score Plain X-ray score\nAVC=0 AVC>0 MVC=0 MVC>0 AMVC=0 AMVC>0 SVCS=0 SVCS>0 SVCS<3 SVCS?3\n\nN=108 N=19 N=90 N=37 N=88 N=39 N=36 N=91 N=64 N=63\n\nNumber of events 15 6 10 11 10 11 20 1 4 17\n\nMean survival (SE), months 43.6 (0.8) 40.1 (2.8) 44.5 (0.8) 39.4 (2.1) 44.5 (0.8) 39.8 (2.0) 46.1 (0.8) 41.8 (1.1) 45.5 (0.8) 40.8 (1.5)\n\nCum. survival (%) 85% 61% 88% 65% 87% 68% 97% 75% 93% 71%\n\nLog Rank 4.30 7.97 6.54 6.22 8.78\n\nSig. 0.038 0.005 0.011 0.010 0.003\n\nAVC, aortic valve calcification; MVC, mitral VC; AMVC, aortic or mitral VC; SVCS, simple vascular calcification score\n\nTeresa Adrag\u00e3o, Ana Pires, Carlos Lucas, Rita Birne, Lu\u00eds Magalh\u00e3es, Margarida Gon\u00e7alves, Ac\u00e1cio Pita Negr\u00e3o\n\n\n\nPort J Nephrol Hypert 2007; 21(4): 293-300 297\n\nFactors independently associated with mortality\nand morbidity (Table V)\n\nIn a Cox regression model adjusting also for all types\nof valvular calcification and simple vascular calcification score,\nfactors associated with all cause mortality, cardiovascular\n\nmortality and cardiovascular hospitalisations were\nidentified (Table V). Aortic valvular calcification was\ndirectly associated with all cause mortality (HR = 3.72,\n95% CI = 1.81 to 7.66, p<0.001). The risk of all cause\ndeath was 3.7 fold higher in patients with aortic valvu-\nlar calcification. Simple vascular calcification score was\n\nFigure 3\n\nLower survival in relation to all cause death in patients with valvular\n\ncalcification (VC)\n\nFigure 4\n\nLower survival in relation to cardiovascular death in patients with valvu-\n\nlar calcification (VC)\n\nTable IV\n\nMortality risk of each valvular calcification and vascular calcification score (Cox Regression)\n\nDependent variable Independent variables B Sig. H.R. 95% CI\nAortic valvular calcification 1.32&lt;0.001 3.8 1.83 to 7.76\n\nAll cause mortality\nMitral valvular calcification 0.89 0.004 2.4 1.32 to 4.50\n\nAortic or Mitral valvular calcification 0.93 0.003 2.5 1.36 to 4.67\n\nAll patients\nVascular calcification score 0.19 0.003 1.2 1.06 to 1.39\n\nAortic valvular calcification 0.96 0.047 2.6 1.01 to 6.77\n\nCardiovascular mortality\nMitral valvular calcification 1.17 0.008 3.2 1.36 to 7.58\n\nAortic or Mitral valvular calcification 1.07 0.015 2.9 1.23 to 6.84\n\nVascular calcification score 0.45&lt;0.001 1.6 1.26 to 1.95\n\nNon- diabetic All cause mortality\nMitral valvular calcification 0.92 0.009 2.5 1.22 to 5.04\n\npatients\nAortic or Mitral valvular calcification 0.88 0.014 2.4 1.19 to 4.82\n\nCardiovascular mortality Vascular calcification score 0.64&lt;0.001 1.89 1.38 to 2.58\n\nResults are adjusted for age, HD duration, diabetes, iPTH, Ca x P product, albumin and vascular disease at baseline. Vascular calcification score and each valvular calcification\n\nwere evaluated in separate models.\n\nVascular and valvular calcifications in dialysis patients: the same pathogenesis?\n\n\n\n298 Port J Nephrol Hypert 2007; 21(4): 293-300\n\ndirectly associated with cardiovascular death (HR=1.56,\n95% CI = 1.25 to 1.94, p<0.001) and with cardiovascu-\nlar hospitalizations (HR=1.34, 95% CI = 1.13 to 1.59,\np=0.001). For each unit increment of the simple vas-\ncular calcification score there was a 56% increase of\ncardiovascular death risk. PTH (p=0.04) was a nega-\ntive predictor of all-cause mortality. Albumin was a neg-\native predictor of all-cause mortality (p<0.001) and of\ncardiovascular hospitalisations (p=0.02). Diabetes (p=0.018)\nand CaxP product (p=0.001) were directly associated\nwith cardiovascular hospitalisations.\n\nFactors independently associated with valvular\nor vascular calcifications (Table VI)\n\nThe simple vascular calcification score was an inde-\npendent predictor of aortic valvular calcification (p=0.002),\nmitral valvular calcification (p<0.001) or any valvular cal-\ncification (p<0.001). For each unit increase in vascular score\n\nthere was, respectively, a 46% and a 66% increase in aor-\ntic and mitral valvular calcification risk (Table VI). PTH was\ndirectly associated with aortic valvular calcification\n(p=0.02). HD duration was directly associated with mitral\nvalvular calcification (p=0.003) or any valvular calcifica-\ntion (p=0.01). Male gender was directly associated with\nmitral valvular calcification (p=0.005) or any valvular cal-\ncification (p=0.006). Phosphorus levels were directly asso-\nciated with mitral valvular calcification (p=0.04). Age\n(p=0.001), diabetes (p=0.01) and HD duration (p=0.01)\nwere associated with simple vascular calcification score. \n\nDISCUSSION\n\nThe first study to demonstrate an association between\nvalvular calcification and mortality in dialysis patients\nwas Wang et al 11. In our group of haemodialysis patients\nwe have also verified that aortic and mitral valvular\n\nTeresa Adrag\u00e3o, Ana Pires, Carlos Lucas, Rita Birne, Lu\u00eds Magalh\u00e3es, Margarida Gon\u00e7alves, Ac\u00e1cio Pita Negr\u00e3o\n\nTable VI\n\nFactors independently associated with valvular or vascular calcification\n\nDependent variable Independent variables B Sig. O.R. 95% CI\n\nAortic valve calcification\nPTH 0.001 0.020 1.00 1.000 to 1.002\n\nvascular calcification score 0.380 0.002 1.46 1.145 to 1.866\n\nmale gender 1.565 0.005 4.78 1.599 to 14.316\n\nMitral valve calcification\nHD duration (months) 0.012 0.003 1.01 1.004 to 1.020\n\nPhosphorus 0.356 0.040 1.42 1.017 to 2.003\nvascular calcification score 0.504&lt;0.001 1.66 1.295 to 2.114\n\nmale gender 1.407 0.006 4.08 1.490 to 11.195\n\nAortic or Mitral valve calcification HD duration (months) 0.010 0.011 1.01 1.002 to 1.017\nvascular calcification score 0.410&lt;0.001 1.51 1.211 to 1.879\n\ndiabetes 1.730 0.012 5.64 1.467 to 21.708\n\nVascular calcification score age 0.049 0.001 1.05 1.020 to 1.027\n\nHD duration (months) 0.015 0.011 1.015 1.004 to 1.027\n\nSimple vascular calcification score is an independent predictor of aortic and mitral calcification\n\nTable V\n\nFactors independently associated with mortality and morbidity (Cox Regression)\n\nDependent variable Independent variables B Sig. H.R. 95% CI\nPTH -0.001 0.043 0.99 0.99 t0 1.00\n\nAll cause mortality albumin -1.89&lt;0.001 0.15 0.06 to 0.36\naortic valvular calcification 1.32&lt;0.001 3.72 1.83 to 7.76\n\nCardiovascular mortality\nmale gender 1.26 0.005 3.54 1.46 to 8.58\n\nsimple vascular calcification score 0.45&lt;0.001 1.56 1.25 to 1.94\n\ndiabetes 1.000 0.018 2.72 1.18 to 6.24\n\nCardiovascular hospitalisations\nalbumin -1.46 0.021 0.23 0.06 to 0.80\n\nCa x P product 0.05 0.001 1.05 1.02 to 1.08\nsimple vascular calcification score 0.09 0.001 1.34 1.13 to 1.59\n\nResults are adjusted for age, HD duration, diabetes, iPTH, Ca x P product, albumin, vascular disease at baseline, vascular calcification score and all types of valvular calcifications.\n\n\n\nPort J Nephrol Hypert 2007; 21(4): 293-300 299\n\ncalcifications and vascular calcifications were associat-\ned with all cause death and with cardiovascular death.\nWhen valvular and vascular calcifications were evaluat-\ned in the same model, aortic valvular calcification was\nan independent predictor of all cause death and the sim-\nple vascular calcification score was an independent pre-\ndictor of cardiovascular death and cardiovascular hos-\npitalisations. Factors associated with valvular calcifications\nwere the simple vascular calcification score, male gen-\nder, PTH and phosphorus levels. Ribeiro S et al 13 were\namong the first authors to verify an association between\ncalcium phosphate product and valvular calcification,\npointing out the role of mineral metabolism in the patho-\ngenesis of valvular calcification in dialysis patients. \n\nMany factors may contribute to the development of\nvascular and valvular calcifications in dialysis patients and\nthere is increasing evidence of a link between bone dis-\nease and vascular disease in these patients. Kidney Dis-\nease: Improving Global Outcomes (K/DIGO) has recom-\nmended a new classification for mineral and bone disorder\nof chronic kidney disease that includes the evaluation\nof biochemical abnormalities (Ca, P, PTH and vitamin D\nlevels), diagnosis of renal osteodystrophy preferably by\nbone biopsy and evaluation of vascular calcifications14.\n\nThe presence of hyperphosphataemia and increased\nCaxP product has been considered a major pathogen-\nic factor leading to vascular and soft tissue calcifica-\ntion in uraemic patients. Hyperphosphataemia can occur\neither with hyperparathyroidism or with adynamic bone\ndisease and this may explain the lack of correlation\nbetween vascular calcifications and PTH levels verified\nin many studies. In this study we have found, as\ndescribed by Wang et al 11, a direct association between\nPTH levels and valvular calcification. Other studies have\nalso verified an association between vascular calcifica-\ntions and low PTH levels15 or an absence of associa-\ntion between vascular calcifications and PTH levels2,16,17.\nGiacheli CM7 has demonstrated, in an in vitro model\nwith vascular smooth muscle cells from human aorta,\nthat increase of phosphorus and calcium outside the\ncell, in the culture media, leads to deposition of calcium\nphosphate in the matrix. This happens via two different\nmechanisms: an extracellular passive mechanism of direct\ndeposition but also by an active mechanism through\nactivation of an intracellular transcription factor, the core\nbinding factor ?-1 (Cbfa-1). This factor upregulates osteo-\ngenic genes and increases the synthesis of osteocalcin, alka-\nline phosphatase, collagen-rich extracellular matrix and\ncreates the conditions for deposition of calcium-phosphate.\n\nUnder these conditions, the vascular smooth muscle cell\nin the vessels acquires the phenotypic characteristics of an\nosteoblast. Some studies have also associated vascular cal-\ncification with oral calcium dose1,15,17,18. However, hyper-\ncalcaemia and hyperphosphataemia are not the only fac-\ntors associated with vascular calcification in dialysis patients. \n\nA deficiency in inhibitor calcification factors such as fetu-\nin-A or matrix-Gla protein have been also associated with\nthe development of vascular calcification8 and it is con-\nsidered that vascular calcification is the final result of the\nbalance between calcification inhibitors and inducers. \n\nIn our patients we have not verified any association\nbetween calcium levels or calcium carbonate dose with\nvascular or valvular calcifications but these parameters\nwere averaged for the six months preceding the eval-\nuation of vascular and valvular calcifications and this\nperiod of observation may not reflect the whole peri-\nod of dialysis which really determines the exposure. Low\nlevels of 25-hydroxivitamin D have also been associat-\ned with vascular calcifications19 and treatment with\nnative or active vitamin D may have an impact on the\ndevelopment of vascular calcifications20. We do not eval-\nuate vitamin D levels routinely in our patients but it is\npossible that this information, in the future, will be use-\nful in the management of bone disease in CKD patients.\n\nIn non renal patients with valvular calcification, ecto-\npic bone formation has been identified in the valves10.\nThis calcification, previously considered to be the result\nof a passive degenerative mechanism, seems to be the\nresult of an active mechanism most likely originated\nfrom differentiated myofibroblasts21. Osteoblastic bone\nformation and osteoclastic bone resorption were iden-\ntified in these calcified valves. Osteopontin, osteocal-\ncin, BMP 2 and BMP 4, which are potent calcification\ninducers, were also identified in these areas. This active\nprocess of yet unclear origin resembles what has been\nalso described for active calcification of arterial walls\nin dialysis7 and non dialysis patients4. \n\nIn this study we have verified that a simple vascu-\nlar calcification score evaluated in plain X-ray of pelvis\nand hands was independently associated with valvu-\nlar calcification. Wang AY et al 22 showed that valvu-\nlar calcification was associated with an increase in\ncarotid media-thickness and carotid calcification.\nThese results suggest that calcification is a systemic\ndisorder in dialysis patients and that vascular and valvu-\nlar calcification may share common characteristics. \n\nVascular and valvular calcifications in dialysis patients: the same pathogenesis?\n\n\n\n300 Port J Nephrol Hypert 2007; 21(4): 293-300\n\nComputed tomography scans are more accurate for\nthe quantitative assessment of vascular calcifications\nbut may be inadequate for an initial screening of vas-\ncular calcifications because of its price and its limit-\ned availability in some areas14. K/DOKI guidelines rec-\nommend the utilisation of plain X-ray for identification\nof vascular calcifications in dialysis patients23. This\nsimple vascular calcification score evaluated in plain\nX-ray was previously demonstrated to be associated\nwith coronary artery disease, peripheral artery disease\nand to be a predictor of cardiovascular mortality and\ncardiovascular hospitalisations in dialysis patients12.\nThis vascular calcification score is an inexpensive and\nvaluable tool that can be used for screening for the\npresence of vascular calcifications in dialysis patients.\n\nLimitations of this study\n\nThis is an observational study evaluating the asso-\nciation of valvular calcifications with mortality and\nthe association of vascular calcifications with valvu-\nlar calcifications. It is not possible to demonstrate\na cause-effect relationship between these variables.\n\nCONCLUSIONS\n\nIn summary, in these patients, male gender, HD\nduration, PTH, phosphorus levels and vascular cal-\ncifications were associated with cardiac valvular cal-\ncification. Valvular and vascular calcifications were\nindependent predictors of all cause and cardiovas-\ncular mortality. Vascular calcification was independ-\nently associated with cardiac valvular calcification,\nsuggesting that these two types of calcification may\nbe the result of the same pathogenic process.\n\nConflicts of interest. None declared.\n\nReferences\n1 Blacher J, Gu\u00e9rin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and car-\n\ndiovascular risk in end-stage renal disease. Hypertension 2001;38:938\u2013942.\n\n2 Guerin AP, London GM, Marchais SJ, Metivier F.Arterial stiffening and vascular calcifica-\ntions in end-stage renal disease. Nephrol Dial Transplant 2000;15:1014-21.\n\n3 Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mor-\ntality in patients undergoing maintenance hemodialysis. J Am Med Assoc 2002;287:\n1548\u20131555.\n\n4 Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regu-\nlating proteins in association with Monckeberg's sclerosis: evidence for smooth mus-\ncle cell-mediated vascular calcification. Circulation 1999;100:2168\u20132176.\n\n5 Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H. Vascular calcification and\ninorganic phosphate. Am J Kidney Dis 2001;38(4 Suppl 1):S34-7.\n\n6 Moe SM, O\u2019Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is asso-\nciated with deposition of bone matrix proteins. Kidney Int 2002;61:638\u2013647.\n\n7 Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004:15:2959\u20132964.\n\n8 Ketteler M, Vermeer C, Wanner C, et al. Novel insights into uremic vascular calcifica-\ntion: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blo-\nod Purif 2002;20:473\u2013476.\n\n9 Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis\nwith cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999;341:142-7.\n\n10 Mohler ER, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone Forma-\ntion and Inflammation in Cardiac Valves Circulation 2001;103:1522-1528.\n\n11 Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE. Cardiac valve calcification\nas an important predictor for all-cause mortality and cardiovascular mortality in long-term\nperitoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14: 159-68.\n\n12 Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardio-\nvascular risk in haemodialysis patients. Nephrol Dial Transplant 2004;19:1480\u20131488.\n\n13 Ribeiro S, Ramos A, Brand\u00e3o A, et al. Cardiac valve calcification in haemodialysis patients:\nrole of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13: 2037-40.\n\n14 Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal\nosteodystrophy: A position statement from Kidney Disease: Improving Global Outco-\nmes (KDIGO). Kidney Int 2006;69:1945\u20131953.\n\n15 London GM, Marty C, Marchais SJ, et al. Arterial Calcifications and Bone Histomorpho-\nmetry in End-Stage Renal Disease. J Am Soc Nephrol 2004;15:1943\u20131951.\n\n16 Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam compu-\nted tomography in the evaluation of cardiac calcification in chronic dialysis patients.\nAm J Kidney Dis 1996;27:394\u2013401.\n\n17 Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with\nend-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478\u20131483.\n\n18 London GM, Gu\u00e9rin AP, Marchais SJ, M\u00e9tivier F, Pannier B, Adda H. Arterial media cal-\ncification in end-stage renal disease: Impact on all-cause and cardiovascular mortality.\nNephrol Dial Transplant 2003;18:1731\u20131740.\n\n19 London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in\nend-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc\nNephrol. 2007 Feb;18(2):613-20\n\n20 Fournier A, Harbouche L, Mansour J et al. Impact of calcium and vitamin D therapy on\narterial and cardiac disease in young adults with childhood-onset end-tage renal dise-\nase.. Nephrol Dial Transplant 2007;22:956-8.\n\n21 Mohler ER, Chawla MK, Chang AW, et al. Identification and characteritization of calcif-\nying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-60.\n\n22 Wang AY, HO SS, Wang M et al. Cardiac valvular calcification as a marker of atheros-\nclerosis and arterial calcification in end stage renal disease. Arch Intern Med 2005;\n165:327-32.\n\n23 National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone Metabolism\nand Disease in Chronic Kidney disease. Am J Kidney Dis 2003;42 [Suppl 3].\n\nCorrespondence to:\nDr Teresa Adrag\u00e3o\nGambro-Healthcare, Nefroclinica-Estoril.\nRua Vale de S Rita, 19, 2765-293 Estoril, Portugal\ntadragao@netcabo.pt\n\nTeresa Adrag\u00e3o, Ana Pires, Carlos Lucas, Rita Birne, Lu\u00eds Magalh\u00e3es, Margarida Gon\u00e7alves, Ac\u00e1cio Pita Negr\u00e3o\n\n\n\n69\n\nCAP\u00cdTULO 6\n\nEXISTE UM ELO DE LIGA\u00c7\u00c3O ENTRE O OSSO E O VASO \nNOS DOENTES EM DI\u00c1LISE? (1.\u00aa PARTE)\n\nCalcifi ca\u00e7\u00e3o vascular e an\u00e1lise histomorfom\u00e9trica de biopsias \u00f3sseas\n\nA insufi ci\u00eancia renal cr\u00f3nica cria um cen\u00e1rio fi siopatol\u00f3gico no qual se verifi cam in\u00fameras \naltera\u00e7\u00f5es minerais e \u00f3sseas interligadas. A diminui\u00e7\u00e3o da excre\u00e7\u00e3o urin\u00e1ria de f\u00f3sforo \ndesencadeia uma cascata de acontecimentos que, se n\u00e3o tratados, conduzem ao \nhiperparatiroidismo secund\u00e1rio. Inicialmente, o aumento dos n\u00edveis do FGF -23 (fi broblast \ngrowth factor) e da paratormona mant\u00e9m o controlo do metabolismo mineral, mas \u00e0 medida \nque a doen\u00e7a renal progride perde -se este equil\u00edbrio e os n\u00edveis elevados da paratormona \ntornam -se prejudicais, com repercuss\u00e3o a n\u00edvel de v\u00e1rios \u00f3rg\u00e3os -alvo, entre os quais o osso. \nA osteodistrofi a renal \u00e9 uma entidade complexa que duma maneira simplista pode ser descrita \ncomo estando entre duas situa\u00e7\u00f5es extremas de remodela\u00e7\u00e3o \u00f3ssea: alta remodela\u00e7\u00e3o \u00f3ssea, \nque corresponde ao hiperparatiroidismo secund\u00e1rio, e baixa remodela\u00e7\u00e3o \u00f3ssea, que corresponde \n\u00e0 doen\u00e7a \u00f3ssea adin\u00e2mica. Entre estes dois extremos existe uma escala de altera\u00e7\u00f5es. Se \u00e0s \naltera\u00e7\u00f5es de remodela\u00e7\u00e3o se associarem altera\u00e7\u00f5es de mineraliza\u00e7\u00e3o, surgem novas entidades: \na osteomalacia, uma situa\u00e7\u00e3o de baixa remodela\u00e7\u00e3o e d\u00e9fi ce de mineraliza\u00e7\u00e3o, e a osteodistrofi a \nur\u00e9mica mista, uma situa\u00e7\u00e3o de alta remodela\u00e7\u00e3o com d\u00e9fi ce de mineraliza\u00e7\u00e3o.\n\nNos anos 80, o principal diagn\u00f3stico feito por biopsia \u00f3ssea era a osteodistrofi a ur\u00e9mica \nmista que resultava de hiperparatiroidismo secund\u00e1rio associado a um defeito de mineraliza\u00e7\u00e3o \nprovavelmente em rela\u00e7\u00e3o ao d\u00e9fi ce da vitamina D1. Outras altera\u00e7\u00f5es presentes eram a oste\u00edte \nfi brosa, resultante de hiperparatiroidismo secund\u00e1rio predominante, e a osteomalacia em rela\u00e7\u00e3o \ncom a toxicidade \u00f3ssea por alum\u00ednio. Nos \u00faltimos anos verifi cou -se um aumento da incid\u00eancia \nde doen\u00e7a \u00f3ssea adin\u00e2mica1 -3 que apresenta um padr\u00e3o de baixa remodela\u00e7\u00e3o \u00f3ssea. Esta nova \npatologia, mais frequente em doentes diab\u00e9ticos e idosos, parece tamb\u00e9m associar -se a outros \nfatores, entre eles o uso de concentra\u00e7\u00f5es elevadas de c\u00e1lcio no dialisante, o uso de doses \nelevadas de carbonato ou acetato de c\u00e1lcio como quelante do f\u00f3sforo e a supress\u00e3o excessiva \ndos n\u00edveis de PTH ap\u00f3s paratiroidectomia ou doses excessivas de vitamina D3. O aumento de \ndoen\u00e7a adin\u00e2mica coincidiu com a modifi ca\u00e7\u00e3o da terap\u00eautica recomendada para a hiperfosfatemia \nnos doentes em di\u00e1lise. No fi nal dos anos 80, o uso de hidr\u00f3xido de alum\u00ednio como quelante \n\n\n\n70\n\ndo f\u00f3sforo foi fortemente desaconselhado devido a estar associado ao desenvolvimento de \nosteomalacia, e foi substitu\u00eddo por doses elevadas de c\u00e1lcio oral. No momento atual, os dois \nprincipais diagn\u00f3sticos \u00f3sseos s\u00e3o a doen\u00e7a \u00f3ssea adin\u00e2mica e o hiperparatiroidismo secund\u00e1rio1, \nsendo a frequ\u00eancia da doen\u00e7a adin\u00e2mica superior \u00e0 do hiperparatiroidismo secund\u00e1rio, tal como \nse comprovou num grupo de doentes portugueses submetidos a biopsia \u00f3ssea4.\n\nA hiperfosfatemia e a hipercalcemia podem ocorrer, quer no hiperparatiroidismo secund\u00e1rio \nquer na doen\u00e7a adin\u00e2mica, embora por mecanismos diferentes. No hiperparatiroidismo, \nsitua\u00e7\u00e3o de elevada remodela\u00e7\u00e3o \u00f3ssea, o pr\u00f3prio osso liberta c\u00e1lcio e f\u00f3sforo para a circula\u00e7\u00e3o. \nNa doen\u00e7a \u00f3ssea adin\u00e2mica, o osso apresenta uma baixa remodela\u00e7\u00e3o \u00f3ssea e \u00e9 incapaz de \nincorporar c\u00e1lcio e f\u00f3sforo. O aumento de c\u00e1lcio e de f\u00f3sforo s\u00e9ricos n\u00e3o s\u00e3o totalmente \nremovidos na di\u00e1lise e depositam -se nos tecidos moles e nos vasos. Nas c\u00e9lulas musculares \nlisas das paredes das art\u00e9rias identifi cou -se um processo ativo de diferencia\u00e7\u00e3o gen\u00e9tica que \nconduz \u00e0 transforma\u00e7\u00e3o destas c\u00e9lulas em osteoblastos e \u00e9 respons\u00e1vel pelo desenvolvimento \ndas calcifi ca\u00e7\u00f5es vasculares5. O aumento dos n\u00edves de f\u00f3sforo e de c\u00e1lcio s\u00e3o alguns dos \nfatores indutores desta transforma\u00e7\u00e3o fenot\u00edpica5.\n\nPor proposta da iniciativa KDIGO 20066, a doen\u00e7a mineral e \u00f3ssea da doen\u00e7a renal cr\u00f3nica \n(CKD -MBD) \u00e9 atualmente defi nida como uma desordem sist\u00e9mica que se manifesta por um \nou mais dos seguintes aspetos: anomalias bioqu\u00edmicas, anomalias \u00f3sseas e calcifi ca\u00e7\u00f5es \nvasculares e de tecidos moles. O log\u00f3tipo da CKD -MBD mostra que a mortalidade, a doen\u00e7a \ncardiovascular e as fraturas \u00f3sseas resultam da intera\u00e7\u00e3o de altera\u00e7\u00f5es laboratoriais, altera\u00e7\u00f5es \n\u00f3sseas e calcifi ca\u00e7\u00f5es vasculares. Estas s\u00e3o as bases fi siopatol\u00f3gicas da atual hip\u00f3tese da \nexist\u00eancia de um elo de liga\u00e7\u00e3o entre a doen\u00e7a \u00f3ssea e a doen\u00e7a vascular nos doentes renais \ncr\u00f3nicos. \u00c9 contudo necess\u00e1rio demonstrar ainda que a corre\u00e7\u00e3o destas altera\u00e7\u00f5es minerais e \n\u00f3sseas conduz a uma redu\u00e7\u00e3o da mortalidade e da morbilidade nestes doentes.\n\nLondon et al7, em 2004, foram os primeiros a analisar a rela\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es \nvasculares e dados de biopsias \u00f3sseas. Verifi caram, num grupo de 58 doentes, uma associa\u00e7\u00e3o \nentre calcifi ca\u00e7\u00f5es vasculares avaliadas por ecografi a e baixa remodela\u00e7\u00e3o \u00f3ssea avaliada por \nbiopsia \u00f3ssea. Este estudo apresentava elevada percentagem de doentes submetidos a \nparatiroidectomia e doentes com dep\u00f3sitos de alum\u00ednio no osso.\n\nRaggi et al demonstraram em 2005 que a terap\u00eautica com c\u00e1lcio, em compara\u00e7\u00e3o com a \nterap\u00eautica de outro quelante do f\u00f3sforo sem c\u00e1lcio, o sevelamer, se associou a um efeito \ndelet\u00e9rio no metabolismo \u00f3sseo e nos vasos8. Estes autores verifi caram um aumento das \ncalcifi ca\u00e7\u00f5es coron\u00e1rias e, simultaneamente, uma diminui\u00e7\u00e3o dos valores da paratormona e \nda fosfatase alcalina. Verifi caram tamb\u00e9m que os doentes tratados com c\u00e1lcio apresentaram \numa diminui\u00e7\u00e3o da densidade mineral \u00f3ssea, enquanto nos doentes tratados com sevelamer \nn\u00e3o houve altera\u00e7\u00e3o da densidade mineral \u00f3ssea.\n\n\n\n71\n\nNum grupo de 38 doentes em hemodi\u00e1lise9 analisamos a rela\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es \ncoron\u00e1rias avaliadas pelo score de Agatston avaliado em TAC helicoidal multicorte com \ndados obtidos por an\u00e1lise histomorfom\u00e9trica de biopsias \u00f3sseas. Este estudo constituiu uma \nan\u00e1lise alargada feita num grupo de doentes que tinham participado num ensaio cl\u00ednico que \ncomparou o efeito do sevelamer e do carbonato da c\u00e1lcio4. Os diagn\u00f3sticos obtidos na biopsia \n\u00f3ssea neste grupo de doentes foram de baixa remodela\u00e7\u00e3o em 50% dos doentes e de alta \nremodela\u00e7\u00e3o em 39%; apenas 11% dos doentes apresentava remodela\u00e7\u00e3o \u00f3ssea normal. Nos \nnossos doentes verifi camos a exist\u00eancia de associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e \ndiminui\u00e7\u00e3o do volume \u00f3sseo. Em an\u00e1lise multivariada, verifi cou -se que esta associa\u00e7\u00e3o \npersistia durante os primeiros anos ap\u00f3s in\u00edcio de di\u00e1lise, desaparecendo nos doentes deste \nestudo ap\u00f3s 6 anos de di\u00e1lise. Verifi cou -se pois uma intera\u00e7\u00e3o entre o volume \u00f3sseo e a \ndura\u00e7\u00e3o de hemodi\u00e1lise. Por cada aumento de uma unidade no volume \u00f3sseo/volume total \nhouve redu\u00e7\u00e3o de risco de apresentar um score de Agatston superior a 400, de 24% nos \ndoentes com 2 anos de di\u00e1lise e de 16% nos doentes com 4 anos de di\u00e1lise. Nos doentes \ncom mais de 6 anos de di\u00e1lise o aumento de volume \u00f3sseo n\u00e3o teve efeito ben\u00e9fi co nas \ncalcifi ca\u00e7\u00f5es coron\u00e1rias.\n\nFig. 6.1. Nos doentes com menos de 4 anos de di\u00e1lise verifi cou -se uma redu\u00e7\u00e3o de risco OR, odds ratio, de ter um \nscore de Agatston > 400 por cada aumento de 1% do volume \u00f3sseo (VO)\n\nA principal conclus\u00e3o do nosso estudo \u00e9 de que a diminui\u00e7\u00e3o do volume \u00f3sseo \u00e9 um fator \nde risco para a presen\u00e7a de calcifi ca\u00e7\u00f5es coron\u00e1rias. Os primeiros anos de tratamento dial\u00edtico \ne provavelmente o per\u00edodo pr\u00e9 -di\u00e1lise podem ser momentos importantes para interven\u00e7\u00e3o \n\n\n\n72\n\nterap\u00eautica. Na an\u00e1lise dos fatores de risco cardiovasculares tradicionais, idade, sexo, \nhipertens\u00e3o arterial, n\u00edveis de colesterol e h\u00e1bitos tab\u00e1gicos, s\u00f3 a idade se associou \u00e0s \ncalcifi ca\u00e7\u00f5es coron\u00e1rias. Este artigo foi publicado na revista Clinical Journal of American \nSociety of Nephrology e mereceu um coment\u00e1rio editorial de G\u00e9rard London10.\n\nNeste nosso estudo, as calcifi ca\u00e7\u00f5es coron\u00e1rias foram avaliadas pelo score de Agatston \nem 38 doentes. Disp\u00fanhamos, contudo, da an\u00e1lise do score de calcifi ca\u00e7\u00e3o vascular simples, \nassim como da an\u00e1lise histomorfom\u00e9trica de biopsias \u00f3sseas num grupo de 50 doentes. \nOs dados relacionados com as calcifi ca\u00e7\u00f5es coron\u00e1rias foram considerados os mais \nrelevantes e originais e foi decidido serem os \u00fanicos admitidos para publica\u00e7\u00e3o. Na presente \ndisserta\u00e7\u00e3o consideramos ser indispens\u00e1vel a apresenta\u00e7\u00e3o da rela\u00e7\u00e3o entre o score de \ncalcifi ca\u00e7\u00e3o vascular simples e as biopsias \u00f3sseas. Neste grupo de 50 doentes (27 homens \ne 23 mulheres), com a idade m\u00e9dia de 53\u00b115 anos e dura\u00e7\u00e3o m\u00e9dia de hemodi\u00e1lise de \n63\u00b154 meses, a presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares foi verifi cada em 30 doentes (60%), \ne um score de calcifi ca\u00e7\u00e3o vascular > 3 estava presente em 19 (38%). Apenas 5 doentes \neram diab\u00e9ticos. Em an\u00e1lise multivariada por regress\u00e3o bin\u00e1ria verifi camos que um score \nde calcifi ca\u00e7\u00e3o vascular > 3 se associou diretamente \u00e0 idade, \u00e0 dura\u00e7\u00e3o de hemodi\u00e1lise e \naos n\u00edveis s\u00e9ricos de c\u00e1lcio e, inversamente, aos n\u00edveis s\u00e9ricos de albumina e ao volume \n\u00f3sseo (Tabela 6.1). Por cada aumento de uma unidade do volume \u00f3sseo houve uma redu\u00e7\u00e3o \nde risco de 15% de SCVS > 3. Nos doentes com volume \u00f3sseo &lt;17,6%, o risco de um \nSCVS >3 foi 21 vezes superior, em compara\u00e7\u00e3o com os doentes com um SCVS ?3 (Tabela \n6.2). Este valor de corte do volume \u00f3sseo foi calculado por curvas ROC relacionando o \nvolume \u00f3sseo com um SCVS > 3. Um volume \u00f3sseo&lt;16%, valor de corte defi nido nas \nKDOQI guidelines para diagnosticar baixo volume \u00f3sseo11 mas n\u00e3o ajustado \u00e0 popula\u00e7\u00e3o \nportuguesa, associou -se a um risco 28 vezes superior de apresentar um SCVS>3 (IC 95% \n2,1 a 366,7; p=0,011).\n\nFatores associados a um score de calcifi ca\u00e7\u00e3o vascular simples >3\nRegress\u00e3o bin\u00e1ria: Modelo 1\n\nVari\u00e1vel dependente: SCVS > 3 B OR IC 95% Sig. R2\nIdade 0,076 1,079 1,004 a 1,159 0,039\n\n54%\nDura\u00e7\u00e3o HD 0,023 1,023 1,005 a 1,042 0,013\nC\u00e1lcio s\u00e9rico 0,169 1,183 1,012 a 1,382 0,034\nAlbumina s\u00e9rica  -0,42 0,643 0,440 a 0,938 0,022\nVolume \u00f3sseo  -0,159 0,853 0,744 a 0,977 0,022\n\nTabela 6.1. Por cada diminui\u00e7\u00e3o de uma unidade de volume \u00f3sseo houve uma redu\u00e7\u00e3o de risco de 15% de \nscore de calcifi ca\u00e7\u00e3o vascular simples SCVS > 3\n\n\n\n73\n\nFactores associados a um score de calcifi ca\u00e7\u00e3o vascular simples >3\nRegress\u00e3o bin\u00e1ria: Modelo 2\n\nVari\u00e1vel dependente: SCVS > 3 B OR IC 95% Sig. R2\n\nIdade 0,087 1,091 1,003 a 1,187 0,043\n\n59%\nDura\u00e7\u00e3o HD 0,024 1,024 1,004 a 1,044 0,021\nC\u00e1lcio s\u00e9rico 0,152 1,165 1,002 a 1,353 0,046\nAlbumina s\u00e9rica  -0,57 0,633 0,426 a 0,941 0,024\nVolume \u00f3sseo &lt;17.6% 3,050 21,115 2,518 a 177,096 0,005\n\nTabela 6.2. Nos doentes com volume \u00f3sseo &lt;17,6%, o risco de ter um score de calcifi ca\u00e7\u00e3o vascular simples >3 \nfoi 21 vezes superior, em compara\u00e7\u00e3o com os doentes com um SCVS ?3\n\nOs estudos de London5 mostram uma associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e baixa \nremodela\u00e7\u00e3o \u00f3ssea. London demonstrou igualmente, noutro grupo de doentes, que a baixa \nremodela\u00e7\u00e3o \u00f3ssea se associou a calcifi ca\u00e7\u00f5es vasculares e a rigidez arterial na presen\u00e7a de \ntratamento com c\u00e1lcio12. Outro estudo demonstrou que as calcifi ca\u00e7\u00f5es vasculares n\u00e3o se \ndesenvolvem exclusivamente em associa\u00e7\u00e3o a baixa remodela\u00e7\u00e3o \u00f3ssea. Barreto D, et al \ndemonstraram que a progress\u00e3o de calcifi ca\u00e7\u00f5es coron\u00e1rias se associa a doen\u00e7a \u00f3ssea n\u00e3o \ncontrolada13. Neste estudo, num grupo de 38 doentes em di\u00e1lise com calcifi ca\u00e7\u00f5es coron\u00e1rias \nna avalia\u00e7\u00e3o inicial, verifi cou -se em duas situa\u00e7\u00f5es progress\u00e3o das calcifi ca\u00e7\u00f5es coron\u00e1rias \nap\u00f3s um ano: nos doentes que evolu\u00edram de uma situa\u00e7\u00e3o de alta remodela\u00e7\u00e3o \u00f3ssea para \nbaixa remodela\u00e7\u00e3o, mas tamb\u00e9m na situa\u00e7\u00e3o oposta, de baixa remodela\u00e7\u00e3o \u00f3ssea para alta \nremodela\u00e7\u00e3o. Esta evolu\u00e7\u00e3o foi independente do tipo de captador de f\u00f3sforo usado, sugerindo \nque a alta ou a baixa remodela\u00e7\u00e3o \u00f3ssea n\u00e3o controladas podem contribuir para a progress\u00e3o \ndas calcifi ca\u00e7\u00f5es vasculares. Em resumo, todos estes estudos confi rmam a hip\u00f3tese da exist\u00eancia \nde um elo de liga\u00e7\u00e3o entre doen\u00e7a \u00f3ssea e doen\u00e7a vascular nos doentes em di\u00e1lise. As \ncalcifi ca\u00e7\u00f5es vasculares podem surgir quer em associa\u00e7\u00e3o a baixa quer a alta remodela\u00e7\u00e3o \n\u00f3ssea. O nosso estudo foi o primeiro a demonstrar que o baixo volume \u00f3sseo \u00e9 um fator de \nrisco para a presen\u00e7a de calcifi ca\u00e7\u00f5es coron\u00e1rias.\n\nRefer\u00eancias\n\n  1. Malluche HH, Mawad H, Monier -Faugere MC. The importance of bone health in end -stage renal \ndisease: out of the frying pan, into the fi re? Nephrol Dial Transplant 2004;19 (Suppl 1):i9 -i13.\n\n  2. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end -stage renal failure -an \nevolving disorder. Kidney Int 1993;43(2):436 -442\n\n\n\n74\n\n  3. Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. \nJ Bone Miner Res 1995;10(1):149 -156.\n\n  4. Ferreira A, Fraz\u00e3o JM, Monier -Faugere MC, et al. Sevelamer study group effects of sevelamer \nhydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc \nNephrol 2008;19(2):405 -412.\n\n  5. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2964.\n  6. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of \n\nrenal osteodystrophy: A position statement from Kidney disease: improving global outcomes \n(KDIGO). Kidney Int 2006; 69: 1945 -1953.\n\n  7. London GM, Marty C, Marchais SJ, et al. Arterial calcifi cations and bone histomorphometry in \nend -stage renal disease. J Am Soc Nephrol 2004; 15: 1943 -1951.\n\n  8. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-\n-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20(5):764 -772.\n\n  9. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Dias Curto J, \nMalluche HH. Low bone volume \u2013 A risk factor for coronary calcifi cations in hemodialysis patients. \nClin J Am Soc Nephrol 2009; 4(2): 450 -455.\n\n10. London GM. Bone \u2013 vascular axis in chronic kidney disease: A reality? Clin J Am Soc Nephrol \n2009; 4: 254 -257.\n\n11. KDOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. \nAm J Kidney Dis 2003; 42 (Suppl 3):S1 -S202\n\n12. London GM, Marchais SJ, Gu\u00e9rin AP, et al. Association of bone activity, calcium load, aortic \nstiffness, and calcifi cations in ESRD. J Am Soc Nephrol 2008; 19: 1827 -1835.\n\n13. Barreto DV, Barreto FC, Carvalho AB, et al. Association of changes in bone remodelling and \ncoronary calcifi cation in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; \n52(6):1139 -1150.\n\n\n\nLow Bone Volume\u2014A Risk Factor for Coronary\nCalcifications in Hemodialysis Patients\n\nTeresa Adragao,* Johann Herberth,\u2020 Marie-Claude Monier-Faugere,\u2020 Adam J. Branscum,\u2021\n\nAnibal Ferreira,\u00a7 Joao M. Frazao,? Jose Dias Curto,\u00b6 and Hartmut H. Malluche\u2020\n\n*Nephrology Department, Santa Cruz Hospital, Lisbon, Portugal; \u2020Division of Nephrology, Bone, and Mineral\nMetabolism and \u2021Department of Biostatistics, Statistics, and Epidemiology, University of Kentucky, Lexington,\nKentucky; \u00a7Nephrology Department, Curry Cabral Hospital, Lisbon, Portugal; ?Nephrology Department, Hospital de S.\nJoa?o, Medical School and Nephrology Research and Development Unit, University of Porto, Porto, Portugal; and\n\u00b6ISCTE, Business School, Lisbon, Portugal\n\nBackground and objectives: There is increasing evidence that altered bone metabolism is associated with cardiovascular\ncalcifications in patients with stage 5 chronic kidney disease on hemodialysis (HD). This study was conducted to evaluate the\nassociation between bone volume, turnover, and coronary calcifications in HD patients.\n\nDesign, setting, participants, &amp; measurements: In a cross-sectional study, bone biopsies and multislice computed tomog-\nraphy were performed in 38 HD patients. Bone volume/total volume, activation frequency, and bone formation rate/bone\nsurface were determined by histomorphometry and coronary calcifications were quantified by Agatston scores.\n\nResults: Prevalence of low bone turnover was 50% and of low bone volume was 16%. Among the studied traditional cardio-\nvascular risk factors, only age was found to be associated with coronary calcifications. Lower bone volume was a significant risk\nfactor for coronary calcifications during early years of HD, whereas this effect was not observed in patients with dialysis duration\n>6 yr. Histomorphometric parameters of bone turnover were not associated with coronary calcifications.\n\nConclusions: Low bone volume is associated with increased coronary calcifications in patients on HD.\nClin J Am Soc Nephrol 4: 450 \u2013 455, 2009. doi: 10.2215/CJN.01870408\n\nC\nardiovascular disease and stroke account for 60 to 70%\nof all deaths in patients with chronic kidney disease\n(CKD) on maintenance hemodialysis (HD) (1,2). In a\n\nstudy utilizing electron beam computed tomography, dialysis\npatients presented with higher coronary calcification scores\nwhen compared with nondialysis patients (3). In HD patients,\nvascular calcifications were shown to be associated with car-\ndiovascular morbidity and mortality (4). Conspicuously, how-\never, two prospective trials on modification of traditional car-\ndiovascular risk factors in CKD patients could not demonstrate\nsignificant differences in cardiovascular outcomes, including\ndeath between an intensive \u201cmultiple traditional risk factor\nintervention\u201d group and the standard therapy group despite\nsignificantly improved traditional risk factor control in the\nformer (5,6). Recent evidence shows that vascular calcifications\nin CKD can occur early, and that deposition of calcium in the\nvascular wall is a complex and tightly regulated process that is\nakin to bone mineralization (7,8). In addition, abnormalities in\nbone turnover and bone volume are associated with more\nvascular calcifications in uremic patients (9,10).\n\nTaking this evidence into consideration, the international initia-\ntive, Kidney Disease: Improving Global Outcomes, recommends\nthe inclusion of evaluation for extraskeletal calcifications into a\nnew classification for \u201cchronic kidney disease-mineral and bone\ndisorder\u201d (11). Although an association between low bone turn-\nover and increased vascular calcification (measured by a semi-\nquantitative vascular calcification score) was reported previously\n(9), the relationship between histomorphometric parameters of\nbone formation and bone volume and quantitative determina-\ntions of coronary calcifications by multislice computed tomog-\nraphy (MSCT) while controlling for the traditional cardiovas-\ncular risk factors of hypertension, gender, age, cholesterol, and\ntobacco use has not been investigated in HD patients. The study\npresented here aims at providing this information.\n\nMaterials and Methods\nStudy Design\n\nThis is an extension study in a cohort of patients who participated in\nthe Sevelamer Study Group randomized trial (12). Briefly, the Sevel-\namer Study Group study was a 54-wk randomized open-label study to\ncompare the effects of sevelamer hydrochloride and calcium carbonate\non bone histomorphometric parameters. This extension study investi-\ngates the interaction between histologically determined parameters of\nbone turnover/bone volume and coronary calcifications measured by\nMSCT in a cross-sectional study design. The Institutional Review\nBoards of all participating institutions approved the protocol. The\nstudy has been conducted in adherence to the Declaration of Helsinki,\nand all patients provided informed consent.\n\nReceived April 21, 2008. Accepted November 7, 2008.\n\nPublished online ahead of print. Publication date available at www.cjasn.org.\n\nCorrespondence: Dr. Hartmut H. Malluche, FACP, Division of Nephrology,\nBone, and Mineral Metabolism, Room MN 564, University of Kentucky Medical\nCenter, 800 Rose Street, Lexington, Kentucky, 40536-0084. Phone: 859-323-5048\next. 221; Fax: 859-257-1052; E-mail: hhmall@uky.edu\n\nCopyright \u00a9 2009 by the American Society of Nephrology ISSN: 1555-9041/402\u20130450\n\n\n\nPopulation\nThirty-eight patients provided informed consent for performing his-\n\ntomorphometric analysis of bone samples and MSCT for evaluation of\ncoronary calcifications and were enrolled in this extension study. In-\nclusion criteria were ages 18 yr or older, dialysis duration of at least 3\nmo, mental competence, and willingness to participate in the study. All\npatients were required to have stable serum phosphorus of ?8.1 mg/dl\nbecause higher levels were considered indicative of medication non-\ncompliance. The extension study called for providing consent to un-\ndergo evaluation for coronary calcifications by MSCT, which was per-\nformed on average 3.8 ? 1.9 mo after the bone biopsy. Exclusion criteria\nwere failed kidney transplant during the past 6 mo; pregnancy; uncon-\ntrolled systemic illnesses or organic diseases with potential influence on\nbone metabolism such as diabetes mellitus, active or chronic liver\ndisease, malabsorption, malignancy, and thyroid dysfunction; history\nof or present treatment with pharmacologic agents known to affect\nbone metabolism such as bisphosphonates, fluoride, calcitonin, glu-\ncocorticoids or other immunosuppressive agents, hormone replacement\ntherapy, and selective estrogen receptor modulators; chronic alcoholism\nand/or drug addiction; and allergy to tetracycline compounds.\n\nHypertension was defined as blood pressure ?140/90 mmHg\nand/or treatment with antihypertensive medications. Tobacco use was\ndefined as inhalative smoking of ?1 cigarette per day.\n\nBone Biopsies\nAnterior iliac crest bone biopsies were done after tetracycline labeling\n\nunder local anesthesia and conscious sedation. The labeling schedule\nconsisted of a 2-d oral administration of tetracycline hydrochloride (250\nmg twice daily) followed by a drug-free interval of 10 d, and subsequent\noral administration of demeclocycline hydrochloride (300 mg twice daily)\nfor 4 d. Bone biopsies were performed 3 to 4 d after completing the second\nlabel. Bone samples were obtained with the one-step electrical drill tech-\nnique (Straumann Medical, Waldenburg, Switzerland). Bone samples\nwere processed undecalcified and sections were stained with the modified\nMasson\u2013Goldner trichrome stain, the aurin tricarboxylic acid stain, and\nsolochrome azurin for assessment of stainable aluminum in bone (13).\nUnstained sections were prepared for phase contrast and fluorescence\nlight microscopy. Histomorphometric analysis of bone was done at stan-\ndardized sites in cancellous bone using the semiautomatic method (Os-\nteoplan II, Kontron, Munich, Germany) at 200? magnification. Bone vol-\nume/total volume (BV/TV) was calculated for assessment of mineralized\nbone volume, whereas activation frequency (Ac.f.) and bone formation\nrate/bone surface (BFR/BS) were calculated for assessment of bone turn-\nover. All bone samples were processed and analyzed without knowledge\nof the clinical data. BV/TV classification was based on three categories\ncharacterized by the distribution of our data (5th, 50th, and 95th percen-\ntile). The classification of \u201clow,\u201d \u201cnormal,\u201d and \u201chigh\u201d bone turnover was\nbased on our normative database (14 \u201316). The outcome group for low\nbone turnover was defined as Ac.f. ?0.49 yr?1 and/or BFR/BS ?1.8\nmm3/cm2/yr. The outcome group for normal bone turnover was defined\nas Ac.f. 0.49 to 0.72 yr?1 and/or BFR/BS 1.8 to 3.9 mm3/cm2/yr. The\noutcome group for hig bone turnover was defined as Ac.f. ?0.72 yr?1\n\nand/or BFR/BS ?3.9 mm3/cm2/yr.\n\nAssessment of Coronary Calcifications\nVascular calcifications were assessed by a quantitative score using\n\nMSCT. MSCT scans were performed with the four-slice technique on\nthe model Somatom Volume Zoom (Siemens AG, Erlangen, Germany).\nSlices of 2.5-mm thickness were acquired under the following condi-\ntions: 120 kVp, 130 mAs, and 0.5 gantry rotation time. All images were\ntransferred to a workstation and analyzed with calcium scoring soft-\n\nware (HeartView CT, Siemens AG, Erlangen, Germany). Quantification\nof coronary calcification was performed by calculating the Agatston\n(Agt.) score on the basis of the maximum x-ray attenuation coefficient\n(measured in Hounsfield units).\n\nBiochemical Analyses\nBlood was drawn at the time of the bone biopsy after an overnight\n\nfast. The following biochemical parameters were measured: serum\ncalcium and phosphorus by an autoanalyzer (Hitachi 747, Globe Sci-\nentific Inc.), immunoreactive parathyroid hormoneby DPC IMMULITE\nPTH IRMA (Diagnostics Products Corporation, Los Angeles, Califor-\nnia; normal range 16 to 87 pg/ml; intra- and interassay coefficients of\nvariation ?7 and ?9%, respectively); 25-(OH)-vitamin D by LIAISON\n25-OH Vitamin D assay (Diasorin, Saluggia, Italy; normal range 25 to\n100 ng/ml; intra- and interassay coefficients of variation 4.1 and 7%,\nrespectively); and total cholesterol was measured by the Synchron LX\nsystem (Beckman Coulter, Fullerton, California; desirable range ?200\nmg/dl; intra- and interassay coefficients of variation both ?3%).\n\nStatistical Analyses\nDescriptive statistics are presented as means, medians, minimums,\n\nmaximums, and SD stratified according to Agt. score groups of ?100,\n100 to 400, and ?400. The variables Ac.f., BFR/BS, and HD duration\nhad right-skewed distributions and were log transformed for analysis.\nBoxplots were used to characterize the distributions of BV/TV, log\nAc.f., and log BFR/BS for each Agt. score group. Bivariate associations\nwere assessed using the nonparametric Kruskal\u2013Wallis test for continuous\nvariables and Fisher\u2019s exact test for categorical variables. Multivariable\nassociations were assessed using separate ordinal (proportional odds)\nlogistic regression analyses to evaluate the effects of BV/TV, log Ac.f., and\nlog BFR/BS on Agt. score, adjusted for measured demographic and\nbiologic factors. All calculations were performed using the R statistical\npackage (R Foundation for Statistical Computing, Vienna, Austria) and\nSAS version 9.1 (SAS Institute Inc., Cary, North Carolina, USA).\n\nResults\nDemographic characteristics of the study population are pre-\n\nsented in Table 1. There were no statistically significant differ-\nences between the coronary Agt. score groups except for age.\nThe study included only nondiabetic patients.\n\nBV/TV was low in 6 (16%), normal in 9 (24%), and high in 23\n(60%) patients. Low bone turnover was diagnosed in 19 pa-\ntients (50%), normal turnover in 4 patients (11%), and high\nturnover in 15 patients (39%) on the basis of Ac.f. and BFR/BS.\nThere were no disagreements regarding classification of bone\nturnover between Ac.f. and BFR/BS. None of the biopsies\nshowed positive staining for aluminum or iron. In unadjusted\nanalyses, there were no statistically significant differences be-\ntween the three Agt. score groups regarding the bone histomor-\nphometric parameters BV/TV, Ac.f., and BFR/BS (Figure 1).\n\nOrdinal logistic regression revealed that, among the studied\ntraditional cardiovascular risk factors, age was the only vari-\nable that predicted Agt. score groups (P ? 0.02). Our data\nshowed that Agt. score groups were also predicted by BV/TV\n(P ? 0.02); one unit (%) increase in BV/TV in patients with the\nsame age and on HD for ?2 yr decreases the odds of being in\nthe high Agt. score group (Agt. ?400) by 24% [odds ratio: 0.76;\n95% confidence interval: 0.61 to 0.94]. In addition, the interac-\ntion term between BV/TV and HD duration was associated\n\nClin J Am Soc Nephrol 4: 450 \u2013 455, 2009 Bone Volume and Coronary Calcifications 451\n\n\n\nwith Agt. score groups (P ? 0.05); the effect of BV/TV on the\nodds of being in a specific Agt. score group decreased with\nincreasing HD duration (Figure 2) and was no longer statisti-\ncally significant in patients on HD for ?6 yr (odds ratio: 0.90;\n95% confidence interval: 0.80 to 1.02).\n\nTo better study the interactions between BV/TV, age, and\nHD duration for predicting Agt. score groups, we divided these\n\nindependent variables into three categories characterized by\nthe distribution of our data (5th, 50th, and 95th percentiles).\nClassification according to these percentiles corresponded to\nBV/TV values of 15, 24, and 37%; ages of 30, 50, and 75 yr; and\nHD durations of 2, 4, and 17 yr. Because ordinal logistic regres-\nsion revealed that the associations between bone volume (BV/\nTV) and coronary calcifications were no longer statistically\n\nTable 1. Demographic characteristics of the study population\n\nCharacteristic\nAgatston Score\n\n?100 100 to 400 ?400 P\n\nAge (yr) 0.03a\n\nN 19 8 11\nmean (SD) 45.2 (15.2) 59.8 (14.9) 57.2 (15.1)\nmedian (min, max) 45 (21, 74) 59 (39, 76) 57 (37, 78)\n\nCholesterol (g/L) 0.44a\n\nN 19 8 11\nmean (SD) 1.70 (0.3) 1.6 (0.2) 1.5 (0.2)\nmedian (min, max) 1.7 (1.2, 2.4) 1.6 (1.2, 2.0) 1.5 (1.2, 2.0)\n\nCalcium (mg/dl) 0.35a\n\nN 19 8 11\nmean (SD) 96 (6.6) 94 (6.2) 98 (5.7)\nmedian (min, max) 95.4 (87, 111) 93.6 (85, 104) 100 (87, 105)\n\nPhosphorus (mg/dl) 0.08a\n\nN 19 8 11\nmean (SD) 5.4 (0.9) 4.6 (0.8) 5.0 (0.7)\nmedian (min, max) 5.5 (3.9, 7.2) 4.8 (3.2, 5.3) 5.0 (3.8, 6.3)\n\niPTHc (pg/ml) 0.47a\n\nN 19 8 11\nmean (SD) 620 (614) 293 (167) 570 (700)\nmedian (min, max) 353.4 (50, 2164) 259 (155, 679) 301 (100, 2572)\n\n25-(OH)-vitamin D (ng/ml) 0.78a\n\nN 19 8 11\nmean (SD) 21.2 (7.8) 19.5 (6.2) 20.2 (10.0)\nmedian (min, max) 21.5 (7.8, 37.6) 17.5 (13.5, 27.8) 14.6 (11.0, 41.4)\n\nDialysis duration (mo) 0.48a\n\nN 19 8 11\nmean (SD) 73.1 (56.6) 44.9 (23) 87.2 (77.2)\nmedian (min, max) 48.3 (21, 206) 39.5 (19, 77) 45 (23, 242)\n\nGender 0.27b\n\nN 19 8 11\nmale (N, %) 9 (47.3) 3 (37.5) 8 (72.7)\nfemale (N, %) 10 (52.6) 5 (62.5) 3 (27.3)\n\nTobacco use 0.88b\n\nN 19 8 11\nyes (N, %) 4 (21.0) 1 (12.5) 3 (27.3)\nno (N, %) 15 (79.0) 7 (87.5) 8 (72.7)\n\nHypertension 0.63b\n\nN 19 8 11\nyes (N, %) 11 (57.9) 4 (50.0) 8 (72.7)\nno (N, %) 8 (42.1) 4 (50.0) 3 (27.3)\n\naP value computed from Kruskal\u2013Wallis test.\nbP value computed from Fisher\u2019s exact test.\nciPTH, immunoreactive parathyroid hormone.\n\n452 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 450 \u2013 455, 2009\n\n\n\nsignificant after a HD duration of 6 yr, the sixth-year HD\nduration time point was also examined. Accordingly, Figure 3\ndepicts changes in the probabilities for the Agt. score group\n?100 (Figure 3, A through D) and for the Agt. score group ?400\n(Figure 3, E through H) for the three different BV/TV values\n(depicted on the x-axis) and three different ages (depicted by\ndifferent lines) on the basis of the four different HD durations\n(Figure 3, A and E ? 2 yr; Figure 3 B and F ? 4 yr; Figure 3, C\nand G ? 6 yr; and Figure 3, D and H ? 17 yr). Irrespective of\nHD duration, increasing age carries a higher likelihood of hav-\ning an Agt. score of ?400 and accordingly a lower likelihood of\nhaving an Agt. score ?100. This age effect was observed in each\nBV/TV class. However, the magnitude of this bone volume\neffect is conditional on HD duration; in the HD duration classes\nof 2 and 4 yr, lower BV/TV bears a higher likelihood of having\nan Agt. score ?400 and, accordingly, lower likelihood of having\n\nan Agt. score ?100 irrespective of the age group (Figure 3).\nHowever, in long HD duration classes (17 yr), higher BV/TV is\nassociated with lower likelihood of an Agt. score ?100 and\nhigher likelihood of an Agt. score ?400 irrespective of age.\n\nIn the case of shorter HD duration (?6 yr), the incremental\nincrease in the likelihood of having an Agt. score ?100 is the\nlargest for increasing BV/TV from the 5th to the 50th percentile\nfor younger patients (30 yr), whereas older patients (75 yr)\nderive the highest benefit from increasing BV/TV from the 50th\nto the 95th percentile. It is of note that, after 2 yr of HD\nduration, a 30-yr-old patient with a low BV/TV has about the\nsame probability of having an Agt. score ?100 (P ? 0.39) than\na 75-yr-old patient with normal BV/TV (P ? 0.36). Figure 3 also\nshows that the likelihood of having an Agt. score ?100 is lower\nat the lowest BV/TV at the shortest HD duration than at normal\nor high BV/TV at the longest HD duration irrespective of age.\n\nOrdinal logistic regression conducted with Ac.f. and BFR/BS\nrevealed that only age was predictive of the Agt. score class of\ncoronary arteries (P ? 0.03). No specific interactions were\nfound between variables of bone turnover and the studied\ntraditional risk factors (P ? 0.05).\n\nDiscussion\nOur data confirm previous studies reporting on the effect of\n\nage on vascular calcifications in HD patients (17,18). We also\nconfirm previous observations reporting lack of predictive\nvalue of the traditional cardiovascular risk factors of hyperten-\nsion, smoking, gender, and cholesterol for cardiovascular out-\ncomes in HD patients (5,6,18,19).\n\nThe novel aspect of our study is the investigation of the\ninteraction between the bone volume and the bone turnover\ncomponents of renal osteodystrophy (determined by histomor-\nphometry) and coronary calcifications (determined by MSCT)\n\nFigure 1. Distribution of values for bone volume/tissue volume\n(BV/TV), activation frequency (Ac.f.), and bone formation\nrate/bone surface (BFR/BS) among the Agatston (Agt.) score\nclasses ?100, 100 to 400, and ?400. Box ? median, 25 to 75%;\nT-bars ? minimum and maximum values.\n\nFigure 2. Effect of the interaction between BV/TV volume and\nhemodialysis (HD) duration on the odds of an Agt. score of\n?400. Odds ratio represents the change in the odds for an Agt.\nscore ?400 for each 1% increase in BV/TV. Vertical bars ? 95%\nconfidence interval.\n\nFigure 3. Changes in the probabilities for (A through D) the Agt.\nscore group ?100 and (E through H) the Agt. score group ?400\nfor different BV/TV values and ages on the basis of four different\nHD durations (A and E ? 2 yr, B and F ? 4 yr, C and G ? 6 yr,\nD and H ? 17 yr). Solid line ? 30-yr-old patient; long dashed\nline ? 50-yr-old patient; short dashed line ? 75-yr-old patient.\n\nClin J Am Soc Nephrol 4: 450 \u2013 455, 2009 Bone Volume and Coronary Calcifications 453\n\n\n\nin prevalent HD patients. Low bone volume and bone loss are\ncommon findings in patients on renal replacement therapy\n(20,21). Our study demonstrates the importance of bone vol-\nume for predicting coronary calcifications. Specifically, it ap-\npears that lower bone volume is predictive of higher Agt.\nscores, reflecting higher risk of cardiovascular events (Agt.\n?100) irrespective of age. Although correlations between bone\nloss and progressive arterial calcifications were described in the\ngeneral population, (22,23) there is little information available\non their possible interaction in HD patients. Peripheral arterial\ncalcifications assessed by plain radiographs and low bone vol-\nume were observed in an early study by Zuchelli and col-\nleagues, but the authors did not examine a possible interrela-\ntion between bone volume and vascular calcifications and did\nnot report on the contribution of traditional risk factors for\ncardiovascular calcifications (24). Similarly, assessment of bone\nmineral density by quantitative computed tomography in HD\npatients showed less coronary calcifications with higher verte-\nbral bone mineral density (25). Although several serum mark-\ners of bone metabolism such as bone morphogenic proteins (26)\nand osteoprotegerin (27) were implicated in the pathogenesis of\nvascular calcifications, to our knowledge this is the first popu-\nlation-based study that describes the predictive value of histo-\nlogically measured bone volume for coronary calcifications in\nHD patients.\n\nAn interesting finding in our study is that the effect of bone\nvolume on Agt. scores is conditional on HD duration; if HD\nduration is ?6 yr, the bone volume effect seems to be overrid-\nden by other risk and/or protective factors that determine\ncoronary calcifications. In light of a 5-yr mortality rate of ?75%\nfor patients on dialysis (1), it appears that the bone volume\neffect is of great importance for most HD patients. The impli-\ncations of lower bone volume for higher Agt. scores is further\nhighlighted by our finding that 30-yr-old patients who exhibit\nlow bone volume early in the course of HD have probabilities\nfor low Agt. scores comparable to 75-yr-old patients with nor-\nmal bone volume.\n\nLondon and colleagues previously reported on the associa-\ntion between histologically diagnosed low bone turnover and\narterial calcifications detected on plain radiographs and evalu-\nated by semiquantitative calcifications scores in HD patients\n(9). Our study presented here did not find an association be-\ntween bone turnover parameters and coronary calcifications\nmeasured by MSCT, although a relationship was demonstrated\nbetween histologically determined bone turnover and thoracic\naorta and iliac artery calcifications in a previous publication\n(10). Discordance between predictors of aortic and coronary\ncalcifications has been described in a series of publications from\nthe large, population-based Multi-Ethnic Study of Atheroscle-\nrosis (MESA) (28 \u201330). Accordingly, our findings supplement\nrather than contradict the findings of London and colleagues\nand highlight that studies aiming at predicting vascular calci-\nfications have to take into account the site examined within the\nvascular tree, the morphology of the vascular tissue, and the\nlocalization of calcification within the vascular wall.\n\nLimitations of our study are that patients were recruited from\ndialysis centers in Portugal and diabetic patients were not\n\nincluded. Accordingly, we cannot generalize our findings to\nother populations and draw inferences on a possible effect of\ndiabetes mellitus on the observed interaction between bone\nvolume and coronary calcifications. We are currently in the\nprocess of designing larger studies that focus on the contribu-\ntion of renal osteodystrophy to coronary calcifications in dif-\nferent HD patient populations. On the basis of recent improve-\nments in the sensitivity of MSCT scanners for detecting\ncoronary calcifications, it is conceivable that the magnitude of\nthe bone volume effect will be greater than observed in our\npresented here. More sensitive detection methods for coronary\ncalcifications might also contribute to a more precise estimation\nof the contribution of bone turnover to coronary calcification.\n\nIn summary, our data implicate that low bone volume is a\nsignificant risk factor for coronary calcifications in HD patients,\nand that this risk is dependent on the patient\u2019s age and HD\nduration. Although statistical associations do not necessarily im-\nply cause and effect relationships, our findings suggest that early\nprevention of bone loss in CKD patients might carry important\nimplications for reducing coronary calcifications, especially be-\ncause age and HD duration are not modifiable risk factors.\n\nAcknowledgments\nThe following colleagues have participated in the study: Ce?lia Gil,\n\nCarlos Oliveira, Jose? Galva?o, Anto?nio Morais Sarmento, Silvia Ribeiro,\nJorge Dickson, Berta Carvalho, Il\u00eddio Rodrigues, Jorge Baldaia, and\nOdete Pereira.\n\nThis study was supported by grant NIH RO1 DK51530 (H.H.M.); by\nthe Kentucky Nephrology Research Trust (M-C.M-F.); by the Dean\u2019s\nClinical Research Scholar Program, University of Kentucky, no\n1012112710 (J.H.); and by a grant from Genzyme.\n\nThe authors thank ISNI, Instituto Nefrolo?gico de Investigac?a?o, for\nassistance in the organization of this study, and Ms. Julia Van Willigen\nand Richard Wheeler for their technical assistance.\n\nDisclosures\nNone.\n\nReferences\n1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of\n\ncardiovascular disease in chronic renal disease. Am J Kid-\nney Dis 32[5 Suppl 3]: S112\u2013S119, 1998\n\n2. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco\nMV, Teehan BP, Levey AS: Atherosclerotic cardiovascular\ndisease risks in chronic hemodialysis patients. Kidney Int\n58: 353\u2013362, 2000\n\n3. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,\nLuft FC: Electron beam computed tomography in the eval-\nuation of cardiac calcification in chronic dialysis patients.\nAm J Kidney Dis 27: 394 \u2013 401, 1996\n\n4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM:\nArterial calcifications, arterial stiffness, and cardiovascular\nrisk in end-stage renal disease. Hypertension 38: 938 \u2013942, 2001\n\n5. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW,\nLeano R, Isbel NM: Effect of aggressive risk factor modi-\nfication on cardiac events and myocardial ischemia in pa-\ntients with chronic kidney disease. Heart 92: 1402\u20131408,\n2006\n\n454 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 450 \u2013 455, 2009\n\n\n\n6. Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C,\nMarwick TH: Increased targeting of cardiovascular risk\nfactors in patients with chronic kidney disease does not\nimprove atheroma burden or cardiovascular function. Am\nHeart J 151: 745\u2013753, 2006\n\n7. Moe SM: Vascular calcification and renal osteodystrophy\nrelationship in chronic kidney disease. Eur J Clin Invest\n36[Suppl 2]: 51\u2013 62, 2006\n\n8. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B,\nSider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff\nRM, Salusky IB: Coronary-artery calcification in young\nadults with end-stage renal disease who are undergoing\ndialysis. N Engl J Med 342: 1478 \u20131483, 2000\n\n9. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F,\nde Vernejoul MC: Arterial calcifications and bone histo-\nmorphometry in end-stage renal disease. J Am Soc Nephrol\n15: 1943\u20131951, 2004\n\n10. Adragao T, Ferreira A, Frazao J, Gil C, Oliveira C, Sar-\nmento J, Ribeiro S, Dickson J, Carvalho B, Rodrigues I,\nBaldaia J, Faugere M, Malluche H: Vascular calcifications\nand bone turnover in hemodialysis patients. Nephrol Dial\nTransplant 21 [Suppl 4]: 292, 2006\n\n11. Moe S, Drueke T, Cunningham J, Goodman W, Martin K,\nOlgaard K, Ott S, Sprague S, Lameire N, Eknoyan G:\nDefinition, evaluation, and classification of renal osteodys-\ntrophy: A position statement from Kidney Disease: Im-\nproving Global Outcomes (KDIGO). Kidney Int 69: 1945\u2013\n1953, 2006\n\n12. Ferreira A, Frazao J, Faugere M, Mueller R, Malluche H:\nEffects of sevelamer hydrochloride and calcium carbonate\non bone mineralisation and turnover in haemodialysis pa-\ntients: A one-year randomised, open-label bone biopsy\nstudy [Abstract]. Nephrol Dial Transplant 21: 293, 2006\n\n13. Malluche HH, Faugere MC: Atlas of Mineralized Bone His-\ntology, New York, Karger, 1986\n\n14. Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ,\nCharytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N,\nMcCary LC, Turner SA, Goodman WG: An assessment of\ncinacalcet HCl effects on bone histology in dialysis patients\nwith secondary hyperparathyroidism. Clin Nephrol 69:\n269 \u2013278, 2008\n\n15. Sawaya BP, Butros R, Naqvi S, Geng Z, Mawad H, Friedler\nR, Fanti P, Monier-Faugere MC, Malluche HH: Differences\nin bone turnover and intact PTH levels between African\nAmerican and Caucasian patients with end-stage renal\ndisease. Kidney Int 64: 737\u2013742, 2003\n\n16. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao\nJ, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S,\nHoenger RM, Duggal A, Malluche HH: Effects of sevel-\namer hydrochloride and calcium carbonate on renal os-\nteodystrophy in hemodialysis patients. J Am Soc Nephrol 19:\n405\u2013 412, 2008\n\n17. Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek\nM, Szumilak D, Podolec P, Klimeczek P, Konieczynska M,\nWicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC,\nDrueke TB, Sulowicz W: Factors involved in vascular cal-\ncification and atherosclerosis in maintenance haemodialy-\nsis patients. Nephrol Dial Transplant 22: 515\u2013521, 2007\n\n18. Fabbian F, Catalano C, Orlandi V, Conte MM, Lupo A,\nCatizone L: Evaluation of aortic arch calcification in hemo-\ndialysis patients. J Nephrol 18: 289 \u2013293, 2005\n\n19. Kalantar-Zadeh K, Kovesdy CP, Derose SF, Horwich TB,\nFonarow GC: Racial and survival paradoxes in chronic\nkidney disease. Nat Clin Pract Nephrol 3: 493\u2013506, 2007\n\n20. Ishani A, Paudel M, Taylor BC, Barrett-Connor E, Jamal S,\nCanales M, Steffes M, Fink HA, Orwoll E, Cummings SR,\nEnsrud KE: Renal function and rate of hip bone loss in\nolder men: The Osteoporotic Fractures in Men Study. Os-\nteoporos Int 19: 1529 \u20131556, 2008\n\n21. Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis\nPK, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R,\nVlachojannis JG, Dombros AN, Utas C, Akpolat T,\nBozfakioglu S, Wu G, Karayaylali I, Arinsoy T, Stathakis\nPC, Yavuz M, Tsakiris JD, Dimitriades CA, Yilmaz ME,\nGultekin M, Karayalcin B, Yardimsever M, Oreopoulos\nDG: Bone mineral density and its correlation with clinical\nand laboratory factors in chronic peritoneal dialysis pa-\ntients. J Bone Miner Metab 24: 79 \u2013 86, 2006\n\n22. Naves M, Rodriguez-Garcia M, Diaz-Lopez JB, Gomez-\nAlonso C, Cannata-Andia JB: Progression of vascular cal-\ncifications is associated with greater bone loss and in-\ncreased bone fractures. Osteoporos Int 19: 1161\u20131166, 2008\n\n23. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcifi-\ncation and the risk of osteoporosis and fractures. J Clin\nEndocrinol Metab 89: 4246 \u2013 4253, 2004\n\n24. Zucchelli P, Catizone L, Casanova S, Fusaroli M, Fabbri L,\nFerrari G: Renal osteodystrophy in CAPD patients. Miner\nElectrolyte Metab 10: 326 \u2013332, 1984\n\n25. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H,\nSchulz W, Neumayer HH, Raggi P, Bommer J: Two year\ncomparison of sevelamer and calcium carbonate effects on\ncardiovascular calcification and bone density. Nephrol Dial\nTransplant 20: 1653\u20131661, 2005\n\n26. Nguyen KQ, Olesen P, Ledet T, Rasmussen LM: Bone\nmorphogenetic proteins regulate osteoprotegerin and its\nligands in human vascular smooth muscle cells. Endocrine\n32: 52\u201358, 2007\n\n27. Mazzaferro S, Pasquali M, Pugliese F, Barresi G, Carbone I,\nFrancone M, Sardella D, Taggi F: Serum levels of calcifica-\ntion inhibition proteins and coronary artery calcium score:\nComparison between transplantation and dialysis. Am J\nNephrol 27: 75\u2013 83, 2007\n\n28. Takasu J, Katz R, Nasir K, Carr JJ, Wong N, Detrano R,\nBudoff MJ: Relationships of thoracic aortic wall calcifica-\ntion to cardiovascular risk factors: The Multi-Ethnic Study\nof Atherosclerosis (MESA). Am Heart J 155: 765\u2013771, 2008\n\n29. Nasir K, Katz R, Takasu J, Shavelle DM, Detrano R, Lima\nJA, Blumenthal RS, O\u2019Brien K, Budoff MJ: Ethnic differ-\nences between extra-coronary measures on cardiac com-\nputed tomography: Multi-Ethnic Study of Atherosclerosis\n(MESA). Atherosclerosis 198: 104 \u2013114, 2008\n\n30. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E,\nOuyang P, Jackson S, Saad MF: Ethnic differences in cor-\nonary calcification: The Multi-Ethnic Study of Atheroscle-\nrosis (MESA). Circulation 111: 1313\u20131320, 2005\n\nSee related editorial, \u201cBone\u2013Vascular Axis in Chronic Kidney Disease: A Reality?\u201d on pages 254 \u2013257.\n\nClin J Am Soc Nephrol 4: 450 \u2013 455, 2009 Bone Volume and Coronary Calcifications 455\n\n\n\nEditorial\n\nBone\u2013Vascular Axis in Chronic Kidney Disease: A Reality?\nGe?rard M. London\nService de Ne?phrologie, Centre Hospitalier Manhe?s, Fleury Me?rogis, France; INSERM U970, Paris, France\n\nClin J Am Soc Nephrol 4: 254 \u2013257, 2009. doi: 10.2215/CJN.06661208\n\nC\nhronic kidney disease (CKD) is characterized by\nchanges in mineral metabolism associated with alter-\nations of its hormonal regulation and various forms of\n\nbone disease. In the past, these associations focused attention\non the kidney\u2013 bone axis. The last decade has seen renewed\ninterest on interactions among mineral metabolism disorders\nand extraosseous and cardiovascular calcifications observed in\nCKD or end-stage renal disease (ESRD). Vascular calcification\nis an active process similar to bone formation that implicates a\nvariety of proteins involved in bone and mineral metabolism\n(1,2) and is considered part of a systemic dysfunction defined\nas CKD\u2013mineral and bone disorder (3). Growing evidence link-\ning bone with different functional and structural characteristics\nof the arterial tree has contributed to developing the concept of\nthe bone\u2013vascular axis (4).\n\nThe first observations suggesting the existence of the bone\u2013\nvascular axis were the frequent associations of osteoporosis and\natherosclerotic vascular calcifications observed in postmeno-\npausal women (5\u20137). Longitudinal population-based studies\nrevealed a relationship between the progression of vascular\ncalcifications and bone demineralization, and others were iden-\ntified between bone mineral density (BMD) and aortic or cen-\ntral artery calcifications (6), or coronary arteries in type 2 dia-\nbetes (8). The osteopenia\u2013 osteoporosis association was also\nlinked with arterial functional indexes, such as aortic stiffness\nand interactions independent of calcifications, suggesting\nbroader biologic interplay (9,10).\n\nRelationships between bone and vascular modifications were\nalso observed in CKD and ESRD patients. In dialysis patients,\ncoronary artery calcification score was found to be inversely\ncorrelated with vertebral bone mass (11,12). In addition, a high\nsystemic arterial calcification score combined with bone histo-\nmorphometry suggestive of low bone activity was observed in\nhemodialysis patients (13,14). Arterial stiffening and low spine\nBMD or calcaneal osteopenia were significantly associated in\nCKD and hemodialysis patients (15\u201317).\n\nIn the present issue of the Journal, Adragao et al. (18) provide\nnew evidence linking altered bone metabolism to coronary\ncalcifications in patients with stage-5 CKD on hemodialysis. In\ntheir cross-sectional study performed on 38 hemodialyzed pa-\ntients, they analyzed the relationships between bone biopsy\n\nparameters (bone volume/total volume, bone formation rate/\nbone surface, and activation frequency) and coronary calcifica-\ntions determined by multislide computer tomography. Their\nprincipal conclusion was that low bone volume is associated\nwith more coronary calcifications, whereas histomorphometric\nparameters of bone turnover were independent of coronary\ncalcifications.\n\nTheir results complete those of Barreto et al. (12), who found\na negative correlation between coronary calcifications and tra-\nbecular bone volume or its thickness. The absence of correla-\ntions between histomorphometric indexes of bone turnover and\ncoronary calcifications differ from reports by London et al.\n(13,14), who found an association between systemic arterial\ncalcifications (aorta and the main peripheral arteries) and in-\ndexes of low bone turnover, but not trabecular volume. One\nimportant difference between these publications resides in the\narterial territories analyzed and the relationships of the differ-\nent bone changes (bone volume, osteoblasts number, or tetra-\ncycline labeling), which do not necessarily reflect the same\nmechanisms. Adragao et al. (18) studied coronary artery calci-\nfications, whereas London et al. (13,14) examined the aorta and\nsystemic arteries.\n\nResearchers investigating the arterial system should keep in\nmind the marked heterogeneity of the arterial tree (19). Blood\nvessel formation recruits cells of different origins whose com-\nponents are derived from vascular smooth muscle cells (VSMC)\nand pericytes. VSMC is a tissue generated by at least seven\nunique and nonoverlapping sources, and different vessels or\neven segments of the same vessel, are composed of VSMC\narising from distinct progenitors that respond in origin-specific\nways to different common stimuli. The observations linking\narterial calcifications to bone usually concern the aorta or large\nconduit arteries and coronary arteries. Whereas the coronary\narteries are derived from proepicardium, the aorta\u2019s origin\neven more complex. The ascending aorta and aortic arch orig-\ninate from neural crest, the thoracic aorta (athero-resistant) is\nderived from somites, and splanchnic mesoderm gives rise to\nthe abdominal aorta (athero-susceptible). The boundaries of\nthese different segments are sharp and are associated with\nquite different responses to common risk factors. Arterial bed-\nspecific susceptibilities were documented in human studies\nshowing that despite common risk factors, each analyzed vas-\ncular segment (coronary arteries, ascending aorta and its major\narteries, thoracic aorta at the renal artery level, and terminal\naorta and femoral arteries) mounted its own distinct response\nto atherogenesis (20).\n\nPublished online ahead of print. Publication date available at www.cjasn.org.\n\nCorrespondence: Dr. Ge?rard London, Centre Hospitalier Manhe?s, 8, rue Roger\nClavier, 91712 Fleury-Me?rogis Cedex, France. Phone: 33 1 69256485; Fax: 33 1\n69256525; E-mail: glondon@club-internet.fr\n\nCopyright \u00a9 2009 by the American Society of Nephrology ISSN: 1555-9041/402\u20130254\n\n\n\nThe eventual biologic link between vascular calcifications\nand bone changes is certainly part of the aging process, but in\nmany studies, these bone\u2013vascular associations remained sig-\nnificant after adjustment for age, which suggests an age-inde-\npendent causal relationship (5\u20137). The mechanisms responsible\nfor bone\u2013vascular interactions are not well understood.\n\nThe results of increasing numbers of experimental studies led\nto the recognition of similarities between bone development\nand mineralization and the process of arterial calcifications. The\ncalcification process involves VSMC differentiation into osteo-\nblast-like cells, with subsequent mineralization. This process is\ninduced and regulated by equilibrium between factors promot-\ning or inhibiting calcification, involving a variety of proteins\nthat are important for bone metabolism but are also expressed\nin arteries (1\u20133). Clinical data on humans indicate that osteo-\nporosis and vascular calcifications are influenced by several\ncommon risk factors, such as diabetes, inflammation, dyslipi-\ndemia, oxidative stress, estrogen deficiency, vitamin D and K\ndeficiencies, and others (21\u201324). The roles of dyslipidemia, ox-\nidative stress, and inflammation seem to be of importance.\nOxidized lipids can paradoxically induce atherosclerosis and\nthe differentiation of osteoblasts, with subsequent arterial wall\nmineralization having the opposite effect, that is, inhibiting\nosteoblastic differentiation into bone osteoblasts (25). Oxidized\nlipids are also a substrate for peroxisome proliferator-activator\nreceptor-? (PPAR?), which redirects the differentiation of mes-\nenchymal progenitors from preosteoblasts to adipocytes and\nCbfa1/Runx2 expression essential for osteoblastogenesis.\n\nIn osteoporosis, it is osteoprotegerin (OPG), the receptor\nactivator of the nuclear factor-kappa B (NF-?B) ligand\n(RANKL) system, that has attracted the most attention (26,27).\nOPG-deficient mice develop osteoporosis with severe cortical\nand trabecular bone porosity and high fractures rates. In par-\nallel with these bone lesions, these mice develop medial calci-\nfication of the aorta and large arteries (28). By binding RANKL,\nOPG inhibits osteoclastogenesis and bone resorption. OPG and\nRANKL are also involved in immune-induced inflammatory\nresponses. OPG can limit local inflammatory responses, and in\nvitro OPG, produced by smooth muscle and endothelial cells,\nacts as an antiapoptotic factor prolonging endothelial cell sur-\nvival (27). Changes of the RANKL/OPG ratio are critical to the\nevaluation of clinical impact, and high OPG-associated cardio-\nvascular risk probably represents an inadequate response of\nOPG to increased RANKL activity (29).\n\nAlthough osteoporosis\u2013arterial calcification interactions\ncould be observed in general populations in the absence of\novert mineral metabolism disorders, in CKD/ESRD patients,\nthe associations between vascular calcifications and bone dis-\norders are linked to deterioration of mineral and bone metab-\nolism caused by serum phosphate and calcium changes, and\ndisruption of endocrine and humoral pathways, including\nparathyroid hormone (PTH), calcitriol, fibroblast growth fac-\ntor-23 (FGF-23)/Klotho, and others (1\u20133). Experimental and\nclinical data indicate that hyperphosphatemia plays a direct\nrole in the osteoblast-like transformation of VSMC by upregu-\nlating Cbfa1/Runx2 and osterix transcription factors (1,2,30,31).\nThe calcification could be enhanced by the imbalance between\n\ninducers and local or systemic inhibitors of calcification, such as\nlow fetuin-A, pyrophosphate, or osteopontin (31\u201333). In CKD\nand ESRD patients, the relationship between bone and vascular\ncalcifications concerns several aspects of bone disorders, such\nas high bone turnover (secondary hyperparathyroidism), and\nlow bone activity (adynamic bone disease), and low bone vol-\nume. In secondary hyperparathyroidism, the increased bone\nresorption associated with the endogenous release of phos-\nphate and calcium could play a critical role in the induction of\nvascular calcification. Chronic PTH elevation upregulates\nRANKL, downregulates OPG gene expression, and raises the\nRANKL/OPG ratio (34). The high prevalence and extent of\narterial calcification is also observed in ESRD patients with\nbone demineralization or low bone activity (11\u201314,18), a clinical\nsituation closer to the osteoporosis\u2013vascular calcification asso-\nciation seen in general populations.\n\nIn general populations and ESRD patients, relationships be-\ntween bone disorders and vascular dysfunction were observed\nindependently of calcifications, age, BP, and other confounding\nfactors, thereby suggesting direct bone\u2013vascular cross-talk.\nBone is an active \u201cendocrine\u201d organ, as demonstrated by fibro-\nblast growth factor 23 (FGF-23) regulation of the phosphate\nbalance. FGF-23 is synthesized and released by osteocytes,\nwhich are terminally differentiated osteoblasts. Osteoblast\nfunction could be an important player in the bone\u2013vascular\naxis. Lee et al. (35) showed that osteoblasts exert endocrine\nregulation of energy metabolism, with osteocalcin (OCN) play-\ning an important role. OCN can regulate the expression of\ninsulin genes, ?-cell proliferation, and adiponectin (ADPN)\nrelease and its expression adipocytes (36). In general popula-\ntions, serum OCN was positively associated with ADPN\n(37,38). ADPN protects arteries against hypertension, slows\natherosclerosis, and activates osteoblastogenesis (39,40). An in-\nverse relationship was found between ADPN and OCN and\narterial stiffness (38). Plasma ADPN levels are low in metabolic\nsyndrome and type 2 diabetes patients. Whether this low\nADPN could account for decreased osteoblastogenesis and fre-\nquently observed adynamic bone disease in diabetic patients\nremains a hypothesis.\n\nMultiple hormones involved in the endocrine regulation of\nadipose tissue and energy metabolism could affect bone struc-\nture, including leptin. Leptin is a powerful inhibitor of in vivo\nbone formation (41) and facilitates vascular calcification (42). In\nESRD, serum leptin is elevated and is associated with low PTH\n(43), suggesting that leptin might diminish bone activity and\npromote arterial calcifications in this setting.\n\nBone loss may also occur as a secondary consequence of\nischemia related to vascular disease. Arteries and arterioles\nwithin the bone are also subject to arteriosclerosis, and a link\nbetween compromised intraosseous circulation and consequent\nosteoporosis may exist (44). Intraosseous angiogenesis and\nbone remodeling are regulated by similar cytokines and growth\nfactors, and interactions between bone formation\u2013resorption\nand blood supply are known to occur (45). A recent study\nshowed that in otherwise healthy women, bone-perfusion in-\ndices were lower in women with osteoporosis compared with\nwomen with osteopenia or normal BMD (46).\n\nClin J Am Soc Nephrol 4: 254 \u2013257, 2009 Bone\u2013Vascular Axis 255\n\n\n\nIn conclusion, increasing numbers of articles on general pop-\nulations and CKD and ESRD patients have reported significant\nassociations among arterial pathology (atherosclerosis and ar-\nterial calcifications) and bone disorders, including osteoporosis,\nand high or low bone activity. The pathophysiology and bio-\nlogic links between bone and arterial abnormalities suggest the\nexistence of bone\u2013vascular cross-talk. The nature of this com-\nmunication is not well understood. It could be a consequence of\n(1) the action of common factors on bone remodeling and\natherosclerosis/calcification, (2) the direct action of bone cells\n(osteoblasts and/or osteocytes) on vascular biology and struc-\nture, and/or (3) the compromised bone blood supply resulting\nfrom arteriosclerosis of bone vessels and reduced perfusion.\n\nDisclosures\nNone.\n\nReferences\n1. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM: Ex-\n\nploring the biology of vascular calcification in chronic kid-\nney disease: What\u2019s circulating? Kidney Int 73: 384 \u2013390,\n2008\n\n2. Demer LL, Tintut Y: Vascular calcification: Pathobiology of\nmultifaceted disease. Circulation 117: 2938 \u20132948, 2008\n\n3. Moe S, Dru?eke T, Cunningham J, Goodman W, Martin K,\nOlgaard K, Ott S, Sprague S, Lameire N, Eknoyan G:\nDefinition, evaluation, and classification of renal osteodys-\ntrophy: A position statement from Kidney Disease: Im-\nproving Global Outcomes (KDIGO). Kidney Int 69: 1945\u2013\n1953, 2006\n\n4. Hamerman D: Osteoporosis and atherosclerosis: Biological\nlinkage and the emergence of dual-purpose therapies. Q\nJ Med 98: 467\u2013 484, 2005\n\n5. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman\nJC: Progression of aortic calcification is associated with\nmetacarpal bone loss during menopause: A population-\nbased longitudinal study. Arterioscler Thromb Vasc Biol 20:\n1926 \u20131931, 2000\n\n6. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcifi-\ncation and the risk of osteoporosis and fractures. J Clin\nEndocrin Metab 89: 4246 \u2013 4253, 2004\n\n7. Tanko LB, Christiansen C, Cox DA, Geiger MJ, McNabb\nMA, Cummings SR: Relationship between osteoporosis\nand cardiovascular disease in postmenopausal women.\nJ Bone Mineral Res 20: 1912\u20131920, 2005\n\n8. Carr JJ, Register TC, Hsu F-Ch, Lohman K, Lenchik L,\nBowden DW, Langefeld CD, Xu J, Rich SS, Wagenknecht\nLE, Freedman BI: Calcified atherosclerotic plaque and bone\nmineral density in type 2 diabetes: The diabetes heart\nstudy. Bone 42: 43\u201352, 2008\n\n9. Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto\nH, Kumakura H, Takayama Y, Kanda T, Murakami M,\nKurabayashi M: Elevated arterial stiffness in postmeno-\npausal women with osteoporosis. Maturitas 55: 212\u2013218,\n2006\n\n10. Sumino H, Ichikawa S, Kasama S, Takahashi T, Sakamoto\nH, Kumakura H, Takayama Y, Kanda T, Murakami M,\nKurabayashi M: Relationship between brachial arterial en-\n\ndothelial function and lumbar spine bone mineral density\nin postmenopausal women. Circ J 71: 1555\u20131559, 2007\n\n11. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,\nLuft FC: Electron-beam computed tomography in the eval-\nuation of cardiac calcifications in chronic dialysis patients.\nAm J Kidney Dis 27: 394 \u2013 401, 1996\n\n12. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cen-\ndoroglo M, Draibe SA, Moyses RM, Neves KR, Jorgetti V,\nBlair A, Guiberteau R, Fernandes Canziani ME: Coronary\ncalcification in hemodialysis patients: The contribution of\ntraditional and uremia-related risk factors. Kidney Int 67:\n1576 \u20131582, 2005\n\n13. London GM, Marty C, Marchais SJ, Gue?rin AP, Me?tivier F,\nde Vernejoul MC: Arterial calcifications and bone histo-\nmorphometry in end-stage renal disease. J Am Soc Nephrol\n15: 1943\u20131951, 2004\n\n14. London GM, Marchais SJ, Gue?rin AP, Boutouyrie P, Me?-\ntivier F, de Vernejoul MC: Association of bone activity,\ncalcium load, aortic stiffness, and calcifications in ESRD.\nJ Am Soc Nephrol 19: 1827\u20131835, 2008\n\n15. Joki N, Hase H, Shiratake M, Kishi N, Tochigi S, Imamura\nY: Calcaneal osteopenia is a new marker for arterial stiff-\nness in chronic hemodialysis patients. Am J Nephrol 25:\n196 \u2013202, 2005\n\n16. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P:\nPulse wave velocity is inversely related to vertebral bone\ndensity in hemodialysis patients. Hypertension 49: 1278 \u2013\n1284, 2007\n\n17. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr\nPG: Association between vascular calcification, arterial\nstiffness and bone mineral density in chronic kidney dis-\nease. Nephrol Dial Transplant 23: 586 \u2013593, 2008\n\n18. Adragao T, Herberth J, Monier-Faugere M-C, Branscum\nAJ, Ferreira A, Frazao JM, Curto JD, Malluche HH: Low\nbone volume\u2014a risk factor for coronary calcifications in\nhemodialysis patients. Clin J Am Soc Nephrol 4: 450 \u2013 455,\n2009\n\n19. Majesky MW: Developmental basis of vascular smooth\nmuscle diversity. Atheroscler Thromb Vasc Biol 27: 1248 \u2013\n1258, 2007\n\n20. DeBackey M, Glaser D: Patterns of atherosclerosis: Effect of\nrisk factors on recurrence and survival \u2013 Analysis of 11,890\ncases with more than 25-years follow-up. Am J Cardiol 85:\n1045\u20131053, 2000\n\n21. Parhami F, Garfinkel A, Demer LL: Role of lipids in osteo-\nporosis. Arterioscler Thromb Vasc Biol 20: 2346 \u20132348, 2000\n\n22. Koh JM, Khang YH, Jung CH, Bae S, Kim DJ, Chung YE,\nKim GS: Higher circulating hsCRP levels are associated\nwith lower bone mineral density in healthy pre- and post-\nmenopausal women: Evidence for a link between systemic\ninflammation and osteoporosis. Osteoporos Int 16: 1263\u2013\n1271, 2005\n\n23. Braam LA, Hoeks APG, Brouns F, Hamulya?k K, Gerich-\nhausen MJ, Vermeer C: Beneficial effects of vitamins D and\nK on the elastic properties of the vessel wall in postmeno-\npausal women: A follow-up study. Thromb Haemost 91:\n373\u2013380, 2004\n\n24. Gerdhem P, Obrant KJ: Effects of cigarette smoking on\nbone mass as assessed by dual-energy X-ray absorptiom-\netry and ultrasound. Osteoporos Int 13: 932\u2013936, 2002\n\n25. Mody N, Parhami F, Sarafian TA, Demer LL: Oxidative\n\n256 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: 254 \u2013257, 2009\n\n\n\nstress modulates osteoblastic differentiation of vascular\nand bone cells. Free Radic Biol Med 31: 509 \u2013519, 2001\n\n26. Hofbauer LC, Schoppet M: Clinical implications of the\nosteoprotegerin/RANKL/RANK system for bone and vas-\ncular diseases. JAMA 292: 490 \u2013 495, 2004\n\n27. Collin-Osdoby P: Regulation of vascular calcification by\nosteoclast regulatory factors RANKL and osteoprotegerin.\nCirc Res 95: 1046 \u20131057, 2004\n\n28. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Cap-\nparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ,\nSimonet WS: Osteoprotegerin-deficient mice develop early\nonset osteoporosis and arterial calcification. Genes Dev 12:\n1260 \u20131268, 1998\n\n29. Flore CE, Pennisi P, Ferro G, Ximenes B, Privitelli L, Mang-\niafico RA, Santoro F, Parisi N, Lombardo T: Altered osteo-\nprotegerin/RANKL ratio and low bone mineral density in\nceliac patients on long-term treatment with gluten-free\ndiet. Horm Metab Res 38: 417\u2013 422, 2006\n\n30. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurg-\ners LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL,\nShanahan CM: Human vascular smooth muscle cells un-\ndergo vesicle-mediated calcification in response to changes\nin extracellular calcium and phosphate concentrations: A\npotential mechanism for accelerated vascular calcification\nin ESRD. J Am Soc Nephrol 15: 2857\u20132867, 2004\n\n31. Scatena M, Liaw L, Ghiachelli CM: Osteopontin: A multi-\nfunctional molecule regulating chronic inflammation and\nvascular disease. Arterioscler Thromb Vasc Biol 27: 2304 \u2013\n2309, 2007\n\n32. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI,\nO\u2019Neill WC: Phosphate-induced vascular calcification:\nRole of pyrophosphate and osteopontin. J Am Soc Nephrol\n15: 1392\u20131401, 2004\n\n33. Hermans MM, Brandenburg V, Ketteler M, Kooman JP,\nvan der Sande FM, Gladziwa U, Rensma PL, Bartelet K,\nKonings CJ, Hoeks AP, Floege J, Leunissen KM: Study on\nthe relationship of serum fetuin-A concentration with aor-\ntic stiffness in patients on dialysis. Nephrol Dial Transplant\n21: 1293\u20131299, 2006\n\n34. Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP,\nBikle DD, Nissenson RA: PTH differentially regulates ex-\npression of RANKL and OPG. J Bone Miner Res 19: 234 \u2013244,\n2004\n\n35. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux\nC, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim\n\nJK, Mauvais-Jarvis F, Ducy P, Karsenty G: Endocrine reg-\nulation of energy metabolism by the skeleton. Cell 130:\n456 \u2013 469, 2007\n\n36. Ferron M, Hinoi E, Karsenty G, Ducy P: Osteocalcin dif-\nferentially regulates ?-cells and adipocyte gene expression\nand affects the development of metabolic disease in wild-\ntype mice. Proc Natl Acad Sci U S A 105: 5266 \u20135270, 2008\n\n37. Richards JB, Valdes AM, Burling K, Perks UC, Spector TD:\nSerum adiponectin and bone mineral density in women.\nJ Clin Endocrin Metab 92: 1517\u20131523, 2007\n\n38. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M,\nKurioka S, Yano S, Sugimoto T. Serum osteocalcin is asso-\nciated with glucose metabolism and atherosclerosis param-\neters in type 2 diabetes mellitus. J Clin Endocrin Metab.\n2008; (ahead of print)\n\n39. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A,\nHashimoto J, Yoshikawa H, Shimomura I: Adiponectin\nincreases bone mass by suppressing osteoclasts and acti-\nvating osteoblasts. Biochem Biophys Res Commun 331: 520 \u2013\n526, 2005\n\n40. Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao\nEY: Adiponectin stimulates human osteoblast proliferation\nand differentiation via the MAPK signaling pathway. Exp\nCell Res 309: 99 \u2013109, 2005\n\n41. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim\nCA, Ogawa Y, Liu X, Ware SM, Craigen WJ, Robert JJ,\nVinson C, Nakao K, Capeau J, Karsenty G: Serum leptin\nlevel is a regulator of bone mass. PNAS 101: 3258 \u20133263,\n2004\n\n42. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL:\nLeptin enhances the calcification of vascular cells: Artery\nwall as a target of leptin. Circ Res 88: 954 \u2013960, 2001\n\n43. Coen G, Ballanti P, Fischer MS, Balducci A, Calabria S,\nColamarco L, Di Zazzo G, Lifrieri F, Manni M, Sardella D,\nNofroni I, Bonucci E: Serum leptin in dialysis renal os-\nteodystrophy. Am J Kidney Dis 42: 1036 \u20131042, 2003\n\n44. Laroche M: Intraosseous circulation from physiology to\ndisease. Joint Bone Spine 69: 262\u2013269, 2002\n\n45. Alagiakrishnan K, Juby A, Hanley D, Tymchak W, Sclater\nA: Role of vascular factors in osteoporosis. J Gerontol 4:\n362\u2013366, 2008\n\n46. Griffith JF, Yeung DK, Tsang PH, Choi KC, Kwok TC,\nAhuja AT, Leung KS, Leung PC: Compromised bone mar-\nrow perfusion in osteoporosis. J Bone Miner Res 23: 1068 \u2013\n1075, 2008\n\nSee related article, \u201cLow Bone Volume\u2014A Risk Factor for Coronary Calcifications in Hemodialysis Patients,\u201d on pages\n450 \u2013 455.\n\nClin J Am Soc Nephrol 4: 254 \u2013257, 2009 Bone\u2013Vascular Axis 257\n\n\n\n    157\n\n INTRODUCTION\n\nHaemodialysis patients are at a very high cardio-\nvascular risk not explained by traditional risk fac-\ntors1,2. Conventional treatment which reduces car-\ndiovascular risk in the general population may not \nbe effective in dialysis patients, as shown in the 4D \ntrial which compared atorvastatin with placebo in a \ngroup of diabetic patients on haemodialysis3. Ator-\nvastatin as compared with placebo did not reduce \nthe primary composite endpoint which included \ncardiovascular death or non fatal acute myocardial \ninfarction or stroke.\n\nThese results may be partially explained by the \ncharacteristics of cardiovascular death observed in \ndialysis patients. Cardiovascular death is the main \ncause of death in dialysis patients and accounts \nfor 48% of all deaths in dialysis patients in the \nUSA, as shown by USRDS annual report4. This \nreport states that sudden death is the main cause \nof cardiovascular death, responsible for 27% of all \ndeaths, while atherosclerosis and acute myocar-\ndial infarction, situations in which statin adminis-\ntration is recommended, accounts for only 11% of \nall deaths4. \n\nAnother possible explanation for the ineffective-\nness of statins observed in the 4D trial is the type \nof vascular calcification that haemodialysis patients \ndevelop. Vascular calcification is another factor \nassociated with cardiovascular mortality in dialysis \npatients and can onset in two different clinical situ-\nations with different treatment options5. There are \ntwo types of vascular calcifications: intimal and \nmedial calcification. Intimal calcification is associ-\nated with atherosclerosis and is related to altered \n\nlipid metabolism. Medial calcification is associated \nwith arteriolosclerosis and in chronic kidney disease \n(CKD) patients is associated with altered mineral \nmetabolism6, in a clinical setting where statins are \nprobably not operative. \n\nThe main manifestations of intimal calcification \nare the result of the formation of atherosclerotic \nplaques with stenotic lesions and ischaemia. Medial \ncalcification does not cause obstructive lesions but \nmodifies the properties of the arterial wall and \nincreases arterial stiffness. Arterial stiffness causes \nan increase in pulse pressure and pulse wave veloc-\nity, alterations associated with the development of \nleft ventricular hypertrophy and decrease in coronary \nperfusion during diastole and which may cause myo-\ncardial ischaemia, even in the absence of stenotic \nlesions. \n\nIt has been demonstrated that vascular calcifica-\ntion in dialysis and non-dialysis patients is an \nactive cellular process, similar to bone formation7-9. \nVascular smooth muscle cells can differentiate into \nosteoblasts with different stimuli, which, in dialysis \npatients, may be hyperphosphataemia and hyper-\ncalcaemia8. Reduction of calcification inhibitors, \nsuch as fetuin-A or matrix-Gla protein, may be \nanother factor associated with the development of \ncalcification10. CKD patients experience two distinct \nsituations associated with an increase in Ca and P \nlevels: hyperparathyroidism, with high bone turn-\nover where the bone itself is the source of the high \nlevels of Ca and P and adynamic bone disease with \nlow bone turnover. Here the bone behaves as a \n\u201cfrozen bone\u201d and it is not able to capture the Ca \nand P that the patient receives in food or with \ntreatment. \n\nIs there a link between bone \nand vessel in dialysis patients?\nTeresa Adrag\u00e3o\n\nDepartment of Nephrology, Hospital de Santa Cruz. Carnaxide, Portugal.\n\nPort J Nephrol Hypert 2008; 22(2): 157-163\n\nReceived for publication: 01/02/2008\n\nAccepted: 28/02/2008\n\nREVIEW ARTICLE\n\nNefro - 22-2.indd   157 17-04-2008   11:00:51\n\n\n\n158    Port J Nephrol Hypert 2008; 22(2): 157-163\n\nTeresa Adrag\u00e3o\n\n  EVALUATION OF VASCULAR \nCALCIFICATIONS\n\nKDIGO has recommended a new classification for \nchronic kidney disease mineral and bone disorder \n(CKD MBD) which for the first time includes evalua-\ntion of vascular calcifications11. In haemodialysis \npatients vascular calcifications can be evaluated by \ndifferent techniques: electron beam computed \ntomography (EBCT)12, multislice computed tomogra-\nphy (MSCT)13, ultrasonography5 and plain X-ray6,14,15. \nEBCT and MSCT allow a quantitative measurement \nand are considered the gold standard for evaluating \nvascular calcification but are very expensive. The use \nof plain X-ray for screening vascular calcifications \nhas been suggested by KDOQI16 and KDIGO11. We \nhave developed a vascular calcification score evalu-\nated by plain X-ray of hands and pelvis which is a \npredictor of cardiovascular death and cardiovascular \nmorbidity in dialysis patients14 (Fig. 1). This simple \nvascular calcification score has also been correlated \nwith valvular calcifications17 and arterial stiffness18. \n\nPlain X-ray and ultrasonography are semi-quan-\ntitative, less expensive and useful for screening for \n\nvascular calcifications. They can be used to identify \npatients at higher risk of a cardiovascular event. \nEBCT and MSCT are useful for evaluating the pro-\ngression of vascular calcification and the effect of \ndifferent treatments on vascular calcification pro-\ngression. These two techniques do not differentiate \nintimal from medial calcification and the explanation \nfor the very high scores evaluated in dialysis \npatients is the presence of both intimal and medial \ncalcification.\n\n  VASCULAR CALCIFICATIONS \nAND HISTOMORPHOMETRIC \nANALYSIS OF BONE BIOPSIES\n\nLondon et al.19 demonstrated an association \nbetween vascular calcifications and low bone turn-\nover in a study evaluating 58 haemodialysis \npatients. 23 of these had undergone parathyroidec-\ntomy and 33 had aluminium deposits in bone. \nVascular calcifications were evaluated by ultra-\nsonography. More calcifications were associated \nwith lower osteoblasts surface and with other \n\nFigure 1\n\nResults after 3 years\u2019  follow-up*\n\n*Adragao T, Pires A, Lucas C. et al. Nephrol Dial Transplant 2004;19:1480\u20138\n\nNefro - 22-2.indd   158 17-04-2008   11:00:52\n\n\n\nPort J Nephrol Hypert 2008; 22(2): 157-163    159\n\nIs there a link between bone and vessel in dialysis patients?\n\nmarkers of low bone turnover, with lower PTH \nlevels and with higher calcium dose. In a group of \n42 Portuguese haemodialysis patients who under-\nwent bone biopsy20 we verified that low bone \nvolume was associated with vascular calcifications \nevaluated by MSCT (Fig. 2) or by plain X-ray and \nwith higher pulse wave velocity. Adynamic bone \ndisease was present in 50% of patients. There were \nno cases of osteomalacia and no aluminium depos-\nits in bone.\n\nGulay et al. demonstrated in a group of 224 \npatients that vascular calcifications evaluated by \nMSCT were associated with lower activation fre-\nquency evaluated in bone biopsies21. These stud-\nies show an association between vascular calcifi-\ncations with low bone volume and with low bone \nturnover in dialysis patients, suggesting that \npatients whose bone is not able to retain calcium \nor phosphorus have higher vascular calcification \nscores. One added risk factor for the development \nof vascular calcifications in the setting of low \nbone turnover could be the administration of \nhigher calcium doses, as verified in the London \nstudy. \n\n  VASCULAR CALCIFICATIONS \nAND BONE MINERAL DENSITY\n\nAn association between low bone mineral den-\nsity and vascular calcifications has already been \ndescribed in the general population. In post-meno-\npausal women it was demonstrated that low bone \nmineral density is associated with increase in aortic \ncalcifications22. \n\nFew studies correlating bone mineral density with \nvascular calcifications have been performed in \ndialysis patients. Taal et al.23 verified that osteope-\nnia and osteoporosis evaluated by DEXA were asso-\nciated with decreased survival in dialysis patients. \nRaggi et al.24 showed that lower bone mineral den-\nsity evaluated in lumbar spine by quantitative com-\nputed tomography was associated with higher pulse \nwave velocity. In a group of 70 Portuguese perito-\nneal dialysis patients we verified that low bone \nmineral density evaluated by DEXA at the femoral \nneck, but not at the lumbar spine, was associated \nwith more vascular calcifications evaluated by plain \nX-ray, with higher pulse wave velocity and with \nperipheral artery disease25 (Fig. 3). \n\nFigure 2\n\nVascular Calcifications and Bone Biopsies*\n\n*Adragao T, Ferreira A, Frazao J, et al. Nephrol Dial Transplant  2006; 21(4), iv 292 (abstract)\n\nNefro - 22-2.indd   159 17-04-2008   11:00:52\n\n\n\n160    Port J Nephrol Hypert 2008; 22(2): 157-163\n\nTeresa Adrag\u00e3o\n\nPatients with osteopenia or osteoporosis had \nhigher prevalence of peripheral artery disease \n(37%) than patients with normal bone mineral \ndensity (7%). These associations were adjusted for \nage, gender, diabetes, haemodialysis duration, \nsystolic pressure and CaxP product. The absence \nof correlation of bone mineral density evaluated at \nthe lumbar spine with vascular calcifications and \narterial stiffness is probably explained by the pres-\nence of vascular calcifications in the aorta which \nmay affect the correct measurement of bone min-\neral density. \n\nThe pathogenesis of the association between low \nbone mineral density parameters and vascular cal-\ncifications is not yet known and may be explained \nby a cause-effect relationship or by a common \naetiological factor affecting both the bone and the \nvessel. Increase in calcium and phosphorus are some \nof the factors that induce vascular calcification8. \nEither hyperparathyroidism or adynamic bone dis-\nease may be associated with osteoporosis26 and \nmay be the cause of hyperphosphataemia and hyper-\ncalcaemia. Oestrogen deficiency is associated with \nosteoporosis27 and oestrogen receptors have been \nidentified in vascular smooth muscle cells28 and in \nosteoblasts29.\n\n  CARDIOVASCULAR RISK FACTORS \nAND VITAMIN D DEFICIENCY\n\nIn several observational studies, treatment with \nactive vitamin D has been associated with reduced \nmortality30-32. This effect was independent of PTH, \nCa and P levels31, suggesting a pleiotropic effect of \nvitamin D, beyond the control of hyperparathyroid-\nism. London et al. demonstrated that vitamin D \ndeficiency in dialysis patients was associated with \nvascular calcification and arterial stiffness33. Vitamin \nD deficiency may also be associated with develop-\nment of cardiac ventricular hypertrophy, as demon-\nstrated in Vitamin D receptor knock-out mice34. \n\nOne possible explanation for this hypothetical \nbeneficial effect of vitamin D is given by the discov-\nery that 1,25-vitD suppresses renin gene expression35 \nand by the association between vitamin D deficiency \nand activation of the renin angiotensin system34. \nActivation of vitamin D receptor has also been asso-\nciated with reduction of vascular calcifications36. In \na group of 48 Portuguese haemodialysis patients we \nverified that vitamin D deficiency was independently \nassociated with vascular calcifications evaluated \neither by plain X-ray or by MSCT. Vitamin D defi-\nciency was also associated with aortic augmentation \n\nFigure 3\n\nVascular Calcifications, Arterial Stiffness and Bone Mineral Density*\n\n*Adragao T, Branco P, Birne R. J Am Soc Nephrol 2006;17:272A TH-PO779 (abstract) \n\nNefro - 22-2.indd   160 17-04-2008   11:00:52\n\n\n\nPort J Nephrol Hypert 2008; 22(2): 157-163    161\n\nIs there a link between bone and vessel in dialysis patients?\n\nindex, a marker of arterial stiffness and with left \nventricular mass index (LVMI) evaluated by M Mode \nechocardiography37 (Fig. 4). This association was \nadjusted for age, mean arterial pressure, haemoglo-\nbin and cholesterol levels. \n\nThe association of 25-vitD deficiency with LVMI \nincrease that we verified in our patients is an impor-\ntant finding that goes towards explaining the reduc-\ntion of mortality associated with treatment with \nactive vitamin D. Left ventricular hypertrophy is \nassociated with arrhythmic risk and with sudden \ndeath38,39 and sudden death is the main cause of \ncardiovascular death in the dialysis population4. \n\n  WILL TREATMENT OF BONE \nDISEASE REDUCE CARDIOVASCULAR \nRISK IN DIALYSIS PATIENTS?\n\nIf it is true that there is a link between bone \ndisease and cardiovascular disease, it is necessary \nto demonstrate that the management of mineral and \nbone disorder is associated with a reduction in \ncardiovascular risk. There is already some evidence \ndemonstrating this effect. The TTG40 and RIND41 \n\ntrials have evaluated the progression of coronary \ncalcifications in patients with hyperphosphataemia \ntreated with sevelamer or calcium salts. The TTG \nevaluated prevalent patients and the RIND evalu-\nated incident patients. The TTG showed that \npatients treated with calcium showed a 25% \nincrease in the coronary Agatston score while coro-\nnary calcification did not increase in patients \ntreated with sevelamer. In the RIND trial patients \ntreated with calcium had an 11-fold increase in \nmedian coronary calcification score as compared \nwith patients treated with sevelamer. \n\nBoth studies also demonstrated that calcium and \nsevelamer had a similar effect on the reduction of \nphosphorus levels, showing that it is not enough to \nreduce phosphorus levels to avoid progression of \nvascular calcifications. In terms of biochemical \nparameters, the main difference was that in patients \ntreated with calcium there was also an increase in \nCa levels and a decrease in PTH levels.\n\nRaggi et al.42 evaluated the effect of phosphate \nbinders on bone mineral density in a group of 200 \nhaemodialysis patients. Vascular calcifications and \nbone mineral density were assessed at baseline and \nat the end of treatment by either sevelamer or \n\nFigure 4\n\nVitamin D deficiency and cardiovascular risk factors*\n\n*AdragaoT, Ferreira A, Fraz\u00e3o J. Port J Nephrol Hypert 2008;22:66 (abstract)\n\nNefro - 22-2.indd   161 17-04-2008   11:00:53\n\n\n\n162    Port J Nephrol Hypert 2008; 22(2): 157-163\n\nTeresa Adrag\u00e3o\n\ncalcium salts. Patients treated with calcium salts \nshowed an increase in coronary calcifications and a \ndecrease in trabecular bone density, in association \nwith higher Ca levels, lower PTH levels and lower \ntotal and bone-specific alkaline-phosphatase levels. \nThis effect of calcium treatment on bone density was \nconfirmed in the Asmus et al.43 study, showing that \ntreatment of 72 haemodialysis patients with calcium \ncarbonate was associated with a decrease in bone \ndensity as compared with sevelamer. \n\nThe follow-up study of the RIND trial44 showed \nthat in incident patients treatment with calcium was \nassociated with lower survival than sevelamer. The \nDCOR trial45, a multicentre, open-label study, com-\npared the effect on mortality of sevelamer versus \ncalcium salts in 2100 prevalent haemodialysis \npatients. All-cause and cardiovascular mortality were \nnot statistically different between the two treatment \ngroups. This study could only demonstrate that \ntreatment with sevelamer reduced mortality in \npatients over 65 years of age, and in patients \ntreated for more than 2 years. \n\nThere are many reasons which could explain the \ndifferent outcomes of the DCOR and RIND trials. \nThe former evaluated prevalent patients while the \nlatter was performed in patients new to dialysis. The \nmean follow-up was shorter in the DCOR trial: 20 \nmonths in DCOR versus 44 months in RIND. In the \nDCOR trial, the number of previewed cardiovascular \nevents necessary to demonstrate a difference \nbetween the two treatment groups was not reached. \nAnnual mortality rate in the DCOR trial was lower \nthan the annual mortality rate reported in USRDS4: \n15.02% in the sevelamer group and 16.15% in the \ncalcium binders group. Vascular calcification was not \nevaluated in DCOR but prevalent patients may have \na higher vascular calcification score than incident \npatients. For instance, baseline coronary calcification \nscore was higher in prevalent patients in the TTG \ntrial, where median score was 641 Hounsfield units, \nthan in incident patients in the RIND trial with a \nmedian score of 473 Hounsfield units. These results \nunderline the need to begin treatment at an earlier \nphase in haemodialysis patients.\n\nIn non-randomised studies, treatment with active \nvitamin D has been associated with a reduction of \nmortality in dialysis patients. In a small cohort of hae-\nmodialysis patients with secondary hyperparathyroidism, \n\ntreatment with calcitriol was associated with regression \nof left ventricular hypertrophy46. This result may be the \nconsequence of a cardioprotective effect of vitamin D \nor could be associated with control of hyperparathyroid-\nism. It is necessary to demonstrate if correction of \n25-vitD deficiency with or without treatment with active \nvitamin D contributes to a reduced cardiovascular risk \nin dialysis patients.\n\n  CONCLUSIONS\n\nVascular calcifications are the result of a complex \nbalance between calcification inducers and inhibitors \nand are associated with cardiovascular risk in dialy-\nsis patients.\n\nVascular calcifications are associated with low \nbone turnover, low bone volume and low bone \ndensity. Management of bone and mineral disorders \nin chronic kidney disease may be associated with \ncardiovascular risk reduction. Plain X-ray can be used \nfor screening vascular calcifications in dialysis \npatients and the evaluation of the simple vascular \ncalcification score identifies patients at higher car-\ndiovascular risk. This information is an important \naid in choosing the most suitable treatment for these \npatients.\n\nPresence of vascular calcifications, old age, dia-\nbetes mellitus, haemodialysis vintage, previous \nparathyroidectomy and adynamic bone disease are \nthe most frequent factors associated with develop-\nment or progression of vascular calcifications. In \nthese patients it is important to avoid positive cal-\ncium balance, hyperphosphataemia and oversup-\npression of PTH. Vitamin D deficiency has also been \nassociated with vascular calcifications, arterial stiff-\nness and left ventricular hypertrophy and it is neces-\nsary to demonstrate if treatment with vitamin D is \nassociated with a reduced cardiovascular risk.\n\nUnderstanding the mechanisms linking bone dis-\nease to cardiovascular disease is opening up a new \ntreatment field that might reduce the high cardio-\nvascular risk of dialysis patients.\n\nConflict of interest statement. Dr Adrag\u00e3o has received research \n\ngrants from Amgen and Genzyme and has received lecture fees \n\nfrom Amgen, Genzyme and Abbott.\n\nNefro - 22-2.indd   162 17-04-2008   11:00:53\n\n\n\nPort J Nephrol Hypert 2008; 22(2): 157-163    163\n\nIs there a link between bone and vessel in dialysis patients?\n\nReferences\n\n 1 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic \nrenal disease. J Am Soc Nephrol 1998;9:(12):S16-23\n\n 2 Longenecker JC, Coresh J, Powe NR et al. Traditional cardiovascular disease risk factors \nin dialysis patients compared with the general population: the CHOICE Study. J Am \nSoc Nephrol 2002;13:1918-27\n\n 3 Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mel-\nlitus undergoing  hemodialysis. N Engl Med 2005;353:238-48\n\n 4 U.S. Renal Data System, USRDS 2005 Annual Data Report; National Institutes of Health, \nNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2005\n\n 5 Blacher J, Gu\u00e9rin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and \ncardiovascular risk in end-stage renal disease. Hypertension 2001;38:938\u2013942\n\n 6 London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage \nrenal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant \n2003;18:1731-40\n\n 7 Shanahan CM, Cary NR, Salisbury JR, et al. Medial localization of mineralization-regu-\nlating proteins in association with Monckeberg\u2019s sclerosis: evidence for smooth \nmuscle cell-mediated vascular calcification. Circulation 1999;100:2168\u20132176\n\n 8 Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004:15:2959\u2013296\n\n 9 Moe SM, O\u2019Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is \nassociated with deposition of bone matrix proteins. Kidney Int 2002;61:638-647\n\n 10 Ketteler M, Vermeer C, Wanner C, et al. Novel insights into uremic vascular calcification: \nrole of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood \nPurif 2002;20:473\u2013476\n\n 11 Moe S, Dr\u00fceke T, Cunningham J, et al. Definition, evaluation, and classification of renal \nosteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes \n(KDIGO). Kidney Int 2006;69:1945\u20131953\n\n 12 Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam com-\nputed tomography in the evaluation of cardiac calcification in chronic dialysis patients. \nAm J Kidney Dis 1996;27:394\u2013401\n\n 13 Moe SM, O\u2019Neill KD, Fineberg N et al. Assessment of vascular calcification in ESRD \npatients using spiral CT. Nephrol Dial Transplant 2003;18:1152-8\n\n 14 Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardio-\nvascular risk in haemodialysis patients. Nephrol Dial Transplant 2004;19:1480-1488.\n\n15  Belasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging tests and \ncoronary artery calcium measured by computed tomography in hemodalysis patients. \nKidney Int 2006;70:16\n\n 16 National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone Metabolism \nand Disease in Chronic Kidney disease. Am J Kidney Dis 2003;42 [Suppl 3]\n\n 17 Adragao T, Pires A, Lucas C et al. Vascular and valvular calcifications in dialysis patients: \nthe same pathogenesis? Port J Nephrol Hypert 2007;21:281-285\n\n 18 T.Adragao, A.Pires, C.Lucas et al. A simple vascular calcification score is a predictor of \npulse wave velocity in hemodialysis patients. J Am Soc Nephrol 2005 16:473A (PO638).\n\n 19 London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphom-\netry in end-stage renal disease. J Am Soc Nephrol 2004;15:1943\u20131951\n\n 20 Adragao T, Ferreira A, Fraz\u00e3o JM, et al. Vascular Calcifications and bone turnover in \nhemodialysis patients. Nephrol Dial Transplant 2006;21(suppl 4) iv 292 (MO014)\n\n 21 Gulay A, Mehmet O, Soner D et al. The Link Between Cardiovascular And Bone Disease \nIn Hemodialysis Patients. SaO012. XLIV ERA-EDTA Congress 2007\n\n 22 Schulz E, Arfai K, Liu X, et al. Aortic calcification and the risk of osteoporosis and \nfractures. J Clin Endocrinol Metab 2004;89:4246-53\n\n 23 Taal MW, Roe S, Masud T, et al. Total hip bone mass predicts survival in chronic \nhemodialysis patients. Kidney Int 2003;63:1116-20\n\n 24 Raggi P, Bellasi A, Ferramosca E et al. Pulse wave velocity is inversely related to \nvertebral bone density in hemodialysis patients. Hypertension 2007;49:1278-84\n\n 25 Adragao T, Branco P, Birne R, et al. Bone Mineral Density, Arterial Calcifications and \nArterial Stiffness in PD patients. J Am Soc Nephrol 17:2006, 272A TH-PO779 (abstract)\n\n 26 Malluche HH, Monier-Faugere MC. Renal osteodystrophy: What\u2019s in a name? Presenta-\ntion of a clinically useful new model to interpret bone histologic findings. Clin Neph-\nrol 2006;65:235-242\n\n 27 Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: \nestrogen deficiency causes both type I and type II osteoporosis in postmenopausal \nwomen and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-73\n\n 28 Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular \nsystem. N Engl J Med 1999;340:1801\u20131811\n\n 29 Eriksen EF, Colvard DS, Berg NJ et al. Evidence of estrogen receptors in normal human \nosteoblast-like cells. Science 1988;241:84-86\n\n 30 Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with \nparicalcitol or calcitriol therapy. N Engl J Med 2003;349:446-56\n\n 31 Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis \nsurvival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-25\n\n 32 Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients \nreceiving different vitamin D analogs. Kidney Int 2006;70:1858-65\n\n 33 London GM, Guerin AP, Verbeke FH, et al. Mineral metabolism and arterial functions \nin end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc \nNephrol 2007;18:613-20\n\n 34 Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout \nmice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endo-\ncrinol Metab 2005;288:E125-32\n\n 35 Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regula-\ntor of the renin-angiotensin system. J Clin Invest 2002;110:229-238\n\n 36 Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin \nD receptor activation. Kidney Int 2006:69:33-43\n\n 37 Adragao T, Ferreira A, Frazao J, et al. D\u00e9ficit de 25-Hidroxivitamina D: um novo factor \nde risco cardiovascular? Port J Nephrol Hypert 2008;22(1):66 CO SE 1005 (abstract).\n\n 38 Oikarinen L, Nieminen MS, Viitasalo M, et al. Relation of QT interval and QT dispersion \nto echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive \npatients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens \n2001;10:1883-91\n\n 39 Paoletti E, Specchia C, Di Maio G, et al. The worsening of left ventricular hypertrophy \nis the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year \nsurvey. Nephrol Dial Transplant 2004;19:1829-34\n\n 40 Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coro-\nnary and aortic calcification in dialysis patients. Kidney Int 2002;62:245-52\n\n 41 Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary \nartery calcification in patients new to dialysis. Kidney Int 2005;68:1815-24\n\n 42 Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with \ncalcium based phosphate binders in hemodialysis. J Bone Miner Res 2005;20:764-72\n\n 43 Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium \ncarbonate effects on cardiovascular calcification and bone density. Nephrol Dial \nTransplant 2005;20:1653-61\n\n 44 Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and \nbinder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41\n\n 45 Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based \nphosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7\n\n 46 Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion \nin secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006;102:21-29\n\nNefro - 22-2.indd   163 17-04-2008   11:00:54\n\n\n\n\n\nTreatment of hyperphosphatemia with sevelamer\nhydrochloride in dialysis patients: effects on vascular\ncalcification, bone and a close look into the\nsurvival data\nJoa?o M. Fraza?o\n\n1\nand Teresa Adraga?o\n\n2\n\n1\nNephrology Department, Hospital de S. Joa?o, Medical School and Nephrology Research and Development Unit, University of Porto,\nPorto, Portugal and 2Department of Nephrology, Hospital de Santa Cruz, Carnaxide, Portugal\n\nIn chronic kidney disease patients, bone and mineral\n\nabnormalities have a major impact on morbidity and\n\nmortality. Hyperphosphatemia has been associated with\n\nincreased mortality and with the development of\n\ncardiovascular calcification, an independent predictor of\n\nmortality. Vascular calcifications have been associated with\n\nlow bone turnover, low bone volume and lower activation\n\nfrequency. In dialysis patients, the treatment of\n\nhyperphospathemia with calcium based compounds, when\n\ncompared with sevelamer, is associated with more frequent\n\nepisodes of hypercalcemia, suppression of intact parathyroid\n\nhormone and with progression of coronary calcifications. In\n\nthe presence of adynamic bone disease, calcium load has a\n\nsignificantly higher impact on aortic calcifications and\n\nstiffening. A randomized, prospective, open label study,\n\nevaluated patients with bone biopsies at the beginning and\n\nafter 1 year treatment period with sevelamer hydrochloride\n\nor calcium carbonate. Sevelamer treatment resulted in no\n\nstatistically significant changes in bone turnover or\n\nmineralization compared with calcium carbonate, but bone\n\nformation rate increased and trabecular architecture\n\nimproved only with sevelamer. In incident dialysis patients,\n\ntreatment with sevelamer has been associated with better\n\nsurvival, while in prevalent patients a clear benefit could only\n\nbe demonstrated in older patients and in patients treated for\n\nmore than 2 years. In conclusion, the treatment of\n\nhyperphosphatemia with sevelamer hydrochloride, a non-\n\ncalcium and non-metal containing phosphate binder, is\n\nassociated with a beneficial effect on vascular calcification\n\nprogression, bone disease and most likely with a survival\n\nbenefit in some hemodialysis patients populations.\n\nKidney International (2008) 74 (Suppl 111), S38\u2013S43; doi:10.1038/ki.2008.544\n\nKEYWORDS: hyperphosphatemia; severelamer hydrochloride; vascular\n\ncalcification; survival\n\nThe last few years have seen major developments in the\nmanagement of bone and mineral disorders associated with\nchronic kidney disease (CKD). Acknowledgment of the fact\nthat these bone and mineral abnormalities in CKD patients\nhave a major impact on morbidity and mortality drove\nnephrologists\u2019 attention to the importance of controlling these\nalterations. In addition, new compounds have been developed\nfor the control of hyperphosphatemia and for the treatment of\nsecondary hyperparathyroidism, raising many questions to-\nward the use of non-calcium-containing phosphate binders.\n\nUntil recently, the only phosphate binders available were\naluminum or calcium-based compounds. These compounds\nwere efficacious but were also associated with significant side\neffects. The use of aluminum-containing phosphate binders is\nassociated with bone disease as well as hematologic and central\nnervous system toxicity, whereas the use of calcium-containing\nphosphate binders is associated with increased risk of\nhypercalcemia and cardiovascular calcification.\n\n1\u20134\nIt is now\n\nknown that serum calcium levels are not accurate in predicting\nthe calcium balance and burden. The excessive amount of\ncalcium ingested from diet and calcium-containing binders has\nbeen associated with cardiovascular calcifications, even in the\npresence of normal calcium serum levels.1\u20134 The non-calcium,\nnon-metal-containing, and non-absorbed phosphate binder,\nsevelamer hydrochloride, has provided an effective way to bind\nphosphorus in the gut without the risks of hypercalcemia, soft\ntissue or vascular calcifications, or heavy metal accumulation.\n\nEFFECTS ON VASCULAR CALCIFICATION\n\nIn recent years, it has become clear that the presence of\nelevated serum phosphorus levels in CKD stage 5 patients is\npositively associated with increased mortality.5,6 Hyperpho-\nsphatemia and elevated calcium-phosphorus product\n(Ca X P) are associated with cardiovascular calcification.1,2\n\nCardiovascular calcification is an independent predictor of\nmortality. Several authors have now reported a strong\npositive association between the presence and extent of\nvascular calcification and both cardiovascular and all-cause\nmortality.3,7,8 Raggi et al.9 reported that previous myocardial\n\nreview http://www.kidney-international.org\n\n&amp; 2008 International Society of Nephrology\n\nCorrespondence: Joa?o M. Fraza?o, Hospital de S. Joa?o, Servic?o de\n\nNefrologia, Alameda Herna?ni Monteiro, 4200 Porto, Portugal.\n\nE-mail: jmmdfrazao@netcabo.pt\n\nS38 Kidney International (2008) 74 (Suppl 111), S38\u2013S43\n\n\n\ninfarction, angina, and known coronary artery disease were\nall more common in CKD stage 5 patients with extensive\ncalcification.\n\nMost stage 5 CKD patients present with hyperpho-\nsphatemia. The clinical outcomes of this mineral abnormality\ninclude secondary hyperparathyroidism with consequent\nrenal bone disease, extra-osseous calcification, and increased\nmortality.\n\nTherapeutic strategies to control phosphorus levels\ninclude dietary restrictions, dialysis, and the use of\nphosphate-binding agents. Reduction of phosphate intake\nin the diet is often difficult and is also limited by the\nassociated protein restriction, as all proteins contain\nphosphate. Phosphate is also difficult to remove by dialysis.\nIncreased dialysis time or frequency may be effective, but it is\noften difficult to implement because of logistic problems and\npoor patient acceptance.\n\nSevelamer hydrochloride has been widely studied and\nshown to be effective in reducing phosphorus levels and\nCa X P without causing hypercalcemia and soft tissue\ncalcification in stage 5 CKD population on hemodialysis,\nwith the added benefit of cholesterol reduction (total and\nlow-density lipoprotein cholesterol). This compound is well\ntolerated with few side effects, the more frequently reported\nones being diarrhea, constipation, dyspepsia, nausea, and\nvomiting.\n\nChertow et al.4 reported the results of a randomized\nparallel design clinical trial comparing sevelamer with\ncalcium-based phosphorus binders in 200 hemodialysis\npatients. Sevelamer and calcium-based compounds provided\nsimilar control of serum phosphorus and Ca X P. Adherence\nto the prescribed dose of binder in the sevelamer and\ncalcium-containing binder groups was similar: 86 vs 80%,\nrespectively. The group treated with sevelamer received an\naverage binder dose of 6.5\u00b12.9 g per day and the group\ntreated with calcium-based binders, 4.3\u00b11.9 g per day (4.6\nand 3.9 g per day of calcium acetate or calcium carbonate,\nrespectively). The calcium-based group had more frequent\nepisodes of hypercalcemia when compared with the sevela-\nmer group: 43 and 17%, respectively. Suppression of intact\nparathyroid hormone secretion below the 150\u2013300 pg/ml\nrange was more common at the end of the study in the\ncalcium-based binders group, 57 vs 30%, despite the\nprotocol-specified reduction or cessation of vitamin D for\nintact parathyroid hormone below 150 pg/ml. Twelve percent\nof patients in the calcium group required rescue therapy with\naluminum-containing binders for a calcium-phosphorus\nproduct above 72 mg\n\n2\n/100ml\n\n2\n, compared with 4% of patients\n\nin the sevelamer group. Total and low-density lipoprotein\ncholesterol decreased significantly in the sevelamer-treated\ngroup compared with a non-change in the calcium binders\ngroup. It is relevant that, the electron beam computed\ntomography (EBCT) performed at the beginning of the study\ndetected a prevalence of coronary artery calcification of 83%\nand aortic calcification of 80% of the study patients. There\nwas significant progression of the coronary artery and aortic\n\ncalcification EBCT score, at weeks 26 and 52, in the calcium-\ncontaining binders-treated group, despite the use of an\naverage dose of calcium-containing binders of only 4.3\u00b11.9 g\nper day, which corresponds to values of elemental calcium\nunder the Kidney Disease Outcomes Quality Initiative\nrecommendations. There was no significant progression in\nthe sevelamer-treated group.\n\nThe high prevalence of vascular calcification seen in the\ndialysis population in the Chertow study4 has been\nconfirmed by other reports and is of major concern because\nof the positive association between the presence and severity\nof calcification and mortality in this population. There is also\nsome evidence that most of the patients develop vascular\ncalcifications while on hemodialysis treatment. In fact, a\nreport from Spiegel et al.10 revealed that only 34% of patients\nwith advanced CKD starting dialysis had coronary artery\ncalcifications scores that placed them above the 90th\npercentile for age and sex. In the same patient population\ninitiating dialysis, 109 patients underwent baseline and at\nleast one additional measurement of coronary artery\ncalcification.11 At baseline, 37% of the patients who under-\nwent treatment with sevelamer and 31% of the patients who\nunderwent treatment with calcium-based binders had no\nevidence of calcification. The authors report that no patients\nwith a zero coronary calcium score progressed to a coronary\nartery calcium score 430, using EBCT, in an 18-month\nperiod of time. Patients already having a coronary artery\ncalcium score 430 at baseline progressed during the time of\nthe study in both arms. The patients treated with calcium-\nbased binders showed a more rapid and severe progression\nwhen compared with those receiving sevelamer. It can be\nnoted that, during this study, all the patients were maintained\non dialysis with a calcium dialysate concentration of\n2.5 mEq/l. The authors conclude that patients new to dialysis,\nwith no evidence of coronary calcification, showed little\nevidence of disease development over a period of 18 months\nindependent of the phosphate binder used. Patients with even\nlittle evidence of coronary calcification progress with both\nbinders; however, the group treated with calcium-based\nbinders have a much more severe progression when\ncompared with the patients treated with sevelamer.11 With-\nout any doubt, this study confirms the importance of the\nKidney Disease Outcomes Quality Initiative clinical practice\nguidelines for bone metabolism and disease in CKD,\nrecommending that calcium-based binders should be avoided\nin patients with evidence of severe calcification.12\n\n\u2018Kidney Disease: Improving Global Outcomes\u2019 has re-\ncommended a new classification for CKD mineral and bone\ndisorder that includes for the first time the evaluation of\nvascular calcifications.13 In hemodialysis patients, vascular\ncalcifications may be evaluated by different techniques:\nEBCT,14 multislice computed tomography (MSCT),15 ultra-\nsonography,7 and plain X-ray.3,8,16 EBCT and MSCT allow a\nquantitative measurement and are considered the gold\nstandard for evaluating vascular calcification, but are very\nexpensive. The utilization of plain X-ray for screening\n\nKidney International (2008) 74 (Suppl 111), S38\u2013S43 S39\n\nJM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival review\n\n\n\nvascular calcifications has been suggested by Kidney Disease\nOutcomes Quality Initiative12 and \u2018Kidney Disease: Improv-\ning Global Outcomes\u2019.13 We have developed a vascular\ncalcification score evaluated in plain X-ray of hands and\npelvis (Figure 1), which was a predictor of cardiovascular\ndeath and cardiovascular morbidity in dialysis patients\n(Figure 2).8 This simple vascular calcification score has been\nalso correlated with valvular calcifications\n\n17\nand with arterial\n\nstiffness.18\n\nPlain X-ray and ultrasonography are semiquantitative, less\nexpensive, and useful for screening the presence of vascular\ncalcifications. They can be used to identify patients at higher\nrisk of a cardiovascular event. EBCT and MSCT are useful for\nevaluating the progression of vascular calcification and the\neffect of different treatments on progression of vascular\ncalcification. These two techniques do not differentiate\nintimal from medial calcification, and the explanation for\nthe very high scores evaluated in dialysis patients is the\npresence of both types of calcification.\n\nEFFECTS ON BONE\n\nIn a randomized prospective, open label study, 119\nhemodialysis patients were evaluated with bone biopsies\nperformed at the beginning and after a 1-year treatment\nperiod, to compare the effects of sevelamer hydrochloride\nand calcium carbonate on bone.19 Biopsy-proven adynamic\nbone disease was the most frequent bone abnormality at\nbaseline (59%). The serum phosphorus levels were similarly\ncontrolled in both groups, although the serum calcium level\nwas consistently lower and intact parathyroid hormone\nhigher in patients treated with sevelamer. Compared with\nbaseline values, there were no changes in mineralization lag\ntime or measures of bone turnover after 1 year of treatment\nwith both sevelamer and calcium carbonate. Bone formation\nrate per bone surface increased significantly from baseline\nonly in the sevelamer-treated patients. In addition, of those\nwith abnormal microarchitecture at baseline (that is,\ntrabecular separation), 7 of 10 in the sevelamer group\nnormalized after 1 year compared with 0 of 3 in the calcium\ngroup. In summary, this study showed that sevelamer\ntreatment resulted in no statistically significant changes in\nbone turnover or mineralization compared with calcium\ncarbonate, but bone formation rate increased and trabecular\narchitecture improved only with sevelamer.\n\nIn a group of 42 hemodialysis patients submitted to bone\nbiopsies,20 we have verified that low bone volume was\nassociated with vascular calcifications evaluated by MSCT or\nby plain X-ray and with higher pulse wave velocity. Adynamic\nbone disease was present in 50% of patients. There were no\ncases of osteomalacia and no aluminum deposits in bone.\n\nLondon et al.21 showed the existence of an association\nbetween vascular calcifications and low bone turnover. In this\nstudy, 58 hemodialysis patients were evaluated; 23 patients\nhad been submitted to parathyroidectomy and 33 patients\nhad aluminum deposits in bone. Vascular calcifications were\nevaluated by ultrasonography. More calcifications were\nassociated with lower osteoblast surface and with other\n\nFigure 1 | Pelvis score evaluates the presence of vascular\ncalcifications in iliac and femoral arteries. Hands score\nevaluates the presence of vascular calcification in the radial and\ndigital arteries. Calcification score is the sum of the presence (1) or\nabsence (0) of vascular calcifications in each section. In this\nexample pelvis score (1 \u00fe 1 \u00fe 1 \u00fe 1) \u00bc 4 and hands score\n(1 \u00fe 1 \u00fe 1 \u00fe 1) \u00bc 4. Total score is 8.\n\nC\nV\n\n M\no\n\nrt\na\n\nlit\ny\n\n403020100\n\nn = 58\n\n3 deaths\n5%\n\n14 deaths\n23%Log rank  =  5.7\n\nP = 0.01\n\nn = 65\n\nsc&lt;3\n\nFollow-up (months)\n\nKaplan\u2013Meier\nn = 123\n\nCOX regression\n\nCV hospitalizations\n\n0.01 100\n\nPeripheral artery disease\n\nVascular disease\n\nCV death\n\n9.3\n\n3.8\n\n3.9\n\n4.4\n\nP = 0.001\n\nP = 0.001\n\nP = 0.02\n\nP = 0.02\n\n1010.1\n\n0.2\n\n0.1\n\n0\n\nsc > 3\n\nVascular score > 3 and CV death Vascular score > 3 and CV risk \n\nFigure 2 | Calcification score from plain X-ray of hands and pelvis was a predictor of cardiovascular death and cardiovascular\nmorbidity in dialysis patients. After 3 years of follow-up vascular score X3 was associated with higher cardiovascular mortality and\nmorbidity.8\n\nS40 Kidney International (2008) 74 (Suppl 111), S38\u2013S43\n\nreview JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival\n\n\n\nmarkers of low bone turnover, with lower parathyroid\nhormone levels and with higher calcium dose. Asci et al.22\n\nshowed, in a group of 224 patients, that vascular calcifica-\ntions evaluated by MSCT were associated with lower\nactivation frequency evaluated in bone biopsies.\n\nA recent study was performed to assess the impact of bone\nactivity on the relationships between the dosage of calcium-\ncontaining binders and aortic stiffness or abdominal aorta\ncalcification score.23 A significant interaction was found\nbetween the dosage of calcium-containing phosphate binders\nand bone activity such that the calcium load had a\nsignificantly higher impact on aortic calcifications and\nstiffening in the presence of adynamic bone disease.\n\nThe data presented suggest that sevelamer treatment has a\nbeneficial effect on bone, with an increase in the bone\nformation rate and an improvement in the trabecular\narchitecture. There is an association between vascular\ncalcifications and low bone volume and with low bone\nturnover in dialysis patients. Finally, in dialysis patients with\nadynamic bone, calcium load has a greater influence on\naortic calcifications and stiffening. Patients whose bone is not\nable to retain calcium or phosphorus have higher vascular\ncalcification scores. One added risk factor for the develop-\nment of vascular calcifications in the setting of low bone\nturnover is the administration of calcium-containing phos-\nphate binders.\n\nA CLOSE LOOK INTO THE SURVIVAL DATA\n\nThe promise of a survival benefit with the use of sevelamer\nhydrochloride has been evaluated in two randomized\nprospective, controlled studies with interesting results that\ngenerate some controversy and certainly have not completely\nsolved the issue.\n\nThe first was the \u2018Dialysis Clinical Outcomes Revisited\n(DCOR)\u2019 study.\n\n24\nThis 3-year trial involving more than 2100\n\npatients compared the difference in mortality and morbidity\noutcomes for patients receiving sevelamer hydrochloride and\nthose receiving calcium-containing phosphate binders. This\nwas the largest outcomes study ever conducted in the\nhemodialysis population. This study showed that the patients\ntreated with sevelamer hydrochloride experienced a reduction\nof 7% in the risk of death from all causes when compared\nwith the patients treated with calcium-based phosphate\nbinders, which was statistically not significant (P \u00bc 0.3). The\npatients aged 65 years or more (a predefined analysis) were\n23% less likely to die when treated with sevelamer\nhydrochloride, as compared with treatment with calcium-\nbased binders. In addition, patients treated with sevelamer\nhydrochloride for more than 2 years had a 34% reduction of\nthe mortality risk for all causes compared with those treated\nwith the calcium-containing binders.\n\nThe second study was the \u2018Renagel in New to Dialysis\nPatients.\u201925 This was a randomized controlled, prospective,\nopen label study with 127 patients incident to dialysis,\nassigned to 18 months treatment with sevelamer hydro-\nchloride or calcium-containing phosphate binders, to assess\n\ncoronary artery calcification progression. Mortality was a\npredetermined secondary end point.25 Twenty-three deaths in\nthe calcium-containing phosphate binders group and 11\ndeaths in the sevelamer hydrochloride-assigned patients\noccurred during the median 44 months of follow-up time\nafter randomization, a significantly lower mortality for\npatients treated with sevelamer hydrochloride. The survival\nbenefit observed with sevelamer hydrochloride treatment\npersisted after full multivariate adjustment.\n\nIt is very important to analyze the reasons for the\ndifferences observed in the outcomes of these two trials. The\nDCOR trial evaluated prevalent patients probably with a\nmore important burden of calcification, whereas \u2018Renagel in\nNew to Dialysis Patients\u2019 trial was performed in patients new\nto dialysis. It is probably very difficult to reverse already\nexisting vascular calcifications. The DCOR trial has been\ncriticized for the short follow-up time of less than 2 years.\nThe median follow-up was shorter in the DCOR trial\ncompared with the \u2018Renagel in New to Dialysis Patients\u2019\ntrial, 19 vs 44 months, respectively. The short follow-up time\nin the DCOR trial did not allow the differences in mortality\nto appear. In fact, for the patients followed for more than 2\nyears, the difference in mortality became significant. In the\nDCOR trial, the number of previewed cardiovascular events\nnecessary to demonstrate a difference between the two\ntreatment groups was not reached. The annual mortality rate\nin the DCOR trial was inferior to the annual mortality rate\nreported in United States Renal Data System.26\n\nThe results of these two studies strongly suggest that the\nuse of sevelamer as a phosphate binder decreases mortality in\nincident and in elderly hemodialysis patients and reinforces\nthe importance of earlier initiation of treatment with\nsevelamer hydrochloride in hemodialysis patients.\n\nA final comment is on the systematic review of the clinical\nefficacy and safety of sevelamer hydrochloride in dialysis\npatients published by Tonelli et al.27 In the mortality analysis,\nthe authors included five studies (Table 1), with only one of\nthem having mortality as the primary end point.25 The other\nthree studies included (Table 1) in the mortality analysis\ninvolved a small number of patients, had a short follow-up,\nand mortality was not an end point. These studies4,28,29 were\nnot powered in terms of follow-up time, number of patients,\nand end points to evaluate mortality. In our view, it is\nimpossible to withdraw any mortality information in studies\nwith 42 patients and a 5-month follow-up, or a crossover\nstudy with 20 patients and a total follow-up of 18 weeks. The\nChertow study\u2019s4 primary end point was vascular calcifica-\ntion; mortality was not even an end point and received 24%\nweight in the analysis. Regarding the \u2018Renagel in New to\nDialysis Patients\u2019 study, with a long follow-up for the\nsecondary end point mortality and evidence of survival\nbenefit in the sevelamer-treated group, the weight attributed\nwas only 4.26%.\n\nIn our opinion, the available data on mortality benefit\nwith sevelamer hydrochloride treatment from two rando-\nmized prospective controlled trials constitute a very positive\n\nKidney International (2008) 74 (Suppl 111), S38\u2013S43 S41\n\nJM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival review\n\n\n\nfact that is certainly innovative in the nephrology field. We\nare not aware of any other pharmacological intervention in\ndialysis patients with such ground in terms of hard outcome\ndata.\n\nIn a recent editorial,\n30\nthe authors state that \u2018to cultivate a\n\nbalanced approach to understanding results generated by\nmeta-analysis of data from small trials it is important to\naccept the limitations implicit in this method.\u2019 Meta-analysis\nonly generates hypotheses and certainly should be carefully\ninterpreted. One should always keep in mind that well-\ndesigned, randomized controlled trials are the strong bases\nfor evidence-based medicine.\n\nThere is mounting evidence from basic science,\n31\n\nobservational studies,32 and randomized trials with surrogate\nend points such as cardiovascular calcification4,11 and\nmortality25 that calcium can be toxic for dialysis patients.\nWith this level of information, the nephrology community\nshould be asking what level of scientific evidence is needed to\nconvince us to discontinue, or at least to be extremely\ncautious with the use of calcium-containing phosphate\nbinders, a potentially harmful therapy.\n\nDISCLOSURE\nJoa?o M Fraza?o has received consulting and lecture fees from\nAmgen and Genzyme. Teresa Adraga?o has declared no financial\ninterests.\n\nREFERENCES\n1. Guerin A, London G, Marchais S et al. Arterial stiffening and vascular\n\ncalcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15:\n1014\u20131021.\n\n2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in\nyoung adults with end-stage renal disease who are undergoing dialysis.\nN Engl J Med 2000; 342: 1478\u20131483.\n\n3. London GM, Gue?rin AP, Marchais SJ et al. Arterial media calcification in\nend-stage renal disease: impact on all-cause and cardiovascular mortality.\nNephol Dial Transplant 2003; 18: 1731\u20131740.\n\n4. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer\nattenuates the progression of coronary and aortic calcification in\nhemodialysis patients. Kidney Int 2002; 62: 245\u2013252.\n\n5. Block G, Hulbert-Shearon T, Levin N et al. Association of serum\nphosphorus and calcium x phosphate product with mortality risk in\nchronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:\n607\u2013617.\n\n6. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and\nmorbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:\n2208\u20132218.\n\n7. Blacher J, Gue?rin AP, Pannier B et al. Arterial calcifications, arterial\nstiffness, and cardiovascular risk in end-stage renal disease. Hypertension\n2001; 38: 938\u2013942.\n\n8. Adraga?o T, Pires A, Lucas C et al. A simple vascular calcification score\npredicts cardiovascular risk in haemodialysis patients. Nephrol Dial\nTransplant 2004; 19: 1480\u20131488.\n\n9. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in\nadult hemodialysis patients. A link between end-stage renal\ndisease and cardiovascular disease? J Am Coll Cardiol 2002; 39:\n695\u2013701.\n\n10. Spiegel DM, Raggi P, Metha R et al. Coronary and aortic calcification in\npatients new to dialysis. Hemodialysis Int 2004; 8: 265\u2013272.\n\n11. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on\ncoronary artery calcification in patients new to hemodialysis. Kidney Int\n2005; 68: 1815\u20131824.\n\n12. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Bone\nMetabolism and Disease in Chronic Kidney disease. Am J Kidney Dis 2003;\n42(Suppl 3): S1\u2013S201.\n\n13. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and\nclassification of renal osteodystrophy: a position statement from Kidney\nDisease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:\n1945\u20131953.\n\n14. Braun J, Oldendorf M, Moshage W et al. Electron beam computed\ntomography in the evaluation of cardiac calcification in chronic dialysis\npatients. Am J Kidney Dis 1996; 27: 394\u2013401.\n\n15. Moe SM, O\u2019Neill KD, Fineberg N et al. Assessment of vascular calcification\nin ESRD patients using spiral CT. Nephrol Dial Transplant 2003; 18:\n1152\u20131158.\n\n16. Belasi A, Ferramosca E, Muntner P et al. Correlation of simple imaging\ntests and coronary artery calcium measured by computed tomography in\nhemodalysis patients. Kidney Int 2006; 70: 16.\n\n17. Adragao T, Pires A, Lucas C et al. Vascular and valvular calcifications in\ndialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; 21:\n281\u2013285.\n\n18. Adragao T, Pires A, Lucas C et al. A simple vascular calcification score is a\npredictor of pulse wave velocity in hemodialysis patients. J Am Soc\nNephrol 2005; 16: 473A (PO638).\n\n19. Ferreira A, Fraza?o JM, Monier-Faugere MC et al. Effects of sevelamer\nhydrochloride and calcium carbonate on renal osteodystrophy in\nhemodialysis patients. J Am Soc Nephrol 2008; 19: 405\u2013412.\n\n20. Adragao T, Ferreira A, Fraza?o JM et al. Vascular Calcifications and bone\nturnover in hemodialysis patients. Nephrol Dial Transp 2006; 21(Suppl 4):\niv 292 (MO014).\n\n21. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone\nhistomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15:\n1943\u20131951.\n\n22. Asci G, Ozkahya M, Duman S et al. The link between cardiovascular and\nbone disease in hemodialysis patients. Nephrol Dial Transp 2007;\n22(Suppl 6): vi 217 (MO014).\n\n23. London GM, Marchais SJ, Ge?rin AP et al. Association of bone activity,\ncalcium load, aortic sitfness, and calcifications in ESRD. J Am Soc Nephrol\n2008; 19: 1827\u20131835.\n\n24. Suki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-\nbased phosphate binders on mortality in hemodialysis patients. Kidney Int\n2007; 72: 1130\u20131137.\n\n25. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification\nand phosphate binder choice in incident hemodialysis patients. Kidney Int\n2007; 71: 438\u2013441.\n\n26. U.S. Renal Data System, USRDS 2005 Annual Data Report National\nInstitutes of Health, National Institute of Diabetes and Digestive and\nKidney Diseases, Bethesda, MD, 2005.\n\n27. Tonelli M, Wiebe N, Culleton B et al. Systematic review of the clinical\nefficacy and safety of sevelamer in dialysis patients. Nephrol Dial\nTransplant 2007; 22: 2856\u20132866.\n\nTable 1 | Summary of the studies used for mortality analysis\n\nAuthor Number of patients Follow-up Primary end points\n\nBlock et al.25 127 18 months for the primary end point (calcifications)\nand 44 months for the secondary end point (mortality)\n\nProgression of calcifications\n\nChertow et al.4 200 52 weeks Progression of calcifications\nSadek et al.28 42 5 months Biochemical parameters\nShaheen et al.\n\n29\n20 Crossover study 18 weeks Biochemical parameters\n\nSuki et al.\n24\n\n2103 22 months Mortality\n\nS42 Kidney International (2008) 74 (Suppl 111), S38\u2013S43\n\nreview JM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival\n\n\n\n28. Sadek T, Mazouz H, Bahloul H et al. Sevelamer hydrochloride with or\nwithout alphacalcidol or higher dialysate calcium vs calcium carbonate in\ndialysis patients: an open-label, randomized study. Nephrol Dial\nTransplant 2003; 18: 582\u2013589.\n\n29. Shaheen FA, Akeel NM, Badawi LS et al. Efficacy and safety of sevelamer.\nComparison with calcium carbonate in the treatment of hyperphosphatemia\nin hemodialysis patients. Saudi Med J 2004; 25: 785\u2013791.\n\n30. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution.\nNat Clin Pract nephrol 2008; 4: 115.\n\n31. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;\n15: 2959\u20132961.\n\n32. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of\ntime-varying indicators of bone disease in maintenance hemodialysis\npatients. Kidney Int 2006; 70: 771\u2013780.\n\nKidney International (2008) 74 (Suppl 111), S38\u2013S43 S43\n\nJM Fraza?o and T Adraga?o: Sevelamer treatment, calcification, and survival review\n\n\n\n99\n\nCAP\u00cdTULO 7\n\nEXISTE UM ELO DE LIGA\u00c7\u00c3O ENTRE O OSSO E O VASO \nNOS DOENTES EM DI\u00c1LISE? (2.\u00aa PARTE)\n\nDensidade mineral \u00f3ssea, histomorfometria \u00f3ssea e calcifi ca\u00e7\u00f5es vasculares\n\nRELA\u00c7\u00c3O ENTRE DENSIDADE MINERAL \u00d3SSEA E HISTOMORFOMETRIA \u00d3SSEA\n\nEm 2001, a osteoporose foi defi nida pelo National Institute of Health (NIH) como uma \npatologia \u00f3ssea caracterizada pela redu\u00e7\u00e3o da for\u00e7a \u00f3ssea predispondo para um aumento \ndo risco de fraturas1. A for\u00e7a \u00f3ssea depende fundamentalmente de dois fatores: da densidade \nmineral \u00f3ssea e da qualidade \u00f3ssea1. Por sua vez, a qualidade \u00f3ssea resulta da remodela\u00e7\u00e3o, \nda mineraliza\u00e7\u00e3o e da arquitetura \u00f3sseas. Nos indiv\u00edduos da popula\u00e7\u00e3o geral, a densidade \nmineral \u00f3ssea contribui em 70% para a for\u00e7a \u00f3ssea1 e a baixa densidade mineral \u00f3ssea \nrelaciona -se com o risco de fraturas. A Organiza\u00e7\u00e3o Mundial de Sa\u00fade defi ne osteoporose \nbaseando -se em valores de densidade mineral \u00f3ssea inferiores a 2,5 desvio -padr\u00e3o do valor \nm\u00e9dio de mulheres jovens caucasianas (T -score ?  -2,5 DP) e defi ne osteopenia para valores \nde T -score inferiores ou iguais a  -1,5 DP2. Os indiv\u00edduos da popula\u00e7\u00e3o geral com osteopenia \nou osteoporose t\u00eam um risco de fraturas \u00f3sseas, respectivamente, de 4 e de 8 vezes superior \nao risco de fraturas dos indiv\u00edduos com densidade mineral \u00f3ssea normal3. Os doentes em \ndi\u00e1lise apresentam um risco de fraturas 4,4 vezes superior ao da popula\u00e7\u00e3o geral4. Pela \ncompreens\u00e3o dos diferentes fatores que contribuem para a for\u00e7a \u00f3ssea, e conhecendo as \ndiversas altera\u00e7\u00f5es \u00f3sseas que se desenvolvem no doente renal cr\u00f3nico, \u00e9 f\u00e1cil compreender \nque as altera\u00e7\u00f5es da densidade mineral \u00f3ssea n\u00e3o podem ser as \u00fanicas a explicar o risco \nde fraturas destes doentes. Ao contr\u00e1rio do que se verifi ca nos indiv\u00edduos da popula\u00e7\u00e3o \ngeral5, j\u00e1 foi demonstrado que a densidade mineral \u00f3ssea, nos doentes renais em di\u00e1lise, \nn\u00e3o permite identifi car o risco de fraturas6,7. Diferentes estudos t\u00eam apresentado resultados \ncontradit\u00f3rios na an\u00e1lise da rela\u00e7\u00e3o entre os dados de biopsias \u00f3sseas e os resultados da \navalia\u00e7\u00e3o da densidade mineral \u00f3ssea por DXA (dual energy X -ray absorptiometry), \nmostrando que a baixa densidade mineral \u00f3ssea pode associar -se tanto a baixa remodela\u00e7\u00e3o \ncomo a alta remodela\u00e7\u00e3o \u00f3ssea. Gerakis et al8 mostraram, num grupo de 62 doentes em \ndi\u00e1lise, que a baixa densidade mineral \u00f3ssea se associou a marcadores bioqu\u00edmicos e \n\n\n\n100\n\nhistol\u00f3gicos de hiperparatiroidismo secund\u00e1rio. Lob\u00e3o R et al9 verifi caram, num grupo de \n40 doentes renais cr\u00f3nicos nos estadios 3 e 4, e com baixa densidade mineral \u00f3ssea, que \no diagn\u00f3stico histol\u00f3gico predominante foi a doen\u00e7a \u00f3ssea adin\u00e2mica e a osteomalacia. \nEstes autores n\u00e3o encontraram qualquer rela\u00e7\u00e3o entre volume \u00f3sseo e densidade mineral \n\u00f3ssea. As guidelines KDIGO 200910 n\u00e3o aconselham a avalia\u00e7\u00e3o da densidade mineral \n\u00f3ssea nos doentes em di\u00e1lise por este m\u00e9todo n\u00e3o predizer nem o risco de fraturas nem o \ntipo de osteodistrofi a renal nesta popula\u00e7\u00e3o. Foi contudo encontrada uma associa\u00e7\u00e3o entre \na densidade mineral \u00f3ssea avaliada no antebra\u00e7o com o risco de fraturas11 e os valores de \nparatormona12. Os resultados medidos nos corpos vertebrais refl etem a avalia\u00e7\u00e3o do osso \ntrabecular, enquanto os resultados medidos no colo do f\u00e9mur ou no antebra\u00e7o avaliam \nfundamentalmente o osso cortical. A biopsia \u00f3ssea usada no diagn\u00f3stico de osteodistrofi a \nrenal avalia geralmente apenas o osso trabecular, mas \u00e9 poss\u00edvel tamb\u00e9m avaliar o osso \ncortical. Num grupo de 46 doentes portugueses em di\u00e1lise, avaliados simultaneamente por \nDXA e por an\u00e1lise histomorfom\u00e9trica de biopsias \u00f3sseas, encontramos uma rela\u00e7\u00e3o inversa \nentre os valores de densidade mineral \u00f3ssea obtidos por DXA e os marcadores bioqu\u00edmicos \ne histol\u00f3gicos de hiperparatiroidismo secund\u00e1rio13 (fosfatase alcalina \u00f3ssea, PTH intacta, \nn\u00famero osteoblastos/cm, taxa de forma\u00e7\u00e3o \u00f3ssea e frequ\u00eancia de ativa\u00e7\u00e3o \u00f3ssea). N\u00e3o \nencontramos qualquer rela\u00e7\u00e3o entre volume \u00f3sseo trabecular e densidade mineral \u00f3ssea. \nNuma an\u00e1lise posterior a este mesmo grupo de doentes, avaliamos a associa\u00e7\u00e3o entra a \ndensidade mineral \u00f3ssea avaliada por DXA e o volume \u00f3sseo cortical e trabecular avaliados \npor biopsia \u00f3ssea. Ajustando para a idade e dura\u00e7\u00e3o de hemodi\u00e1lise, verifi c\u00e1mos que a \ndensidade mineral \u00f3ssea avaliada no colo do f\u00e9mur, mas n\u00e3o na coluna lombar, se \ncorrelacionava de forma muito signifi cativa com a porosidade cortical mas n\u00e3o com o \nvolume \u00f3sseo trabecular (Tabela 7.1). Fomos os primeiros a descrever esta associa\u00e7\u00e3o e \neste estudo foi publicado na Osteoporosis International14. Este achado inovador do nosso \nestudo foi mencionado pela ERBP (European Renal Best Practice) no coment\u00e1rio feito \u00e0 \nposi\u00e7\u00e3o da KDIGO que considera ser reduzida a utilidade da densidade mineral \u00f3ssea nos \ndoentes em di\u00e1lise15\n\nVari\u00e1veis preditoras de porosidade cortical (regess\u00e3o linear)\n\nVari\u00e1vel dependente: porosidade cortical B SE Sig.\nDMO femoral  -157,49 52,36 0,005\nIdade > 50 anos  -8,7 2,18&lt;0,001\nDura\u00e7\u00e3o de HD  -25,44 8,40 0,005\n\nTabela 7.1. A densidade mineral \u00f3ssea (DMO) femoral, a idade superior a 50 anos e a dura\u00e7\u00e3o da hemodi\u00e1lise \n(HD) correlacionaram -se negativamente com a porosidade cortical avaliada nas biopsias \u00f3sseas\n\n\n\n101\n\nJ\u00e1 foi demonstrado que o hiperparatiroidismo secund\u00e1rio pode ter efeitos opostos no osso \ntrabecular e no osso cortical16,17, e este dado pode explicar os diferentes resultados obtidos \npela DXA consoante o local estudado e a aus\u00eancia de correla\u00e7\u00e3o entre os dados da densidade \nmineral \u00f3ssea obtida por DXA e o risco de fraturas. Nos indiv\u00edduos do sexo masculino da \npopula\u00e7\u00e3o geral, n\u00e3o existe correla\u00e7\u00e3o entre as fraturas osteopor\u00f3ticas vertebrais e os resultados \nda densidade mineral \u00f3ssea. Ostertag A et al mostraram que as fraturas vertebrais no sexo \nmasculino se associaram \u00e0 porosidade cortical avaliada em biopsia \u00f3ssea18.\n\nA utilidade diagn\u00f3stica da DXA nos doentes renais cr\u00f3nicos ainda n\u00e3o est\u00e1 demonstrada. \nNa nossa opini\u00e3o, o termo \u201costeoporose\u201d deve ser usado com cuidado nos doentes renais \ncr\u00f3nicos, pois n\u00e3o existe uniformidade neste diagn\u00f3stico utilizando estes dois m\u00e9todos de \ndiagn\u00f3stico: a biopsia \u00f3ssea e a DXA. \u00c9 mais correto falar de baixa densidade mineral \u00f3ssea \nquando se utiliza a DXA e de baixo volume \u00f3sseo trabecular, porosidade, ou menor espessura \ncortical quando se utiliza a biopsia \u00f3ssea. O nosso estudo atribui pela primeira vez \u00e0 DXA \num papel no diagn\u00f3stico de porosidade cortical nos doentes em di\u00e1lise. A utilidade da avalia\u00e7\u00e3o \ndiferencial da densidade mineral \u00f3ssea cortical e trabecular necessita de ser confi rmada em \nestudos prospetivos. \u00c9 necess\u00e1rio avaliar se a baixa densidade mineral \u00f3ssea femoral avaliada \nem doentes renais cr\u00f3nicos, que no nosso estudo se associou \u00e0 porosidade cortical, se associa \na maior risco de fraturas nesta popula\u00e7\u00e3o.\n\nRELA\u00c7\u00c3O ENTRE DENSIDADE MINERAL \u00d3SSEA E CALCIFICA\u00c7\u00d5ES VASCULARES\n\nA associa\u00e7\u00e3o entre baixa densidade mineral \u00f3ssea e calcifi ca\u00e7\u00f5es vasculares j\u00e1 foi \ndemonstrada em in\u00fameros estudos na popula\u00e7\u00e3o geral19 -22. Os mecanismos respons\u00e1veis por \nesta associa\u00e7\u00e3o n\u00e3o est\u00e3o bem esclarecidos, podendo ser explicados por um fator comum ou \npor uma rela\u00e7\u00e3o causal entre a doen\u00e7a \u00f3ssea e a doen\u00e7a vascular. A dislipidemia pode contribuir \nsimultaneamente para a forma\u00e7\u00e3o de placas ateroscler\u00f3ticas e para a osteoporose23. J\u00e1 foi \ndemonstrado in vitro que os produtos de oxida\u00e7\u00e3o dos l\u00edpidos s\u00e3o capazes de promover uma \ndiferencia\u00e7\u00e3o osteog\u00e9nica de c\u00e9lulas musculares lisas humanas24 mas tamb\u00e9m t\u00eam um efeito \ninibit\u00f3rio na diferencia\u00e7\u00e3o de pr\u00e9 -osteoblastos25. Esta dupla a\u00e7\u00e3o da dislipidemia poderia \nexplicar a associa\u00e7\u00e3o, inicialmente considerada paradoxal, entre calcifi ca\u00e7\u00f5es arteriais e \nosteoporose. Contradizendo estes achados in vitro, o estudo observacional PERF26, que avaliou \n1176 mulheres dos 60 aos 85 anos, demonstrou a exist\u00eancia de uma associa\u00e7\u00e3o entre doen\u00e7a \narterial perif\u00e9rica e osteoporose, mas n\u00e3o conseguiu evidenciar uma rela\u00e7\u00e3o independente \nentre a dislipidemia e as altera\u00e7\u00f5es da densidade mineral \u00f3ssea. Uma das hip\u00f3teses destes \nautores \u00e9 a de que a dislipidemia n\u00e3o tem um efeito modulador direto mas indireto na densidade \nmineral \u00f3ssea, atrav\u00e9s das les\u00f5es que provoca nos vasos nutritivos do osso.\n\n\n\n102\n\nA associa\u00e7\u00e3o entre densidade mineral \u00f3ssea e calcifi ca\u00e7\u00f5es vasculares, amplamente \nestudada nos indiv\u00edduos idosos da popula\u00e7\u00e3o geral, tem sido pouco investigada nos doentes \nem di\u00e1lise. O grupo de trabalho de imagiologia das KDIGO, International Controversies \nConference em 200627 prop\u00f4s o estudo da rela\u00e7\u00e3o entre densidade mineral \u00f3ssea e calcifi ca\u00e7\u00f5es \nvasculares nos doentes em di\u00e1lise. At\u00e9 ao momento, poucos estudos tinham avaliado esta \nassocia\u00e7\u00e3o. Taal et al mostraram que a osteoporose e a osteopenia, num grupo de 88 doentes \nem di\u00e1lise, se associaram a maior mortalidade28. Braun et al mostraram a exist\u00eancia de uma \nrela\u00e7\u00e3o inversa entre calcifica\u00e7\u00f5es card\u00edacas e massa \u00f3ssea avaliadas por tomografia \ncomputorizada de feixes de eletr\u00f5es29. Num grupo de 110 doentes em di\u00e1lise, Raggi P et al30 \ndemonstraram a exist\u00eancia de uma rela\u00e7\u00e3o inversa entre a velocidade de onda de pulso \ncarotidofemoral e a densidade mineral \u00f3ssea vertebral avaliada por tomografi a computorizada \nquantitativa. N\u00e3o encontraram rela\u00e7\u00e3o entre a velocidade de onda de pulso e a densidade \nmineral \u00f3ssea avaliada por DXA na coluna lombar. Nos doentes sem calcifi ca\u00e7\u00f5es vasculares, \nverifi caram a exist\u00eancia de uma correla\u00e7\u00e3o entre os resultados obtidos por DXA e por tomografi a \ncomputorizada. Na presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares, esta correla\u00e7\u00e3o desaparecia, e a \nhip\u00f3tese apresentada por estes autores foi a de que a presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares na \naorta, muito prevalentes nos doentes em di\u00e1lise, falsearia os resultados da DXA. Num grupo \nde 70 doentes portugueses em di\u00e1lise peritoneal31, demonstramos a exist\u00eancia de uma associa\u00e7\u00e3o \n\nDensidade Mineral \u00d3ssea no Colo do F\u00e9mur\n\nFig. 7.1. A velocidade de onda de pulso (VOP) \ncorrelacionou -se inversamente com a densidade \nmineral \u00f3ssea avaliada no colo do f\u00e9mur\n\nFig. 7.2. Um score de calcifi ca\u00e7\u00e3o vascular simples \n(SCVS) > 3 associou -se a menor densidade mineral \n\u00f3ssea avaliada no colo do f\u00e9mur, em compara\u00e7\u00e3o com \num SCVS<3 (teste T de Student)\n\n\n\n103\n\ninversa entre a densidade mineral \u00f3ssea avaliada por DXA no colo do f\u00e9mur e a velocidade \nde onda de pulso carotidofemoral avaliada atrav\u00e9s do Complior (Artech Medical, Pantin, \nFrance) (Fig.7.1), com calcifi ca\u00e7\u00f5es vasculares avaliadas pelo score simples de calcifi ca\u00e7\u00e3o \n(Fig 7.2) e com a presen\u00e7a de doen\u00e7a coron\u00e1ria e doen\u00e7a arterial perif\u00e9rica (Fig.7.3).\n\nEstas correla\u00e7\u00f5es n\u00e3o se verifi caram com a densidade mineral \u00f3ssea avaliada na coluna \nlombar. Em an\u00e1lise multivariada confi rmou -se a associa\u00e7\u00e3o independente e inversa entre a \ndensidade mineral \u00f3ssea avaliada no colo do f\u00e9mur e a velocidade de onda de pulso, com um \nSCVS >3 e com a presen\u00e7a de doen\u00e7a arterial perif\u00e9rica31. Verifi camos que os doentes com \ncalcifi ca\u00e7\u00f5es vasculares apresentavam um T -score lombar superior quando comparados com \nos doentes sem calcifi ca\u00e7\u00f5es vasculares, enquanto o T -score femoral era semelhante nos \ndoentes com e sem calcifi ca\u00e7\u00f5es vasculares. Este dado sugere que as calcifi ca\u00e7\u00f5es vasculares \ncontribuem para os valores mais elevados do T -score lombar e est\u00e1 de acordo com os achados \nde Raggi et al30. O nosso estudo foi o primeiro a demonstrar, numa popula\u00e7\u00e3o de doentes no \nestadio 5D, uma associa\u00e7\u00e3o independente e inversa entre a densidade mineral \u00f3ssea e as \ncalcifi ca\u00e7\u00f5es vasculares avaliadas por RX simples e com doen\u00e7a arterial perif\u00e9rica. Em \nconclus\u00e3o, demonstramos com este estudo a exist\u00eancia de uma associa\u00e7\u00e3o entre valores mais \nbaixos de densidade mineral \u00f3ssea femoral e calcifi ca\u00e7\u00f5es vasculares avaliadas por RX \nsimples, com rigidez arterial e com doen\u00e7a arterial perif\u00e9rica. Os mecanismos para esta \nassocia\u00e7\u00e3o n\u00e3o est\u00e3o ainda identifi cados, mas estes dados refor\u00e7am a hip\u00f3tese da exist\u00eancia \nde um elo de liga\u00e7\u00e3o entre a doen\u00e7a \u00f3ssea e a doen\u00e7a vascular nos doentes em di\u00e1lise.\n\nDensidade Mineral \u00d3ssea no Colo do F\u00e9mur\n\nFig.7.3. Associa\u00e7\u00e3o inversa entre a densidade mineral \u00f3ssea avaliada no colo do f\u00e9mur e a presen\u00e7a de doen\u00e7a \ncoron\u00e1ria (CAD+) e doen\u00e7a arterial perif\u00e9rica (DAP+) (teste T de Student)\n\n\n\n104\n\nRefer\u00eancias\n\n  1. Malluche HH, Mawad H, Monier -Faugere MC. The importance of bone health in end -stage renal \ndisease: out of the frying pan, into the fi re? Nephrol Dial Transplant 2004;19 Suppl (1):i9 -i13.\n\n  2. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end -stage renal failure -an \nevolving disorder. Kidney Int 1993;43(2):436 -442.\n\n  3. Pei Y, Hercz G, Greenwood C, et al. Risk factors for renal osteodystrophy: a multivariant analysis. \nJ Bone Miner Res 1995;10(1):149 -156.\n\n  4. Ferreira A, Fraz\u00e3o JM, Monier -Faugere MC, et al. Sevelamer study group effects of sevelamer \nhydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc \nNephrol 2008;19(2):405 -412.\n\n  5. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2964.\n  6. Moe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation of \n\nrenal osteodystrophy: A position statement from kidney disease: improving global outcomes \n(KDIGO). Kidney Int 2006; 69: 1945 -1953.\n\n  7. London GM, Marty C, Marchais SJ, et al. Arterial calcifi cations and bone histomorphometry in \nend -stage renal disease. J Am Soc Nephrol 2004; 15: 1943 -1951.\n\n  8. Raggi P, James G, Burke SK, et al. Decrease in thoracic vertebral bone attenuation with calcium-\n-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20(5):764 -772.\n\n  9. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Dias Curto J, \nMalluche HH. Low bone volume \u2013 A risk factor for coronary calcifi cations in hemodialysis patients. \nClin J Am Soc Nephrol 2009; 4(2): 450 -455.\n\n10. London GM. Bone -vascular axis in chronic kidney disease: A reality? Clin J Am Soc Nephrol \n2009; 4: 254 -257.\n\n11. London GM, Marchais SJ, Gu\u00e9rin AP, et al. Association of bone activity, calcium load, aortic \nstiffness, and calcifi cations in ESRD. J Am Soc Nephrol 2008; 19: 1827 -1835.\n\n12. Barreto DV, Barreto FC, Carvalho AB, et al. Association of changes in bone remodelling and coronary \ncalcifi cation in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 52(6):1139 -1150.\n\n13. Adrag\u00e3o T, Ferreira A, Fraz\u00e3o J, et al. Bone mineral density, bone histomorphometric analysis \nand vascular calcifi cations in hemodialysis patients. Nephrol Dial Transplant 2007; 22 (Suppl 6): \nvi 172 -vi 173. [Abstract FP456.]\n\n14. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Malluche HH. \nFemoral bone mineral density reflects histologically determined cortical bone volume in \nhemodialysis patients. Osteoporos Int 2010; 21(4):619 -625.\n\n15. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, Zoccali \nC, London GM, Vanholder R. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) \nChronic Kidney Disease -Mineral and Bone Disorder (CKD -MBD). Guidelines: a European Renal Best \nPractice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 9. [Epub ahead of print.]\n\n\n\n105\n\n16. Miller MA, Chin J, Miller SC, Fox J. Disparate effects of mild, moderate, and severe secondary \nhyperparathyroidism on cancellous and cortical bone in rats with chronic renal insuffi ciency. Bone \n1998;23(3): 257 -266.\n\n17. Yunbo D, Luca V, Seeman E. Parathyroid hormone defi ciency and excess: similar effects on trabecular \nbone but differing effects on cortical bone. J Clin Endocrinol Metab 1999; 84(2): 718 -722.\n\n18. Ostertag A, Cohen -Solal M, Audran M, et al. Vertebral fractures are associated with increased cortical \nporosity in iliac crest bone biopsy of men with idiopathic osteoporosis. Bone 2009; 44: 413-417.\n\n19. Hak AE, Pols HA, van Hemert AM, et al. Progression of aortic calcifi cation is associated with \nmetacarpal bone loss during menopause: a population -based longitudinal study. Arterioscler \nThromb Vasc Biol 2000; 20(8):1926 -1931.\n\n20. Kiel DP, Kauppila LI, Cupples LA, et al. Bone loss and the progression of abdominal aortic calcifi cation \nover a 25 year period: the Framingham heart study. Calcif Tissue Int 2001; 68(5):271 -276.\n\n21. Schulz E, Arfai K, Liu X, et al. Aortic calcifi cation and the risk of osteoporosis and fratures. J \nClin Endocrinol Metab 2004; 89(9): 4246 -4253.\n\n22. Tanko LB, Christiansen C, Cox DA et al. Relationship between osteoporosis and cardiovascular \ndisease in postmenopausal women. J Bone Miner Res 2005; 20(11):1912 -1920.\n\n23. Parhami F, Garfi nkel A, Demer LL. Role of lipids in osteoporosis. Arterioscl Thromb Vasc Biol \n2000; 20: 2346 -2348.\n\n24. Proudfoot D, Davies JD, Skepper JN, et al. Acetylated low density lipoprotein stimulates human \nvascular smooth muscle cell calcifi cation by promoting osteoblastic differentiation and inhibiting \nphagocytosis. Circulation 2002; 106: 3044 -3050.\n\n25. Parhami F, Morow ADS, Ballucan J, et al. Lipid oxidation products have opposite effects on \ncalcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of \narterial calcifi cation in osteoporotic patients. Arterioscl Thromb Vasc Biol 1997; 17 (4): 680 -687.\n\n26. Bagger YZ, Rasmussen HB, Alexandersen P, et al. The PERF study group links between \ncardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis \nper se? Osteoporos Int 2007; 18: 505 -512.\n\n27. Moe S, Drueke T, Cunningham J, et al. Defi nition, evaluation, and classifi cation of renal \nosteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). \nKidney Int 2006; 69: 1945 -1953.\n\n28. Taal MW, Roe S, Masud T, Green D, et al. Total hip bone mass predicts survival in chronic \nhemodialysis patients. Kidney Int 2003; 63(3):1116 -1120.\n\n29. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation \nof cardiac calcifi cation in chronic dialysis patients. Am J Kidney Dis 1996; 27:394 -401.\n\n30. Raggi P, Bellasi A, Ferramosca E, et al. Pulse wave velocity is inversely related to vertebral bone \ndensity in hemodialysis patients. Hypertension 2007; 49:1278 -1284.\n\n31. Adrag\u00e3o T, Branco P, Birne R, Curto JD, Almeida E, Prata MM, Pais MJ. Bone mineral density, vascular \ncalcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; 28 (6): 668 -672.\n\n\n\n\n\n668\n\nSHORT REPORTS NOVEMBER 2008 \u2013 VOL. 28, NO. 6 PDI\n\nlation in medulla of cats. Neurosci Res 1998; 30:287\u201393.\n6. Porzio G, Aielli F, Narducci F, Varrassi G, Ricevuto E,\n\nFicorella C, et al. Hiccup in patients with advanced cancer\nsuccessfully treated with gabapentin: report of three\ncases. N Z Med J 2003; 116(1182):U605.\n\n7. Petroianu G, Hein G, Stegmeier-Petroianu A, Bergler W,\nRufer R. Gabapentin \u201cadd-on therapy\u201d for idiopathic\nchronic hiccup (ICH). J Clin Gastroenterol 2000; 30:321\u20134.\n\n8. Hernandez JL, Pajaron M, Garcia-Regata O, Jimenez V,\nGonzalez-Macias J, Ramos-Estebanez C. Gabapentin for\nintractable hiccup. Am J Med 2004; 117:279\u201381.\n\n9. Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker\nH. Gabapentin therapy for pruritis in haemodialysis pa-\ntients: a randomized, placebo-controlled, double-blind\ntrial. Nephrol Dial Transplant 2004; 19:3137\u20139.\n\n10. Molnar MZ, Novak M, Mucsi I. Management of restless leg\nsyndrome in patients on dialysis. Drugs 2006; 66:607\u201324.\n\nBone Mineral Density, Vascular\nCalcifications, and Arterial Stiffness in\n\nPeritoneal Dialysis Patients\n\nThe objective of this study was to evaluate the correla-\ntion of bone mineral density (BMD), evaluated by DXA, with\nvascular calcifications, arterial stiffness, and vascular dis-\nease in patients on peritoneal dialysis. Vascular calcifica-\ntions were evaluated by vascular calcification score on plain\nx ray, and arterial stiffness was measured by pulse wave\nvelocity using the Complior device (Artech Medical, Pantin,\nFrance). Adjusting for multiple factors, lower BMD at the\nfemoral neck, but not at the lumbar spine, was associated\nwith higher pulse wave velocity (p = 0.037), higher vascu-\nlar calcification score (p = 0.013), and peripheral artery\ndisease (p = 0.006). These data reinforce the hypothesis of\nthe existence of a link between bone disease and cardio-\nvascular disease in dialysis patients.\n\nPerit Dial Int 2008; 28:668\u2013672 www.PDIConnect.com\n\nKEY WORDS: Bone mineral density; vascular calcif ica-\ntions; arterial stif fness.\n\nIn dialysis patients there is increasing evidence of theexistence of a link between bone disease and cardio-\nvascular disease. Low bone mineral density (BMD) in the\ngeneral population is associated with atherosclerotic\ncalcifications (1). The relationship between BMD values\nand vascular calcif ications is one of the issues recom-\nmended for clinical research by the imaging work group\nof the KDIGO International Controversies Conference (2).\nThe objective of this study was to evaluate, in a group of\n\nbrain and cerebrospinal fluid of ESRF patients (3,4).\nGuanidine is a competitive gamma-amino butyric acid\n(GABA) receptor antagonist and may counteract GABA\ninhibition of respiratory muscles (4). In this particular\ncase, gabapentin, a novel amino acid derived by the ad-\ndition of a cyclohexyl group to the chemical backbone of\nGABA, may have been effective in treating hiccups for\ntwo reasons: it increased endogenous GABA-mediated\ninhibition of inspiratory muscles (3,4), or it reduced cal-\ncium influx via inhibition of voltage-operated calcium\nchannels in presynaptic terminals of respiratory muscles.\nFurthermore, gabapentin also increases the levels of se-\nrotonin, an important neurotransmitter for the raphe\nmagnus nucleus in the medulla, the most likely source\nof GABAergic inhibitory inputs to the hiccup reflex arc\n(5). Indeed, there are several reports of gabapentin\nbeing used for the treatment of intractable hiccups in\nthe setting of cancer or gastrointestinal disorders, but\nnot in ESRF (6\u20138).\n\nDizziness, somnolence, and peripheral edema are the\nmost frequent side effects of gabapentin. However, in\ntrials where gabapentin was used for treating hiccups\n(6\u20138), no side effects were reported. Gabapentin is also\nadvantageous in that it is effective for restless leg syn-\ndrome, neuropathic pain, and pruritis in patients with\nrenal failure (9,10). Thus, gabapentin may be useful for\nESRF patients with intractable idiopathic hiccups.\n\nAndrew M.L. Ong*\nChieh Suai Tan\n\nMarjorie W.Y. Foo\nTerence Y.S. Kee\n\nRenal Medicine\nSingapore General Hospital\n\nSingapore\n\n*e-mail: andrew.mingliang@gmail.com\n\nREFERENCES\n\n1. Alonso-Navarro H, Rubio L, Jimenez-Jimenez FJ. Refrac-\ntory hiccups: successful treatment with gabapentin. Clin\nNeuropharmacol 2007; 30:186\u20137.\n\n2. Hansen BJ, Rosenberg J. Persistent postoperative hic-\ncups: a review. Acta Anaesthesiol Scand 1993; 37:643\u20136.\n\n3. Fraser CL, Arieff AI. Nervous system complications in ure-\nmia. Ann Intern Med 1988; 109:143\u201353.\n\n4. De Deyn PP, D\u2019Hooge R, Van Bogaert PP, Marescau B. En-\ndogenous guanidino compounds as uremic neurotoxins.\nKidney Int Suppl 2001; 78:S77\u201383.\n\n5. Oshima T, Sakamoto M, Tatsuta H, Arita H. GABAergic in-\nhibition of hiccup-like reflex induced by electrical stimu-\n\n\n\n669\n\nPDI NOVEMBER 2008 \u2013 VOL. 28, NO. 6 SHORT REPORTS\n\nperitoneal dialysis patients, the relationship of BMD with\nvascular calcifications, pulse pressure, pulse wave veloc-\nity (PWV), and cardiovascular disease.\n\nPATIENTS\n\nThis study was a cross-sectional analysis of a cohort\nof per it oneal dialy sis patients. Seventy patients\n(37 males, 33 females) without previous parathyroidec-\ntomy were evaluated after signing an informed consent\nform. Mean age was 52 \u00b1 14 years and mean dialysis du-\nration was 46 \u00b1 28 months; 17 patients were diabetic.\nDuring the 6 months preceding BMD evaluation, 29 and\n33 patients were treated, respectively, with calcium car-\nbonate (1.2 \u00b1 0.45 g/day) and calcitriol (1.6 \u00b1 1.2 ?g/\nweek). During this period, dialysate calcium concentra-\ntions of 1.25 and 1.75 mmol/L were used, respectively,\nin 40 and 30 patients. No patient had been previously\ntreated with bisphosphonates or cinacalcet. Coronary\nartery disease, peripheral artery disease (PAD), and ce-\nrebral vascular disease were diagnosed, respectively, in\n20, 18, and 8 patients, based on clinical manifestations\nand diagnostic tests.\n\nMETHODS\n\nBone mineral density was evaluated by dual-energy\nx-ray absorptiometry (DXA) using the Hologic QDR Dis-\ncovery scanner (Hologic, Bedford, Massachusetts, USA)\nin the lumbar spine and the femoral neck, using NHANES\nIII as the database reference (3). DXA parameters are\nnot standardized for dialysis patients and we used the\nWHO cutoff of a T-score > \u20131 SD, which def ines normal\nBMD. According to the Osteoporosis Work Group (4), a\nZ-score ? \u20131 SD, which is adjusted to age, could be more\nappropriate to diagnose low BMD in dialysis patients.\nDuring the first month af ter BMD evaluation, vascular\ncalcifications were evaluated on plain x rays of pelvis and\nhands using a method previously described (5), with the\nf inal score ranging from 0 to 8. Arterial stiffness was\nevaluated by pulse pressure (pulse pressure = systolic\nblood pressure \u2013 diastolic blood pressure) and by ca-\nrotid\u2013femoral PWV using a noninvasive automated de-\nvice (Complior; Artech Medical, Pantin, France). Serum\nlevels of the following biochemical parameters were\nevaluated ever y month and time averaged for the\n6 months preceding the DXA evaluation: calcium, phos-\nphorus, calcium\u2013phosphate product, albumin, alkaline\nphosphatase, and C-reactive protein. Total intact par-\nathyroid hormone was evaluated ever y 3 months by\nimmunochemiluminescence using a second-generation\nassay.\n\nStatistical Analysis: Data are presented as frequencies\nfor categorical variables and as mean values with SD for\ncontinuous variables. Univariate analysis was performed\nby independent samples t-test, chi-square, Fisher\u2019s exact\ntest, paired-samples t-tests, and Pearson correlation\ncoeff icient. The association of DXA parameters with car-\ndiovascular factors was evaluated by linear and logistic\nregression models adjusting for age, gender, diabetes,\nand body mass index. Absence of colinearity was checked\nin all models. Vascular calcif ication score (VCS) was\nevaluated as a categorical dependent variable (VCS ? 3)\nbased on our previous studies showing an association\nbetween VCS ? 3 and higher cardiovascular mortality (5).\nStatistical analyses were performed using the SPSS sys-\ntem 14.0 (SPSS Inc., Chicago, Illinois, USA). A p value&lt;\n0.05 was considered statistically signif icant.\n\nRESULTS\n\nVascular calcif ications were present in 43 patients. A\nT-score ? \u20131 SD was obser ved at the lumbar spine in\n39 patients and at the femoral neck in 43 patients. A\nZ-score ? \u20131 SD was present at the lumbar spine in 21 pa-\ntients and at the femoral neck in 24 patients.\n\nIn univariate analysis, lower femoral T-score (Table 1)\nwas associated with higher pulse pressure, higher PWV,\nhigher prevalence of vascular calcification, and higher\nprevalence of PAD. Lower femoral BMD was associated\nwith higher VCS and higher PWV (Figure 1). Lower femo-\nral BMD was also associated with presence of coronary\nartery disease (0.66 \u00b1 0.15 vs 0.74 \u00b1 0.13 g/cm2, p = 0.03)\nand PAD (0.64 \u00b1 0.14 vs 0.75 \u00b1 0.13 g/cm2, p = 0.006)\n(Figure 1). Patients with vascular calcif ications had a\nhigher lumbar T-score than patients without calcifica-\ntions (\u20131.1 \u00b1 1.5 vs \u20131.7 \u00b1 1.6 SD, p = 0.02). In multi-\nvariate analysis, BMD evaluated at the femoral neck was\nnegatively associated with VCS ? 3, PAD (Table 2), and\nPWV (Table 3), adjusting for age, gender, diabetes, and\nbody mass index. In similar models, a lower femoral\nZ-score, but not T-score, was associated with VCS ? 3\n[odds ratio (OR) = 0.5, p = 0.030] and PAD (OR = 0.44,\np = 0.016).\n\nDISCUSSION\n\nIn this group of peritoneal dialysis patients, we have\nverified that low BMD at the femoral neck, but not at the\nlumbar spine, is independently associated with VCS on\nplain x ray and with arterial stif fness. The association of\nlower bone mineral mass or density with vascular calci-\nf ications or PWV has already been demonstrated in\nnonrenal and dialysis patients (1,6,7) but, for the first\n\n\n\n670\n\nSHORT REPORTS NOVEMBER 2008 \u2013 VOL. 28, NO. 6 PDI\n\nTABLE 1\nCardiovascular Characteristics According to T-Score\n\nAll patients  T-score in lumbar spine T-score in femoral neck\n(n=70)  > \u20131 SD (n=31)  ? \u20131 SD (n=39)  > \u20131 SD (n=27)  ? \u20131 SD (n=43)\n\nPP (mmHg) 57.9\u00b116.8 55.8\u00b114.4 59.5\u00b118.5 52.8\u00b113.2 61.0\u00b118.2a\n\nPWV (m/s) 7.8\u00b11.6 7.6\u00b11.6 8.1\u00b11.6 7.4\u00b11.5 8.2\u00b11.6a\n\nVCS?3 29 (41%) 12 (39%) 17 (44%) 7 (26%) 22 (51%)b\nPAD 18 (26%) 5 (16%) 13 (3%) 2 (7%) 16 (37%)c\n\nPP = pulse pressure; PWV = pulse wave velocity; VCS = vascular calcification score; PAD = peripheral artery disease; SD = standard\ndeviation.\na p &lt;0.05: comparison between groups by t-test.\nb p &lt;0.05: comparison between groups by chi-square.\nc p &lt;0.01: comparison between groups by Fisher\u2019s exact test.\n\nFigure 1 \u2014 Lower bone mineral density (BMD) at femoral neck is associated with higher pulse wave velocity, with more calcifica-\ntions, and with peripheral artery disease (PAD).\n\ntime, an association between low BMD and plain x-ray\nvascular calcif ications and vascular disease is shown in\ndialysis patients. Evaluation of vascular calcif ications is\nnow required to classify the mineral and bone disorder\nseen in chronic kidney disease (2), and plain x ray may\nbe a simple and inexpensive method to do so. One ex-\nplanation for the association of lower BMD with PWV or\nvascular disease is their common relationship with vas-\ncular calcifications (6,8). The absence of association be-\ntween lumbar BMD and ar ter ial stif fness or vascular\ncalcifications present in our study has already been de-\nscribed in dialysis patients (7) and may be explained by\nthe presence of vascular calcifications in the aorta pos-\nsibly contributing to a higher BMD value (7). This can\nalso explain why, in our study, patients with calcifica-\ntions had a higher lumbar T-score compared with patients\nwithout calcifications. The pathogenesis of the associa-\n\ntion between low BMD parameters and vascular calcif i-\ncations is not known yet and might be explained by a\ncommon etiologic factor. Both hyperparathyroidism and\nadynamic bone disease may be associated with low bone\nvolume (9) and may also be associated with hyperphos-\nphatemia and hypercalcemia, which are inducers of vas-\ncular calcifications (10). Low bone turnover has also been\nassociated with vascular calcif ications (11). This study\npresents, however, some limitations: Vascular score has\nthe advantage of simplicity and low cost but it is a\nsemiquantitative evaluation, and the cross-sectional\nanalysis allows only identif ication of associations be-\ntween the variables.\n\nIn conclusion, in this group of patients, lower values\nof bone mineral density, evaluated by DXA, at the femo-\nral neck but not at the lumbar spine were associated with\nmore calcif ications, arter ial stif fness, and peripheral\n\n\n\n671\n\nPDI NOVEMBER 2008 \u2013 VOL. 28, NO. 6 SHORT REPORTS\n\nartery disease. The mechanisms for this association are\nnot yet identif ied but these findings reinforce the hy-\npothesis of the existence of a link between bone disease\nand vascular disease in dialysis patients.\n\nTeresa Adragao1*\nPatr\u00edcia Branco2\n\nRita Birne1\n\nJos\u00e9 Dias Curto3\n\nEdgar de Almeida2\n\nMateus Martins Prata2\n\nMaria Joao Pais1\n\nNephrology Department1\n\nSanta Cruz Hospital, Carnaxide\nNephrology Department2\n\nSanta Maria Hospital\nISCTE Business School3\n\nLisbon, Portugal\n\n*e-mail: tadragao@netcabo.pt\n\nTABLE 3\nFactors Associated with Pulse Wave Velocity (PWV)\n\nDependent variable Independent variable B 95% CI p Value R 2\n\nPWVa 0.58\nAge 0.07 0.05 to 0.09&lt;0.001\nSBP 0.02 0.00 to 0.03 0.020\nCa\u00d7P 0.03 0.00 to 0.05 0.028\nBMD (femoral neck) \u20132.52 \u20134.87 to \u20130.16 0.037\n\nSBP = systolic blood pressure; Ca\u00d7P = calcium\u2013phosphate product; BMD = bone mineral density; CI = confidence interval.\na Adjusted for gender, diabetes, and body mass index.\n\nREFERENCES\n\n1. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O\u2019Donnel CJ,\nWilson PW, et al. Bone loss and the progression of abdomi-\nnal aortic calcification over a 25 year period: the Framing-\nham Heart Study. Calcif Tissue Int 2001; 68:271\u20136.\n\n2. Moe S, Drueke T, Cunningham J, Goodman W, Martin K,\nOlgaard K, et al. Definition, evaluation, and classification\nof renal osteodystrophy: a position statement from Kid-\nney Disease: Improving Global Outcomes (KDIGO). Kidney\nInt 2006; 69:1945\u201353.\n\n3. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY,\nBorgstrom F, et al. European guidance for the diagnosis\nand management of osteoporosis in postmenopausal\nwomen [Published erratum appears in Osteoporos Int\n2008; 19:1103\u20134]. Osteoporos Int 2008; 19:399\u2013428.\n\n4. Cunningham J, Sprague SM, Cannata-Andia J, Coco M,\nCohen-Solal M, Fitzpatrick L, et al. Osteoporosis Work\nGroup. Osteoporosis in chronic kidney disease. Am J Kid-\nney Dis 2004; 43:566\u201371.\n\n5. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L,\nGon\u00e7alves M, et al. A simple vascular calcification score\npredicts cardiovascular risk in haemodialysis patients.\n\nTABLE 2\nFactors Associated with Vascular Calcifications and Peripheral Artery Disease (PAD)\n\nDependent variable Independent variable B OR 95% CI p Value R 2\n\nVCS?3a 0.45\nAge 0.11 1.12 1.05 to 1.20 0.001\nDiabetes 2.58 13.13 1.96 to 87.73 0.008\nPhosphorus 0.76 2.13 1.16 to 3.93 0.015\nBMD (femoral neck) \u20138.83 0.00 0.00 to 0.15 0.013\n\nPADb 0.29\nDiabetes 2.11 8.24 1.65 to 41.14 0.010\nPhosphorus 0.74 2.09 1.07 to 4.10 0.031\nBMD (femoral neck) \u20138.82 0.00 0.00 to 0.08 0.006\n\nVCS = vascular calcification score; BMD = bone mineral density; OR = odds ratio; CI = confidence interval.\na Adjusted for gender and body mass index.\nb Adjusted for age, gender, and body mass index.\n\n\n\n672\n\nSHORT REPORTS NOVEMBER 2008 \u2013 VOL. 28, NO. 6 PDI\n\nNephrol Dial Transplant 2004; 19:1480\u20138.\n6. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E,\n\nLuft FC. Electron beam computed tomography in the evalu-\nation of cardiac calcification in chronic dialysis patients.\nAm J Kidney Dis 1996; 27:394\u2013401.\n\n7. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P.\nPulse wave velocity is inversely related to vertebral bone\ndensity in hemodialysis patients. Hypertension 2007; 49:\n1278\u201384.\n\n8. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial\nstiffening and vascular calcifications in end-stage renal\n\ndisease. Nephrol Dial Transplant 2000; 15:1014\u201321\n9. Malluche HH, Monier-Faugere MC. Renal osteodystrophy:\n\nwhat\u2019s in a name? Presentation of a clinically useful new\nmodel to interpret bone histologic findings. Clin Nephrol\n2006; 65:235\u201342.\n\n10. Giachelli CM. Vascular calcification mechanisms. J Am Soc\nNephrol 2004; 15:2959\u201364.\n\n11. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F,\nde Vernejoul MC. Ar ter ial calcif ications and bone\nhistomorphometry in end-stage renal disease. J Am Soc\nNephrol 2004; 15:1943\u201351.\n\n\n\n\n\nORIGINAL ARTICLE\n\nFemoral bone mineral density reflects histologically\ndetermined cortical bone volume in hemodialysis patients\n\nT. Adragao &amp; J. Herberth &amp; M.-C. Monier-Faugere &amp; A. J. Branscum &amp; A. Ferreira &amp;\nJ. M. Frazao &amp; H. H. Malluche\n\nReceived: 6 January 2009 /Accepted: 22 May 2009\n# International Osteoporosis Foundation and National Osteoporosis Foundation 2009\n\nAbstract\nSummary We evaluated the associations between dual\nenergy X-ray absorptiometry (DXA) and histologically\ndetermined cancellous and cortical bone volume by control-\nling for vascular calcifications and demographic variables in\nhemodialysis (HD) patients. Femoral bone mineral density\n(f-BMD) was associated with cortical porosity.\nIntroduction Assessment of bone mass in chronic kidney\ndisease patients is of clinical importance because of the\nassociation between low bone volume, fractures, and vascular\n\ncalcifications. DXA is used for noninvasive assessment of\nbone mass whereby vertebral results reflect mainly cancellous\nbone and femoral results reflect mainly cortical bone. Bone\nhistology allows direct measurements of cancellous and\ncortical bone volume. The present study evaluates the\nassociation between DXA and histologically determined\ncancellous and cortical bone volumes in HD patients.\nMethods In 38 HD patients, DXA was performed for\nassessment of bone mass, anterior iliac crest bone biopsies\nfor bone volume, and multislice computed tomography for\nvascular calcifications.\nResults While lumbar bone mineral density (l-BMD) by DXA\nwas not associated with histologically measured cancellous\nbone volume, coronary Agatson score showed a borderline\nstatistically significant association (P=0.055). When controlled\nfor age and dialysis duration, f-BMD by DXA was associated\nwith cortical porosity determined by histology (P=0.005).\nConclusions The usefulness of l-BMD for predicting bone\nvolume is limited most probably because of interference by\nsoft tissue calcifications. In contrast, f-BMD shows signif-\nicant association with cortical porosity.\n\nKeywords Bone biopsy. Bone mineral density.\n\nBone volume . Chronic kidney disease . Cortical porosity.\n\nVascular calcifications\n\nIntroduction\n\nLow bone mass is a common complication of chronic\nkidney disease (CKD), and the most prominent clinical\ncomplications of low bone mass are fractures. Compared to\nthe general population, the incidence of fractures was\nreported to be 3.6\u20139.8 times higher for stage 5 CKD\npatients on dialysis (CKD-5 patients) [1]. In the Dialysis\n\nOsteoporos Int\nDOI 10.1007/s00198-009-0988-9\n\nT. Adragao\nNephrology Department, Santa Cruz Hospital,\nLisbon, Portugal\n\nJ. Herberth : M.-C. Monier-Faugere : H. H. Malluche\nDivision of Nephrology, Bone and Mineral Metabolism,\nUniversity of Kentucky,\nLexington, KY, USA\n\nA. J. Branscum\nDepartments of Biostatistics, Statistics, and Epidemiology,\nUniversity of Kentucky,\nLexington, KY, USA\n\nA. Ferreira\nNephrology Department, Curry Cabral Hospital,\nLisbon, Portugal\n\nJ. M. Frazao\nNephrology Department, Hospital de S. Jo\u00e3o, Medical School and\nNephrology Research and Development Unit, University of Porto,\nPorto, Portugal\n\nH. H. Malluche (*)\nDivision of Nephrology, Bone &amp; Mineral Metabolism,\nUK Medical Center,\nRoom MN 564, 800 Rose Street,\nLexington 40536-0084 KY, USA\ne-mail: hhmall@uky.edu\n\n\n\nOutcomes and Practice Patterns Study, the authors found a 7%\nincreased risk of hip fracture per year of dialysis treatment [2].\nMost recently, low bone mass has also been shown to be\nassociated with increased cardiovascular calcifications in\nnon-CKD and CKD patients [3, 4]. In light of the high\nmortality associated with fractures and cardiovascular disease\nin CKD [5, 6], noninvasive methods for assessing bone mass\nin this patient population is of great clinical importance.\n\nDual energy X-ray absorptiometry (DXA) is the most\nwidely used tool for assessment of bone mass in the general\npopulation [7, 8]. However, DXA measures not only the\nmineral content of bone but also of the surrounding soft\ntissue [9, 10] limiting the interpretation of results [11].\nCKD-5 patients represent a unique population particularly\nprone to developing soft tissue and vascular calcifications\n[12, 13]. Therefore, overestimation of bone mineral density\n(BMD) by anterioposterior (AP) lumbar DXA represents a\ngreat problem in these patients; this limitation should be\nless pronounced but not excluded in femoral DXA\nmeasurements [14]. Overall, studies evaluating the role of\nBMD determination by DXA for assessment of fracture risk\nin CKD-5 patients report conflicting results [15\u201318].\n\nIn order to guide appropriate therapeutic interventions,\ncharacterization of the relationship between DXA measure-\nments and histologically determined bone volume in CKD-5\npatients is desirable. In an early study, Lindergard and\ncolleagues could not find a correlation between BMD\nmeasured at the radius (consisting primarily of cortical bone)\nand histologically determined bone volume at the iliac crest of\nCKD-5 patients (cancellous bone) [19]. In contrast, a more\nrecent study in CKD-5 patients reported that hip and spine T-\nscores were associated with histologically determined bone\nvolume at the iliac crest [20]. In light of these conflicting\nresults, we evaluated the associations between BMD\nmeasured by DXA at the spine and femur and histologically\ndetermined bone volume in cancellous bone (bone volume/\ntissue volume) and in cortical bone (cortical width and\ncortical porosity) in CKD-5 patients. Moreover, vascular\ncalcifications were assessed by multislice computed tomog-\nraphy (MSCT) and adjusted for in statistical analyses.\n\nMaterials and methods\n\nStudy design\n\nThis study investigates the association between BMD\nmeasured by DXA at the hip and spine and histologically\ndetermined parameters of bone volume in cancellous and\ncortical bone in a cross-sectional study design. In addition,\nvascular calcifications were measured by multislice com-\nputed tomography at the thoracic aorta and the coronary\nand iliac arteries and were adjusted for in the analyses. The\n\nprotocol was approved by the Institutional Review Boards\nof participating institutions. The study has been conducted\nin adherence to the Declaration of Helsinki, and all patients\nprovided informed consent.\n\nPatients\n\nThirty-eight white stage 5 CKD patients on hemodialysis were\nrecruited from 11 medical centers in Portugal. All patients\nprovided informed consent for performing DXA measure-\nments, bone biopsies, and multislice computed tomography.\nDXA measurements were performed at time of bone biopsy\nand patients underwent multislice computed tomography on\naverage 3.8\u00b11.9 months after the bone biopsy.\n\nInclusion criteria These are age 18 years or older, dialysis\nduration of at least 3 months, mental competence, and\nwillingness to participate in the study.\n\nExclusion criteria These are kidney transplant; pregnancy;\nuncontrolled systemic illnesses or organic diseases with\npotential influence on bone metabolism such as diabetes\nmellitus, active or chronic liver disease, malabsorption,\nmalignancy, and thyroid dysfunction; history of or present\ntreatment with bisphosphonates, fluoride, calcitonin, gluco-\ncorticoids, or other immunosuppressive agents, hormone\nreplacement therapy, and selective estrogen receptor mod-\nulators; and chronic alcoholism and/or drug addiction.\n\nBone biopsies\n\nAnterior iliac crest bone biopsies were performed under\nlocal anesthesia and conscious sedation. Bone samples were\nobtained with the one-step electrical drill technique (Strau-\nmann Medical, Waldenburg, Switzerland). Bone samples\nwere processed undecalcified and cut avoiding cracks or\noverlaps of bone tissue. Sections were stained with the\nmodified Masson\u2013Goldner trichrome stain [21], the aurin\ntricarboxylic acid stain [22], and solochrome azurin [23],\nassessment of stainable aluminum, and modified Gomori\nstain for detection of iron [24]. Unstained sections were\nprepared for phase contrast and fluorescent light microsco-\npy. Histomorphometric analysis of bone was done at\nstandardized sites in cancellous (\u00d7200 magnification) and\ncortical bone (\u00d780 magnification) using the semi-automatic\nmethod (Osteoplan II, Kontron, Munich, Germany). For\ncancellous bone, the volume of bone trabecules (BV) and\ntotal tissue volume (TV) were traced and bone volume/total\nvolume (BV/TV) was calculated for assessment of miner-\nalized trabecular bone volume. For cortical bone, cortical\nwidth was measured; cortical porosity was determined by\ntracing the total cortex and all Haversian canals and\n\nOsteoporos Int\n\n\n\ncomputing the ratio between canal area over total cortical\ntissue area.\n\nResults were compared to our normative database\nconsisting of histomorphometric results of age- and gender-\nmatched healthy individuals [25, 26]. \u201cLow\u201d cancellous bone\nvolume was defined as BV/TV&lt;16.8%, \u201cnormal\u201d as BV/TV\nbetween 16.8% and 22.9%, and \u201chigh\u201d as BV/TV >22.9%.\nCortical width was considered \u201clow\u201d for values&lt;0.52 mm,\n\u201cnormal\u201d for values between 0.52 and 1.65 mm, and \u201chigh\u201d\nfor values >1.65 mm. Cortical porosity was classified \u201clow\u201d\nfor values&lt;1.9%, \u201cnormal\u201d for values between 1.9% and\n12%, and \u201chigh\u201d for values >12%. All bone samples were\nprocessed and analyzed without knowledge of the clinical\ndata at the Bone Diagnostic and Research Laboratory,\nUniversity of Kentucky, Lexington, KY, USA.\n\nBone mineral density\n\nDXA was performed by the same operator on the same\nHologic QDR Discovery scanner according to the manu-\nfacturer\u2019s recommendations for patient positioning, scan\nprotocols, and scan analysis. Measurements of the spine\nand hip were obtained from the AP projection. For AP\nlumbar spine, lumbar vertebrae 1 to 4 were measured and\nBMD results were analyzed for mean measurements of L1\u2013\nL4. For proximal femur scans, BMD was measured at the\nfemoral neck. The coefficients of variation for these BMD\nmeasurements are AP spine 1.2% and femur 0.9%.\n\nAssessment of vascular calcifications\n\nVascular calcifications were assessed at the thoracic aorta\nand coronary and iliac arteries by a quantitative score using\nMSCT. MSCT scans were performed on the model\nSomatom Volume Zoom (Siemens AG, Erlangen, Ger-\nmany). Slices of 2.5 mm thickness were acquired under the\nfollowing conditions: 120 kVp, 130 mAs, and 0.5 gantry\nrotation time. All images were transferred to a workstation\nand analyzed with calcium scoring software (HeartView\nCT, Siemens AG, Erlangen, Germany). Quantification of\nvascular calcifications was performed by calculating the\nAgatston score based on the maximum X-ray attenuation\ncoefficient (measured in Hounsfield units) [27].\n\nBiochemical measurements\n\nBlood was drawn at the time of the bone biopsy after an\novernight fast. The following biochemical parameters were\nmeasured: serum calcium and phosphorus by an autoan-\nalyzer (Hitachi 747, Globe Scientific Inc, USA), intact\nparathyroid hormone (iPTH) by DPC IMMULITE\u00ae PTH\nIRMA from Diagnostics Products Corporation (Los\nAngeles, CA, USA; normal range 16\u201387 pg/ml; intra- and\n\ninterassay coefficients of variation&lt;7% and&lt;9%), and 25-\n(OH)-vitamin D by LIAISON\u00ae 25-OH Vitamin D assay\n(Diasorin, Saluggia, Italy; normal range 25\u2013100 ng/ml;\nintra- and interassay coefficients of variation 4.1% and 7%).\n\nStatistical analysis\n\nDescriptive statistics are presented as means, medians,\nminimums, maximums, and standard deviations (SDs). The\nvariables iPTH and hemodialysis (HD) duration were log-\ntransformed for analysis. Boxplots were used to characterize\nthe distributions of BV/TV, cortical width, and cortical\nporosity. Bivariate associations were assessed using scatter\nplots, nonparametric Spearman rank correlations, locally\nweighted regression, and generalized additive models to\ncharacterize the associations between femoral/lumbar BMD\nand cortical porosity, cortical width, and BV/TV. Linear\nregression analyses were performed to evaluate possible\nrelationships while controlling for relevant measured corre-\nlates. All calculations were performed using the R statistical\npackage (R Foundation for Statistical Computing, Vienna,\nAustria) and SAS version 9.1 (SAS Institute Inc., Cary, NC,\nUSA).\n\nResults\n\nCharacteristics of the study population are presented in\nTable 1. All patients were receiving phosphate binder\ntherapy (58% sevelamer hydrochloride, 42% calcium\nacetate) and 19 patients (50%) were treated with active\nvitamin D analogs. None of the patients were treated with a\ncalcimimetic agent. There were no clinically symptomatic\nfractures prior and during the study.\n\nIn cancellous bone, BV/TV was low in 16%, normal in\n24%, and high in 60% patients. In cortical bone, cortical\nporosity was low in 3%, normal 40%, and high in 57%, and\ncortical width was low in 8%, normal 89%, and high in 3%.\nNone of the biopsies showed positive staining for alumi-\nnum or iron.\n\nDXA results are reported as \u201cmeasured bone mineral\ndensity\u201d (in grams per centimeter squared). The correlation\nbetween lumbar and femoral BMD measurements was r=\n0.49 (P=0.01).\n\nFemoral bone mineral density\n\nUnadjusted analysis of the association between femoral\nBMD and cortical porosity revealed a correlation coeffi-\ncient r=?0.20 (P=0.24). When adjusted for different\nAgatston score groups, no statistically significant effects\nof the different vascular calcifications sites were found. In\nthe final model, a forward predictor selection routine\n\nOsteoporos Int\n\n\n\nidentified femoral BMD (point estimate ?157.49; P=\n0.005), age >50 years (point estimate ?8.37; P=0.001),\nand HD duration (point estimate ?25.44; P=0.005) as being\nassociated with cortical porosity (Table 2). Further statisti-\ncal analysis recognized a statistically significant interaction\nbetween femoral BMD and HD duration (point estimate\n32.48; P=0.01): independent of age group, cortical porosity\nincreased as femoral BMD decreased, and this increase in\ncortical porosity was more rapid for patients with shorter\nHD duration (Fig. 1).\n\nUnadjusted correlation analysis of femoral BMD and\ncancellous bone volume (BV/TV) yielded r=?0.06 (P=\n0.73). While age, gender, and HD duration were not\npredictive of cancellous bone volume (BV/TV), the model\ncontaining femoral BMD and coronary Agatston score\n>100 revealed a statistically significant negative association\n(point estimate ?4.93; P=0.03); this association was,\nhowever, lost when the model was adjusted for age and\ngender.\n\nWhen examining a possible association between femoral\nBMD and cortical width, unadjusted (r=0.004; P=0.98)\nand adjusted analyses (models containing age, gender, HD\nduration, and vascular calcifications) did not yield any\nsignificant predictors.\n\nLumbar bone mineral density\n\nIn unadjusted analysis, the correlation between lumbar\nBMD and cancellous bone volume (BV/TV) was not\nstatistically significant (r=?0.1; P=0.53) and remained\nstatistically nonsignificant when the model was adjusted\nfor gender, age, and HD duration (P>0.05 for all variables).\nSimilar results were found for the correlations between\nlumbar DXA and cortical width/porosity (r=?0.09, P=\n0.60; r=?0.15, P=0.39, respectively) and adjusted models\n(gender, age, HD duration, all variables P>0.05).\n\nIn the next analytical step, the model was adjusted for\nAgatston scores measured at the thoracic aorta, coronary\nartery, or iliac artery. For this purpose, patients were\nclassified according to an Agatston score cutoff of 100\n(?100 versus >100). Regression modeling revealed that\n\nTable 2 Predictor variables of cortical porosity (from linear regression\nanalysis)\n\nEstimate Standard error P value\n\nfBMD ?157.49 52.36 0.005\nAge >50 years ?8.37 2.18 0.0005\nHD ?25.44 8.40 0.005\nfBMD/HD 32.48 12.09 0.01\n\nfBMD femoral bone mineral density, HD hemodialysis duration,\nfBMD/HD interaction term between femoral bone mineral density\nand hemodialysis duration\n\nFig. 1 Estimated mean cortical porosity based on age group and HD\nduration. The three lines in each plot correspond to patients with\ndialysis durations equal to the 25th (solid line), 50th (dashed line), and\n75th (dotted line) empirical percentiles\n\nMean (SD) Median (min\u2013max)\n\nAge (years) 45.2 (15.2) 45 (21\u201374)\n\nGender\n\nMale (N, %) 20 (52.6)\nFemale (N, %) 18 (47.4)\n\nDialysis duration (months) 73.1 (56.6) 48.3 (21\u2013206)\n\nCalcium (mg/dl) 96 (6.6) 95.4 (87\u2013111)\n\nPhosphorus (mg/dl) 5.4 (0.9) 5.5 (3.9\u20137.2)\n\niPTH (pg/ml) 620 (614) 353.4 (50\u20132,164)\n\nVIT D25 (ng/ml) 21.2 (7.8) 21.5 (7.8\u201337.6)\n\nAgatston scores\n\nCoronary arteries 958.3 (1,888.4) 99.25 (0.0\u20136,726.0)\n\nThoracic aorta 1,391.0 (3,026.9) 3.2 (0.0\u201312,576.2)\n\nIliac arteries 2,916.0 (5,430.6) 848.2 (0.0\u201328,670.0)\n\nTable 1 Characteristics of the\nstudy population\n\niPTH intact parathyroid hor-\nmone, vit D25 25(OH)-hydroxy\nvitamin D\n\nOsteoporos Int\n\n\n\nonly coronary Agatston score >100 showed borderline\nsignificant negative association with lower cancellous bone\nvolume (BV/TV) (point estimate ?4.14; P=0.055) but this\nassociation was lost when the model was also adjusted for\ngender and age.\n\nConclusions\n\nThe National Institutes of Health consensus conference on\n\u201cOsteoporosis prevention, diagnosis and therapy\u201d defines\nosteoporosis as a systemic disease of impaired bone\nstrength [28]. Clinically and in specific populations, the\ndiagnosis \u201costeoporosis\u201d is defined on the basis of\nstandardized BMD levels (T-score??2.5 SD) determined\nby DXA at the spine, hip, or forearm [29]. In the case of\npatients suffering from CKD, the use of this traditional\napproach to diagnose osteoporosis is problematic since all\nforms of renal bone disease may be accompanied by low\nBMD [30, 31], and erroneously high BMD measurements\ndue to vascular/soft tissue calcifications\u2014which are com-\nmonly encountered pathologic findings in CKD patients\u2014\nare known problems of anterioposterior DXA projections\n[32]. Accordingly, it has been proposed that, currently, the\nonly way to establish the diagnosis of osteoporosis in\npatients with stage 5 CKD is the histomorphometrical\nfinding of low bone volume [33]. Based on these\nobservations, we selected not to classify our patients\naccording to specific scores but to evaluate the association\nbetween measured bone mineral density (expressed in\ngrams per centimeter squared) at the lumbar and femoral\nsites and histomorphometric determinants of cancellous\nbone volume (BV/TV) and cortical bone volume (cortical\nwidth and cortical porosity). Furthermore, we adjusted our\nmodels for Agatston scores measured by multislice com-\nputed tomography.\n\nOur study results corroborate previous observations\nregarding lack of associations between histologically\ndetermined cancellous bone volume (BV/TV) and BMD\nmeasurements reported in CKD patients (creatinine clear-\nance 10\u201378 ml/min) [34] and expand those findings to stage\n5 CKD patients on hemodialysis. The usefulness of iliac\ncrest bone biopsies for assessment of bone changes in the\nfemur has been reported in patients requiring total hip\nreplacement [35]. Although there is paucity of data\nregarding the association between cortical bone and\nfractures in CKD patients, the role of increased cortical\nporosity and decreased cortical thickness in femoral neck\nfractures has been described in the general population [36\u2013\n38]. A novel finding of our study is the statistically highly\nsignificant association between cortical porosity and fem-\noral BMD in stage 5 CKD patients that persisted after\nstatistical adjustments. Since cortical changes of the\n\nfemoral neck contribute to the risk of hip fractures [38]\nand fractures of the axial skeleton are highly prevalent in\nstage 5 CKD patients [39], our findings suggest a possible\nclinical role of femoral DXA measurements for identifying\nstage 5 CKD patients on hemodialysis at risk for fracture.\nThe stronger association between femoral BMD and\ncortical porosity at shorter HD durations implies that\nadditional factors present after longer HD vintage such as\nmore extensive soft tissue calcifications will limit the value\nof femoral BMD for assessing cortical porosity as dialysis\nvintage progresses.\n\nWe would like to acknowledge the following limitations\nof our study: Goal of our study was not the comprehensive\nevaluation of all risk factors for hip fractures in stage 5\nCKD patients but to investigate the role of DXA measure-\nments for assessing histological parameters of cancellous\n(BV/TV) and cortical bone volume (cortical porosity and\ncortical width). In order to limit the influence of potentially\nconfounding variables of bone metabolism and vascular\ncalcifications, we imposed strict inclusion and exclusion\ncriteria for study participation; accordingly, our findings\ncall for larger population-based studies to validate a\npossible role of femoral BMD measurements by DXA\nincluding hip structural analysis for assessing bone fracture\nrisk not only in stage 5 CKD patients on different dialysis\nmodalities but also to include patients suffering from\ndifferent levels of CKD as well as CKD patients with\nprevious fractures. Future large age-matched population-\nbased studies will also need to answer the question on\ndifferences in bone volume between healthy and CKD\npatients.\n\nIn summary, our data suggest a role for femoral DXA\nmeasurements to assess cortical porosity in stage 5 CKD\npatients on hemodialysis. Anterioposterior lumbar measure-\nments by DXA do not yield information useful for\nassessment of cancellous bone volume (BV/TV) that has\nbeen shown to be associated with coronary calcifications\n[4]. In light of the high morbidity and mortality of stage 5\nCKD patients, future prospective clinical studies will need\nto further characterize the role of this relatively inexpensive\nand widely available clinical tool (DXA) for assessment of\nclinical outcomes such as fractures.\n\nAcknowledgments The following colleagues have participated in\nthe study: C\u00e9lia Gil, Carlos Oliveira, Jos\u00e9 Galv\u00e3o, Ant\u00f3nio Morais\nSarmento, Silvia Ribeiro, Jorge Dickson, Berta Carvalho, Il\u00eddio\nRodrigues, Jorge Baldaia, and Odete Pereira. This study was\nsupported by grants National Institutes of Health NIH RO1\nDK51530 (H.H.M.), by the Kentucky Nephrology Research Trust\n(M-C.M-F., H.H.M.), by the Dean\u2019s Clinical Research Scholar\nProgram, University of Kentucky, no 1012112710 (J.H.), and by a\ngrant from Genzyme. The authors would like to thank ISNI, Instituto\nNefrol\u00f3gico de Investiga\u00e7\u00e3o, for the assistance in the organization of\nthis study and Ms. Juliana Van Willigen and Richard Wheaton for\ntheir technical assistance.\n\nOsteoporos Int\n\n\n\nConflicts of interest None.\n\nReferences\n\n1. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA,\nHeckbert SR, Wong C, Stehman-Breen C (2000) Increased risk of\nhip fracture among patients with end-stage renal disease. Kidney\nInt 58:396\u2013399\n\n2. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-\nGresham JL, Mason N, Prutz KG, Young EW, Pisoni RL (2006)\nIncidence and risk factors for hip or other bone fractures among\nhemodialysis patients in the dialysis outcomes and practice\npatterns study. Kidney Int 70:1358\u20131366\n\n3. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V (2004) Aortic\ncalcification and the risk of osteoporosis and fractures. J Clin\nEndocrinol Metab 89:4246\u20134253\n\n4. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ,\nFerreira A, Frazao JM, Dias Curto J, Malluche HH (2009) Low\nbone volume\u2014a risk factor for coronary calcifications in\nhemodialysis patients. Clin J Am Soc Nephrol 4:450\u2013455\n\n5. Coco M, Rush H (2000) Increased incidence of hip fractures in\ndialysis patients with low serum parathyroid hormone. Am J\nKidney Dis 36:1115\u20131121\n\n6. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM\n(2006) PTH and the risks for hip, vertebral, and pelvic fractures\namong patients on dialysis. Am J Kidney Dis 47:149\u2013156\n\n7. Hans DB, Shepherd JA, Schwartz EN, Reid DM, Blake GM,\nFordham JN, Fuerst T, Hadji P, Itabashi A, Krieg MA, Lewiecki\nEM (2008) Peripheral dual-energy X-ray absorptiometry in the\nmanagement of osteoporosis: the 2007 ISCD Official Positions. J\nClin Densitom 11:188\u2013206\n\n8. Writing Group for the ISCD Position Development Conference\n(2004) Indications and reporting for dual-energy X-ray absorpti-\nometry. J Clin Densitom 7:37\u201344\n\n9. Hangartner TN, Johnston CC (1990) Influence of fat on bone\nmeasurements with dual-energy absorptiometry. Bone Miner\n9:71\u201381\n\n10. Formica C, Loro ML, Gilsanz V, Seeman E (1995) Inhomogeneity\nin body fat distribution may result in inaccuracy in the\nmeasurement of vertebral bone mass. J Bone Miner Res\n10:1504\u20131511\n\n11. Wren TA, Kim PS, Janicka A, Sanchez M, Gilsanz V (2007)\nTiming of peak bone mass: discrepancies between CT and DXA. J\nClin Endocrinol Metab 92:938\u2013941\n\n12. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV,\nTeehan BP, Levey AS (2000) Atherosclerotic cardiovascular\ndisease risks in chronic hemodialysis patients. Kidney Int\n58:353\u2013362\n\n13. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of\ncardiovascular disease in chronic renal disease. Am J Kidney Dis\n32:S112\u2013S119\n\n14. Taal MW, Masud T, Green D, Cassidy MJ (1999) Risk factors for\nreduced bone density in haemodialysis patients. Nephrol Dial\nTransplant 14:1922\u20131928\n\n15. Jamal SA, Chase C, Goh YI, Richardson R, Hawker GA (2002)\nBone density and heel ultrasound testing do not identify patients\nwith dialysis-dependent renal failure who have had fractures. Am\nJ Kidney Dis 39:843\u2013849\n\n16. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J (1988)\nFractures and vertebral bone mineral density in patients with renal\nosteodystrophy. Clin Nephrol 30:57\u201362\n\n17. Urena P, Bernard-Poenaru O, Ostertag A, Baudoin C, Cohen-Solal\nM, Cantor T, de Vernejoul MC (2003) Bone mineral density,\nbiochemical markers and skeletal fractures in haemodialysis\npatients. Nephrol Dial Transplant 18:2325\u20132331\n\n18. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E,\nNishizawa Y (2005) Increased incidence of vertebral fracture in\nolder female hemodialyzed patients with type 2 diabetes mellitus.\nCalcif Tissue Int 76:256\u2013260\n\n19. Lindergard B, Johnell O, Nilsson BE, Wiklund PE (1985) Studies\nof bone morphology, bone densitometry and laboratory data in\npatients on maintenance hemodialysis treatment. Nephron\n39:122\u2013129\n\n20. Van Eps CL, Jeffries JK, Anderson JA, Bergin PT, Johnson DW,\nCampbell SB, Carpenter SM, Isbel NM, Mudge DW, Hawley CM\n(2007) Mineral metabolism, bone histomorphometry and vascular\ncalcification in alternate night nocturnal haemodialysis. Nephrol-\nogy (Carlton) 12:224\u2013233\n\n21. Goldner J (1938) A modification of the Masson trichrome\ntechnique for routine laboratory purposes. Am J Pathol 14:237\u2013\n243\n\n22. Lillie PD, Fullmer HM (1976) Histopathologic technique and\npractical histochemistry. McGraw Hill, New York\n\n23. Denton J, Freemont AJ, Ball J (1984) Detection of distribution of\naluminum in bone. J Clin Pathol 37:136\u2013142\n\n24. Gomori G (1936) Microtechnical demonstration: a criticism of its\nmethods. Am J Pathol 12:655\u2013663\n\n25. Malluche HH, Meyer W, Sherman D, Massry SG (1982)\nQuantitative bone histology in 84 normal American subjects.\nMicromorphometric analysis and evaluation of variance in iliac\nbone. Calcif Tissue Int 34:449\u2013455\n\n26. Malluche HH, Faugere MC (1986) Atlas of mineralized bone\nhistology. Karger, New York\n\n27. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M\nJr, Detrano R (1990) Quantification of coronary artery calcium\nusing ultrafast computed tomography. J Am Coll Cardiol 15:827\u2013\n832\n\n28. NIH Consensus Development Panel (2001) Osteoporosis preven-\ntion, diagnosis, and therapy. JAMA 285:785\u2013795\n\n29. Miller PD, Bonnick SL, Rosen CJ (1996) Consensus of an\ninternational panel on the clinical utility of bone mass measure-\nments in the detection of low bone mass in the adult population.\nCalcif Tissue Int 58:207\u2013214\n\n30. Lindberg JS, Moe SM (1999) Osteoporosis in end-state renal\ndisease. Semin Nephrol 19:115\u2013122\n\n31. Hruska KA, Teitelbaum SL (1995) Renal osteodystrophy. N Engl\nJ Med 33:166\u2013174\n\n32. Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-\nSolal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard\nM, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J\n(2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis\n43:566\u2013571\n\n33. Miller PD (2005) Treatment of osteoporosis in chronic kidney\ndisease and end-stage renal disease. Curr Osteoporos Rep 3:5\u2013\n12\n\n34. Lobao R, Carvalho AB, Cuppari L, Ventura R, Lazaretti-Castro\nM, Jorgetti V, Vieira JG, Cendoroglo M, Draibe SA (2004) High\nprevalence of low bone mineral density in pre-dialysis chronic\nkidney disease patients: bone histomorphometric analysis. Clin\nNephrol 62:432\u2013439\n\n35. Dorr LD, Arnala I, Faugere MC, Malluche HH (1990) Five-year\npostoperative results of cemented femoral arthroplasty in patients\nwith systemic bone disease. Clin Orthop Relat Res 259:114\u2013\n121\n\nOsteoporos Int\n\n\n\n36. Boyce TM, Bloebaum RD (1993) Cortical aging differences and\nfracture implications for the human femoral neck. Bone 14:769\u2013778\n\n37. Bell KL, Loveridge N, Power J, Garrahan N, Meggitt BF, Reeve J\n(1999) Regional differences in cortical porosity in the fractured\nfemoral neck. Bone 24:57\u201364\n\n38. Mayhew PM, Thomas CD, Clement JG, Loveridge N, Beck TJ,\nBonfield W, Burgoyne CJ, Reeve J (2005) Relation between age, fem-\noral neck cortical stability, and hip fracture risk. Lancet 366:129\u2013135\n\n39. Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis PK,\nOzener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis\nJG, Dombros AN, Utas C, Akpolat T, Bozfakioglu S, Wu G,\nKarayaylali I, Arinsoy T, Stathakis PC, Yavuz M, Tsakiris JD,\nDimitriades CA, Yilmaz ME, Gultekin M, Karayalcin B, Yard-\nimsever M, Oreopoulos DG (2006) Bone mineral density and its\ncorrelation with clinical and laboratory factors in chronic\nperitoneal dialysis patients. J Bone Miner Metab 24:79\u201386\n\nOsteoporos Int\n\n\n\n\n\n121\n\nCAP\u00cdTULO 8\n\nQUE M\u00c9TODOS UTILIZAR PARA AVALIAR \nA CALCIFICA\u00c7\u00c3O VASCULAR?1 -3\n\nDiversos estudos em doentes renais cr\u00f3nicos t\u00eam utilizado diferentes m\u00e9todos para \ndiagnosticar calcifi ca\u00e7\u00f5es vasculares. Braun et al4, em 1996, foram os primeiros a mostrar que \nos doentes em di\u00e1lise apresentam um score de Agatston muito superior ao da popula\u00e7\u00e3o geral. \nBlacher et al5, em 2001, demonstraram que calcifi ca\u00e7\u00f5es vasculares avaliadas por ecografi a \nem grandes vasos s\u00e3o preditoras de mortalidade nos doentes em di\u00e1lise. Em 2003, Moe S et \nal6 verifi caram que a tomografi a axial computorizada multicorte pode ser utilizada em vez da \ntomografi a de feixe de eletr\u00f5es para medir o score de Agatston nos doentes em di\u00e1lise. Em \n2003, London et al7 usaram, pela primeira vez, um RX simples do abd\u00f3men para avaliar \ncalcifi ca\u00e7\u00f5es vasculares e demonstraram que calcifi ca\u00e7\u00f5es vasculares avaliadas por este m\u00e9todo \nse associavam a maior risco de mortalidade nos doentes em di\u00e1lise. Em Fevereiro de 2004 foi \naceite para publica\u00e7\u00e3o e em Mar\u00e7o de 2004 foi publicado on -line o nosso estudo8, que descrevia \num m\u00e9todo original e semiquantitativo para avalia\u00e7\u00e3o de calcifi ca\u00e7\u00f5es vasculares nos doentes \nem di\u00e1lise usando RX simples da bacia e das m\u00e3os. Demonstramos nesse estudo que este \nscore, de utiliza\u00e7\u00e3o muito simples, \u00e9 preditor de mortalidade cardiovascular, de internamentos \ncardiovasculares e de doen\u00e7a coron\u00e1ria e arterial perif\u00e9rica nos doentes em di\u00e1lise.\n\nAvalia\u00e7\u00e3o quantitativa das calcifi ca\u00e7\u00f5es vasculares: score de Agatston\n\nO score de Agatston permite a avalia\u00e7\u00e3o quantitativa das calcifi ca\u00e7\u00f5es vasculares. Este \nm\u00e9todo baseia -se no coefi ciente de atenua\u00e7\u00e3o m\u00e1ximo dos raios X, medido por unidades \nhounsfi eld. Braun et al4 demonstraram que o valor m\u00e9dio do score de calcifi ca\u00e7\u00e3o nos doentes \nem di\u00e1lise era 10 vezes superior a doentes da popula\u00e7\u00e3o geral com doen\u00e7a coron\u00e1ria prov\u00e1vel \nou documentada. O signifi cado cl\u00ednico do score de Agatston \u00e9, contudo, diferente nos doentes \ncom ou sem doen\u00e7a renal cr\u00f3nica. Na popula\u00e7\u00e3o geral est\u00e1 bem demonstrado que o score de \ncalcifi ca\u00e7\u00e3o de Agatston se relaciona com a carga ateroscler\u00f3tica e que um valor superior a \n400 \u00e9 preditor de eventos cardiovasculares ou de necessidade de procedimentos coron\u00e1rios \nnos 2 a 5 anos ap\u00f3s a determina\u00e7\u00e3o deste score. A localiza\u00e7\u00e3o ou o grau de calcifi ca\u00e7\u00e3o podem \n\n\n\n122\n\nn\u00e3o se relacionar com o local da estenose, mas, quanto maior o score, maior a probabilidade \nde estenose em qualquer local, nas art\u00e9rias coron\u00e1rias 9.\n\nOs doentes em di\u00e1lise podem, contudo, ter scores de Agatston muito elevados sem se verifi car \nestenose coron\u00e1ria, e isso foi demonstrado por Haydar et al, que compararam coronariografi as \ncom a avalia\u00e7\u00e3o de calcifi ca\u00e7\u00f5es coron\u00e1rias pelo score de Agatston num grupo de 46 doentes em \ndi\u00e1lise10. Esta discrep\u00e2ncia entre os dados da angiografi a e os dados da quantifi ca\u00e7\u00e3o da calcifi ca\u00e7\u00e3o \ncoron\u00e1ria que se verifi ca nos doentes em di\u00e1lise pode ser explicada pela exist\u00eancia simult\u00e2nea de \ncalcifi ca\u00e7\u00f5es da \u00edntima e de calcifi ca\u00e7\u00f5es n\u00e3o estenosantes da m\u00e9dia. Numa an\u00e1lise anatomopatol\u00f3gica \ndas art\u00e9rias coron\u00e1rias, comparando indiv\u00edduos com e sem doen\u00e7a renal, demonstrou -se de forma \ninequ\u00edvoca que os doentes renais cr\u00f3nicos apresentam uma maior quantidade de c\u00e1lcio, quer na \n\u00edntima quer na m\u00e9dia, e maior intensidade de marcadores infl amat\u00f3rios quando comparados com \ndoentes n\u00e3o renais11. Por outro lado, nos doentes em di\u00e1lise, valores de score de Agatston superiores \nou iguais a 40012 ou a 20013 relacionam -se com a mortalidade cardiovascular, sendo esta associa\u00e7\u00e3o \nconsistente com todos os restantes estudos que demonstram que as calcifi ca\u00e7\u00f5es vasculares, \nqualquer que seja o local, se associam a aumento de mortalidade.\n\nAtualmente, a avalia\u00e7\u00e3o do score de Agatston \u00e9 feita geralmente por tomografi a axial \ncomputorizada multicorte, pois esta tecnologia tem m\u00faltiplas utiliza\u00e7\u00f5es e est\u00e1 amplamente \ndistribu\u00edda, bastando uma especifi ca\u00e7\u00e3o do seu software para poder medir este score.\n\nEcografi a e ecocardiografi a\n\nBlacher et al5 usaram a ecografi a de grandes art\u00e9rias para avaliar as calcifi ca\u00e7\u00f5es vasculares \nem quatro territ\u00f3rios vasculares: aorta, car\u00f3tidas, art\u00e9rias il\u00edacas e femorais. Este estudo, \nrealizado em 2001, foi o primeiro a demonstrar que as calcifi ca\u00e7\u00f5es vasculares se associam \na maior risco de morte. As calcifi ca\u00e7\u00f5es valvulares avaliadas por ecocardiografi a s\u00e3o preditoras \nde mortalidade nos doentes em di\u00e1lise14 -16 e a iniciativa KDIGO 200917 reconhece que a \necocardiografi a pode ser utilizada para o diagn\u00f3stico de calcifi ca\u00e7\u00f5es valvulares, de modo a \nidentifi car os doentes com maior risco cardiovascular. Num grupo de 123 doentes em di\u00e1lise, \nverifi camos, como previamente demonstrado, que a calcifi ca\u00e7\u00e3o valvular a\u00f3rtica ou mitral se \nassocia a um risco aumentado de morte de causa global ou cardiovascular. Verifi camos que \nas calcifi ca\u00e7\u00f5es vasculares avaliadas por RX simples s\u00e3o preditoras de calcifi ca\u00e7\u00f5es valvulares \ndiagnosticadas por ecocardiografi a18. Por cada aumento de uma unidade no score de calcifi ca\u00e7\u00e3o \nvascular simples, verifi cou -se um aumento de 46% de risco de ter simultaneamente calcifi ca\u00e7\u00e3o \nda v\u00e1lvula a\u00f3rtica e de 66% de ter calcifi ca\u00e7\u00e3o da v\u00e1lvula mitral. A presen\u00e7a de calcifi ca\u00e7\u00f5es \nvalvulares apresenta um alto valor preditivo positivo e um baixo valor preditivo negativo para \n\n\n\n123\n\nindicar presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares. Isto signifi ca que, no caso de haver calcifi ca\u00e7\u00f5es \nvalvulares, existe elevada probabilidades de tamb\u00e9m haver calcifi ca\u00e7\u00f5es vasculares. No caso \nde n\u00e3o haver calcifi ca\u00e7\u00f5es valvulares, a probabilidade de n\u00e3o haver calcifi ca\u00e7\u00f5es vasculares \n\u00e9 baixa. O ecocardiograma n\u00e3o substitui a utiliza\u00e7\u00e3o do RX simples para identifi car o risco \ncardiovascular associado \u00e0s calcifi ca\u00e7\u00f5es.\n\nRX simples\n\nLondon G et al foram os primeiros a demonstrar que calcifi ca\u00e7\u00f5es vasculares avaliadas \nem RX simples s\u00e3o preditoras de mortalidade nos doentes em di\u00e1lise7. Baseando -se numa \nmetodologia previamente descrita por Letho19, diferenciaram calcifi ca\u00e7\u00e3o da camada m\u00e9dia \ne da \u00edntima pelas imagens radiol\u00f3gicas. A calcifi ca\u00e7\u00e3o da m\u00e9dia \u00e9 linear e regular e apresenta \nfrequentemente um tra\u00e7ado duplo em linha de comboio. A calcifi ca\u00e7\u00e3o da \u00edntima \u00e9 irregular \ne descont\u00ednua. Este importante estudo demonstrou que as calcifi ca\u00e7\u00f5es da camada m\u00e9dia n\u00e3o \ns\u00e3o achados radiol\u00f3gicos, mas t\u00eam signifi cado cl\u00ednico. Neste estudo, os autores demonstraram \nque as calcifi ca\u00e7\u00f5es da m\u00e9dia e da \u00edntima foram preditores independentes de mortalidade. O \nnosso estudo8 foi publicado alguns meses ap\u00f3s o estudo de London e foi o primeiro a usar \num score semiquantitativo para avaliar as calcifi ca\u00e7\u00f5es vasculares. As calcifi ca\u00e7\u00f5es s\u00e3o \navaliadas em setores defi nidos nos RX das m\u00e3os ou da bacia. Os limites do score s\u00e3o de 0 e \n8. Posteriormente, mais estudos foram publicados mostrando a associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es \nvasculares avaliadas por RX simples e mortalidade. A presen\u00e7a de calcifi ca\u00e7\u00f5es na aorta \nabdominal20 ou a presen\u00e7a de calcifi ca\u00e7\u00f5es no acesso vascular 21 associaram -se a maior risco \nde morte, O score da calcifi ca\u00e7\u00e3o aortoabdominal descrito por Kauppila L22, que avalia as \ncalcifi ca\u00e7\u00f5es na aorta abdominal de L1 a L4, usando um RX simples de perfi l, \u00e9 preditor de \nmortalidade na popula\u00e7\u00e3o geral23 e, nos doentes em di\u00e1lise, apresenta uma boa correla\u00e7\u00e3o \ncom o score coron\u00e1rio de Agatston24. Os resultados preliminares do estudo CORD25 mostram \nque o score de Kauppila se associa \u00e0 idade, \u00e0 dura\u00e7\u00e3o da di\u00e1lise e \u00e0 doen\u00e7a vascular pr\u00e9via. \nEm comunica\u00e7\u00e3o apresentada no Congresso da EDTA, em 2008, Honkanen E et al mostraram \nque um score de Kauppila superior ou igual a 7 se associa a maior risco de mortalidade.\n\nComparamos o score simples de calcifi ca\u00e7\u00e3o com o score de calcifi ca\u00e7\u00e3o na aorta abdominal, \nou score de Kauppila, na avalia\u00e7\u00e3o do \u00edndice tornozelo -bra\u00e7o num grupo de 219 doentes em \nhemodi\u00e1lise26. Os valores preditivos positivo e negativo de um score vascular simples superior \na 3 identifi car um score de Kauppila superior ou igual a 6 foram, respectivamente, 79% e 85%. \nAmbos os m\u00e9todos se associaram a maior risco de doen\u00e7a arterial obliterativa, defi nida por \u00edndice \ntornozelo -bra\u00e7o, inferior a 0,9, apresentando uma \u00e1rea semelhante sob a curva. S\u00f3 as calcifi ca\u00e7\u00f5es \n\n\n\n124\n\ndetetadas no RX das m\u00e3os e nas art\u00e9rias colaterais da bacia se associaram a maior risco de \u00edndice \ntornozelo -bra\u00e7o superior a 1,3. O padr\u00e3o radiol\u00f3gico mais comum das calcifi ca\u00e7\u00f5es vasculares \ndestas art\u00e9rias colaterais ou distais \u00e9 linear. Esta associa\u00e7\u00e3o sugere uma eventual contribui\u00e7\u00e3o \nde calcifi ca\u00e7\u00f5es da camada m\u00e9dia arterial para o aumento do \u00edndice tornozelo -bra\u00e7o.\n\nV\u00e1rias t\u00e9cnicas n\u00e3o invasivas permitem fazer o rastreio de calcifi ca\u00e7\u00f5es vasculares: \nt\u00e9cnicas de tomografi a axial computorizada para avalia\u00e7\u00e3o do score de calcifi ca\u00e7\u00e3o coron\u00e1rio, \necografi a de grandes vasos, ecocardiografi a para avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es valvulares a\u00f3rtica \ne mitral e RX simples para avaliar diferentes territ\u00f3rios arteriais. A tomografia axial \ncomputorizada multicorte ou a tomografi a computorizada de feixe de eletr\u00f5es s\u00e3o consideradas \nt\u00e9cnicas gold -standard para avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es coron\u00e1rias ou a\u00f3rticas. S\u00e3o t\u00e9cnicas \nquantitativas dispendiosas que t\u00eam sido usadas em v\u00e1rios ensaios cl\u00ednicos para avalia\u00e7\u00e3o da \nprogress\u00e3o das calcifi ca\u00e7\u00f5es coron\u00e1rias. Estas t\u00e9cnicas n\u00e3o distinguem a calcifi ca\u00e7\u00e3o da \u00edntima \nda da m\u00e9dia e apresentam valores muito elevados nos doentes renais cr\u00f3nicos, devido \u00e0 elevada \npreval\u00eancia de calcifi ca\u00e7\u00f5es da m\u00e9dia nestes doentes11. Os elevados scores de calcifi ca\u00e7\u00e3o \ndiagnosticados por estes m\u00e9todos associam -se a maior risco cardiovascular, mas podem n\u00e3o \nse relacionar com doen\u00e7a coron\u00e1ria obstrutiva. O RX simples, a ecografi a dos grandes vasos \ne a ecocardiografi a s\u00e3o m\u00e9todos simples e baratos mais indicados para o rastreio das calcifi ca\u00e7\u00f5es \nvasculares nos doentes em di\u00e1lise. A iniciativa KDIGO 200917 reconhece a utilidade do RX \nsimples e da ecocardiografi a para fazer o rastreio das calcifi ca\u00e7\u00f5es vasculares. Na escolha do \nmelhor m\u00e9todo a usar nos nossos doentes para este fi m devemos, contudo, ter em conta que \no ecocardiograma subavalia o risco cardiovascular relacionado com as calcifi ca\u00e7\u00f5es.\n\nQual a utilidade de avaliar as calcifi ca\u00e7\u00f5es vasculares \nnos doentes renais cr\u00f3nicos?\n\nA mortalidade cardiovascular \u00e9 a principal causa de morte nos doentes em di\u00e1lise. At\u00e9 \nao momento atual, muito poucas interven\u00e7\u00f5es terap\u00eauticas se associaram a uma redu\u00e7\u00e3o da \nmortalidade, e isto verificou -se apenas em ensaios cl\u00ednicos com reduzido n\u00famero de \nparticipantes. O candesartan associou -se \u00e0 redu\u00e7\u00e3o de eventos cardiovasculares27, o carvedilol \nreduziu a mortalidade em doentes com cardiomiopatia28 e o sevelamer reduziu a mortalidade \nnum grupo de 127 doentes em di\u00e1lise com hiperfosfatemia12.\n\nA presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares \u00e9 um sinal de alerta para um elevado risco \ncardiovascular nos doentes renais cr\u00f3nicos. Nestes doentes justifi ca -se a interven\u00e7\u00e3o terap\u00eautica \nem todos os fatores associados ao desenvolvimento e progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares, \nsendo a corre\u00e7\u00e3o das altera\u00e7\u00f5es do metabolismo fosfoc\u00e1lcico um dos campos de atua\u00e7\u00e3o. \n\n\n\n125\n\nEsperamos que o progressivo conhecimento dos m\u00faltiplos mecanismos fi siopatol\u00f3gicos na \nbase do desenvolvimento das calcifi ca\u00e7\u00f5es vasculares permitam alargar o campo de interven\u00e7\u00e3o \nterap\u00eautica nos nossos doentes. Ser\u00e1 sempre necess\u00e1rio confi rmar se este tipo de interven\u00e7\u00e3o \nterap\u00eautica se associa \u00e0 redu\u00e7\u00e3o da morbilidade e da mortalidade nestes doentes.\n\nRefer\u00eancias\n\n  1. Adrag\u00e3o T, Fraz\u00e3o JM. Cardiovascular risk in dialysis patients: an X -ray vision on vascular \ncalcifi cations. Kidney Int 2008; 74(12):1505 -1507.\n\n  2. Adrag\u00e3o T. Evaluation of vascular calcifi cations in CKD patients. Int J Artif Organs 2009;32(2):81-\n-86.\n\n  3. Adrag\u00e3o T, Ferreira A, Fraz\u00e3o J. Evaluaci\u00f3n no invasiva de la calcifi caci\u00f3n vascular en pacientes \ncon ERC. (Aceite para publica\u00e7\u00e3o no livro \u201cAlteraciones del metabolismo \u00f3seo -mineral en la \nenfermedad renal cr\u00f3nica\u201d, editado pelo Prof. Jorge Cannata).\n\n  4. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation \nof cardiac calcifi cation in chronic dialysis patients. Am J Kidney Dis 1996; 27:394 -401.\n\n  5. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifi cations, arterial stiffness, and cardiovascular \nrisk in end -stage renal disease. Hypertension 2001;38:938 -942.\n\n  6. Moe SM, O\u2019Neill KD, Fineberg N, et al. Assessment of vascular calcifi cation in ESRD patients \nusing spiral CT. Nephrol Dial Transplant 2003; 18: 1152 -1158.\n\n  7. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: \nimpact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-\n-1740.\n\n  8. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. A simple vascular \ncalcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant \n2004;19(6):1480 -1488.\n\n  9. Wexler L, Brundage B, Crouse J, et al. Coronary artery calcifi cation: Patophysiology, epidemiology, \nimaging methods and clinical implications. A statement for health professionals from the American \nHeart Association. Circulation 1996; 94: 1175 -1192.\n\n10. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery calcifi cation is related to coronary \natherosclerosis in chronic renal disease patients: a study comparing EBCT -generated coronary \nartery calcium scores and coronary angiography. Nephrol Dial Transplant 2004; 19: 2307 -2312.\n\n11. Gross ML, Meyer HP, Ziebart H, et al. Calcification of coronary intima and media: \nimmunohistochemistry, backscatter imaging, and x -ray analysis in renal and nonrenal patients. \nClin J Am Soc Nephrol 2007;2(1):121 -134.\n\n12. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcifi cation and phosphate binder \nchoice in incident hemodialysis patients. Kidney Int 2007;71(5):438 -441.\n\n13. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcifi cation score \n(CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004; 8(1):54 -58.\n\n\n\n126\n\n14. Wang AY, Wang M, Woo J, et al. Cardiac valve calcifi cation as an important predictor for all -cause \nmortality and cardiovascular mortality in long -term peritoneal dialysis patients: a prospective \nstudy. J Am Soc Nephrol 2003;14(1):159 -168.\n\n15. Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve \ncalcium with coronary artery disease, atherosclerotic vascular disease, and all -cause mortality in 137 \npatients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 15;95(6):742 -743.\n\n16. Sharma R, Pellerin D, Gaze DC, et al. Mitral annular calcifi cation predicts mortality and coronary \nartery disease in end stage renal disease. Atherosclerosis 2007;191(2):348 -354.\n\n17. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney disease: Improving global \noutcomes (KDIGO). Kidney Int 2009; 76 (Suppl): S113.\n\n18. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP.Vascular and \nvalvular calcifi cations in dialysis patients: the same pathogenesis? Port J Nephrol Hypert 2007; \n21(4): 293 -300.\n\n19. Lehto S, Niskanen L, Suhonen M, et al. Medial artery calcifi cation. A neglected harbinger of \ncardiovascular complications in non -insulin -dependent diabetes mellitus. Arterioscler Thromb \nVasc Biol 1996; 16: 978 -983.\n\n20. Okuno S, Maeno Y, Maekawa K, et al. Presence of abdominal aortic calcifi cation is signifi cantly \nassociated with all -cause and cardiovascular mortality in maintenance hemodialysis patients. Am \nJ Kidney Dis; 2007: 49: 417 -425.\n\n21. Schlieper G, Kr\u00fcger T, Djuric Z, et al. Calcifi cation of the arteriovenous fi stula predicts mortality \nin haemodialysis patients. Kidney Int 2008; 74: 1582 -1587.\n\n22. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression \nof calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245-\n-250.\n\n23. Wilson PWF, Kauppila LI, O\u2019Donnell CJ, et al. Abdominal aortic calcifi c deposits are an important \npredictor of vascular morbidity and mortality. Circulation 2001;103: 1529 -1534.\n\n24. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium \nmeasured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623 -1628.\n\n25. Honkanen E, Kauppila L, Wikstr\u00f6m B, et al; CORD study group. Abdominal aortic calcifi cation \nin dialysis patients: results of the CORD study. Nephrol Dial Transplant 2008; 23: 4009 -4015.\n\n26. Adrag\u00e3o T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Bordalo J, Prata MM. Ankle \nbrachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3 \n(Suppl 3): iii492. [Abstract Su545.]\n\n27. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type -1 receptor blocker, \nreduces cardiovascular events in patients on chronic haemodialysis \u2013 a randomized study. Nephrol \nDial Transplant 2006; 21: 2507 -2512.\n\n28. Cice G, Ferrara L, D\u2019Andrea A, et al. Carvedilol increases two -year survival in dialysis patients \nwith dilated cardiomyopathy: a prospective, placebo -controlled trial. J Am Coll Cardiol 2003; 41: \n1438 -1444.\n\n\n\nKidney International (2008) 74          1505\n\nc o m m e n t a r yhttp://www.kidney-international.org\n\u00a9 2008 International Society of Nephrology\n\nsee original article on page 1582\n\nCardiovascular risk in dialysis \npatients: an X-ray vision on \nvascular calcifications\nTeresa Adrag\u00e3o1 and Jo\u00e3o M. Fraz\u00e3o2\n\nIn dialysis patients, there is an association between vascular \ncalcifications and mortality. Hyperphosphatemia and calcium overload \nare associated with development of vascular calcifications, especially \nin the presence of low bone turnover. Different plain X-ray methods are \nnow available to evaluate vascular calcifications in dialysis patients. \nThe presence of vascular calcifications is an alert sign for increased \ncardiovascular risk, and this information is important for choosing the \nmost suitable treatment for dialysis patients.\nKidney International (2008) 74, 1505\u20131507. doi:10.1038/ki.2008.503 \n\nIntroduction\nIn recent years, observational studies in \ndialysis patients have verified the exist-\nence of an association between vascu-\nlar calcifications and mortality.1\u20135 The \nabnormal mineral metabolism, a conse-\nquence of chronic kidney disease (CKD), \nhas been associated with development \nof vascular calcifications. In an in vitro \nmodel using smooth muscle cells from \nthe human aorta, it was demonstrated \nthat high levels of phosphorus, calcium, \nor both induce vascular calcification6 \nby an active intracellular process that \ntransforms vascular smooth muscle cells \ninto osteoblast-like cells. Vascular cal-\ncifications are associated with low bone \nturnover,7 and the hypothesis of the exist-\nence of a link between bone disease and \ncardiovascular disease has been raised. \nKidney Disease: Improving Global Out-\ncomes (KDIGO) has recommended a new \nclassification for chronic kidney disease \n\nmineral and bone disorder (CKD-MBD) \nthat includes the presence of vascular \ncalcifications.\n\nMethods to evaluate  \nvascular calcifications\nBraun et al.,8 in 1996, used electron \nbeam computed tomography to evaluate \ncoronary calcifications and showed that \nhemodialysis patients had a very high \ncoronary Agatston score when compared \nwith nonrenal patients. Blacher et al.,1 \nin 2001, demonstrated for the first time \nthat the presence of vascular calcifica-\ntions in hemodialysis patients, evaluated \nby ultrasonography in large arteries, was \nassociated with increased mortality. In \n2003, London et al.2 showed that vascu-\nlar calcifications evaluated in plain X-ray \nwere associated with all-cause and cardi-\novascular mortality in dialysis patients. \nAfter these initial observations, other \nstudies3,5 confirmed the association \nbetween vascular calcifications, evalu-\nated with plain X-ray, and mortality in \nthe CKD stage 5 hemodialysis popula-\ntion. We developed a simple vascular \ncalcification score, using the presence of \nvascular calcification, in a plain X-ray \nof the pelvis and hands3 (Figure 1). This \nsimple score was an independent pre-\ndictor of cardiovascular death, cardio-\nvascular hospitalizations, and vascular \n\ndisease in dialysis patients. The Kauppila \nscore, using the presence of vascular cal-\ncification in a plain X-ray of the lateral \nabdominal aorta, previously associated \nwith cardiovascular death in the general \npopulation, has been recently validated \nfor evaluating mortality risk in hemo-\ndialysis patients (E. Honkanen et al., \n2008; EDTA Congress; Stockholm, Swe-\nden; abstr.). Even a simpler evaluation of \nvascular calcifications in the abdominal \naorta, identifying only the presence or \nabsence of calcifications,5 was also a pre-\ndictor of mortality in dialysis patients. \nSchlieper et al.9 (this issue) now publish \nan interesting observation showing that \nthe presence of vascular calcification \nof the hemodialysis vascular access, \nevaluated by plain X-ray, is also an \nindependent predictor of mortality.\n\nElectron beam computed tomo graphy \nand multislice computed tomo graphy \nare considered the gold standard for \nquantitative evaluation of vascular cal-\ncifications, but they are expensive and \nnot widely available. In the setting of \nclinical trials performed with CKD \npatients, these quantitative techniques \nhave been useful to evaluate the effect \nof different treatment options on vascu-\nlar calcification progression. However, \nthe meaning of the coronary Agatston \nscore is different in dialysis patients as \ncompared with the general population. \nIn the general population, the coronary \nAgatston score is correlated with the \natherosclerotic calcium load and is a \npredictor of cardiovascular events. In \ndialysis patients, there is no precise \ncorrelation between calcium score and \ncoronary angiography. The Agatston \nscore does not differentiate intimal from \nmedial calcification, and hemodialysis \npatients can have a very high coronary \nAgatston score, because both intimal and \nmedial calcifications may be present in \ncoronary arteries. Medial calcifications \ncontribute to aortic stiffness and to \ndecreased coronar y perfusion dur-\ning diastole without causing coronary \nstenotic lesions. For that reason, a high \ncoronary Agatston score cannot be used \nto identify dialysis patients who will \nbenefit from a coronary angioplasty.\n\n1Nephrology Department, Hospital de Santa \nCruz, Carnaxide, Portugal; and 2Nephrology \nDepartment, Hospital de S\u00e3o Jo\u00e3o, School \nof Medicine and Nephrology Research and \nDevelopment Unit, Porto University, Porto, \nPortugal\nCorrespondence: Teresa Adrag\u00e3o, Nephrology \nDepartment, Hospital de Santa Cruz, Av Prof \nReinaldo Santos, 2795-523, Carnaxide, Portugal.  \nE-mail: tadragao@netcabo.pt\n\n\n\n1506   Kidney International (2008) 74   \n\nc o m m e n t a r y\n\nVascular calcification evaluated  \nin the vascular access\nSchlieper et al.9 evaluated calcification of \narteriovenous fistulas or synthetic grafts \nwith plain X-ray and verified that cal-\ncification of the vascular access was an \nindependent predictor of mortality. The \nauthors conclude that this is a cost-effective \nand easy-to-perform method to identify \ndialysis patients at increased mortality \nrisk. Calcification of the vascular access \nwas present in 23% of patients and was \nassociated with male gender, diabetes, and \ndialysis vintage. The authors have verified \nthat the presence of calcifications in the \nvascular access was highly correlated with \nthe presence of vascular calcifications of \niliac and femoral arteries, suggesting that \nthere is a common pathogenic process \naffecting these different sites of the vascu-\nlature. This common pathogenic process \ncould explain why vascular calcifications, \nindependently of their localization, are \nassociated with mortality risk. The pres-\nence of calcification in the vascular access \nmay have, however, a different mean-\ning from that observed in other arteries. \nIntimal calcification is associated with \natherosclerotic plaques, and medial calci-\nfication is associated with arteriolosclero-\nsis. In hemodialysis patients it has already \nbeen demonstrated2 that these two types \nof vascular calcifications may coexist in \nthe same patient and in the same vessel \nand that they are independent predictors \nof cardiovascular and all-cause mortality. \nCalcification of the vascular access seems \nto be predominantly composed of medial \ncalcification.10 Most probably, a method \n\nto evaluate vascular calcifications that \nincludes these two types of vascular cal-\ncification, intimal and medial calcifica-\ntion2,3,5 (E. Honkanen et al., 2008; EDTA \nCongress; Stockholm, Sweden; abstr.), \nshould be more appropriate for evaluating \nthe global mortality risk. In our opinion, \nthere are other limitations in the choice \nof this method to evaluate vascular calci-\nfications. One limitation is the exclusion \nof all patients who do not have a vascular \naccess, such as peritoneal dialysis patients \nand patients without vascular conditions \nto receive an access. Also, local hemody-\nnamic factors, unrelated to cardiovascular \nrisk, may be associated with development \nof calcifications of the vascular access. The \npresence of calcification in the vascular \naccess might have an interesting advantage \nof identifying calcium deposition occur-\nring after initiation of dialysis. However, \nthe identification of this phenomenon at \nsuch a late stage might not be so helpful \nto guide a therapeutic intervention. An \nearlier identification of vascular calcifica-\ntions, in predialysis or in incident patients, \nis probably a more intelligent and useful \napproach. Such patients constitute a popu-\nlation with elevated risk of rapid calcifica-\ntion progression and certainly deserve a \nmore aggressive therapeutic approach.\n\nWhat is the preferable vascular  \ncalcification screening method?\nA method adequate for screening vascu-\nlar calcifications should be inexpensive \nand simple to interpret. Any of the plain \nX-ray methods mentioned here for evalu-\nation of vascular calcifications can be easily \n\ninterpreted by the attending physician. \nAnother important quality for choosing \na screening method is a correct balance \nbetween sensitivity and specificity. Which \nof the methods using plain X-ray for evalu-\nation of vascular calcification is the best? \nFor a definitive answer to this question, \ncomparative studies in the same population \nwill be required and certainly welcome.\n\nIn our opinion, all of the methods \ndescribed here that recognize the presence \nof vascular calcification with plain X-ray \nof different vascular territories have been \ndemonstrated to be very useful in the eval-\nuation of CKD population mortality risk. \nCertainly, the final choice of the method to \nbe used in a specific institution should be \nbased on the experience and preference of \nthe nephrology attending physicians.\n\nWhat is the importance of screening  \nvascular calcifications in dialysis patients?\nThe identification of dialysis patients with \ncalcified vessels and the evaluation of vas-\ncular calcification extension could be very \nuseful for cardiovascular risk stratification \nand therapeutic guidance. Vascular calci-\nfications most likely are multifactorial and \nresult from a complex balance between \ninducers and inhibitors. However, at this \nstage of knowledge, we can only interfere \nin a very small number of those factors \n\u2014 mainly, alterations of mineral metabo-\nlism. Several studies have already dem-\nonstrated that vascular calcifications in \ndialysis patients may progress or remain \nstable depending on the control of the \nmineral metabolism alterations, such as \nhyperphosphatemia. Another important \naspect besides the control of hyperphos-\nphatemia per se is the choice of the phos-\nphate-binding agent. One should avoid \nthe use of calcium-containing phosphate \nbinders in patients with calcified vessels.\n\nLondon et al. demonstrated an associa-\ntion between vascular calcifications and \nlow bone turnover.7 The same group11 \nfound a significant interaction between \ndosage of calcium-containing phos-\nphate binders and bone activity such \nthat calcium load had a significantly \nhigher impact on aortic calcifications \nand stiffening in the presence of ady-\nnamic bone disease. Low-bone-turnover \nstatus should b e prevented, when \npossible, avoiding para thyroid hormone \n\nFigure 1 | Simple vascular calcification score evaluation. Calcification score is the sum \nof the presence (1) or absence (0) of vascular calcifications in each section. Pelvis score \n(1+1+1+1) = 4 and hands score (1+1+1+1) = 4. Total score is 8.\n\n\n\nKidney International (2008) 74          1507\n\nc o m m e n t a r y\n\noversuppression, and calcium-containing \nbinders should be avoided in patients with \nsuch a condition.11\n\nIn summary, vascular calcifications are \nassociated with increased mortality in dial-\nysis patients. Different methods can be used \nto identify vascular calcifications in these \npatients. Plain X-ray evaluation of vascular \ncalcifications is inexpensive and simple to \ninterpret and should be used for the screen-\ning of vascular calcifications. Nephrologists \nhave now at their disposal different plain \nX-ray methods to evaluate vascular calcifi-\ncations in their CKD patients. The presence \nof vascular calcifications in CKD patients \nconstitutes an important alert sign for an \nincreased cardiovascular risk. This infor-\nmation is important and should serve to \nguide nephrologists in the design of more \nappropriate and aggressive therapeutic \nstrategies to control mineral metabolism \nin their patients.\nDISCLOSURE\nTeresa Adrag\u00e3o has received research grants \nfrom Amgen and Genzyme and has received \nlecture fees from Amgen, Genzyme, Abbott, \nand Novartis. Jo\u00e3o M. Fraz\u00e3o has received \nconsultancy and lecture fees from Amgen \nand Genzyme. He is also an advisory board \nmember for Amgen and Genzyme.\n\nREFERENCES\n1. Blacher J, Gu\u00e9rin AP, Pannier B et al. \n\nArterial calcifications, arterial stiffness, and \ncardiovascular risk in end-stage renal disease. \nHypertension 2001; 38: 938\u2013942.\n\n2. London GM, Guerin AP, Marchais SJ et al. Arterial \nmedia calcification in end-stage renal disease: \nimpact on all-cause and cardiovascular mortality. \nNephrol Dial Transplant 2003; 18: 1731\u20131740.\n\n3. Adragao T, Pires A, Lucas C et al. A simple vascular \ncalcification score predicts cardiovascular risk in \nhaemodialysis patients. Nephrol Dial Transplant \n2004; 19: 1480\u20131488.\n\n4. Block GA, Raggi P, Bellasi A et al. Mortality effect \nof coronary calcification and binder choice in \nincident hemodialysis patients. Kidney Int 2007; \n71: 438\u2013441.\n\n5. Okuno S, Maeno Y, Maekawa K et al. Presence \nof abdominal aortic calcification is significantly \nassociated with all-cause and cardiovascular \nmortality in maintenance hemodialysis patients. \nAm J Kidney Dis 2007; 49: 417\u2013425.\n\n6. Yang H, Curinga G, Giachelli CM. Elevated \nextracellular calcium levels induce smooth \nmuscle cell matrix mineralization in vitro. Kidney \nInt 2004; 66: 2467\u20132468.\n\n7. London GM, Marty C, Marchais SJ et al. Arterial \ncalcifications and bone histomorphometry in \nend-stage renal disease. J Am Soc Nephrol 2004; \n15: 1943\u20131951.\n\n8. Braun J, Oldendorf M, Moshage W et al. Electron \nbeam computed tomography in the evaluation \nof cardiac calcification in chronic dialysis \npatients. Am J Kidney Dis 1996; 27: 394\u2013401.\n\n9. Schlieper G, Kr\u00fcger T, Djuric Z et al. Vascular \naccess calcification predicts mortality in \n\nhemodialysis patients. Kidney Int 2008; 74: 1582\u20131587. \n10. Wang N, Yang J, Yu X et al. Radial artery calcification \n\nin end-stage renal disease patients is associated \nwith deposition of osteopontin and diminished \nexpression of alpha-smooth muscle actin. \n\nNephrology (Carlton) 2008; 13: 367\u2013375.\n11. London GM, Marchais SJ, Gu\u00e9rin AP et al. \n\nAssociation of bone activity, calcium load, aortic \nstiffness, and calcifications in ESRD. J Am Soc \nNephrol 2008; 19: 1827\u20131835.\n\nsee original article on page 1588 \n\nDRIVE it home:  \nmaking the case for prospective \neconomic data collection  \nin randomized clinical trials\nEric L. Eisenstein1\n\nAlthough the results of Pizzi et al. point to the potential economic \nattractiveness of a ferric gluconate treatment strategy, they may not be \nsufficient to change public policy and reimbursement practices. What is \nrequired is a large, simple trial that will replicate the results of the DRIVE trial \nin a broader population with longer follow-up and a prospectively defined \neconomic and quality-of-life study conducted from the societal perspective.\nKidney International (2008) 74, 1507\u20131509. doi:10.1038/ki.2008.553 \n\nIn 1972, Archie Cochrane put forth three \ntests that all medical technologies must \npass.1 The first test, of efficacy, assesses \nwhether the new technology can work \nunder ideal circumstances, such as those \nfound in a randomized clinical trial. The \nsecond test, of effectiveness, evaluates \nwhether the technology works under usual \ncircumstances, such as those found in actual \npractice. And the third test, of efficiency, \ndetermines whether the new technology is \nworth it\u2014put differently, whether there is \na proper relationship between the benefits \nderived through the use of the technol-\nogy and the resources it consumes (Figure \n1). While the renal research community \nhas demonstrated increasing success in \nanswering Cochrane\u2019s first two questions \nwith respect to important clinical and pol-\nicy issues, it has exhibited less interest in his \nthird question. In few areas is the disparity \n\nbetween clinical and economic research \ngreater than in the appropriate use of epo-\netin alfa for anemia correction in patients \nwith kidney disease.\n\nIn recent years, our understanding of \nthe efficacy and effectiveness of epoetin \nalfa in patients with kidney disease has \nincreased substantially. The Cardiovascu-\nlar Risk Reduction by Early Anemia Treat-\nment with Epoetin Beta (CREATE) study \nreported that complete correction of ane-\nmia in patients with chronic kidney disease \ndoes not reduce the risk of cardiovascular \nevents.2 This message was amplified by the \nCorrection of Hemoglobin and Outcomes \nin Renal Insufficiency (CHOIR) study, \nwhich reported that the use of higher ver-\nsus lower target hemoglobin levels is asso-\nciated with increased cardiovascular risk \nwith no improvement in quality of life.3 \nSubsequently, a secondary analysis from the \nCHOIR study refocused the discussion by \nreporting that patients who achieved their \nhemoglobin targets (whether lower- or \nhigher-level) had better cardiovascular out-\ncomes than those who did not.4 The under-\nlying issue was that a greater proportion of \n\n1Duke Clinical Research Institute, Durham, North \nCarolina, USA\nCorrespondence: Eric Eisenstein, Duke Clinical \nResearch Institute, P.O. Box 17969, Durham, North \nCarolina 27715, USA.  \nE-mail: Eric.Eisenstein@duke.edu\n\n\n\n\n\n0391-3988/081-06 $25.00/0\n\nThe International Journal of Artificial Organs / Vol. 32 / no. 2, 2009 / pp. 81-86\n\nEvaluation of vascular calcifications in CKD patients\nTERESA ADRAG\u00c3O\n\nNephrology Department, Santa Cruz Hospital, Carnaxide - Portugal\n\n\u00a9 Wichtig Editore, 2009\n\nABSTRACT: In observational studies on dialysis patients, there has been a consistent association\nbetween vascular calcifications and mortality. Hyperphosphatemia and calcium treatment are some\nof the factors associated with development of vascular calcifications, especially in the presence of\nlow bone turnover disease. Several non-invasive imaging techniques have been used to screen for\nthe presence of vascular calcifications: plain X-Ray, echocardiography, ultrasonography, and com-\nputed tomography. Presence of vascular calcifications is a warning sign for increased cardiovascular\nrisk and this information may be relevant for choosing the most suitable treatment for dialysis pa-\ntients. (Int J Artif Organs 2009; 32: 81-6)\n\nKEY WORDS: Vascular calcifications, Imagiology, Chronic kidney disease\n\nINTRODUCTION\n\nHigh cardiovascular risk in chronic kidney disease pa-\ntients is not fully explained by traditional risk factors. The\nFramingham risk score, based on age, gender, diabetes,\nhypertension, lipid profile and smoking habits, fails to\npredict cardiovascular events in dialysis (1) and pre-dialy-\nsis (2) patients and several non-traditional risk factors are\ncommonly considered to contribute to the high cardio-\nvascular risk in this population.\n\nIn the last few years a new explanation has been added\nto the list of the already numerous cardiovascular risk\nfactors of chronic kidney disease patients. The associa-\ntion of cardiovascular calcifications with mortality, veri-\nfied in multiple observational studies, is considered to be\na consistent finding and has been classified as grade B\nevidence in recent KDIGO recommendations. In experi-\nmental studies, it is demonstrated that an altered mineral\nmetabolism has a direct causal effect on vascular calcifi-\ncations. In a model using vascular smooth muscle cells\nfrom the human aorta, Giachelli (3) demonstrated that hy-\nperphosphatemia and hypercalcemia were inducers of\nvascular calcification by activation of intracellular Cbfa1,\nwhich led to the transformation of the vascular smooth\nmuscle cell into an osteoblast. \n\nHypercalcemia and hyperphosphatemia are commonly\nseen in dialysis patients under two opposing conditions.\nIn secondary hyperparathyroidism, a situation with high\n\nbone turnover, the bone itself contributes to the high lev-\nels of phosphorus and calcium. In adynamic bone dis-\nease, a condition with low bone turnover, the bone be-\nhaves as if it were \u201cfrozen\u201d and is unable to capture ex-\ntraosseus calcium and phosphorus derived mainly from\nfood and, in the case of calcium, from treatment as well.\n\nThese observations have led to the hypothesis that a\nlink exists between bone disease and vascular disease in\ndialysis patients. In the KDIGO position paper published\nin 2006 , the presence of soft tissue and of vascular cal-\ncifications have been included in the definition of chronic\nkidney disease mineral and bone disorder (CKD-MBD)\n(4).\n\nTypes of vascular calcification\n\nVascular calcifications present two different histological\ntypes: intimal and medial calcification. Thus far, intimal\nand medial calcifications have been considered to be two\ndistinct entities, with different clinical presentations and\nprognoses. The possibility that these two entities may\nconstitute a continuum of vascular pathology in CKD pa-\ntients has been hypothesized (5). However, the fact that\nmedia calcification is detected earlier in the course of\nCKD, and in the absence of lipid and cholesterol deposi-\ntion, challenges this hypothesis (6). Intimal calcification is\nrelated to dyslipidemia and accompanies the progression\n\nReview\n\n\n\n82\n\nNon-invasive diagnosis of vascular calcifications in CKD patients\n\nof atherosclerotic plaque. Medial calcification is associat-\ned with arteriolosclerosis, and develops mainly in diabet-\nic, chronic kidney disease, and elderly patients. Clinical\nmanifestations of intimal calcification are related to the\npresence of atherosclerotic plaques that obstruct the ar-\nteries by rupture and /or thrombosis. Medial calcification\ndoes not cause arterial obstruction and was once consid-\nered a radiological finding with no clinical consequences.\nToday we know that medial calcification modifies the\nproperties of the arterial wall and is one of the factors\nthat contributes to arterial stiffness. Arterial stiffness in\nmanifested by an increase in pulse wave velocity and in\npulse pressure. Due to the loss of distensibility in the aor-\nta, there is an earlier reflection of the aortic wave that\nfinds the aortic valve still opened. The consequence is an\nincrease in the systolic and a decrease in the diastolic\npressure. Systolic pressure increase contributes to the\ndevelopment of left ventricular hypertrophy. Decrease in\ndiastolic pressure may compromise the coronary perfu-\nsion that is mainly performed during diastole. Medial cal-\ncification may then be associated with symptomatic\ncoronary disease in the absence of obstructive coronary\nartery disease. \n\nMethods to diagnose vascular calcifications:\nquantitative evaluation of coronary \ncalcifications\n\nElectron Beam Computed Tomography (EBCT) and\nMultislice Computed Tomography (MSCT)\n\nBraun et al (7) in 1996 used Electron Beam Computed\nTomography (EBCT) to evaluate coronary calcifications in\ndialysis patients. Quantification of calcification is per-\nformed by calculating the Agatston score. This method is\nbased on the maximum X-ray attenuation coefficient,\nmeasured in Hounsfield units, and the area of calcifica-\ntion is multiplied by the density scores. Analysis of 49 he-\nmodialysis patients demonstrated that the mean cardiac\ncalcification score was more than 10-fold higher in he-\nmodialysis patients than in 102 non-dialysis control pa-\ntients with documented or suspected cardiovascular dis-\nease. The meaning of the Agatston score may be differ-\nent in renal and non-renal patients. In non-renal patients\nthe amount of coronary calcium is related to the overall\natherosclerotic plaque burden and is an effective predic-\n\ntor of coronary artery disease. It is well established that\nindividuals with Agatston scores above 400 have an in-\ncreased occurrence of coronary procedures (bypass,\nstent placement and angioplasty) and of cardiac events\n(myocardial infarction and cardiac death) within the 2 to 5\nyears after the test. The extent and site of calcification\nmay not correspond to the site of stenosis but the greater\nthe amount of calcification, the greater the likelihood of\nobstructive disease somewhere in the coronary arteries.\nIn general population, several studies have shown a good\ncorrelation between calcium scores and coronary steno-\nsis (8). \n\nDialysis patients, however, can have very high coronary\nAgatston scores without coronary stenosis. Haydar et al\n(9) compared coronary angiographies with coronary\nAgatston scores obtained by EBCT in a group of 46 he-\nmodialysis patients. A higher coronary Agatston score\nwas associated with a higher number of diseased ves-\nsels, however, eleven patients with no occlusive coronary\ndisease in the angiography had a median coronary Agat-\nston score of 619, which, in the general population, is as-\nsociated with coronary stenosis. Three- or four-vessel\ndisease in twenty dialysis patients was associated with a\nmedian coronary Agatston score of 3748, a score rarely\nseen in the general population. Since this method does\nnot discriminate intimal from medial calcification, these\nvery high calcification scores in dialysis patients may be\nexplained by the probable occurrence of both types of\nvascular calcification in coronary arteries. \n\nThe existence of a different morphology of coronary le-\nsions in CKD and non-CKD patients has been demon-\nstrated in an autopsy study (10). CKD patients show\nheavy calcification of the media, with higher calcium con-\ntent in the media and in the intima and with more fre-\nquent presence and greater intensity of inflammation\nmarkers. In dialysis patients, there is, however, a good\ncorrelation between coronary calcifications and cardio-\nvascular risk. Coronary calcifications have been related\nwith cardiovascular events (11) and with mortality (12,\n13). Nevertheless, the clinical significance of Agatston\nscore cut-off values in the general population for the di-\nagnosis of occlusive coronary disease cannot be applied\nto dialysis patients. Likewise, coronary calcification has\nalso been a predictor of mortality in dialysis patients but\nin association with lower coronary Agatston score values\nthan those described in association with coronary occlu-\nsive disease (9). In prevalent patients a coronary Agat-\nston score greater than 200 was associated with all-\n\n\n\nAdragao \n\n83\n\ncause death (12), and in incident patients, a coronary\nAgatston score greater than 400 was associated with\nlower survival (13). Therefore, the association of coronary\ncalcifications with mortality is consistent with all the other\nobservational studies showing that the presence of vas-\ncular calcifications, independently of their location, is\npredictive of mortality. \n\nCurrently, evaluation of coronary calcifications with\nEBCT has been substituted by multislice computed to-\nmography (MSCT). Application of EBCT is limited to the\nassessment of coronary calcification, while MSCT has\nmultiple uses and with software adjustments may also\nevaluate coronary calcification. This technique is widely\navailable and is now an alternative for quantitative evalu-\nation of coronary calcification. It has been demonstrated\nthat MSCT is a viable technique for the evaluation of\ncoronary arteries and aortic vascular calcification in CKD\npatients (14).\n\nUltrasonography and echocardiography\n\nUltrasonography was the method used by Blacher (15)\nto evaluate vascular calcifications in four arterial territo-\nries in dialysis patients: the carotid, aorta, iliac and\nfemoral arteries. This study, performed in 2001, was the\nfirst to demonstrate that vascular calcifications were as-\nsociated with increased mortality in dialysis patients and\nit showed that the higher the number of territories affect-\ned, the lower the survival. \n\nCalcification of heart valves can be evaluated by\nechocardiography; this type of calcification was associat-\ned with lower survival in peritoneal dialysis patients (16).\nIn a group of 127 hemodialysis patients we have also ver-\n\nified that valvular calcification is a predictor of all-cause\nand cardiovascular death. The simple vascular calcifica-\ntion score evaluated in plain X-ray of pelvis and hands\n(17), described in the next section, was associated with\nvalvular calcification, raising the hypothesis of a common\npathogenesis for valvular and vascular calcification in this\npopulation (18). \n\nPlain X-ray\n\nIn 2003 London et al (19) were the first to demonstrate\nthat vascular calcifications evaluated by plain X-ray were\nassociated with all-cause and cardiovascular mortality.\nThese authors differentiated medial from intimal calcifica-\ntion in plain X-ray films. Medial calcification is linear and\nregular, presenting a railroad track type, while intimal cal-\ncification is patchy and irregular. This study demonstrat-\ned that medial calcification is not a radiological finding\nbut has an important clinical signification. These two\ntypes of calcification were sometimes found in the same\npatient and in the same vessel and were independent\npredictors of mortality. Intimal calcification was associat-\ned with older age and higher LDL-cholesterol levels. Me-\ndial calcification was associated with hemodialysis vin-\ntage and diabetes. Calcium carbonate dose and phos-\nphorus levels were associated with both types of calcifi-\ncation. \n\nOther studies (17, 20) have confirmed the association\nbetween vascular calcifications, evaluated with plain X-\nray, and mortality in the CKD stage-5 hemodialysis popu-\nlation. We developed a simple vascular calcification\nscore, evaluated in a plain X-ray of the pelvis and hands\n(17) (Fig. 1). This simple score was an independent pre-\n\nFig. 1 - Simple va-\nscular calcification\ns core  e valu at ion .\nCalcification score\nis  the  su m of  t he\npresence (1) or ab-\nsence (0) of vascu-\nlar calcifications in\neach section. Pelvis\nscore (1+1+1+1) =\n4 and hands score\n(1+1+1+1) = 4. To-\ntal score is 8.\n\n\n\n84\n\nNon-invasive diagnosis of vascular calcifications in CKD patients\n\ndictor of cardiovascular death, cardiovascular hospital-\nizations and vascular disease in dialysis patients and was\nan independent predictor of arterial stiffness evaluated by\npulse wave velocity and pulse pressure (21). \n\nThe Kauppila score evaluates the presence of vascular\ncalcifications in the anterior and posterior wall of the ab-\ndominal aorta using a lateral plain X-ray of the lumbar\nvertebral segments from L1 to L4. This score has been\nassociated with cardiovascular death in a subgroup of\nparticipants of the Framingham Heart Study (22). This\nscore has also been tested in dialysis patients. It pre-\nsents a good correlation with the coronary Agatston\nscore and demonstrates high sensitivity and specificity in\npredicting a high coronary Agatston score (23). The pre-\nliminary results of the CORD study, evaluating outcomes\nin relation with the Kauppila score, have shown that ab-\ndominal aortic calcification is associated with age, dialy-\nsis duration and previous cardiovascular disease (24).\nThe plain X-ray score and Kauppila scores are semi-\nquantitative evaluations of vascular calcifications. Simpler\nevaluations of vascular calcifications, assessing only the\npresence or absence of vascular calcifications have also\nbeen associated with mortality, such as the identification\nby plain X-ray of vascular calcifications in the abdominal\naorta (20) or in the hemodialysis vascular access (25). \n\nCONCLUSIONS\n\nWhat is the best non-invasive method to diagnose\nvascular calcifications?\n\nSeveral non-invasive imaging techniques have been\nused to screen for the presence of vascular calcifications:\nplain X-ray to evaluate different arterial territories,\nechocardiography for assessment of valvular calcifica-\ntion; two-dimensional ultrasound for calcification of\ncarotid arteries, femoral arteries and aorta; and comput-\ned tomography technologies.\n\nExisting studies demonstrate that vascular calcifica-\ntions, independently of their location, are predictors of\nmortality in CKD patients. EBCT and MSCT are consid-\nered to be the gold standard for evaluating coronary cal-\ncifications. They allow a quantitative assessment of vas-\ncular calcifications and have been used in several ran-\ndomized clinical trials for evaluating progression of calci-\nfication. These methods do not differentiate intimal from\nmedial calcification, and high coronary scores in dialysis\n\npatients, though related with higher cardiovascular risk,\nmay not be related with coronary obstructive disease.\nThe clinical implications of this score in dialysis patients\nare not identical to those for the general population. \n\nPlain X-Ray, ultrasonography and echocardiography\nare less expensive and, for that reason, more convenient\nfor screening vascular calcifications. Plain X-ray methods\nhave the advantage of greater simplicity and the possibil-\nity of being easily interpreted by the attending physician.\nThe simple vascular calcification score and Kauppila\nscore perform a semi-quantitative evaluation of vascular\ncalcification with cut-off values that allow the identifica-\ntion of patients with a higher cardiovascular risk. A car-\ndiovascular calcification index using the Kauppila score\nand valvular calcification evaluated by echocardiography\nhave been demonstrated to be associated with coronary\ncalcification in hemodialysis patients evaluated by EBCT\n(26). Simpler methods to evaluate vascular calcifications\nseem to be an attractive option but the final choice of the\nmethod to employ would depend on the available tests\nand on the preference of the nephrologist.\n\nIs it useful to screen vascular calcifications in dialysis\npatients?\n\nCardiovascular death is the main cause of mortality in\nCKD patients and, at present, very few therapeutic inter-\nventions have shown success in the reduction of all-\ncause or cardiovascular mortality in this population. Can-\ndesartan (27), which has been associated with reduction\nof cardiovascular events in dialysis patients, carvedilol\n(28) in patients with dilated cardiomyopathy, and seve-\nlamer (29), used to control phosphorus levels in incident\npatients, are some of the few treatments that have been\nassociated with increased survival in dialysis patients. In\nCKD patients, the presence of vascular calcifications is a\nmarker of increased cardiovascular risk and this associa-\ntion, based on observational studies, is classified as\ngrade B evidence by the recent KDIGO recommenda-\ntions. Vascular calcifications are multifactorial and result\nfrom a complex balance between inducers and inhibitors.\nAt the present stage of knowledge we can only intervene\nin a very small number of these factors, mainly, in the\ncorrection of the mineral metabolism. Several studies\nhave already demonstrated that vascular calcifications in\ndialysis patients may progress or remain stable depend-\ning on the control of the mineral metabolism and on the\ntype of phosphate binder (30-32). London et al demon-\n\n\n\nAdragao \n\n85\n\nstrated an association between vascular calcifications\nand low bone turnover (33) and found a significant inter-\naction between calcium-containing phosphate binders\nand aortic calcification and stiffness in the presence of\nadynamic bone disease (34). \n\nIdentification of vascular calcifications in CKD patients\nis included in the classification of CKD-MBD. This infor-\nmation may be used for selecting the most suitable con-\ntrol of the mineral metabolism, such as intensive control\nof hyperphosphatemia, suitable choice of phosphate\nbinder and prevention of low bone turnover status, for \ninstance, by avoidance of calcium-containing binders or\nof PTH oversupression. In predialysis (35) and dialysis\npatients it has been demonstrated that, vascular calcifi-\ncations are progressive and for this reason it seems logi-\ncal to begin evaluation of vascular calcifications at an\nearly stage, possibly in predialysis patients.\n\nIn conclusion, different methods can be used for\nscreening vascular calcifications. Plain-X-ray is a simple\n\nand inexpensive method to perform this evaluation. Con-\nsidering the poor results of therapeutic interventions on\ncardiovascular mortality in CKD patients, the available\nevidence justifies the more frequent use of this simple\nevaluation in these patients. This information may be\nused to detect cardiovascular risk and to guide therapeu-\ntic intervention in chronic kidney disease patients.\n\nConflict of interest statement \nTeresa Adragao has received research grants from Genzyme; lectu-\nre fees from Amgen, Genzyme, Abbot and Novartis; and consul-\ntancy fees from Genzyme and Abbot.\n\nAddress for correspondence: \nTeresa Adrag\u00e3o, MD\nNephrology Department\nHospital de Santa Cruz\nAv Prof Reinaldo Santos \n2795-523, Carnaxide, Portugal\ne-mail: tadragao@netcabo.pt\n\nREFERENCES\n\n1. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic car-\ndiovascular disease risks in chronic hemodialysis patients.\nKidney Int 2000; 58: 353-62.\n\n2. Weiner DE, Tighiouart H, Elsayed EF, et al. Griffith JL. The\nFramingham predictive instrument in chronic kidney disea-\nse. J Am Coll Cardiol 2007; 50: 217-24.\n\n3. Giachelli CM. Vascular calcification mechanisms. J Am Soc\nNephrol 2004: 15: 2959-64.\n\n4. Moe S, Drueke T, Cunningham J, et al. Definition, evalua-\ntion, and classification of renal osteodystrophy: A position\nstatement from Kidney Disease: Improving Global Outco-\nmes (KDIGO). Kidney Int 2006; 69: 1945-53.\n\n5. McCullough PA, Agrawal V, Danielewicz E, et al. Accelera-\nted atherosclerotic calcification and Monckeberg\u2019s sclero-\nsis: A continuum of advanced vascular pathology in chronic\nkidney disease. Clin J Am Soc Nephrol 2008; 3: 1585- 98.\n\n6. Amann K. Media calcification and intima calcification are di-\nstinct entities in chronic kidney disease. Clin J Am Soc\nNephrol 2008; 3: 1599-1605. \n\n7. Braun J, Oldendorf M, Moshage W, et al. Electron beam\ncomputed tomography in the evaluation of cardiac calcifica-\ntion in chronic dialysis patients. Am J Kidney Dis 1996; 27:\n394-401.\n\n8. Wexler L, Brundage B, Crouse J, et al. Coronary artery cal-\ncification: Patophysiology, epidemiology, imaging methods\nand clinical implications. A statement for health professio-\n\nnals from the American Heart Association. Circulation 1996;\n94: 1175-92.\n\n9. Haydar AA, Hujairi NM, Covic AA, et al. Coronary artery cal-\ncification is related to coronary atherosclerosis in chronic\nrenal disease patients: a study comparing EBCT-generated\ncoronary artery calcium scores and coronary angiography.\nNephrol Dial Transplant 2004; 19: 2307-12.\n\n10. Gross ML, Meyer HP, Ziebart H, et al. Calcification of Coro-\nnary Intima and Media: Immunohistochemistry, Backscatter\nImaging, and X-Ray Analysis in Renal and Nonrenal Pa-\ntients. Clin J Am Soc Nephrol 2007; 2: 121-34.\n\n11. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcifica-\ntion in adult hemodialysis patients. A link between end-sta-\nge renaldisease and cardiovascular disease? J Am Coll Car-\ndiol 2002; 39: 695-701.\n\n12. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coro-\nnary artery calcification score (CACS) on survival in patients\non chronic hemodialysis. Clin Exp Nephrol 2004; 8: 54-8.\n\n13. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coro-\nnary calcification and phosphate binder choice in incident\nhemodialysis patients. Kidney Int 2007; 71:438-41.\n\n14. Moe SM, O\u2019Neill KD, Fineberg N, et al. Assessment of va-\nscular calcification in ESRD patients using spiral CT. Neph-\nrol Dial Transplant 2003; 18: 1152-8.\n\n15. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications,\narterial stiffness, and cardiovascular risk in end-stage renal\ndisease. Hypertension 2001; 38: 938-42.\n\n16. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification\n\n\n\n86\n\nNon-invasive diagnosis of vascular calcifications in CKD patients\n\nas an important predictor for all-cause mortality and cardio-\nvascular mortality in long-term peritoneal dialysis patients: a\nprospective study. J Am Soc Nephrol 2003; 14: 159-68.\n\n17. Adragao T, Pires A, Lucas C, et al. A simple vascular calcifi-\ncation score predicts cardiovascular risk in haemodialysis\npatients. Nephrol Dial Transplant 2004;19: 1480-8.\n\n18. Adragao T, Pires A, Lucas C, et al. Vascular and valvular\ncalcifications in dialysis patients: the same pathogenesis?\nPort J Nephrol Hypertens 2007; 21: 281-5.\n\n19. London GM, Guerin AP, Marchais SJ, et al. Arterial media\ncalcification in end-stage renal disease: impact on all-cause\nand cardiovascular mortality. Nephrol Dial Transplant 2003;\n18: 1731-40.\n\n20. Okuno S, Maeno Y, Maekawa K, et al. Presence of Abdomi-\nnal Aortic Calcification Is Significantly Associated With All-\nCause and Cardiovascular Mortality in Maintenance Hemo-\ndialysis Patients. Am J Kidney Dis; 2007: 49: 417-25.\n\n21. Adrag\u00e3o T, Pires A, Birne R, et al. A plain X-ray vascular cal-\ncification score is associated with arterial stiffness and mor-\ntality in dialysis patients. Nephrol Dial Transplant 2009; 24:\n997-1002. \n\n22. Wilson PWF, Kauppila LI, O\u2019Donnell CJ, et al. Abdominal\nAortic Calcific Deposits Are an Important Predictor of Va-\nscular Morbidity and Mortality. Circulation 2001; 103: 1529.\n\n23. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of\nsimple imaging tests and coronary artery calcium measured\nby computed tomography in hemodialysis patients. Kidney\nInt 2006; 70: 1623-8.\n\n24. Honkanen E, Kauppila L, Wikstr\u00f6m B, et al; CORD study\ngroup. Abdominal aortic calcification in dialysis patients: re-\nsults of the CORD study. Nephrol Dial Transplant 2008; 23:\n4009-15. \n\n25. Schlieper G, Kr\u00fcger T, Djuric Z, et al. Calcification of the ar-\nteriovenous fistula predicts mortality in haemodialysis pa-\n\ntients. Kidney Int 2008; 74: 1582-7. \n26. Muntner P, Ferramosca E, Bellasi A, et al. Development of a\n\ncardiovascular calcification index using simple imaging\ntools in haemodialysis patients. Nephrol Dial Transplant\n2007; 22: 508-14.\n\n27. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an\nangiotensin II type-1 receptor blocker, reduces cardiova-\nscular events in patients on chronic haemodialysis \u2013 a ran-\ndomized study. Nephrol Dial Transplant 2006; 21: 2507-12.\n\n28. Cice G, Ferrara L, D\u2019Andrea A, et al. Carvedilol increases\ntwo-year survival in dialysis patients with dilated cardiomyo-\npathy: a prospective, placebo-controlled trial. J Am Coll\nCardiol 2003: 41: 1438-44.\n\n29. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coro-\nnary calcification and binder choice in incident hemodialysis\npatients. Kidney Int 2007; 71: 438-41.\n\n30. Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenua-\ntes the progression of coronary and aortic calcification in\ndialysis patients. Kidney Int 2002; 62: 245-52.\n\n31. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer\nand calcium on coronary artery calcification in patients new\nto dialysis. Kidney Int 2005; 68: 1815-24.\n\n32. Russo D, Miranda I, Ruocco C, et al. The progression of co-\nronary artery calcification in predialysis patients on calcium\ncarbonate or sevelamer. Kidney Int  2007; 72: 1255-61.\n\n33. London GM, Marty C, Marchais SJ, et al. Arterial calcifica-\ntions and bone histomorphometry in end-stage renal disea-\nse. J Am Soc Nephrol 2004; 15: 1943-51.\n\n34. London GM, Marchais SJ, Gu\u00e9rin AP, et al. Association of\nbone activity, calcium load, aortic stiffness, and calcifica-\ntions in ESRD. J Am Soc Nephrol 2008; 19: 1827-35.\n\n35. Russo D, Corrao S, Miranda I, et al. Progression of coronary\nartery calcification in predialysis patients.  Am J Nephrol\n2007; 27: 152-8.\n\n\n\n137\n\nCAP\u00cdTULO 9\n\nCOMENT\u00c1RIOS FINAIS\n\nO score de calcifi ca\u00e7\u00e3o vascular simples avaliado em RX simples da bacia e das m\u00e3os \nrevelou -se, como fi cou demonstrado com os estudos descritos, um m\u00e9todo simples para \nidentifi ca\u00e7\u00e3o do risco cardiovascular. Este m\u00e9todo de avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es vasculares \ntamb\u00e9m foi usado por outros grupos nacionais e internacionais, o que permitiu confi rmar a \nfacilidade e a reprodutibilidade da sua aplica\u00e7\u00e3o.\n\nUtiliza\u00e7\u00e3o do score de calcifi ca\u00e7\u00e3o vascular simples em estudos \npublicados por outros grupos.\n\n1. Matias P et al1 demonstraram, num grupo de 223 doentes em hemodi\u00e1lise, que os n\u00edveis \nde 25 -hidroxvitamina D3 se correlacionaram inversamente com a presen\u00e7a de diabetes \nmellitus, com os n\u00edveis s\u00e9ricos de albumina e de BNP (brain natriuretic peptide) e com \num score de calcifi ca\u00e7\u00e3o vascular simples superior a 3 (Tabela. 9.1).\n\nDependent \nvariable \n\nIndependent \nvariables\n\n? 95% CI P R2\n\n[25(OH)D3]\n\nDiabetes mellitus -0.44 -0.23 to -0.01&lt;0.001\n\n0.532\nAlbumin 0.41 1.24 to 2.68 0.003\nLog10 BNP -0.37 -0.24 to -0.02 0.005\nPP > 65 mmHg -0.36 -0.41 to -0.05 0.006\nSVCS ?3 -0.39 -0.28 to -0.04 0.002\n\nBNP. brain natriuretic peptide: PP. pulse pressure: SVCS. simple vascular calcifi cation score.\n\nTabela 9.1. Preditores dos n\u00edveis s\u00e9ricos de 25(OH) vitamina D por regress\u00e3o linear. O score de \ncalcifi ca\u00e7\u00e3o vascular simples ? 3 (SVCS, simple vascular calcifi cation score) apresentou uma associa\u00e7\u00e3o \ninversa com os n\u00edveis s\u00e9ricos de 25(OH) vitamina D\n\nRefer\u00eancia: Matias PJ et al. 25 -hydroxyvitamin D3, arterial calcifi cations and cardiovascular risk markers in \n\nhaemodialysis patients. Nephrol Dial Transplant 2009; 24(2):611 -618.\n\n\n\n138\n\n2. Este mesmo grupo demonstrou noutro estudo2 que os doentes submetidos a amputa\u00e7\u00e3o \napresentavam um score de calcifi ca\u00e7\u00e3o vascular mais elevado (Fig. 9.1). As calcifi ca\u00e7\u00f5es \nvasculares foram avaliadas pelo score de calcifi ca\u00e7\u00e3o vascular simples, e um score de \ncalcifi ca\u00e7\u00e3o mais elevado foi um preditor independente de amputa\u00e7\u00e3o (OR 2,01; IC \n1,41 -3.01; p=0,01).\n\nFig. 9.1. O score de calcifi ca\u00e7\u00e3o vascular foi mais elevado nos doentes submetidos a amputa\u00e7\u00e3o\n\nRefer\u00eancia: Matias P, et al. Factors associated with lower -extremity amputations in haemodialysis \npatients. Port J Nephrol Hypert 2008; 22(1): 31 -36.\n\n3. Wei T et al avaliaram, num grupo de 47 doentes em hemodi\u00e1lise, a rela\u00e7\u00e3o entre o \nsRANKL (soluble receptor activator of nuclear factor kB ligand) e os eventos \ncardiovasculares3. Neste estudo, os preditores de eventos cardiovasculares foram os n\u00edveis \n\nFactors of cardiovascular events determined by multivariate regression analysis\n\nFactors\nStandardized \ncoeffi cients, ?\n\nt p value 95% CI\n\nsRANKL, pmol/l -0.322 -2.215 0.035 -2.948 ~ -0.115\nCalcifi cation score 0.584 4.087 0.000 0.051 ~0.152\nPhosphate, mmol/l 0.732 2.935 0.007 0.105 ~0.588\nCa \u00d7 P, mmol2 /l2 -0.658 -2.818 0.009 - 0.284 ~0.045\n\nTabela 9.2. O score de calcifi ca\u00e7\u00e3o constitu\u00eddo pelo SCVS (0 -8) + calcifi ca\u00e7\u00f5es na aorta abdominal \n(0 -2) foi um dos preditores de eventos cardiovasculares\n\nRefer\u00eancia: Wei T et al. Relationship of sRANKL level and vascular calcifi cation score to cardiovascular \nevents in maintenance hemodialysis patients. Blood Purif 2009; 28:342 -345.\n\n\n\n139\n\nde sRANKL, os n\u00edveis de f\u00f3sforo s\u00e9rico e as calcifi ca\u00e7\u00f5es vasculares (Tabela 9.2). As  \ncalcifi ca\u00e7\u00f5es vasculares foram avaliadas por um score composto pelo score de calcifi ca\u00e7\u00e3o \nvascular simples (de 0 a 8), ao qual foi somado um score de calcifi ca\u00e7\u00e3o a\u00f3rtico (0 a 2), \nsendo o score fi nal 0 a 10. Wei T et al foram o primeiro grupo internacional a incluir o \nscore de calcifi ca\u00e7\u00e3o vascular simples na avalia\u00e7\u00e3o de calcifi ca\u00e7\u00f5es vasculares.\n\n4. Schlieper G et al4 avaliaram os fatores associados \u00e0 presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares \nusando o score de calcifi ca\u00e7\u00e3o vascular simples avaliado no RX simples da bacia e das \nm\u00e3os e um score de calcifi ca\u00e7\u00e3o que associava as calcifi ca\u00e7\u00f5es vasculares da bacia e \ndas m\u00e3os \u00e0s calcifi ca\u00e7\u00f5es das f\u00edstulas arteriovenosas, calcifi ca\u00e7\u00f5es valvulares card\u00edacas \ne calcifi ca\u00e7\u00f5es carot\u00eddeas (Tabelas 9.3 e 9.4).\n\n Estes autores verifi caram que a idade, o sexo masculino, a dura\u00e7\u00e3o da di\u00e1lise, um valor \nmais baixo de Kt/V, o produto fosfoc\u00e1lcico, os h\u00e1bitos tab\u00e1gicos e a prote\u00edna C reactiva \nde alta sensibilidade foram preditores independentes das calcifi ca\u00e7\u00f5es vasculares. Ambos \nos scores se relacionaram com o aumento da velocidade de onda de pulso e foram ambos \npreditores de mortalidade. Segundo estes autores, a avalia\u00e7\u00e3o do score combinado n\u00e3o \nmostrou vantagens em rela\u00e7\u00e3o ao score de calcifi ca\u00e7\u00e3o vascular simples e, sob um ponto \nde vista pr\u00e1tico, o score de calcifi ca\u00e7\u00e3o vascular simples que utiliza apenas um RX da \nbacia e das m\u00e3os pode representar um m\u00e9todo mais f\u00e1cil para avalia\u00e7\u00e3o dos doentes.\n\nMultivariate analysis of risk factors for vascular calcifi cations \n(ordinal logistic regression, Adrag\u00e3o score)\n\nScore 0\n(n=89)\n\nScore 1-2\n(n=45)\n\nScore 3-8\n(n=54)\n\nOR 95% CI P\n\nAge years 57 \u00b1 10 61 \u00b1 10 61 \u00b1 11 1.08 1.04-1.11&lt;0.001\nMale gender 36 (40%) 24 (53%) 40 (74%) 2.75 1.41-5.38 0.003\nSmoking 17 (19%) 22 (42%) 22 (42%) 2.32 1.16-4.65 0.017\nDialysis vintage, years 5.74 \u00b1 4.43 7.54 \u00b1 4.41 7.69 \u00b1 4.83 1.13 1.03-1.23 0.006\nCa \u00d7 PO4  product, mmol\n\n2/l2 3.55 \u00b1 1.02 3.76 \u00b11.02 3.96 \u00b1 1.14 1.75 1.29-2.37 0.0003\nKt/V 1.33 \u00b1 0.18 1.25 \u00b1 0.13 1.23 \u00b1 0.18 0.095 0.01-0.64 0.015\nAnti-HCV antibody 16 (18%) 17 (38%) 18 (33%) 1.39 0.59-3.31 0.454\nhsCRP, mg/l 7.71 \u00b118.9 7.88 \u00b1 10.68 14.31 \u00b1 20.43 1.01 1.00-1.03 0.096\nTotal cholesterol, mmol/l 5.35 \u00b1 1.27 4.94 \u00b1 1.04 5.01 \u00b1 0.98 0.99 0.75-1.30 0.930\n\nTabela 9.3. Preditores do score de calcifi ca\u00e7\u00e3o vascular simples\n\nRefer\u00eancia: Schlieper et al. Risk factors for cardiovascular calcifi cations in non -diabetic Caucasian \nhaemodialysis patients. Kidney Blood Pres Res 2009;32(3):161 -168.\n\n\n\n140\n\nMultivariate analysis of risk factors for cardiovascular calcifi cations \n(ordinal logistic regression, composite score)\n\nScore 0-2\n(n = 84)\n\nScore 3-5\n(n = 42)\n\nScore 6-15\n(n = 48) \n\nOR 95% CI p\n\nAge years 56.75 \u00b1 10.03 61.07 \u00b1 9.90 60.81 \u00b1 11.23 1.06 1.02-1.09 0.002\nMale gender 35 (42%) 19 (45%) 37 (77%) 2.32 1.19-4.52 0.014\nDialysis vintage, years 5.84 \u00b1 4.13 7.36 \u00b1 5.29 7.66 \u00b1 4.55 1.13 1.04-1.24 0.005\nhsCRP, mg/l 6.18 \u00b1 8.16 6.21 \u00b1 9.79 12.85 \u00b1 17.23 1.04 1.01-1.07 0.012\nKt/V 1.34 \u00b1 0.18 1.27 \u00b1 0.16 1.23 \u00b1 0.19 0.11 0.02-0.70 0.019\nSmoking 20 (24%) 12 (29%) 20 (43%) 1.84 0.89-3.83 0.097\nAnti-HCV antibody 16 (19%) 15 (36%) 15 (31%) 1.25 0.52-3.02 0.614\n\nTabela 9.4. Preditores de um score composto de calcifi ca\u00e7\u00e3o vascular (SCVS+calcifi ca\u00e7\u00e3o da f\u00edstula \nAV + calcifi ca\u00e7\u00e3o valvular card\u00edaca + calcifi ca\u00e7\u00f5es carot\u00eddeas)\n\nRefer\u00eancia: Schlieper et al. Risk factors for cardiovascular calcifi cations in non -diabetic Caucasian \nhaemodialysis patients. Kidney Blood Pres Res 2009;32(3):161 -168.\n\n5. As calcifi ca\u00e7\u00f5es da c\u00f3rnea e da conjuntiva s\u00e3o calcifi ca\u00e7\u00f5es extravasculares relativamente \nfrequentes nos doentes em di\u00e1lise. Seyahi N et al5 foram os primeiros a mostrar uma associa\u00e7\u00e3o \nentre este tipo de calcifi ca\u00e7\u00e3o extravascular e as calcifi ca\u00e7\u00f5es vasculares. O SCVS foi o m\u00e9todo \nescolhido para avaliar as calcifi ca\u00e7\u00f5es vasculares. No grupo de doentes com mais calcifi ca\u00e7\u00f5es \nconjuntivais e corneanas (CCC) verifica -se maior percentagem de doentes com \ncalcifi ca\u00e7\u00f5es vasculares avaliadas no RX simples da bacia e das m\u00e3os (Tabela 9.5).\n\nClinical and biochemical data. BMD results, \nand vascular calcifi cation frequency of patients\n\nAll Patients\n(N = 63)\n\nLow CCC \nScore\n\n(n = 17)\n\nHigh CCC \nScore\n\n(n = 16)\np\n\nMen/women 30/33 7/10 8/8 NS\nAge (y) 43.5 \u00b1 11.7 37.9 \u00b1 14.8 46.31 \u00b1 14.3 NS\nPeritoneal dialysis/hemodialysis 44/19 10/7 12/4 NS\nRRT duration (mo) 54.5 \u00b1 39.9 21.1 \u00b1 5.1 42.2 \u00b1 10.6 0.003\nParathyroidectomy 5 (7.9) 1 (5.9) 1 (6.3) NS\nCalcium (mg/dL) 9.22 \u00b1 0.56 9.08 \u00b1 0.38 9.39 \u00b1 0.6 NS\nPhosphorus (mg/dL) 5.38 \u00b1 1.30 5.17 \u00b1 1.04 5.96 \u00b1 1.58 NS\nCa \u00d7 P (mg2/dL2) 48.47 \u00b1 12.41 44.76 \u00b1 10.36 56.11 \u00b1 17.44 0.021\nALP (U/L) 161.0 \u00b1 116.7 133.1 \u00b1 65.7 156.5 \u00b1 96.5 NS\nPTH (pg/mL) 310.8 \u00b1 257.4 292.2 \u00b1 272.5 320.6 \u00b1 243.4 NS\n\n(Continua)\n\n\n\n141\n\nAll Patients\n(N = 63)\n\nLow CCC \nScore\n\n(n = 17)\n\nHigh CCC \nScore\n\n(n = 16)\np\n\nAlbumin (g/dL) 3.75 \u00b1 0.46 3.62 \u00b1 0.61 3.88 \u00b1 0.36 NS\nCRP (mg/dL) 14.31 \u00b1 22.40 13.09 \u00b1 17.95 13.14 \u00b1 22.71 NS\nLumbar BMD (g/cm2) 1.01 \u00b1 0.19 1.02 \u00b1 0.19 1.02 \u00b1 0.23 NS\nFemoral BMD (g/cm2) 0.78 \u00b1 0.13 0.81 \u00b1 0.16 0.79 \u00b1 0.09 NS\nActive vitamin D (?g/d) 0.36 \u00b1 0.34 0.37 \u00b1 0.32 0.28 \u00b1 0.20 NS\nElemental calcium (g/d) 0.84 \u00b1 0.41 0.71 \u00b10.42 0.82 \u00b1 0.39 NS\nElemental aluminium (g/d) 0.42 \u00b1 0.32 0.52 \u00b1 0.41 0.47 \u00b1 0.28 NS\nPresence of vascular calcifi cation\n Pelvis\n Hands\n\n21 (33.3)\n16 (27.0)\n9 (14.3)\n\n1 (5.6 ) \n1 (5.6)\n0 (0.0)\n\n9 (56.3)\n7 (43.8)\n3 (18.8)\n\n002\n017\nNS\n\nTabela 9.5. Associa\u00e7\u00e3o de calcifi ca\u00e7\u00f5es conjuntivais corneanas (CCC) \u00e0s calcifi ca\u00e7\u00f5es vasculares\n\nRefer\u00eancia: Seyahi N et al. Association of conjunctival and corneal calcifi cation with vascular calcifi cation \nin dialysis patients. Am J Kidney Dis 2005 45(3):550 -556\n\n6. Jung JY et al 6, num grupo de 69 doentes submetidos a di\u00e1lise peritoneal, analisaram \nos fatores associados \u00e0 rigidez arterial. Verifi caram que a fetu\u00edna -A e a PTH se \ncorrelacionaram inversamente e que a press\u00e3o arterial m\u00e9dia se correlacionou diretamente \ncom a velocidade de onda de pulso. A fetu\u00edna -A \u00e9 um inibidor da calcifi ca\u00e7\u00e3o vascular \ne estes autores demonstraram que um score de calcifi ca\u00e7\u00e3o vascular simples superior \n\nFig. 9.2. Um score de calcifi ca\u00e7\u00e3o vascular simples ? 2 (SVCS, simples vascular calcifi cation score) \nassociou -se a valores mais baixos de fetu\u00edna -A e mais elevados de velocidade de onda de pulso\n\nRefer\u00eancia: Jung JY et al. Factors associated with aortic stiffness and its change over time in peritoneal \ndialysis patients. Nephrol Dial Transplant 2010; 25. [Epub ahead of print.]\n\n(Continua\u00e7\u00e3o)\n\n\n\n142\n\na 2 se associou a valores mais baixos de fetu\u00edna -A e a valores mais elevados de velocidade \nde onda de pulso (Fig. 9.2).\n\n7. Este mesmo grupo7 verifi cou a const\u00e2ncia desta associa\u00e7\u00e3o inversa entre o score de \ncalcifi ca\u00e7\u00e3o vascular simples e os n\u00edveis de fetu\u00edna -A num grupo de 249 doentes \nem di\u00e1lise peritoneal (Tabela 9.6).\n\nParameter r P\n\nDependent variable : Fetuin \u2013 A\nSVCS - 0.468&lt;0.001\nhfPWV - 0.338&lt;0.001\nAge - 0.327&lt;0.001\nAlbumin 0.284 0.001\n\nMean \u00b1 SD P\n\nDiabetes Yes 0.32 \u00b1 0.08 0.002\nNo 0.35 \u00b1 0.07\n\nASVD history Yes 0.30 \u00b1 0.08 0.007\nNo 0.35 \u00b1 0.07\n\nSVCS: Simple vascular calcifi cation score. r : Pearson\u00b4s correlation coeffi cient. hfPWV: heart-to-femoral \npulse wave velocity.SD: standard deviation ASVD: Atherosclerotic vascular disease\n\nTabela 9.6. O score de calcifi ca\u00e7\u00e3o vascular simples (SVCS, simple vascular calcifi cation score) foi \num dos fatores que apresentou uma correla\u00e7\u00e3o negativa com os n\u00edveis s\u00e9ricos de fetu\u00edna -A\n\nRefer\u00eancia: Jung JY et al. Association of AHSG gene polymorphisms and aortic stiffness in peritoneal \ndialysis patients. Am J Nephrol 2010;31(6):510 -517.\n\n8. Kim SC et al 8 analisaram, num grupo de 93 doentes em di\u00e1lise peritoneal, as \nrela\u00e7\u00f5es entre os n\u00edveis de PTH, as calcifica\u00e7\u00f5es vasculares avaliadas pelo score \nde calcifica\u00e7\u00e3o vascular simples e pelo score coron\u00e1rio de Agatston e a rigidez \narterial avaliada pela velocidade de onda de pulso. Verificaram que os doentes \ncom valores mais baixos de PTH (<150 pg/mL) apresentavam mais calcifica\u00e7\u00f5es \n(SCVS ? 3). A presen\u00e7a de diabetes mellitus e os valores mais baixos de PTH \nforam preditores independentes de calcifica\u00e7\u00f5es vasculares (Tabela 9.7). Este \ngrupo mostrou ainda que um SCVS > 1 foi preditor de um score de calcifica\u00e7\u00e3o \ncoron\u00e1rio de Agatston > 400 (Tabela 9.8).\n\n\n\n143\n\nBinary logistic regression analysis of risk factors associated \nwith vascular calcifi cation score of ? 3 (forward method)\n\nVariable OR 95% CI p value\n\nDM 31.3 6.3 -155.8&lt;0.001\nPTH group (inter) 1.00  \u2013  \u2013\nPTH group (low) 5.75 1.27 -25.9 0.023\nPTH group (high) 4.19 0.85 -20.7 0.078\n\nOR, Odds ratio; CI, confi dence interval; DM, diabetes mellitus; PTII, parathyroid hormone. Excluded: \nage, cholesterol, HbAlc, and albumin \n\nTabela 9.7. A presen\u00e7a de diabetes mellitus e valores mais baixos de PTH foram preditores de um SCVS ? 3\n\nRefer\u00eancia: Kim SC et al. Low iPTH can predict vascular and coronary calcifi cations in patients \nundergoing peritoneal dialysis. Nephron Clin Pract 2010 6,117(2):c113 -c119. [Epub ahead of print.]\n\nBinary logistic regression analysis of factors associated \nwith a CAC score of ? 400 (forward method)\n\nVariables OR 95% CI p value\n\nSVCS ? 1 76.0 6.00 -962.3 0.001\n\nOR, Odds ratio; SVCS, simple vascular calcifi cation score. Excludes variables; diabetes mellitus, age, body \nmass index, HbAlc, and diastolic blood pressure.\n\nTabela 9.8. Um score de calcifi ca\u00e7\u00e3o vascular simples > 1 (SVCS, simple vascular calcifi cation score) foi \num preditor de um score de calcifi ca\u00e7\u00e3o coron\u00e1ria de Agatston > 400 (CAC, coronary artery calcifi cation)\n\nRefer\u00eancia: Kim SC et al. Low iPTH can predict vascular and coronary calcifi cations in patients undergoing \nperitoneal dialysis. Nephron Clin Pract 2010; 6,117(2):c113 -c119. [Epub ahead of print.]\n\n9. Garcia -Cant\u00f3n et al9 avaliaram as calcifi ca\u00e7\u00f5es vasculares num grupo de 210 doentes \nrenais cr\u00f3nicos n\u00e3o em di\u00e1lise (estadios 4 e 5), utilizando o score de calcifi ca\u00e7\u00e3o vascular \n\n25-Hydroxyvitamin D SVCS (Adrag\u00e3o) Kauppila\n\nDefi ciency (<15 ng/mL) Mean 4.8 \u00b1 2 / median 6 Mean 12 \u00b1 7 / median 13\nInsuffi ciency (15-30 ng/mL) Mean 3.7 \u00b1 3 / median 4 Mean 9.6 \u00b1 7 / median 9\nNormal (>30 ng/mL) Mean 2.3 \u00b1 2 / median 2 Mean 6.3 \u00b1 6 / median 3\n\nSVCS, simple vascular calcifi cation score.\n\nRefer\u00eancia: Garc\u00eda -Cant\u00f3n C, Bosch E, Ram\u00edrez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin \nD levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant \n2010; 18. [Epub ahead of print].\n\nTabela 9.9. N\u00edveis s\u00e9ricos de 25 -hidroxi -vitamina D e calcifi ca\u00e7\u00f5es vasculares em doentes n\u00e3o em di\u00e1lise\n\n\n\n144\n\nsimples descrito por n\u00f3s e o score de Kauppila10 avaliado na aorta abdominal; 120 \ndoentes (57%) apresentaram um SCVS>3; 114 doentes (54%) apresentaram um score \nde Kauppila >7. S\u00f3 18,5% desta popula\u00e7\u00e3o apresentava n\u00edveis s\u00e9ricos adequados de \n25 -hidroxivitamina D. Os n\u00edveis s\u00e9ricos baixos de 25 -hidroxivitamina D foram preditores \nindependentes de calcifi ca\u00e7\u00f5es vasculares avaliadas pelos dois m\u00e9todos.\n\nBinary logistic regression with SVCS\n\nVariables entering the equation\n\nOR 95% CI Signifi cance\n\nAge 1.058 1.021-1.096 0.002\nDiabetes 5.229 2.290-11.940 0.0001\nCVD 2.957 1.343-6.511 0.007\n25(OH)D 0.954 0.917-0.993 0.020\n\nSVCS, simple vascular calcifi cation score; CVD, cardiovascular disease.\n\nTabela 9.10. Preditores do score de calcifi ca\u00e7\u00e3o vascular simples\n\nRefer\u00eancia: Garc\u00eda -Cant\u00f3n C, Bosch E, Ram\u00edrez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin \nD levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. \n2010; 18. [Epub ahead of print.]\n\nBinary logistic regression with Kauppila\n\nVariables entering the equation\n\nOR 95% CI Signifi cance\n\nAge 1.103 1.061-1.146 0.0001\nCVD 2.609 1.249-5.450 0.011\n25(OH)D 0.953 0.918-0.992 0.017\n\nCVD, cardiovascular disease.\n\nTabela 9.11. Preditores de score de calcifi ca\u00e7\u00e3o de Kauppila.\n\nRefer\u00eancia: Garc\u00eda -Cant\u00f3n C, Bosch E, Ram\u00edrez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin \nD levels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant. \n2010; 18. [Epub ahead of print.]\n\nEste estudo reveste -se de particular import\u00e2ncia, pois \u00e9 o primeiro a avaliar as calcifi ca\u00e7\u00f5es \nvasculares utilizando RX simples num grupo de doentes renais cr\u00f3nicos n\u00e3o em di\u00e1lise, \nrevelando, nesta popula\u00e7\u00e3o, que a preval\u00eancia das calcifi ca\u00e7\u00f5es vasculares \u00e9 elevada. Tal \n\n\n\n145\n\ncomo foi demonstrado numa popula\u00e7\u00e3o em di\u00e1lise1, tamb\u00e9m nesta popula\u00e7\u00e3o se verifi cou \numa associa\u00e7\u00e3o inversa entre o score de calcifi ca\u00e7\u00e3o vascular simples e os n\u00edveis de \nhidroxivitamina D. O score de calcifi ca\u00e7\u00e3o vascular simples mostrou ser um instrumento \u00fatil \ncom resultados semelhantes aos obtidos com o score de Kauppila.\n\nA utiliza\u00e7\u00e3o do score de calcifi ca\u00e7\u00e3o vascular simples para avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es \nvasculares nos doentes em di\u00e1lise foi j\u00e1 sugerida por duas sociedades internacionais de \nnefrologia: pela Sociedade Espanhola de Nefrologia em SEN guidelines. Recommendations \nof the Spanish society of nephrology for managing bone -mineral metabolic alterations in \nchronic renal disease patients11 e pelo grupo de Estudos do Metabolismo Mineral e \u00d3sseo \nda Sociedade Uruguaia de Nefrologia, em Recomendaciones para el manejo de las alteraciones \ndel metabolismo mineral y oseo de la enfermedad renal cr\u00f3nica en estadio 512. O estudo \nOSERCE II observacional, de iniciativa da Sociedade Espanhola de Nefrologia, com in\u00edcio \nem 2009, pretende avaliar nos doentes renais cr\u00f3nicos nos estadios 3 a 5 altera\u00e7\u00f5es do \nmetabolismo mineral e \u00f3sseo, entre outras. Prev\u00ea a inclus\u00e3o de 1500 doentes. Um dos \npar\u00e2metros a analisar neste estudo \u00e9 a preval\u00eancia de calcifi ca\u00e7\u00f5es vasculares. Os m\u00e9todos \nescolhidos para diagn\u00f3stico das calcifi ca\u00e7\u00f5es vasculares foram dois scores avaliados em RX \nsimples: o score de calcifi ca\u00e7\u00e3o da aorta abdominal descrito por Kauppila L10 e o score de \ncalcifi ca\u00e7\u00e3o vascular simples descrito por n\u00f3s13.\n\nNos diferentes estudos efectuados por n\u00f3s, verifi camos que as calcifi ca\u00e7\u00f5es vasculares \navaliadas por este m\u00e9todo nos doentes renais cr\u00f3nicos foram preditoras de maior risco de \nmortalidade cardiovascular13, de mortalidade de causa global14, de maior risco de doen\u00e7a \ncoron\u00e1ria13 e de doen\u00e7a arterial perif\u00e9rica13. O score de calcifi ca\u00e7\u00e3o vascular simples foi ainda \num preditor independente de rigidez arterial 14 avaliada por velocidade de onda de pulso ou por \npress\u00e3o de pulso. Este score de calcifi ca\u00e7\u00e3o associou -se inversamente \u00e0 densidade mineral \u00f3ssea \ndo colo do f\u00e9mur, avaliada por dual energy X -ray absorptiometry (DXA)15. Em estudos efetuados \npor outros grupos foi demonstrado que as calcifi ca\u00e7\u00f5es vasculares avaliadas por este m\u00e9todo s\u00e3o \npreditoras de maior risco de eventos cardiovasculares3, de amputa\u00e7\u00f5es dos membros inferiores2, \nde velocidade de onda de pulso4,6, de calcifi ca\u00e7\u00f5es corneanas e conjuntivais5 e de calcifi ca\u00e7\u00f5es \ncoron\u00e1rias8. Tamb\u00e9m foi demonstrada uma associa\u00e7\u00e3o inversa entre o score de calcifi ca\u00e7\u00e3o \nvascular simples e os n\u00edveis de PTH 8, com os n\u00edveis de 25(OH)vitamina D1,9 e com os n\u00edveis \nde fetu\u00edna A6,7. O score de calcifi ca\u00e7\u00e3o vascular simples mostrou ser um instrumento \u00fatil para \na avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es vasculares tamb\u00e9m em doentes renais cr\u00f3nicos n\u00e3o em di\u00e1lise9.\n\nTodos estes estudos realizados por diferentes grupos, que utilizaram o score de calcifi ca\u00e7\u00e3o \nvascular simples na sua metodologia, comprovam a facilidade de utiliza\u00e7\u00e3o deste score, e a \nconcord\u00e2ncia de resultados comprova a sua reprodutibilidade e utilidade na avalia\u00e7\u00e3o dos \ndoentes renais cr\u00f3nicos.\n\n\n\n146\n\nCompara\u00e7\u00e3o entre o score de calcifi ca\u00e7\u00e3o vascular simples \ne o score de Kauppila.\n\nAs guidelines KDIGO 2009 sugerem que o conhecimento da presen\u00e7a de calcifi ca\u00e7\u00f5es \nvasculares pode ser usado para orientar o tratamento da doen\u00e7a mineral e \u00f3ssea nos \ndoentes renais cr\u00f3nicos e sugerem a avalia\u00e7\u00e3o de calcifi ca\u00e7\u00f5es vasculares na aorta \nabdominal10. Este score da aorta abdominal avaliado em RX simples foi comparado com \no score coron\u00e1rio de Agatston. Bellasi et al16 demonstraram que um score Kauppila \nsuperior ou igual a 7 apresentava uma elevada sensibilidade e especifi cidade para \ndiagnosticar um score de Agatston superior a 400 ou 1000. O score coron\u00e1rio de Agatston \n\u00e9 considerada a t\u00e9cnica gold -standard para a avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es coron\u00e1rias e \na\u00f3rticas17. Esta ser\u00e1 provavelmente a raz\u00e3o pela qual as guidelines KDIGO 2009 sugerem \na utiliza\u00e7\u00e3o do score de calcifi ca\u00e7\u00e3o na aorta abdominal avaliado em RX simples como \nalternativa ao score de Agatston. \u00c9 contudo necess\u00e1rio demonstrar que as calcifi ca\u00e7\u00f5es \ncoron\u00e1rias nos doentes renais cr\u00f3nicos s\u00e3o o paradigma do fen\u00f3meno de calcifi ca\u00e7\u00e3o \nvascular sist\u00e9mica nesta popula\u00e7\u00e3o.\n\nTivemos j\u00e1 a oportunidade de comparar o score de calcifi ca\u00e7\u00e3o vascular simples com o \nscore de calcifi ca\u00e7\u00e3o na aorta abdominal, ao estudarmos a doen\u00e7a arterial perif\u00e9rica num \ngrupo de 219 doentes em hemodi\u00e1lise18. Verifi camos que ambos os scores de calcifi ca\u00e7\u00e3o \ns\u00e3o preditores de um \u00edndice tornozelo -bra\u00e7o&lt;0,9, apresentando uma semelhante \u00e1rea sob a \ncurva. O score de calcifi ca\u00e7\u00e3o vascular simples superior a 3 teve uma sensibilidade de 73% \ne uma especifi cidade de 86% para identifi car um score de calcifi ca\u00e7\u00e3o aorticoabdominal \nsuperior a 6. O score de calcifi ca\u00e7\u00e3o vascular simples permite ainda identifi car calcifi ca\u00e7\u00f5es \nem art\u00e9rias colaterais e distais, sendo este tipo de calcifi ca\u00e7\u00f5es preditoras de um \u00edndice \ntornozelo -bra\u00e7o >1,3. O padr\u00e3o t\u00edpico da calcifi ca\u00e7\u00e3o vascular neste territ\u00f3rio arterial (art\u00e9rias \ncolaterais e distais) \u00e9 linear, correspondendo \u00e0 calcifi ca\u00e7\u00e3o da camada m\u00e9dia da parede \narterial descrita por London19. A calcifi ca\u00e7\u00e3o da \u00edntima e da m\u00e9dia s\u00e3o preditores independentes \nde mortalidade nos doentes em di\u00e1lise19. Ao contr\u00e1rio do score de calcifi ca\u00e7\u00e3o vascular \nsimples, o score de calcifi ca\u00e7\u00e3o aorticoabdominal n\u00e3o identifi ca este tipo de calcifi ca\u00e7\u00e3o da \nm\u00e9dia. Futuros estudos poder\u00e3o avaliar a vantagem cl\u00ednica de distinguir os dois tipos de \ncalcifi ca\u00e7\u00e3o vascular nestes doentes.\n\nGarc\u00eda -Cant\u00f3n et al tamb\u00e9m utilizaram os dois m\u00e9todos, o score de calcifi ca\u00e7\u00e3o vascular \nsimples e o score Kauppila, na avalia\u00e7\u00e3o das calcifi ca\u00e7\u00f5es vasculares na mesma popula\u00e7\u00e3o9. \nOs resultados obtidos pelos dois m\u00e9todos foram muito semelhantes. Kim et al verifi caram \nque um score de calcifi ca\u00e7\u00e3o vascular simples foi um preditor independente de um score \ncoron\u00e1rio de Agatston > 4008.\n\n\n\n147\n\nCalcifi ca\u00e7\u00f5es vasculares em doentes renais cr\u00f3nicos: \nquest\u00f5es ainda em avalia\u00e7\u00e3o\n\nTal como outros, defendemos a hip\u00f3tese da exist\u00eancia de um elo de liga\u00e7\u00e3o entre as \naltera\u00e7\u00f5es do metabolismo mineral e \u00f3sseo e a doen\u00e7a cardiovascular na doen\u00e7a renal cr\u00f3nica. \nAs calcifi ca\u00e7\u00f5es vasculares s\u00e3o um dos elementos desta associa\u00e7\u00e3o e resultam da transforma\u00e7\u00e3o \nfenot\u00edpica das c\u00e9lulas musculares lisas da parede dos vasos. A hipercalcemia e a hiperfosfatemia \ns\u00e3o alguns dos fatores respons\u00e1veis por este processo celular ativo20, estabelecendo o elo de \nliga\u00e7\u00e3o entre as altera\u00e7\u00f5es minerais e as calcifi ca\u00e7\u00f5es vasculares. Barreto D et al demonstraram \nque a progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares se associam as altera\u00e7\u00f5es do metabolismo \n\u00f3sseo21. Em situa\u00e7\u00f5es de baixa ou de alta remodela\u00e7\u00e3o \u00f3ssea, o osso \u00e9 incapaz de exercer a \nsua fun\u00e7\u00e3o de tamp\u00e3o que permite a manuten\u00e7\u00e3o do c\u00e1lcio s\u00e9rico nos limites adequados e, \nno caso de se verifi car hipercalcemia, o dep\u00f3sito extra\u00f3sseo de c\u00e1lcio \u00e9 obrigat\u00f3rio22,23. London \net al foram os primeiros a demonstrar, num grupo de doentes em hemodi\u00e1lise, associa\u00e7\u00e3o \nentre calcifi ca\u00e7\u00f5es vasculares e baixa remodela\u00e7\u00e3o \u00f3ssea diagnosticada por biopsia \u00f3ssea24.O \nnosso grupo foi o primeiro a demonstrar, tamb\u00e9m em doentes em hemodi\u00e1lise, uma associa\u00e7\u00e3o \nentre calcifi ca\u00e7\u00f5es vasculares e baixo volume \u00f3sseo diagnosticado por biopsia \u00f3ssea25. Fomos \nigualmente os primeiros a verifi car, num grupo de doentes em di\u00e1lise peritoneal, uma associa\u00e7\u00e3o \nentre calcifi ca\u00e7\u00f5es vasculares e a baixa densidade mineral \u00f3ssea avaliada no colo do f\u00e9mur15. \nA import\u00e2ncia deste achado foi demonstrada pela associa\u00e7\u00e3o, descrita por n\u00f3s, tamb\u00e9m pela \nprimeira vez, entre a densidade mineral \u00f3ssea avaliada no colo do f\u00e9mur e a porosidade cortical \nmedida em biopsia \u00f3ssea26. Os nossos diferentes trabalhos refor\u00e7am assim esta hip\u00f3tese da \nexist\u00eancia de um elo de liga\u00e7\u00e3o entre o osso e o vaso na doen\u00e7a renal cr\u00f3nica.\n\nExistem ainda algumas quest\u00f5es sem resposta defi nitiva. Ser\u00e3o as calcifi ca\u00e7\u00f5es da camada \nm\u00e9dia e da \u00edntima da parede arterial duas entidades diferentes ou uma diferente manifesta\u00e7\u00e3o \nda mesma patologia? No doente renal cr\u00f3nico, as calcifi ca\u00e7\u00f5es podem surgir em diversos \ntipos de art\u00e9rias, desde as art\u00e9rias el\u00e1sticas \u00e0s art\u00e9rias musculares, mas nem todas as art\u00e9rias \ndesenvolvem aterosclerose. A aorta tor\u00e1cica e as art\u00e9rias dos membros superiores, por exemplo, \nparecem resistentes ao processo ateroscler\u00f3tico. Haimovici H demonstrou, com estudos de \ntransposi\u00e7\u00e3o de art\u00e9rias em c\u00e3es, que a aorta tor\u00e1cica, independentemente do local para onde \nera transposta, se mantinha resistente \u00e0 aterosclerose, enquanto o inverso se verifi cava com \na aorta abdominal 27.\n\nMcCullough PA et al defendem a hip\u00f3tese de que a calcifi ca\u00e7\u00e3o ateroscler\u00f3tica e a \ncalcifi ca\u00e7\u00e3o da m\u00e9dia s\u00e3o um cont\u00ednuo da patologia vascular na doen\u00e7a renal cr\u00f3nica e que \na esclerose de Monckberg, que corresponde \u00e0 calcifi ca\u00e7\u00e3o da m\u00e9dia, corresponde a um processo \nde aterosclerose avan\u00e7ada28. Esta hip\u00f3tese foi revogada por Amann K, demonstrando que \n\n\n\n148\n\nestes dois tipos de calcifi ca\u00e7\u00e3o s\u00e3o distintos sob os pontos de vista histol\u00f3gico, fi siopatol\u00f3gico \ne cl\u00ednico, e que a calcifi ca\u00e7\u00e3o da m\u00e9dia pode preceder a calcifi ca\u00e7\u00e3o da \u00edntima29. A calcifi laxis \n\u00e9 um tipo muito particular de calcifi ca\u00e7\u00e3o da camada m\u00e9dia que afeta as arter\u00edolas da pele e \n\u00e9 um processo independente da aterosclerose.\n\nA possibilidade de estabiliza\u00e7\u00e3o ou regress\u00e3o das calcifi ca\u00e7\u00f5es vasculares \u00e9 outra quest\u00e3o \namplamente debatida. J\u00e1 se demonstrou que um captador de f\u00f3sforo \u00e0 base de c\u00e1lcio pode \naumentar a progress\u00e3o das calcifi ca\u00e7\u00f5es coron\u00e1rias30 -32, mas este achado n\u00e3o foi universal33,34. \nA patologia \u00f3ssea, impedindo o osso de se comportar como tamp\u00e3o para o c\u00e1lcio, \u00e9 uma das \nexplica\u00e7\u00f5es para a progress\u00e3o das calcifica\u00e7\u00f5es vasculares22,23. O cinacalcet, agente \ncalcimim\u00e9tico usado no tratamento do hiperparatiroidismo secund\u00e1rio, tamb\u00e9m pode afetar \na progress\u00e3o das calcifi ca\u00e7\u00f5es. Os resultados do estudo ADVANCE foram apresentados na \nsess\u00e3o \u201cLate Breaking Trials\u201d durante o XLVVII ERA -EDTA Congress 2010, em Munique. \nEste estudo comparou, num grupo de doentes em hemodi\u00e1lise, o efeito da terap\u00eautica conjunta \nde cinacalcet e dose baixa de vitamina D com a terap\u00eautica com doses fl ex\u00edveis de vitamina \nD e demonstrou uma redu\u00e7\u00e3o signifi cativa da progress\u00e3o das calcifi ca\u00e7\u00f5es na v\u00e1lvula a\u00f3rtica \nno grupo tratado com cinacalcet. A progress\u00e3o das calcifi ca\u00e7\u00f5es coron\u00e1rias, o par\u00e2metro de \nefi c\u00e1cia prim\u00e1rio, n\u00e3o atingiu diferen\u00e7a com signifi cado estat\u00edstico entre os dois grupos.\n\nA semelhan\u00e7a entre a remodela\u00e7\u00e3o \u00f3ssea e a calcifi ca\u00e7\u00e3o vascular est\u00e1 na base de in\u00fameros \nestudos que avaliaram o efeito dos bifosfonatos na progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares35. \nOs bifosfonatos inibem a calcifi ca\u00e7\u00e3o vascular em modelos animais de insufi ci\u00eancia renal \ncr\u00f3nica. Este efeito tamb\u00e9m se verificou em quatro estudos envolvendo doentes em \nhemodi\u00e1lise36 -39, mas o n\u00famero de doentes avaliados nestes estudos foi pequeno e s\u00f3 dois \ndeles randomizados. A normaliza\u00e7\u00e3o da fun\u00e7\u00e3o renal obtida com a transplanta\u00e7\u00e3o renal \u00e9 \noutro fator que pode infl uenciar a progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares. At\u00e9 agora, o efeito \nda transplanta\u00e7\u00e3o renal na progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares foi analisado apenas em \nalguns estudos que envolveram um pequeno n\u00famero de doentes. Verifi cou -se uma estabiliza\u00e7\u00e3o \ndas calcifi ca\u00e7\u00f5es coron\u00e1rias em dois destes estudos40,41 e a progress\u00e3o das calcifi ca\u00e7\u00f5es \nnoutro42. Em doentes renais cr\u00f3nicos n\u00e3o em di\u00e1lise j\u00e1 foi demonstrado que existe progress\u00e3o \nacelerada das calcifi ca\u00e7\u00f5es coron\u00e1rias, em compara\u00e7\u00e3o com indiv\u00edduos com fun\u00e7\u00e3o renal \nnormal43, e a altera\u00e7\u00e3o da fun\u00e7\u00e3o renal ap\u00f3s a transplanta\u00e7\u00e3o renal pode explicar essa \nprogress\u00e3o. O tiossulfato de s\u00f3dio, ant\u00eddoto do cianeto e usado em casos de toxicidade da \ncisplatina, tem sido tamb\u00e9m aplicado com sucesso no tratamento de casos de arteriolopatia \nur\u00e9mica c\u00e1lcica, tamb\u00e9m denominada calcifi laxis. Esta patologia traduz -se histologicamente \npor calcifi ca\u00e7\u00e3o da camada m\u00e9dia de arter\u00edolas do tecido celular subcut\u00e2neo com fi brose \nendovascular e trombose. Este agente antioxidante consegue sequestrar i\u00f5es c\u00e1lcio e formar \ncompostos de c\u00e1lcio muito sol\u00faveis, impedindo a sua precipita\u00e7\u00e3o44.\n\n\n\n149\n\nEm resumo, o desenvolvimento e a progress\u00e3o das calcifica\u00e7\u00f5es vasculares nos \ndoentes renais cr\u00f3nicos s\u00e3o processos complexos para os quais contribuem in\u00fameros \nfatores indutores e inibidores, muito provavelmente em associa\u00e7\u00e3o com o estado da \nremodela\u00e7\u00e3o \u00f3ssea e da capacidade ou incapacidade de o osso se comportar como tamp\u00e3o \npara o c\u00e1lcio. O diagn\u00f3stico das calcifica\u00e7\u00f5es vasculares pode ser um instrumento \u00fatil \nna orienta\u00e7\u00e3o terap\u00eautica destes doentes. V\u00e1rias t\u00e9cnicas n\u00e3o invasivas permitem fazer \no rastreio de calcifica\u00e7\u00f5es vasculares, mas, independentemente do m\u00e9todo usado, pensamos \nque o importante \u00e9 que as calcifica\u00e7\u00f5es vasculares sejam diagnosticadas nos doentes \nrenais cr\u00f3nicos.\n\nCongratulamo -nos com o facto de dois dos nossos estudos13,14 terem sido inclu\u00eddos nas \nrefer\u00eancias das guidelines KDIGO 2009 nas tabelas da preval\u00eancia das calcifi ca\u00e7\u00f5es \nvasculares (KDIGO 2009: Tabela suplementar 10, Fig. 3.6) e da associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es \nvasculares e mortalidade (KDIGO 2009: Tabela suplementar 12, Fig. 3.7). A inclus\u00e3o destes \nnossos dois estudos nas refer\u00eancias destas guidelines que utilizaram o exigente sistema \nGRADE (grades of recommendation, assessment, development, and evaluation) na \nclassifi ca\u00e7\u00e3o e sele\u00e7\u00e3o dos estudos valida o interesse cient\u00edfi co destes dois trabalhos.\n\nA presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares identifi ca os doentes com mais elevado risco \ncardiovascular. Concordamos com a sugest\u00e3o das guidelines KDIGO 2009, que considera \nque a presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares nos doentes renais cr\u00f3nicos nos est\u00e1dios 3 a 5 \u00e9 \numa informa\u00e7\u00e3o que pode ser usada para orientar o tratamento da doen\u00e7a mineral e \u00f3ssea \nnestes doentes. \u00c9 necess\u00e1rio contudo ainda analisar se a aus\u00eancia de desenvolvimento ou \nde progress\u00e3o das calcifi ca\u00e7\u00f5es vasculares se associa a uma redu\u00e7\u00e3o da morbilidade ou da \nmortalidade nestes doentes. \u00c9 necess\u00e1rio tamb\u00e9m avaliar se uma atua\u00e7\u00e3o diagn\u00f3stica e \nterap\u00eautica nos estadios mais precoces da doen\u00e7a renal cr\u00f3nica poder\u00e1 ter efeito na redu\u00e7\u00e3o \nda progress\u00e3o da doen\u00e7a \u00f3ssea e do risco cardiovascular nestes doentes.\n\nRefer\u00eancias\n\n  1. Matias PJ, Ferreira C, Jorge C, et al. 25 -hydroxyvitamin D3, arterial calcifi cations and cardiovascular \nrisk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24(2):611 -618.\n\n  2. Matias P, Aires I, Jorge C, Factors associated with lower -extremity amputations in haemodialysis \npatients. Port J Nephrol Hypert 2008; 22(1): 31 -36.\n\n  3. Wei T, Wang M, Wang Mi, et al. Relationship of sRANKL level and vascular calcifi cation score \nto cardiovascular events in maintenance hemodialysis patients. Blood Purif 2009;28:34 -345.\n\n  4. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Schurgers L, Kr\u00fcger T, \nWestenfeld R, Ackermann D, Haselhuhn A, Dimkovic S, Ketteler M, Floege J, Dimkovic N. Risk \n\n\n\n150\n\nfactors for cardiovascular calcifi cations in non -diabetic Caucasian haemodialysis patients. Kidney \nBlood Pres Res 2009;32(3):161 -168.\n\n  5. Seyahi N, Altiparmak MR, Kahveci A, Yetik H, Kanberoglu K, Serdengecti K, Ataman R, Erek \nE. Association of conjunctival and corneal calcifi cation with vascular calcifi cation in dialysis \npatients. Am J Kidney Dis 2005;45(3):550 -556.\n\n  6. Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over \ntime in peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25. [Epub ahead of print.]\n\n  7. Jung JY, Hwang YH, Lee H, et al. Association of AHSG gene polymorphisms and aortic stiffness \nin peritoneal dialysis patients. Am J Nephrol 2010;31(6):510 -517.[ Epub 2010 May 7.]\n\n  8. Kim SC, Kim HW, Oh SW, Yang HN, Kim MG, Jo SK, Cho WY, Kim HK. Low iPTH can predict \nvascular and coronary calcifi cations in patients undergoing peritoneal dialysis. Nephron Clin Pract \n2010; (6)117(2):c113 -c119. [Epub ahead of print.]\n\n  9. Garc\u00eda -Canton C, Bosch E, Ram\u00edrez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin D \nlevels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant \n2010; 18. [Epub ahead of print.]\n\n10. Kauppila LI, Polak JF, Cupples LA, et al. New indices to classify location, severity and progression \nof calcifi c lesions in the abdominal aorta: a 25 -year follow -up study. Atherosclerosis 1997;132(2):245-\n-250.\n\n11. Torregrosa JV, Cannata Andia J, Bover J, Caravaca F, Lorenzo V, Mart\u00edn de Francisco AL, Mart\u00edn-\n-Malo A, Mart\u00ednez I, Gonz\u00e1lez Parra E, Fern\u00e1ndez Gir\u00e1ldez E, Rodr\u00edguez Portillo M, Sociedad \nEspa\u00f1ola de Nefrologia. SEN guidelines. Recommendations of the Spanish Society of Nephrology \nfor managing bone -mineral metabolic alterations in chronic renal disease patients. Nefrologia \n2008;28 (Suppl 1):1 -22.\n\n12. Grupo de Estudio de Alteraciones del Metabolismo Mineral y \u00d3seo, Fajardo L, Olaizola I, Alvarez \nA, Petraglia A, Mimbacas C, Caorsi H, Ambrosoni P. Recomendaciones para el manejo de las \nalteraciones del metabolismo mineral y oseo de la enfermedad renal cr\u00f3nica en 2008. de nefrolog\u00eda, \nc de nefrologia,2008. nefrouruguay.com\n\n13. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. A simple vascular \ncalcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant \n2004;19(6):1480 -1488.\n\n14. Adrag\u00e3o T, Pires A, Birne R, Curto JD, Lucas C, Gon\u00e7alves M, Negr\u00e3o AP. A plain X -ray vascular \ncalcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol \nDial Transplant 2009;24(3):997 -1002.\n\n15. Adrag\u00e3o T, Branco P, Birne R, Curto JD, Almeida E, Prata MM, Pais MJ.Bone mineral density, \nvascular calcifications, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int \n2008;28(6):668 -672.\n\n16. Bellasi A, Ferramosca E, Muntner P, et al. Correlation of simple imaging tests and coronary artery calcium \nmeasured by computed tomography in hemodialysis patients. Kidney Int 2006; 70: 1623 -1628.\n\n\n\n151\n\n17. Bellasi A, Raggi P. Techniques and technologies to assess vascular calcifi cation. Semin Dial 2007; \n20(2):129 -133.\n\n18. Adrag\u00e3o T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Joaquim Bordalo J, Prata MM. \nAnkle brachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus \n2010; 3: (Suppl 3): iii492 (Abstract Su545).\n\n19. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: \nimpact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731 -1740.\n\n20. Giachelli CM. Vascular calcifi cation mechanisms. J Am Soc Nephrol 2004:15:2959 -2964.\n21. Barreto DV, Barreto F C, Carvalho AB, et al. Association of changes in bone remodelling and \n\ncoronary calcifi cation in hemodialysis patients: a prospective study. Am J Kidney Dis 2008; 6: \n1139 -1150.\n\n22. Braun J. Extraosseous calcifi cation in patients with chronic renal failure \u2013 no escape? Nephrol \nDial Transplant 2005; 20: 2054 -2059.\n\n23. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fl uid calcium \ncontent. Clin J Am Soc Nephrol 2010; 5: S12 -S22.\n\n24. London GM, Marty C, Marchais SJ, et al. Arterial calcifi cations and bone histomorphometry in \nend -stage renal disease. J Am Soc Nephrol 2004; 15: 1943 -1951.\n\n25. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Dias Curto J, \nMalluche HH. Low bone volume \u2013 A risk factor for coronary calcifi cations in hemodialysis patients. \nClin J Am Soc Nephrol 2009; 4(2): 450 -455.\n\n26. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Malluche HH. \nFemoral bone mineral density reflects histologically determined cortical bone volume in \nhemodialysis patients. Osteoporos Int 2010; 4: 619 -625.\n\n27. Haimovici H. The role of arterial tissue suceptibility in atherogenesis. Tex Heart Inst 1991; 18: \n81 -83.\n\n28. McCullough PA, Agrawal V, Danielewicz E, et al. Accelerated atherosclerotic calcifi cation and \nMonckeberg\u2019s sclerosis: A continuum of advanced vascular pathology in chronic kidney disease. \nClin J Am Soc Nephrol 2008; 3:1585 -1598.\n\n29. Amann K. Media calcifi cation and intima calcifi cation are distinct entities in chronic kidney \ndisease. Clin J Am Soc Nephrol 2008; 3: 1599 -1605.\n\n30. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic \ncalcifi cation in hemodialysis patients. Kidney Int 2002; 62: 245 -252.\n\n31. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery \ncalcifi cation in patients new to hemodialysis. Kidney Int 2005; 68: 1815 -1824.\n\n32. Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcifi cation in predialysis \npatients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255 -1261.\n\n33. Qunibi W, Moustafa M, Muenz LR, et al. A 1 -year randomized trial of calcium acetate versus \nsevelamer on progression of coronary artery calcifi cation in hemodialysis patients with comparable \n\n\n\n152\n\nlipid control: the calcium acetate renagel evaluation -2 (CARE -2) study. Am J Kidney Dis 2008; \n51: 952 -965.\n\n34. Barreto DV, Barreto F, Carvalho AB, et al. Phosphate binder impact on bone remodeling and \ncoronary calcifi cation -results from the BRiC study. Nephron 2008; 110: 273 -283.\n\n35. Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential \nbenefi ts and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2009; 4: 221 -233.\n\n36. Nitta K, Akiba T, Suzuki K, et al. Effects of cyclic intermittent etidronate therapy on coronary \nartery calcifi cation in patients receiving long -term hemodialysis. Am J Kidney Dis 2004; 44: 680-\n-688.\n\n37. Hashiba H, Aizawa S, Tamura K, et al: Inhibitory effects of etidronate on the progression of \nvascular calcifi cation in hemodialysis patients. Ther Apher Dial 2004; 8 (3): 241 -247.\n\n38. Hashiba H, Aizawa S, Tamura K, et al: Inhibition of the progression of aortic calcifi cation by \netidronate treatment in hemodialysis patients: Long -term effects. Ther Apher Dial 2006; 10: 59-\n-64.\n\n39. Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T. Effect of etidronic acid on arterial \ncalcifi cation in dialysis patients. Clin Drug Investig 2006; 26: 215 -222.\n\n40. Moe, SM, O\u2019Neill, KD, Resterova, M, et al. Natural history of vascular calcifi cation in dialysis \nand transplant patients. Nephrol Dial Transplant 2004; 19:2387 -2393.\n\n41. Oschatz, E, Benesch, T, Kodras, K, et al. Changes of coronary calcifi cation after kidney \ntransplantation. Am J Kidney Dis 2006; 48:307.\n\n42. Schankel, K, Robinson, J, Bloom, RD, et al. Determinants of coronary artery calcifi cation \nprogression in renal transplant recipients. Am J Transplant 2007; 7:2158 -2164.\n\n43. Russo D, Corrao S, Miranda I, et al. Progression of coronary artery calcifi cation in predialysis \npatients. Am J Nephrol 2007;27(2):152 -158.\n\n44. Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcifi c \nuremic arteriolopathy. Nat Rev Nephrol 2009; 5(9):539 -543.\n\n\n\n153\n\nCAP\u00cdTULO 10\n\nRESUMO DA DISSERTA\u00c7\u00c3O\n\nA presente disserta\u00e7\u00e3o para tese de doutoramento apresenta o desenvolvimento e a \nvalida\u00e7\u00e3o de um m\u00e9todo simples e original para o diagn\u00f3stico de calcifi ca\u00e7\u00f5es vasculares em \ndoentes em di\u00e1lise, utilizando um score semiquantitativo criado por n\u00f3s e obtido em RX \nsimples da bacia e das m\u00e3os, denominado score de calcifi ca\u00e7\u00e3o vascular simples. Demonstramos \nque este score vascular simples \u00e9 preditor de risco cardiovascular nos doentes em di\u00e1lise. O \nscore de calcifi ca\u00e7\u00e3o vascular simples associou -se ainda \u00e0 baixa densidade mineral \u00f3ssea \navaliada por dual energy X -ray absortiometry (DXA) no colo do f\u00e9mur. Verifi camos igualmente \nque, em doentes em di\u00e1lise, as calcifi ca\u00e7\u00f5es coron\u00e1rias quantifi cadas pelo score de Agatston \ne o score de calcifi ca\u00e7\u00e3o vascular simples se associaram a um menor volume \u00f3sseo avaliado \nem biopsias \u00f3sseas. Estes trabalhos corroboram a hip\u00f3tese da exist\u00eancia de um elo de liga\u00e7\u00e3o \nentre a doen\u00e7a \u00f3ssea e a doen\u00e7a vascular nos doentes em di\u00e1lise, e um dos elementos que \ncontribuem para este elo de liga\u00e7\u00e3o podem ser as calcifi ca\u00e7\u00f5es vasculares.\n\nEste score de calcifi ca\u00e7\u00e3o vascular simples avalia calcifi ca\u00e7\u00f5es em art\u00e9rias de grande, \nm\u00e9dio e pequeno calibre, e inclui os dois padr\u00f5es radiol\u00f3gicos de calcifi ca\u00e7\u00e3o: calcifi ca\u00e7\u00e3o \nlinear, associada \u00e0 calcifi ca\u00e7\u00e3o da camada m\u00e9dia da parede arterial, e calcifi ca\u00e7\u00e3o irregular, \nassociada \u00e0 calcifi ca\u00e7\u00e3o da camada \u00edntima arterial1. Nos diferentes trabalhos por n\u00f3s publicados \ndemonstramos que as calcifi ca\u00e7\u00f5es vasculares avaliadas por este m\u00e9todo simples e barato \npermitem a identifi ca\u00e7\u00e3o de indiv\u00edduos com elevado risco cardiovascular. Este score vascular \nassocia -se a maior risco de mortalidade cardiovascular2, de mortalidade de causa global3, de \ninternamentos cardiovasculares2, de doen\u00e7a cardiovascular2, de doen\u00e7a arterial perif\u00e9rica2,4, \nde calcifi ca\u00e7\u00f5es valvulares5 e de rigidez arterial3.\n\nAs guidelines KDIGO (Kidney disease: improving global outcomes), publicadas em 2009, \nsugerem que os doentes renais cr\u00f3nicos nos estadios 3 a 5, com calcifi ca\u00e7\u00f5es vasculares e \nvalvulares, devem ser considerados como apresentando o mais elevado risco cardiovascular6. \nA elevada mortalidade dos doentes renais cr\u00f3nicos n\u00e3o \u00e9 totalmente explicada pelos fatores \nde risco tradicionais7. A organiza\u00e7\u00e3o KDIGO defende, desde 2006, a hip\u00f3tese da exist\u00eancia de \num elo de liga\u00e7\u00e3o entre a doen\u00e7a \u00f3ssea e a doen\u00e7a vascular8. Esta liga\u00e7\u00e3o pode ser explicada \npelas altera\u00e7\u00f5es do metabolismo mineral e \u00f3sseo e pela sua intera\u00e7\u00e3o com as calcifi ca\u00e7\u00f5es \nvasculares. Verifi camos, nos nossos trabalhos, uma associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares \n\n\n\n154\n\ne doen\u00e7a \u00f3ssea. O baixo volume \u00f3sseo diagnosticado por an\u00e1lise histomorfom\u00e9trica de biopsias \n\u00f3sseas foi preditor de maior risco de calcifi ca\u00e7\u00f5es vasculares avaliadas pelo score de calcifi ca\u00e7\u00e3o \nvascular simples (dados apresentados nesta disserta\u00e7\u00e3o, no cap\u00edtulo 6) e pelo score coron\u00e1rio \nde Agatston num grupo de doentes em di\u00e1lise9. A contribui\u00e7\u00e3o original deste artigo9 foi \nconsiderada merecedora de um editorial feito pelo Dr. G\u00e9rard London10, investigador l\u00edder na \n\u00e1rea da calcifi ca\u00e7\u00e3o vascular dos doentes renais cr\u00f3nicos e actual Presidente da EDTA (European \nDialysis and Transplantation Association). Fomos tamb\u00e9m os primeiros a descrever uma \nassocia\u00e7\u00e3o independente e inversa entre a densidade mineral avaliada no colo do f\u00e9mur por \nDXA (dual energy X -ray absortiometry) com calcifi ca\u00e7\u00f5es vasculares avaliadas pelo score de \ncalcifi ca\u00e7\u00e3o vascular simples, com rigidez arterial avaliada por velocidade de onda de pulso \ncarotidofemoral e com doen\u00e7a arterial perif\u00e9rica diagnosticada por crit\u00e9rios cl\u00ednicos11. Fomos \nigualmente os primeiros a mostrar uma correla\u00e7\u00e3o signifi cativa entre a densidade mineral \u00f3ssea \navaliada por DXA no colo do f\u00e9mur, mas n\u00e3o na coluna lombar, com a espessura cortical \navaliada por an\u00e1lise histomorfom\u00e9trica em biopsia \u00f3ssea12. O nosso estudo atribui pela primeira \nvez \u00e0 DXA um papel no diagn\u00f3stico de porosidade cortical nos doentes em di\u00e1lise. A utilidade \nda avalia\u00e7\u00e3o diferencial da densidade mineral \u00f3ssea cortical e trabecular necessita ainda de ser \nconfi rmada em estudos prospectivos. Este achado inovador do nosso estudo foi mencionado \npela ERBP (European Renal Best Practice) no coment\u00e1rio feito \u00e0 posi\u00e7\u00e3o da KDIGO que \nconsidera ser reduzida a utilidade da densidade mineral \u00f3ssea nos doentes em di\u00e1lise13.\n\nDois dos trabalhos inclu\u00eddos nesta disserta\u00e7\u00e3o foram referenciados nas guidelines KDIGO \n2009 para avaliar a preval\u00eancia das calcifi ca\u00e7\u00f5es vasculares (KDIGO 2009: Tabela suplementar \n10, Fig. 3.6) e para validar a associa\u00e7\u00e3o entre calcifi ca\u00e7\u00f5es vasculares e mortalidade \ncardiovascular (KDIGO 2009: Tabela suplementar 12, Fig. 3.7)6. A inclus\u00e3o destes nossos \ndois estudos nas refer\u00eancias destas guidelines, que utilizaram o exigente sistema GRADE \n(Grades of recommendation, assessment, development, and evaluation) na classifi ca\u00e7\u00e3o e \nselec\u00e7\u00e3o dos estudos, valida o interesse cient\u00edfi co dos nossos trabalhos.\n\nO diagn\u00f3stico de calcifi ca\u00e7\u00f5es vasculares tem um interesse pr\u00e1tico para os doentes renais \ncr\u00f3nicos. A presen\u00e7a de calcifi ca\u00e7\u00f5es vasculares \u00e9 um sinal de alerta para a exist\u00eancia de um \nelevado risco cardiovascular, e esta informa\u00e7\u00e3o pode ser utilizada para modifi car a terap\u00eautica \nnestes doentes6. Diferentes m\u00e9todos podem ser usados para diagnosticar calcifi ca\u00e7\u00f5es vasculares \nnos doentes em di\u00e1lise14,15. O score de calcifi ca\u00e7\u00e3o vascular simples tem a vantagem da \nsimplicidade e de poder ser facilmente interpretado pelo nefrologista, sem necessidade de um \nradiologista. A reprodutibilidade deste score j\u00e1 foi demonstrada por diferentes grupos em estudos \nnacionais e internacionais16 -24. Nestes estudos foi demonstrado que as calcifi ca\u00e7\u00f5es vasculares \navaliadas pelo m\u00e9todo criado por n\u00f3s s\u00e3o preditoras de maior risco de eventos cardiovasculares16, \nde amputa\u00e7\u00f5es dos membros inferiores17, de velocidade de onda de pulso18,19, de calcifi ca\u00e7\u00f5es \n\n\n\n155\n\ncorneanas e conjuntivais20 e de calcifi ca\u00e7\u00f5es coron\u00e1rias21. Tamb\u00e9m foi demonstrada uma \nassocia\u00e7\u00e3o inversa entre o score de calcifi ca\u00e7\u00e3o vascular simples com os n\u00edveis s\u00e9ricos de \nPTH21, com os n\u00edveis de 25(OH)vitamina D 22,23 e com os n\u00edveis de fetu\u00edna A19,24.\n\nTodos estes estudos, realizados por diferentes grupos, que utilizaram o score de calcifi ca\u00e7\u00e3o \nvascular simples na sua metodologia, comprovam a facilidade de utiliza\u00e7\u00e3o deste score e a \nconcord\u00e2ncia de resultados atestam a sua reprodutibilidade e a utilidade na avalia\u00e7\u00e3o dos \ndoentes renais cr\u00f3nicos.\n\nAbstract\n\nThis thesis presents the development and validation of a simple and original method to \nidentify vascular calcifi cations in dialysis patients, using a semi -quantitative score that we \nhave created and that is obtained in plain X -ray of pelvis and hands. This score was named \nin different publications as \u201csimple vascular calcifi cation score\u201d.\n\nWe have demonstrated that this score is a predictor of higher cardiovascular risk in dialysis \npatients. The simple vascular calcifi cation score was also associated with lower mineral bone \ndensity evaluated by DXA in femoral neck. In hemodialysis patients coronary calcifi cations \nevaluated by the coronary Agatston score and by the simple vascular calcifi cation score were \nassociated with lower bone volume analysed in bone biopsies. These studies corroborate the \nhypothesis of the existence of a link between bone disease and vascular disease in dialysis \npatients and one of the elements of this link may be vascular calcifi cations.\n\nThis simple vascular calcifi cation score identifi es calcifi cations in large, medium and small \ncalibre arteries and includes the two radiological patterns of arterial calcifi cation: linear calcifi cation \nwhich has been associated with the calcifi cation of the media layer of the arterial wall and irregular \nand patchy calcifi cation which has been associated with the calcifi cation of the intima layer of \nthe arterial wall1. In the several studies that we have published we have demonstrated that vascular \ncalcifi cations evaluated by this simple and inexpensive method allow the identifi cation of patients \nwith high cardiovascular risk. This simple vascular calcifi cation score is an independent predictor \nof cardiovascular mortality2, all -cause mortality3, cardiovascular hospitalizations2, cardiovascular \ndisease2, peripheral artery disease2,4, valvular calcifi cations5 and arterial stiffness3.\n\nKDIGO (Kidney Disease: Improving Global Outcomes) guidelines published in 2009 suggest \nthat chronic kidney disease patients in stages 3 to 5, with vascular and valvular calcifi cations should \nbe considered to be at the highest cardiovascular risk6. The high mortality of chronic kidney disease \npatients is not completely explained by the traditional risk factors7 and KDIGO group supports, \nsince 2006, the hypothesis of the existence of a link between bone disease and vascular disease8. \n\n\n\n156\n\nThis link may be explained by the alterations of the bone and mineral metabolism and their interaction \nwith development and progression of vascular calcifi cations. We have also verifi ed in our studies \nthe existence of an association between vascular calcifi cations and bone disease. Low bone volume \ndiagnosed by histomorphometric analysis of bone biopsies, in a group of dialysis patients, was \nindependently associated with the simple vascular calcifi cation score (data presented in this thesis, \nchapter 6) and with coronary calcifi cations evaluated by the Agatston score9. The original contribution \nof this article published in CJASN9 deserved a commentary in an Editorial written by Prof. G\u00e9rard \nLondon10 leader investigator in this area and current EDTA (European Dialysis and Transplantation \nAssociation) President. We were also the fi rst group to describe an independent and inverse \nassociation between bone mineral density evaluated in the femoral neck by DXA (dual energy \nX -ray absortiometry) with vascular calcifi cations evaluated by the simple vascular calcifi cation \nscore, with arterial stiffness evaluated by carotid -femoral pulse wave velocity and with peripheral \nartery disease diagnosed by clinical criteria11. We were also the fi rst group to demonstrate a signifi cant \ncorrelation between bone mineral density evaluated by DXA in femoral neck but not in lumbar \nspine, with cortical thickness evaluated by histomorphometric analysis of bone biopsy12. Our study \nhas attributed to DXA, for the fi rst time, a role in the diagnosis of cortical porosity in dialysis \npatients. The clinical utility of the differential evaluation of bone mineral density in cortical or \ntrabecular bone needs, however, to be confi rmed in prospective studies. This original fi nding of our \nstudy was mentioned by ERBP (European Renal Best Practice) commenting the KDIGO position \nin relation with the reduced utility of bone mineral density evaluation in dialysis patients13.\n\nTwo of the studies included in this thesis have been integrated in a group of studies \nselected as references by the KDIGO guidelines published in 2009 to evaluate the prevalence \nof vascular calcifi cations in CKD patients (KDIGO 2009: Supplementary Table 10, Fig. 3.6) \nand to corroborate the association between vascular calcifi cations and cardiovascular mortality \n(KDIGO 2009: Supplementary Table 12, Fig. 3.7)6. The inclusion of both studies as references \nin the KDIGO guidelines that have used the exigent GRADE system (Grades of Recommendation, \nAssessment, Development, and Evaluation) in the classifi cation and selection of studies, \nvalidates the scientifi c value of our studies.\n\nThe diagnosis of vascular calcifi cations has a practical interest for chronic kidney disease \npatients. The presence of vascular calcifi cations is an alert sign to the existence of a high \ncardiovascular risk and this information may be used to modify the treatment of these patients6. \nDifferent methods may be used to detect the presence of vascular calcifi cations in dialysis \npatients14,15. The simple vascular calcifi cation score has the advantage of being simple, \ninexpensive and easily evaluated by the Nephrologist without the need for a Radiologist \ninterpretation. The reproducibility of this method has already been demonstrated by other \ngroups in national and international studies16 -24. It was demonstrated in those studies that \n\n\n\n157\n\nvascular calcifi cations evaluated by the method created by us, predict higher risk of cardiovascular \nevents16, higher risk of lower limbs amputations17, higher pulse wave velocity18,19, corneal \nand conjuntival calcifi cations 20 and coronary calcifi cations21. A negative association between \nthe simple vascular calcifi cation score and PTH levels21, 25(OH) vitamin D levels22,23 and \nFetuin A levels19,24 has also been demonstrated. All these studies performed by different groups \nthat have used the simple vascular calcifi cation score in their methods demonstrate that this \nscore is simple, useful and reproducible in the evaluation of chronic kidney disease patients.\n\nRefer\u00eancias\n\n  1. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcifi cation in end -stage renal disease: \nimpact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18:1731 -1740.\n\n  2. Adrag\u00e3o T, Pires A, Lucas C, Birne R, Magalh\u00e3es L, Gon\u00e7alves M, Negr\u00e3o AP. A simple vascular \ncalcifi cation score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant \n2004;19(6):1480 -1488.\n\n  3. Adrag\u00e3o T, Pires A, Birne R, Curto JD, Lucas C, Gon\u00e7alves M, Negr\u00e3o AP A plain X -ray vascular \ncalcifi cation score is associated with arterial stiffness and mortality in dialysis patients. Nephrol \nDial Transplant 2009;24(3):997 -1002.\n\n  4. Adrag\u00e3o T, Pires A, Branco P, Castro R, Oliveira A, Nogueira AC, Bordalo J, Prata MM. Ankle \nbrachial index, mortality and vascular calcifi cations in hemodialysis patients. NDT Plus 2010; 3: \n(Suppl3): iii492 (Abstract Su545).\n\n  5. Adrag\u00e3o T. Vascular calcifi cation, cardiovascular risk and arterial stiffness in hemodialysis patients. \nRev Port Nefrol Hipert 2005; 19 (Suppl 1): 51 -56.\n\n  6. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of \nchronic kidney disease -mineral and bone disorder (CKD -MBD). Kidney Disease: Improving \nGlobal Outcomes (KDIGO). Kidney Int 2009; (76) (Suppl): S113.\n\n  7. Weiner DE, Tighiouart H, Elsayed EF, et al. Griffi th JL. The Framingham predictive instrument \nin chronic kidney disease J Am Coll Cardiol 2007; 50: 217 -224.\n\n  8. Smoe S, Drueke T, Cunningham J, Goodman W, et al. Defi nition, evaluation, and classifi cation \nof renal osteodystrophy: A position statement from kidney disease: improving global outcomes \n(KDIGO). Kidney Int 2006; 69: 1945 -1953.\n\n  9. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Dias Curto J, \nMalluche HH. Low bone volume \u2013 A risk factor for coronary calcifi cations in hemodialysis patients. \nClin J Am Soc Nephrol 2009; 4(2): 450 -455.\n\n10. London GM. Bone  \u2013 vascular axis in chronic kidney disease: A reality? Clin J Am Soc Nephrol \n2009; 4: 254 -257.\n\n\n\n158\n\n11. Adrag\u00e3o T, Branco P, Birne R, Curto JD, de Almeida E, Prata MM, Pais MJ.Bone mineral density, \nvascular calcifi cations, and arterial stiffness in peritoneal dialysis patients. Perit Dial Int 2008; \n28(6):668 -672.\n\n12. Adrag\u00e3o T, Herberth J, Monier -Faugere MC, Branscum AJ, Ferreira A, Fraz\u00e3o JM, Malluche HH. \nFemoral bone mineral density reflects histologically determined cortical bone volume in \nhemodialysis patients. Osteoporos Int 2010; 21(4):619 -625.\n\n13. Goldsmith DJ, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, Spasovski G, Urena P, \nZoccali C, London GM, Vanholder R. Endorsement of the Kidney Disease Improving Global \nOutcomes (KDIGO) Chronic Kidney Disease -Mineral and Bone Disorder (CKD -MBD) Guidelines: \na European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010; 9. \n[Epub ahead of print.]\n\n14. Adrag\u00e3o T. Evaluation of vascular calcifi cations in CKD patients. Int J Artif Organs 2009;32(2):81-\n-86.\n\n15. Adrag\u00e3o T, Fraz\u00e3o JM. Cardiovascular risk in dialysis patients: an X -ray vision on vascular \ncalcifi cations. Kidney Int 2008;74(12):1505 -1507.\n\n16. Wei T, Wang M, Wang Mi, et al. Relationship of sRANKL level and vascular calcifi cation score \nto cardiovascular events in maintenance hemodialysis patients. Blood Purif 2009;28:34 -345\n\n17. Matias P, Aires I, Jorge C, associated with lower -extremity amputations in haemodialysis patients. \nPort J Nephrol Hypert 2008; 22(1): 31 -36.\n\n18. Schlieper G, Brandenburg V, Djuric Z, Damjanovic T, Markovic N, Schurgers L, Kr\u00fcger T, \nWestenfeld R, Ackermann D, Haselhuhn A, Dimkovic S, Ketteler M, Floege J, Dimkovic N. Risk \nfactors for cardiovascular calcifi cations in non -diabetic Caucasian haemodialysis patients. Kidney \nBlood Pres Res 2009; 32(3):161 -168.\n\n19. Jung JY, Hwang YH, Lee SW, et al. Factors associated with aortic stiffness and its change over \ntime in peritoneal dialysis patients. Nephrol Dial Transplant 2010; 25. [Epub ahead of print.]\n\n20. Seyahi N, Altiparmak MR, Kahveci A, Yetik H, Kanberoglu K, Serdengecti K, Ataman R, Erek \nE. Association of conjunctival and corneal calcifi cation with vascular calcifi cation in dialysis \npatients. Am J Kidney Dis 2005;45(3):550 -556.\n\n21. Kim SC, Kim HW, Oh SW, Yang HN, Kim MG, Jo SK, Cho WY, Kim HK. Low iPTH can predict \nvascular and coronary calcifi cations in patients undergoing peritoneal dialysis. Nephron Clin Pract \n2010; (6) 117(2):c113 -c119. [Epub ahead of print.]\n\n22. Matias PJ, Ferreira C, Jorge C et al. 25 -Hydroxyvitamin D3, arterial calcifi cations and cardiovascular \nrisk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24(2):611 -618.\n\n23. Garc\u00eda -Canton C, Bosch E, Ram\u00edrez A, et al. Vascular calcifi cation and 25 -hydroxyvitamin D \nlevels in non -dialysis patients with chronic kidney disease stages 4 and 5. Nephrol Dial Transplant \n2010; 18. [Epub ahead of print.]\n\n24. Jung JY, Hwang YH, Lee H, et al. Association of AHSG gene polymorphisms and aortic stiffness \nin peritoneal dialysis patients. Am J Nephrol 2010;31(6):510 -517.\n\n\n\n\n\nCALCIFICA\u00c7\u00d5ES VASCULARES \nNOS DOENTES EM DI\u00c1LISE: \n\nELO DE LIGA\u00c7\u00c3O ENTRE DOEN\u00c7A \u00d3SSEA \nE DOEN\u00c7A VASCULAR\n\nTERESA ADRAG\u00c3O\n\n2011\n\n\n\tTese Teresa Adrag\u00e3o - CAPA\n\tTese Teresa Adrag\u00e3o - 3\u00aa PROVA.pdf\n\tTese Teresa Adrag\u00e3o - CONTRACAPA\n\n<<\n  /ASCII85EncodePages false\n  /AllowTransparency false\n  /AutoPositionEPSFiles true\n  /AutoRotatePages /None\n  /Binding /Left\n  /CalGrayProfile (Dot Gain 20%)\n  /CalRGBProfile (sRGB IEC61966-2.1)\n  /CalCMYKProfile (Kodak SWOP Proofer CMYK - Uncoated Stock)\n  /sRGBProfile (sRGB IEC61966-2.1)\n  /CannotEmbedFontPolicy /Error\n  /CompatibilityLevel 1.4\n  /CompressObjects /Tags\n  /CompressPages true\n  /ConvertImagesToIndexed true\n  /PassThroughJPEGImages true\n  /CreateJobTicket false\n  /DefaultRenderingIntent /Default\n  /DetectBlends false\n  /DetectCurves 0.0000\n  /ColorConversionStrategy /CMYK\n  /DoThumbnails false\n  /EmbedAllFonts true\n  /EmbedOpenType false\n  /ParseICCProfilesInComments true\n  /EmbedJobOptions true\n  /DSCReportingLevel 0\n  /EmitDSCWarnings false\n  /EndPage -1\n  /ImageMemory 1048576\n  /LockDistillerParams false\n  /MaxSubsetPct 100\n  /Optimize false\n  /OPM 1\n  /ParseDSCComments true\n  /ParseDSCCommentsForDocInfo true\n  /PreserveCopyPage true\n  /PreserveDICMYKValues true\n  /PreserveEPSInfo true\n  /PreserveFlatness true\n  /PreserveHalftoneInfo false\n  /PreserveOPIComments true\n  /PreserveOverprintSettings true\n  /StartPage 1\n  /SubsetFonts true\n  /TransferFunctionInfo /Apply\n  /UCRandBGInfo /Preserve\n  /UsePrologue false\n  /ColorSettingsFile ()\n  /AlwaysEmbed [ true\n  ]\n  /NeverEmbed [ true\n  ]\n  /AntiAliasColorImages false\n  /CropColorImages true\n  /ColorImageMinResolution 300\n  /ColorImageMinResolutionPolicy /OK\n  /DownsampleColorImages true\n  /ColorImageDownsampleType /Bicubic\n  /ColorImageResolution 300\n  /ColorImageDepth -1\n  /ColorImageMinDownsampleDepth 1\n  /ColorImageDownsampleThreshold 1.00333\n  /EncodeColorImages true\n  /ColorImageFilter /DCTEncode\n  /AutoFilterColorImages true\n  /ColorImageAutoFilterStrategy /JPEG\n  /ColorACSImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /ColorImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /JPEG2000ColorACSImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /JPEG2000ColorImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /AntiAliasGrayImages false\n  /CropGrayImages true\n  /GrayImageMinResolution 300\n  /GrayImageMinResolutionPolicy /OK\n  /DownsampleGrayImages true\n  /GrayImageDownsampleType /Bicubic\n  /GrayImageResolution 300\n  /GrayImageDepth -1\n  /GrayImageMinDownsampleDepth 2\n  /GrayImageDownsampleThreshold 1.00333\n  /EncodeGrayImages true\n  /GrayImageFilter /DCTEncode\n  /AutoFilterGrayImages true\n  /GrayImageAutoFilterStrategy /JPEG\n  /GrayACSImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /GrayImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /JPEG2000GrayACSImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /JPEG2000GrayImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /AntiAliasMonoImages false\n  /CropMonoImages true\n  /MonoImageMinResolution 1200\n  /MonoImageMinResolutionPolicy /OK\n  /DownsampleMonoImages true\n  /MonoImageDownsampleType /Bicubic\n  /MonoImageResolution 1200\n  /MonoImageDepth -1\n  /MonoImageDownsampleThreshold 1.00833\n  /EncodeMonoImages true\n  /MonoImageFilter /CCITTFaxEncode\n  /MonoImageDict&lt;<\n    /K -1\n  >>\n  /AllowPSXObjects false\n  /CheckCompliance [\n    /None\n  ]\n  /PDFX1aCheck false\n  /PDFX3Check false\n  /PDFXCompliantPDFOnly false\n  /PDFXNoTrimBoxError true\n  /PDFXTrimBoxToMediaBoxOffset [\n    0.00000\n    0.00000\n    0.00000\n    0.00000\n  ]\n  /PDFXSetBleedBoxToMediaBox true\n  /PDFXBleedBoxToTrimBoxOffset [\n    0.00000\n    0.00000\n    0.00000\n    0.00000\n  ]\n  /PDFXOutputIntentProfile (None)\n  /PDFXOutputConditionIdentifier ()\n  /PDFXOutputCondition ()\n  /PDFXRegistryName ()\n  /PDFXTrapped /False\n\n  /CreateJDFFile false\n  /Description&lt;<\n    /ARA&lt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n    /BGR&lt;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>\n    /CHS&lt;FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000410064006f006200650020005000440046002065876863900275284e8e9ad88d2891cf76845370524d53705237300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002>\n    /CHT&lt;FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef69069752865bc9ad854c18cea76845370524d5370523786557406300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002>\n    /CZE&lt;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>\n    /DAN&lt;FEFF004200720075006700200069006e0064007300740069006c006c0069006e006700650072006e0065002000740069006c0020006100740020006f007000720065007400740065002000410064006f006200650020005000440046002d0064006f006b0075006d0065006e007400650072002c0020006400650072002000620065006400730074002000650067006e006500720020007300690067002000740069006c002000700072006500700072006500730073002d007500640073006b007200690076006e0069006e00670020006100660020006800f8006a0020006b00760061006c0069007400650074002e0020004400650020006f007000720065007400740065006400650020005000440046002d0064006f006b0075006d0065006e0074006500720020006b0061006e002000e50062006e00650073002000690020004100630072006f00620061007400200065006c006c006500720020004100630072006f006200610074002000520065006100640065007200200035002e00300020006f00670020006e0079006500720065002e>\n    /DEU&lt;FEFF00560065007200770065006e00640065006e0020005300690065002000640069006500730065002000450069006e007300740065006c006c0075006e00670065006e0020007a0075006d002000450072007300740065006c006c0065006e00200076006f006e002000410064006f006200650020005000440046002d0044006f006b0075006d0065006e00740065006e002c00200076006f006e002000640065006e0065006e002000530069006500200068006f006300680077006500720074006900670065002000500072006500700072006500730073002d0044007200750063006b0065002000650072007a0065007500670065006e0020006d00f60063006800740065006e002e002000450072007300740065006c006c007400650020005000440046002d0044006f006b0075006d0065006e007400650020006b00f6006e006e0065006e0020006d006900740020004100630072006f00620061007400200075006e0064002000410064006f00620065002000520065006100640065007200200035002e00300020006f0064006500720020006800f600680065007200200067006500f600660066006e00650074002000770065007200640065006e002e>\n    /ESP&lt;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>\n    /ETI&lt;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>\n    /FRA&lt;FEFF005500740069006c006900730065007a00200063006500730020006f007000740069006f006e00730020006100660069006e00200064006500200063007200e900650072002000640065007300200064006f00630075006d0065006e00740073002000410064006f00620065002000500044004600200070006f0075007200200075006e00650020007100750061006c0069007400e90020006400270069006d007000720065007300730069006f006e00200070007200e9007000720065007300730065002e0020004c0065007300200064006f00630075006d0065006e00740073002000500044004600200063007200e900e90073002000700065007500760065006e0074002000ea0074007200650020006f007500760065007200740073002000640061006e00730020004100630072006f006200610074002c002000610069006e00730069002000710075002700410064006f00620065002000520065006100640065007200200035002e0030002000650074002000760065007200730069006f006e007300200075006c007400e90072006900650075007200650073002e>\n    /GRE&lt;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>\n    /HEB&lt;FEFF05D405E905EA05DE05E905D5002005D105D405D205D305E805D505EA002005D005DC05D4002005DB05D305D9002005DC05D905E605D505E8002005DE05E105DE05DB05D9002000410064006F006200650020005000440046002005D405DE05D505EA05D005DE05D905DD002005DC05D405D305E405E105EA002005E705D305DD002D05D305E405D505E1002005D005D905DB05D505EA05D905EA002E002005DE05E105DE05DB05D90020005000440046002005E905E005D505E605E805D5002005E005D905EA05E005D905DD002005DC05E405EA05D905D705D4002005D105D005DE05E605E205D505EA0020004100630072006F006200610074002005D5002D00410064006F00620065002000520065006100640065007200200035002E0030002005D505D205E805E105D005D505EA002005DE05EA05E705D305DE05D505EA002005D905D505EA05E8002E05D005DE05D905DD002005DC002D005000440046002F0058002D0033002C002005E205D905D905E005D5002005D105DE05D305E805D905DA002005DC05DE05E905EA05DE05E9002005E905DC0020004100630072006F006200610074002E002005DE05E105DE05DB05D90020005000440046002005E905E005D505E605E805D5002005E005D905EA05E005D905DD002005DC05E405EA05D905D705D4002005D105D005DE05E605E205D505EA0020004100630072006F006200610074002005D5002D00410064006F00620065002000520065006100640065007200200035002E0030002005D505D205E805E105D005D505EA002005DE05EA05E705D305DE05D505EA002005D905D505EA05E8002E>\n    /HRV (Za stvaranje Adobe PDF dokumenata najpogodnijih za visokokvalitetni ispis prije tiskanja koristite ove postavke.  Stvoreni PDF dokumenti mogu se otvoriti Acrobat i Adobe Reader 5.0 i kasnijim verzijama.)\n    /HUN&lt;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>\n    /ITA&lt;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>\n    /JPN&lt;FEFF9ad854c18cea306a30d730ea30d730ec30b951fa529b7528002000410064006f0062006500200050004400460020658766f8306e4f5c6210306b4f7f75283057307e305930023053306e8a2d5b9a30674f5c62103055308c305f0020005000440046002030d530a130a430eb306f3001004100630072006f0062006100740020304a30883073002000410064006f00620065002000520065006100640065007200200035002e003000204ee5964d3067958b304f30533068304c3067304d307e305930023053306e8a2d5b9a306b306f30d530a930f330c8306e57cb30818fbc307f304c5fc59808306730593002>\n    /KOR&lt;FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020ace0d488c9c80020c2dcd5d80020c778c1c4c5d00020ac00c7a50020c801d569d55c002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e>\n    /LTH&lt;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>\n    /LVI&lt;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>\n    /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die zijn geoptimaliseerd voor prepress-afdrukken van hoge kwaliteit. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.)\n    /NOR&lt;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>\n    /POL&lt;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>\n    /PTB&lt;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>\n    /RUM&lt;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>\n    /RUS&lt;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>\n    /SKY&lt;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>\n    /SLV&lt;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>\n    /SUO&lt;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>\n    /SVE&lt;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>\n    /TUR&lt;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>\n    /UKR&lt;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>\n    /ENU (Use these settings to create Adobe PDF documents best suited for high-quality prepress printing.  Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.)\n  >>\n  /Namespace [\n    (Adobe)\n    (Common)\n    (1.0)\n  ]\n  /OtherNamespaces [\n   &lt;<\n      /AsReaderSpreads false\n      /CropImagesToFrames true\n      /ErrorControl /WarnAndContinue\n      /FlattenerIgnoreSpreadOverrides false\n      /IncludeGuidesGrids false\n      /IncludeNonPrinting false\n      /IncludeSlug false\n      /Namespace [\n        (Adobe)\n        (InDesign)\n        (4.0)\n      ]\n      /OmitPlacedBitmaps false\n      /OmitPlacedEPS false\n      /OmitPlacedPDF false\n      /SimulateOverprint /Legacy\n    >>\n   &lt;<\n      /AddBleedMarks false\n      /AddColorBars false\n      /AddCropMarks false\n      /AddPageInfo false\n      /AddRegMarks false\n      /ConvertColors /ConvertToCMYK\n      /DestinationProfileName ()\n      /DestinationProfileSelector /DocumentCMYK\n      /Downsample16BitImages true\n      /FlattenerPreset&lt;<\n        /PresetSelector /MediumResolution\n      >>\n      /FormElements false\n      /GenerateStructure false\n      /IncludeBookmarks false\n      /IncludeHyperlinks false\n      /IncludeInteractive false\n      /IncludeLayers false\n      /IncludeProfiles false\n      /MultimediaHandling /UseObjectSettings\n      /Namespace [\n        (Adobe)\n        (CreativeSuite)\n        (2.0)\n      ]\n      /PDFXOutputIntentProfileSelector /DocumentCMYK\n      /PreserveEditing true\n      /UntaggedCMYKHandling /LeaveUntagged\n      /UntaggedRGBHandling /UseDocumentProfile\n      /UseDocumentBleed false\n    >>\n  ]\n>> setdistillerparams\n<<\n  /HWResolution [2400 2400]\n  /PageSize [612.000 792.000]\n>> setpagedevice\n\n\n\n<<\n  /ASCII85EncodePages false\n  /AllowTransparency false\n  /AutoPositionEPSFiles true\n  /AutoRotatePages /None\n  /Binding /Left\n  /CalGrayProfile (Dot Gain 20%)\n  /CalRGBProfile (sRGB IEC61966-2.1)\n  /CalCMYKProfile (Kodak SWOP Proofer CMYK - Uncoated Stock)\n  /sRGBProfile (sRGB IEC61966-2.1)\n  /CannotEmbedFontPolicy /Error\n  /CompatibilityLevel 1.4\n  /CompressObjects /Tags\n  /CompressPages true\n  /ConvertImagesToIndexed true\n  /PassThroughJPEGImages true\n  /CreateJobTicket false\n  /DefaultRenderingIntent /Default\n  /DetectBlends false\n  /DetectCurves 0.0000\n  /ColorConversionStrategy /CMYK\n  /DoThumbnails false\n  /EmbedAllFonts true\n  /EmbedOpenType false\n  /ParseICCProfilesInComments true\n  /EmbedJobOptions true\n  /DSCReportingLevel 0\n  /EmitDSCWarnings false\n  /EndPage -1\n  /ImageMemory 1048576\n  /LockDistillerParams false\n  /MaxSubsetPct 100\n  /Optimize false\n  /OPM 1\n  /ParseDSCComments true\n  /ParseDSCCommentsForDocInfo true\n  /PreserveCopyPage true\n  /PreserveDICMYKValues true\n  /PreserveEPSInfo true\n  /PreserveFlatness true\n  /PreserveHalftoneInfo false\n  /PreserveOPIComments true\n  /PreserveOverprintSettings true\n  /StartPage 1\n  /SubsetFonts true\n  /TransferFunctionInfo /Apply\n  /UCRandBGInfo /Preserve\n  /UsePrologue false\n  /ColorSettingsFile ()\n  /AlwaysEmbed [ true\n  ]\n  /NeverEmbed [ true\n  ]\n  /AntiAliasColorImages false\n  /CropColorImages true\n  /ColorImageMinResolution 300\n  /ColorImageMinResolutionPolicy /OK\n  /DownsampleColorImages true\n  /ColorImageDownsampleType /Bicubic\n  /ColorImageResolution 300\n  /ColorImageDepth -1\n  /ColorImageMinDownsampleDepth 1\n  /ColorImageDownsampleThreshold 1.00333\n  /EncodeColorImages true\n  /ColorImageFilter /DCTEncode\n  /AutoFilterColorImages true\n  /ColorImageAutoFilterStrategy /JPEG\n  /ColorACSImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /ColorImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /JPEG2000ColorACSImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /JPEG2000ColorImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /AntiAliasGrayImages false\n  /CropGrayImages true\n  /GrayImageMinResolution 300\n  /GrayImageMinResolutionPolicy /OK\n  /DownsampleGrayImages true\n  /GrayImageDownsampleType /Bicubic\n  /GrayImageResolution 300\n  /GrayImageDepth -1\n  /GrayImageMinDownsampleDepth 2\n  /GrayImageDownsampleThreshold 1.00333\n  /EncodeGrayImages true\n  /GrayImageFilter /DCTEncode\n  /AutoFilterGrayImages true\n  /GrayImageAutoFilterStrategy /JPEG\n  /GrayACSImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /GrayImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /JPEG2000GrayACSImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /JPEG2000GrayImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /AntiAliasMonoImages false\n  /CropMonoImages true\n  /MonoImageMinResolution 1200\n  /MonoImageMinResolutionPolicy /OK\n  /DownsampleMonoImages true\n  /MonoImageDownsampleType /Bicubic\n  /MonoImageResolution 1200\n  /MonoImageDepth -1\n  /MonoImageDownsampleThreshold 1.00833\n  /EncodeMonoImages true\n  /MonoImageFilter /CCITTFaxEncode\n  /MonoImageDict&lt;<\n    /K -1\n  >>\n  /AllowPSXObjects false\n  /CheckCompliance [\n    /None\n  ]\n  /PDFX1aCheck false\n  /PDFX3Check false\n  /PDFXCompliantPDFOnly false\n  /PDFXNoTrimBoxError true\n  /PDFXTrimBoxToMediaBoxOffset [\n    0.00000\n    0.00000\n    0.00000\n    0.00000\n  ]\n  /PDFXSetBleedBoxToMediaBox true\n  /PDFXBleedBoxToTrimBoxOffset [\n    0.00000\n    0.00000\n    0.00000\n    0.00000\n  ]\n  /PDFXOutputIntentProfile (None)\n  /PDFXOutputConditionIdentifier ()\n  /PDFXOutputCondition ()\n  /PDFXRegistryName ()\n  /PDFXTrapped /False\n\n  /CreateJDFFile false\n  /Description&lt;<\n    /ARA&lt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n    /BGR&lt;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>\n    /CHS&lt;FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000410064006f006200650020005000440046002065876863900275284e8e9ad88d2891cf76845370524d53705237300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002>\n    /CHT&lt;FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef69069752865bc9ad854c18cea76845370524d5370523786557406300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002>\n    /CZE&lt;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>\n    /DAN&lt;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>\n    /DEU&lt;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>\n    /ESP&lt;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>\n    /ETI&lt;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>\n    /FRA&lt;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>\n    /GRE&lt;FEFF03a703c103b703c303b903bc03bf03c003bf03b903ae03c303c403b5002003b103c503c403ad03c2002003c403b903c2002003c103c503b803bc03af03c303b503b903c2002003b303b903b1002003bd03b1002003b403b703bc03b903bf03c503c103b303ae03c303b503c403b5002003ad03b303b303c103b103c603b1002000410064006f006200650020005000440046002003c003bf03c5002003b503af03bd03b103b9002003ba03b103c42019002003b503be03bf03c703ae03bd002003ba03b103c403ac03bb03bb03b703bb03b1002003b303b903b1002003c003c103bf002d03b503ba03c403c503c003c903c403b903ba03ad03c2002003b503c103b303b103c303af03b503c2002003c503c803b703bb03ae03c2002003c003bf03b903cc03c403b703c403b103c2002e0020002003a403b10020005000440046002003ad03b303b303c103b103c603b1002003c003bf03c5002003ad03c703b503c403b5002003b403b703bc03b903bf03c503c103b303ae03c303b503b9002003bc03c003bf03c103bf03cd03bd002003bd03b1002003b103bd03bf03b903c703c403bf03cd03bd002003bc03b5002003c403bf0020004100630072006f006200610074002c002003c403bf002000410064006f00620065002000520065006100640065007200200035002e0030002003ba03b103b9002003bc03b503c403b103b303b503bd03ad03c303c403b503c103b503c2002003b503ba03b403cc03c303b503b903c2002e>\n    /HEB&lt;FEFF05D405E905EA05DE05E905D5002005D105D405D205D305E805D505EA002005D005DC05D4002005DB05D305D9002005DC05D905E605D505E8002005DE05E105DE05DB05D9002000410064006F006200650020005000440046002005D405DE05D505EA05D005DE05D905DD002005DC05D405D305E405E105EA002005E705D305DD002D05D305E405D505E1002005D005D905DB05D505EA05D905EA002E002005DE05E105DE05DB05D90020005000440046002005E905E005D505E605E805D5002005E005D905EA05E005D905DD002005DC05E405EA05D905D705D4002005D105D005DE05E605E205D505EA0020004100630072006F006200610074002005D5002D00410064006F00620065002000520065006100640065007200200035002E0030002005D505D205E805E105D005D505EA002005DE05EA05E705D305DE05D505EA002005D905D505EA05E8002E05D005DE05D905DD002005DC002D005000440046002F0058002D0033002C002005E205D905D905E005D5002005D105DE05D305E805D905DA002005DC05DE05E905EA05DE05E9002005E905DC0020004100630072006F006200610074002E002005DE05E105DE05DB05D90020005000440046002005E905E005D505E605E805D5002005E005D905EA05E005D905DD002005DC05E405EA05D905D705D4002005D105D005DE05E605E205D505EA0020004100630072006F006200610074002005D5002D00410064006F00620065002000520065006100640065007200200035002E0030002005D505D205E805E105D005D505EA002005DE05EA05E705D305DE05D505EA002005D905D505EA05E8002E>\n    /HRV (Za stvaranje Adobe PDF dokumenata najpogodnijih za visokokvalitetni ispis prije tiskanja koristite ove postavke.  Stvoreni PDF dokumenti mogu se otvoriti Acrobat i Adobe Reader 5.0 i kasnijim verzijama.)\n    /HUN&lt;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>\n    /ITA&lt;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>\n    /JPN&lt;FEFF9ad854c18cea306a30d730ea30d730ec30b951fa529b7528002000410064006f0062006500200050004400460020658766f8306e4f5c6210306b4f7f75283057307e305930023053306e8a2d5b9a30674f5c62103055308c305f0020005000440046002030d530a130a430eb306f3001004100630072006f0062006100740020304a30883073002000410064006f00620065002000520065006100640065007200200035002e003000204ee5964d3067958b304f30533068304c3067304d307e305930023053306e8a2d5b9a306b306f30d530a930f330c8306e57cb30818fbc307f304c5fc59808306730593002>\n    /KOR&lt;FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020ace0d488c9c80020c2dcd5d80020c778c1c4c5d00020ac00c7a50020c801d569d55c002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e>\n    /LTH&lt;FEFF004e006100750064006f006b0069007400650020016100690075006f007300200070006100720061006d006500740072007500730020006e006f0072011700640061006d00690020006b0075007200740069002000410064006f00620065002000500044004600200064006f006b0075006d0065006e007400750073002c0020006b00750072006900650020006c0061006200690061007500730069006100690020007000720069007400610069006b007900740069002000610075006b01610074006f00730020006b006f006b007900620117007300200070006100720065006e006700740069006e00690061006d00200073007000610075007300640069006e0069006d00750069002e0020002000530075006b0075007200740069002000500044004600200064006f006b0075006d0065006e007400610069002000670061006c006900200062016b007400690020006100740069006400610072006f006d00690020004100630072006f006200610074002000690072002000410064006f00620065002000520065006100640065007200200035002e0030002000610072002000760117006c00650073006e0117006d00690073002000760065007200730069006a006f006d00690073002e>\n    /LVI&lt;FEFF0049007a006d0061006e0074006f006a00690065007400200161006f00730020006900650073007400610074012b006a0075006d00750073002c0020006c0061006900200076006500690064006f00740075002000410064006f00620065002000500044004600200064006f006b0075006d0065006e007400750073002c0020006b006100730020006900720020012b00700061016100690020007000690065006d01130072006f00740069002000610075006700730074006100730020006b00760061006c0069007401010074006500730020007000690072006d007300690065007300700069006501610061006e006100730020006400720075006b00610069002e00200049007a0076006500690064006f006a006900650074002000500044004600200064006f006b0075006d0065006e007400750073002c0020006b006f002000760061007200200061007400760113007200740020006100720020004100630072006f00620061007400200075006e002000410064006f00620065002000520065006100640065007200200035002e0030002c0020006b0101002000610072012b00200074006f0020006a00610075006e0101006b0101006d002000760065007200730069006a0101006d002e>\n    /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die zijn geoptimaliseerd voor prepress-afdrukken van hoge kwaliteit. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.)\n    /NOR&lt;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>\n    /POL&lt;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>\n    /PTB&lt;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>\n    /RUM&lt;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>\n    /RUS&lt;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>\n    /SKY&lt;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>\n    /SLV&lt;FEFF005400650020006e006100730074006100760069007400760065002000750070006f0072006100620069007400650020007a00610020007500730074007600610072006a0061006e006a006500200064006f006b0075006d0065006e0074006f0076002000410064006f006200650020005000440046002c0020006b006900200073006f0020006e0061006a007000720069006d00650072006e0065006a016100690020007a00610020006b0061006b006f0076006f00730074006e006f0020007400690073006b0061006e006a00650020007300200070007200690070007200610076006f0020006e00610020007400690073006b002e00200020005500730074007600610072006a0065006e006500200064006f006b0075006d0065006e0074006500200050004400460020006a00650020006d006f0067006f010d00650020006f0064007000720065007400690020007a0020004100630072006f00620061007400200069006e002000410064006f00620065002000520065006100640065007200200035002e003000200069006e0020006e006f00760065006a01610069006d002e>\n    /SUO&lt;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>\n    /SVE&lt;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>\n    /TUR&lt;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>\n    /UKR&lt;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>\n    /ENU (Use these settings to create Adobe PDF documents best suited for high-quality prepress printing.  Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.)\n  >>\n  /Namespace [\n    (Adobe)\n    (Common)\n    (1.0)\n  ]\n  /OtherNamespaces [\n   &lt;<\n      /AsReaderSpreads false\n      /CropImagesToFrames true\n      /ErrorControl /WarnAndContinue\n      /FlattenerIgnoreSpreadOverrides false\n      /IncludeGuidesGrids false\n      /IncludeNonPrinting false\n      /IncludeSlug false\n      /Namespace [\n        (Adobe)\n        (InDesign)\n        (4.0)\n      ]\n      /OmitPlacedBitmaps false\n      /OmitPlacedEPS false\n      /OmitPlacedPDF false\n      /SimulateOverprint /Legacy\n    >>\n   &lt;<\n      /AddBleedMarks false\n      /AddColorBars false\n      /AddCropMarks false\n      /AddPageInfo false\n      /AddRegMarks false\n      /ConvertColors /ConvertToCMYK\n      /DestinationProfileName ()\n      /DestinationProfileSelector /DocumentCMYK\n      /Downsample16BitImages true\n      /FlattenerPreset&lt;<\n        /PresetSelector /MediumResolution\n      >>\n      /FormElements false\n      /GenerateStructure false\n      /IncludeBookmarks false\n      /IncludeHyperlinks false\n      /IncludeInteractive false\n      /IncludeLayers false\n      /IncludeProfiles false\n      /MultimediaHandling /UseObjectSettings\n      /Namespace [\n        (Adobe)\n        (CreativeSuite)\n        (2.0)\n      ]\n      /PDFXOutputIntentProfileSelector /DocumentCMYK\n      /PreserveEditing true\n      /UntaggedCMYKHandling /LeaveUntagged\n      /UntaggedRGBHandling /UseDocumentProfile\n      /UseDocumentBleed false\n    >>\n  ]\n>> setdistillerparams\n<<\n  /HWResolution [2400 2400]\n  /PageSize [612.000 792.000]\n>> setpagedevice\n\n\n\n<<\n  /ASCII85EncodePages false\n  /AllowTransparency false\n  /AutoPositionEPSFiles true\n  /AutoRotatePages /None\n  /Binding /Left\n  /CalGrayProfile (Dot Gain 20%)\n  /CalRGBProfile (sRGB IEC61966-2.1)\n  /CalCMYKProfile (Kodak SWOP Proofer CMYK - Uncoated Stock)\n  /sRGBProfile (sRGB IEC61966-2.1)\n  /CannotEmbedFontPolicy /Error\n  /CompatibilityLevel 1.4\n  /CompressObjects /Tags\n  /CompressPages true\n  /ConvertImagesToIndexed true\n  /PassThroughJPEGImages true\n  /CreateJobTicket false\n  /DefaultRenderingIntent /Default\n  /DetectBlends false\n  /DetectCurves 0.0000\n  /ColorConversionStrategy /CMYK\n  /DoThumbnails false\n  /EmbedAllFonts true\n  /EmbedOpenType false\n  /ParseICCProfilesInComments true\n  /EmbedJobOptions true\n  /DSCReportingLevel 0\n  /EmitDSCWarnings false\n  /EndPage -1\n  /ImageMemory 1048576\n  /LockDistillerParams false\n  /MaxSubsetPct 100\n  /Optimize false\n  /OPM 1\n  /ParseDSCComments true\n  /ParseDSCCommentsForDocInfo true\n  /PreserveCopyPage true\n  /PreserveDICMYKValues true\n  /PreserveEPSInfo true\n  /PreserveFlatness true\n  /PreserveHalftoneInfo false\n  /PreserveOPIComments true\n  /PreserveOverprintSettings true\n  /StartPage 1\n  /SubsetFonts true\n  /TransferFunctionInfo /Apply\n  /UCRandBGInfo /Preserve\n  /UsePrologue false\n  /ColorSettingsFile ()\n  /AlwaysEmbed [ true\n  ]\n  /NeverEmbed [ true\n  ]\n  /AntiAliasColorImages false\n  /CropColorImages true\n  /ColorImageMinResolution 300\n  /ColorImageMinResolutionPolicy /OK\n  /DownsampleColorImages true\n  /ColorImageDownsampleType /Bicubic\n  /ColorImageResolution 300\n  /ColorImageDepth -1\n  /ColorImageMinDownsampleDepth 1\n  /ColorImageDownsampleThreshold 1.00333\n  /EncodeColorImages true\n  /ColorImageFilter /DCTEncode\n  /AutoFilterColorImages true\n  /ColorImageAutoFilterStrategy /JPEG\n  /ColorACSImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /ColorImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /JPEG2000ColorACSImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /JPEG2000ColorImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /AntiAliasGrayImages false\n  /CropGrayImages true\n  /GrayImageMinResolution 300\n  /GrayImageMinResolutionPolicy /OK\n  /DownsampleGrayImages true\n  /GrayImageDownsampleType /Bicubic\n  /GrayImageResolution 300\n  /GrayImageDepth -1\n  /GrayImageMinDownsampleDepth 2\n  /GrayImageDownsampleThreshold 1.00333\n  /EncodeGrayImages true\n  /GrayImageFilter /DCTEncode\n  /AutoFilterGrayImages true\n  /GrayImageAutoFilterStrategy /JPEG\n  /GrayACSImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /GrayImageDict&lt;<\n    /QFactor 0.15\n    /HSamples [1 1 1 1] /VSamples [1 1 1 1]\n  >>\n  /JPEG2000GrayACSImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /JPEG2000GrayImageDict&lt;<\n    /TileWidth 256\n    /TileHeight 256\n    /Quality 30\n  >>\n  /AntiAliasMonoImages false\n  /CropMonoImages true\n  /MonoImageMinResolution 1200\n  /MonoImageMinResolutionPolicy /OK\n  /DownsampleMonoImages true\n  /MonoImageDownsampleType /Bicubic\n  /MonoImageResolution 1200\n  /MonoImageDepth -1\n  /MonoImageDownsampleThreshold 1.00833\n  /EncodeMonoImages true\n  /MonoImageFilter /CCITTFaxEncode\n  /MonoImageDict&lt;<\n    /K -1\n  >>\n  /AllowPSXObjects false\n  /CheckCompliance [\n    /None\n  ]\n  /PDFX1aCheck false\n  /PDFX3Check false\n  /PDFXCompliantPDFOnly false\n  /PDFXNoTrimBoxError true\n  /PDFXTrimBoxToMediaBoxOffset [\n    0.00000\n    0.00000\n    0.00000\n    0.00000\n  ]\n  /PDFXSetBleedBoxToMediaBox true\n  /PDFXBleedBoxToTrimBoxOffset [\n    0.00000\n    0.00000\n    0.00000\n    0.00000\n  ]\n  /PDFXOutputIntentProfile (None)\n  /PDFXOutputConditionIdentifier ()\n  /PDFXOutputCondition ()\n  /PDFXRegistryName ()\n  /PDFXTrapped /False\n\n  /CreateJDFFile false\n  /Description&lt;<\n    /ARA&lt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n    /BGR&lt;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>\n    /CHS&lt;FEFF4f7f75288fd94e9b8bbe5b9a521b5efa7684002000410064006f006200650020005000440046002065876863900275284e8e9ad88d2891cf76845370524d53705237300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c676562535f00521b5efa768400200050004400460020658768633002>\n    /CHT&lt;FEFF4f7f752890194e9b8a2d7f6e5efa7acb7684002000410064006f006200650020005000440046002065874ef69069752865bc9ad854c18cea76845370524d5370523786557406300260a853ef4ee54f7f75280020004100630072006f0062006100740020548c002000410064006f00620065002000520065006100640065007200200035002e003000204ee553ca66f49ad87248672c4f86958b555f5df25efa7acb76840020005000440046002065874ef63002>\n    /CZE&lt;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>\n    /DAN&lt;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>\n    /DEU&lt;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>\n    /ESP&lt;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>\n    /ETI&lt;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>\n    /FRA&lt;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>\n    /GRE&lt;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>\n    /HEB&lt;FEFF05D405E905EA05DE05E905D5002005D105D405D205D305E805D505EA002005D005DC05D4002005DB05D305D9002005DC05D905E605D505E8002005DE05E105DE05DB05D9002000410064006F006200650020005000440046002005D405DE05D505EA05D005DE05D905DD002005DC05D405D305E405E105EA002005E705D305DD002D05D305E405D505E1002005D005D905DB05D505EA05D905EA002E002005DE05E105DE05DB05D90020005000440046002005E905E005D505E605E805D5002005E005D905EA05E005D905DD002005DC05E405EA05D905D705D4002005D105D005DE05E605E205D505EA0020004100630072006F006200610074002005D5002D00410064006F00620065002000520065006100640065007200200035002E0030002005D505D205E805E105D005D505EA002005DE05EA05E705D305DE05D505EA002005D905D505EA05E8002E05D005DE05D905DD002005DC002D005000440046002F0058002D0033002C002005E205D905D905E005D5002005D105DE05D305E805D905DA002005DC05DE05E905EA05DE05E9002005E905DC0020004100630072006F006200610074002E002005DE05E105DE05DB05D90020005000440046002005E905E005D505E605E805D5002005E005D905EA05E005D905DD002005DC05E405EA05D905D705D4002005D105D005DE05E605E205D505EA0020004100630072006F006200610074002005D5002D00410064006F00620065002000520065006100640065007200200035002E0030002005D505D205E805E105D005D505EA002005DE05EA05E705D305DE05D505EA002005D905D505EA05E8002E>\n    /HRV (Za stvaranje Adobe PDF dokumenata najpogodnijih za visokokvalitetni ispis prije tiskanja koristite ove postavke.  Stvoreni PDF dokumenti mogu se otvoriti Acrobat i Adobe Reader 5.0 i kasnijim verzijama.)\n    /HUN&lt;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>\n    /ITA&lt;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>\n    /JPN&lt;FEFF9ad854c18cea306a30d730ea30d730ec30b951fa529b7528002000410064006f0062006500200050004400460020658766f8306e4f5c6210306b4f7f75283057307e305930023053306e8a2d5b9a30674f5c62103055308c305f0020005000440046002030d530a130a430eb306f3001004100630072006f0062006100740020304a30883073002000410064006f00620065002000520065006100640065007200200035002e003000204ee5964d3067958b304f30533068304c3067304d307e305930023053306e8a2d5b9a306b306f30d530a930f330c8306e57cb30818fbc307f304c5fc59808306730593002>\n    /KOR&lt;FEFFc7740020c124c815c7440020c0acc6a9d558c5ec0020ace0d488c9c80020c2dcd5d80020c778c1c4c5d00020ac00c7a50020c801d569d55c002000410064006f0062006500200050004400460020bb38c11cb97c0020c791c131d569b2c8b2e4002e0020c774b807ac8c0020c791c131b41c00200050004400460020bb38c11cb2940020004100630072006f0062006100740020bc0f002000410064006f00620065002000520065006100640065007200200035002e00300020c774c0c1c5d0c11c0020c5f40020c2180020c788c2b5b2c8b2e4002e>\n    /LTH&lt;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>\n    /LVI&lt;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>\n    /NLD (Gebruik deze instellingen om Adobe PDF-documenten te maken die zijn geoptimaliseerd voor prepress-afdrukken van hoge kwaliteit. De gemaakte PDF-documenten kunnen worden geopend met Acrobat en Adobe Reader 5.0 en hoger.)\n    /NOR&lt;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>\n    /POL&lt;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>\n    /PTB&lt;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>\n    /RUM&lt;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>\n    /RUS&lt;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>\n    /SKY&lt;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>\n    /SLV&lt;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>\n    /SUO&lt;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>\n    /SVE&lt;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>\n    /TUR&lt;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>\n    /UKR&lt;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>\n    /ENU (Use these settings to create Adobe PDF documents best suited for high-quality prepress printing.  Created PDF documents can be opened with Acrobat and Adobe Reader 5.0 and later.)\n  >>\n  /Namespace [\n    (Adobe)\n    (Common)\n    (1.0)\n  ]\n  /OtherNamespaces [\n   &lt;<\n      /AsReaderSpreads false\n      /CropImagesToFrames true\n      /ErrorControl /WarnAndContinue\n      /FlattenerIgnoreSpreadOverrides false\n      /IncludeGuidesGrids false\n      /IncludeNonPrinting false\n      /IncludeSlug false\n      /Namespace [\n        (Adobe)\n        (InDesign)\n        (4.0)\n      ]\n      /OmitPlacedBitmaps false\n      /OmitPlacedEPS false\n      /OmitPlacedPDF false\n      /SimulateOverprint /Legacy\n    >>\n   &lt;<\n      /AddBleedMarks false\n      /AddColorBars false\n      /AddCropMarks false\n      /AddPageInfo false\n      /AddRegMarks false\n      /ConvertColors /ConvertToCMYK\n      /DestinationProfileName ()\n      /DestinationProfileSelector /DocumentCMYK\n      /Downsample16BitImages true\n      /FlattenerPreset&lt;<\n        /PresetSelector /MediumResolution\n      >>\n      /FormElements false\n      /GenerateStructure false\n      /IncludeBookmarks false\n      /IncludeHyperlinks false\n      /IncludeInteractive false\n      /IncludeLayers false\n      /IncludeProfiles false\n      /MultimediaHandling /UseObjectSettings\n      /Namespace [\n        (Adobe)\n        (CreativeSuite)\n        (2.0)\n      ]\n      /PDFXOutputIntentProfileSelector /DocumentCMYK\n      /PreserveEditing true\n      /UntaggedCMYKHandling /LeaveUntagged\n      /UntaggedRGBHandling /UseDocumentProfile\n      /UseDocumentBleed false\n    >>\n  ]\n>> setdistillerparams\n<<\n  /HWResolution [2400 2400]\n  /PageSize [612.000 792.000]\n>> setpagedevice"}]}}}